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Abstract	
Despite having a similar healthcare system, Portugal has almost 50% higher cervical cancer 
incidence than the United Kingdom and twice that of its neighbouring country Spain. This 
disparity is particularly noteworthy in the European context, where countries who have 
invested in organised screening have seen significant reductions of the burden of cervical 
cancer and have started the transition to a molecular-based assessment of risk for progression 
to cancer enabled by technologies like HPV testing. 
The overall aim of this thesis was to evaluate the clinical impact and cost-effectiveness of 
alternative cervical screening strategies in Portugal. This was achieved by (i) identifying the key 
factors determining burden of cervical cancer in Portugal, (ii) reviewing the literature on 
model-based evaluations of cervical screening, (iii) parameterising, adapting, and calibrating an 
existing mathematical model of HPV infection and progression to cervical cancer to Portuguese 
sexual behaviour, HPV prevalence and cervical cancer incidence, and (iv) evaluating the clinical 
impact and cost-effectiveness of alternative screening protocols.  
The first analysis found that cervical cancer incidence and mortality in Portugal would likely 
have declined more sharply had screening been organised, based on a comparison on burden 
and risk factors for cervical cancer in England. The review of the literature on modelling 
cervical screening showed that model calibration to country-specific data is not standard 
practice yet and that there was only one cost-effectiveness analysis concerning Portugal, which 
did not investigate the utility of the currently relevant technologies.  
In the analysis of the impact of alternative screening protocols, our mathematical model 
predicts that primary HPV DNA screening as part of an organised programme is likely more 
effective than cytology-based strategies preventing cervical cancer cases. The economic 
evaluation showed that HPV primary screening with extended interval may be cost-effective 
but this is highly dependent on the unit cost of HPV DNA testing relative to cytology.	
.   
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	1. Chapter1.	Introduction		
 Background	
1.1.1. Human	papillomavirus	infection	and	cervical	cancer	
Human papillomavirus (HPV) infection is a major cause of infection-related cancer worldwide, 
with approximately 83% of HPV-associated cancers being that of the cervix uteri.[1] In 2012, 
cervical cancer was the second most common malignancy and cancer-related deaths among 
women aged 15 to 44 years old worldwide.[2] This was the case in Portugal and Europe as well 
that year where the age-standardised (European 1976 standard population) mortality of 
cervical cancer  was 4.9 per 100,000 women-years, and incidence was 10.8 and 13.4 per 
100,000 women-years, respectively.[3] 
The causal association of HPV infection with cervical cancer is currently well established, with 
more than 95% of cervical cancer biopsies containing high-risk HPV genomes.[4] Over seventy 
per cent of invasive cervical cancer was HPV16 and/or 18 positive in all world regions except 
Asia.[5] In Portugal, the three most prevalent high-risk HPV types in invasive cervical cancer 
cases are 16 (71%), 18 (10%), and 33 (9%).[6] 
HPV infection is ubiquitous and sexually transmitted. Prevalence of high-risk HPV in women 
aged under 25 with normal cytology was 23.9 (21.4 – 26.6 95% confidence interval, CI) and 
27.6 (26.9 – 28.3 95%CI) in Portugal and Europe in 2015, respectively.[7] Most infections are 
benign and transient, naturally cleared by immune response; however, persistent infections 
have higher probability of progression to invasive carcinoma.[8] The major steps of the natural 
history of cervical disease are HPV infection, persistence, progression to cervical precancerous 
lesions, and malignant cells invasion.[9] 
1.1.2. Current	approaches	to	cervical	cancer	prevention	in	high-
income	settings	
Vaccination		
Three prophylactic HPV vaccines are currently available having demonstrated safety and 
immunogenicity against infection by the two most carcinogenic types (HPV16 and 18). The 
bivalent vaccine confers protection against types 16 and 18, the quadrivalent vaccine protects 
additionally against HPV 6 and 11 (responsible for 90% of external genital warts in men and 
women), and the nonavalent vaccine immunises as well against cervical cancer high-risk types 
31, 33, 45, 52, and 58. 
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Both bi- and quadrivalent vaccines demonstrated over 90% efficacy in HPV-naïve women (aged 
15-25) at the prevention of new infections and a range of precancerous endpoints. They were  
also shown to induce partial cross-protection against a limited number of non-vaccine 
types.[10][11] The nonavalent vaccine is expected to prevent over 90% of cervical cancer cases 
as it has shown similar immunogenicity to the quadrivalent vaccine (regarding HPV 6, 11, 16, 
and 18), as well as efficacy against infection and disease by the additional 5 high-risk HPV types 
in women aged 16-26 years.[12]  
Duration of protection has not yet been established; however, antibody persistence up to 10, 
12, and 6 years has been demonstrated for three-dose schedules of the two-, four-, and nine-
valent vaccines, respectively.[12–14]   
High-coverage vaccination programmes are likely to considerably reduce HPV prevalence and 
therefore significantly impact the need to screen.[15] However, long-term efficacy monitoring 
is needed. The only study of the early impact of HPV vaccination of girls on cervical high-grade 
lesions shows significant reduction in girls aged 15-19 but no effect on those aged over 19. 
Also, mathematical modelling studies suggest that HPV vaccination of girls is highly cost-
effective in most countries, but short-term vaccine-conferred protection could result in a delay 
and not a decrease in cancer incidence.[16][17]  
Given the evidence of non-inferior immunogenicity for two-dose compared to three-dose 
schemes, the World Health Organisation currently recommends a two-dose schedule at 6 or 12 
months for girls under 15 years, and several countries (including Portugal) have adopted it.[18] 
One-dose schedules alone or alongside screening are also being investigated as simple 
vaccination schemes are likely more effective.[19] 
Screening	
The purpose of screening for cervical cancer is to reduce its related morbidity and mortality by 
early detection and treatment of precancerous lesions likely to progress to cancer. For that 
purpose, a large number of asymptomatic individuals at risk of cancer are tested for 
precancerous lesions that only rarely progress to cancer. Test results determine then further 
diagnosis and treatment. Considering that tests are prone to error (there is always a 
proportion of false-positive and of false-negative results), when choosing a screening test or 
designing a screening strategy, the decision maker must consider the accuracy of the tests 
available and face the trade-off between the potential benefits and harms of screening. In 
cervical cancer screening, this trade-off is mainly related to the consequences of not detecting 
all cancer cases and to those of having a large number of false-positives or of over-diagnosing 
and treating naturally regressive precancerous lesions. Additionally, decision makers need to 
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understand the resource use and costs implied in a screening programme, which may involve a 
formal assessment of the programme opportunity cost (e.g. cost-effectiveness 
analysis).[20,21] 
Cytology-based screening programmes are recognized for having significantly reduced cervical 
cancer incidence and mortality in countries such as Japan, Sweden, and the United Kingdom, 
as screening allows diagnosing and treating high-grade or persistent pre-cancerous lesions, 
and therefore reducing the incidence of invasive cervical cancer.[22] 
Despite the introduction of vaccination programmes in some high-income countries, screening 
remains highly relevant worldwide. Most women at risk of cervical cancer have not been 
vaccinated, particularly in countries with higher burden of cervical cancer, and it will take 
many years before all women in screening ages are vaccinated.[23] Moreover, the bi- and 
quadri-valent vaccines available before 2015 confer nearly full protection against a few high-
risk HPV types only (accountable for about 70% of cervical cancer).[24] Besides the 
demonstrated high efficacy (over 95% for CIN3) in women without prior exposure who 
adhered to all aspects of the trials’ protocol, the intention-to-treat cohorts (including women 
with prior exposure to HPV) showed lower efficacy (about 45% for CIN3).[10,25] 
Vaccination is expected to reduce the incidence of pre-cancerous lesions and therefore to 
reduce the positive predictive value of cytology or any other screening technology as well, 
implying a reassessment of screening strategies.[24] The timing of such reassessment depends 
on the age of vaccinated girls (mainly the oldest catch-up cohort and its coverage) and the 
starting age for screening. Moreover, as efficacy in pre- and early-adolescents, currently the 
primary targets for vaccination, has not been demonstrated (trials in this age group would 
require longer follow-up), screening has also be used to assess the impact of vaccination and 
gather evidence on changes in prevalence of the several HPV types.[10,15,26] 
Screening	technologies	and	strategies	
The selection of a particular screening test depends ultimately on the existing evidence of its 
clinical utility for a given role as part of a screening strategy, i.e. its impact on improving 
patients’ health outcomes in the relevant population, compared to a comparator strategy 
(current best standard practice).[27,28] Provided evidence of its clinical utility, other 
characteristics of the screening test are considered before recommendation of its integration 
in a screening strategy, namely its cost-effectiveness and its broader impact in society (e.g. 
acceptability and feasibility of implementation).  
Screening for cervical cancer aims at early detection of a rare preventable life-threatening 
disease. Hence, a highly sensitive test is preferred to detect as many people with progressive 
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precancerous lesions as possible (minimising the number of false negatives, in contrast with a 
scenario of high prevalence of a deadly disease where a highly specific test would be 
preferable aiming at minimising the number of false positives, as not to treat women without 
cervical cancer).   
As an ideal precursor of cervical cancer (only present in women that will develop the disease) 
has not been found yet, none of the available screening tests distinguishes perfectly women 
that will develop cervical cancer from those that will not. Currently used precursors and 
biomarkers are present in both groups of women in overlapping levels and test results depend 
on the threshold established for that particular test (e.g. cytological abnormal outcomes occur 
in women who will and will not develop cancer and the current threshold for diagnosis referral 
varies from atypical squamous cells of undetermined significance (ASCUS) to high-grade 
intraepithelial lesion (HSIL)).  
Therefore, the selection of a technology for cervical screening entails a trade-off between 
sensitivity and specificity where the lower the threshold, the more sensitive the test becomes 
(larger number of true positives) and less specific the test is in identifying as negative women 
who will not develop cervical cancer (larger number of false positives as well). So that this later 
group of women, who will not develop cancer despite testing positive at a primary screening 
stage, are not referred to diagnostic testing (by colposcopy – an expensive medical procedure 
of visual inspection of the cervix with a colposcope that can cause discomfort and anxiety[29]), 
a triage screening test can be performed to reduce the proportion of false-positive results or 
to help interpreting ambiguous results, as to distinguish those who are at greater risk of cancer 
from those who are not and select only the first for further testing.[21]  
Cervical cytology, using the Papanicolaou test, or Pap smear is the most commonly used 
screening procedure in high-income countries, broadly consisting of the microscopic analysis 
after staining of collected cells to detect epithelial cell abnormalities or malignancy.[30] The 
conventional method is still widely used in Portugal and involves a sample collected with a 
spatula which was smeared onto a glass slide and then fixed.[31,32]  
Cytology accuracy is highly variable as it depends on the availability of adequately collected 
samples and well-trained cytotechnicians, leading to high rates of false negatives. Its sensitivity 
is on average 53% (ranging from around 20% to 75%), and its average specificity is 97%. [33] 
Cytology is based on the subjective interpretation of morphological cellular alterations, and 
the repetitive nature of work leads to errors of interpretation. Given its low sensitivity, women 
are asked to repeat cytology frequently before they can be safely followed according to an 
extended screening schedule.[24]  
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In liquid-based cytology (LBC), the cervical sample is put in a fluid medium which contains 
fixative and the cells are then selected and fixated onto a slide producing a more 
homogeneous preparation of cervical cells.[32]  Compared with conventional cytology, LBC 
results in a lower proportion of unsatisfactory smears, enables faster interpretation, and 
allows repeated smears from the sample and the application of other techniques (e.g. HPV 
DNA testing) to that same sample. LBC has therefore made processing cellular samples easier 
compared with conventional cytology by improving sample adequacy and laboratory 
productivity. However, LBC has not demonstrated to be more sensitive than the conventional 
cytology, and thus this limitation remains.[24,34,35]  
Following the discovery of a causal relationship between persistent high-risk HPV infection and 
cervical cancer, several technologies have been developed to detect HPV DNA and other 
biomarkers in smear samples, aiming at overcoming the current limitations of cytology. These 
relate mainly to its subjectivity, its variable sub-optimal accuracy in detecting precancerous 
lesions most likely to progress, and its costs.[22,36] As a technique dependent on the 
interpretation of a highly trained cytotechnician that uses qualitative criteria to identify cells 
with altered morphology, cytology reproducibility and accuracy is highly variable. Some 
molecular-based tests are thought to have the potential to improve cytology’s accuracy and 
reproducibility (e.g. p16 immunostaining), while other are thought to be promising alternatives 
to cytology (e.g. HPV DNA, p16/ki-67 dual immunostaining, or methylation markers) as they 
can be subject to automated quantification. However, only HPV DNA testing (with or without 
genotyping) is currently used in clinical practice.[37–39]  
High-risk HPV DNA testing has been diversely integrated in different cytology-based 
algorithms: for triage of minor cytological abnormalities (e.g. in Canada, and Catalonia, Spain), 
as an adjunct test to cytology screening (i.e. co-testing in the USA and Spain), and as test of 
cure after treatment in the UK. In Portugal, LBC with HPV triage has been introduced gradually 
with the implementation of regional organised cervical screening programmes.[31] 
More recently, HPV DNA testing has been adopted as primary screening test by several 
countries, such as the Netherlands and Sweden,[40][41] following robust evidence of its 
greater sensitivity to CIN3 and cancer compared to cytology, lower risk of precancer for HPV-
negative women (compared to cytology-negative) allowing for extension of the screening 
interval, and efficiency in improving screening coverage when offered as self-sampling. [42] 
[43] 
The introduction of HPV DNA testing in primary screening for cervical cancer entails 
introducing a strategy for the management of HPV-positive women, given the potential over 
screening and treatment of women with temporary infections. Most countries where HPV DNA 
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testing has been introduced as primary test have selected cytology alone for triage of HPV-
positive women, whereas a  few chose to use HPV 16/18 genotyping as well (e.g. Australia and 
New Zealand) with immediate colposcopy of HPV 16/18 positives.[41]  
There is extensive evidence of the clinical validity of cytology in triage of high-risk HPV-positive 
women from European randomised controlled trials, and that its use in triage of HPV-positive 
women can safely reduce the high colposcopy referral rates expected with HPV primary 
screening.[42] However, cytology triage is still reliant on subjective morphological assessment 
which entails inter-site performance variation and permanent investment on quality assurance 
and training of specialist technicians, and it is not applicable to self-sampling. 
Using HPV 16/18 genotyping to triage high-risk HPV-positive women is based on their high 
prevalence in cervical cancer (65% and 17% for HPV 16 and 18, respectively) and increased risk 
of precancer and cancer for women infected by these HPV subtypes.[44] [43] HPV 16/18 
genotyping has shown higher sensitivity and similar positive predictive value for CIN3+ as 
cytology ASCUS+ in triage of HPV-positive women, while necessarily entailing over referral to 
colposcopy and potential over screening and over treatment.[45][46]   
Other potentially useful tools for triage of HPV-positive women with some evidence of 
superior clinical performance compared to cytology alone or combined with HPV 16/18 
genotyping include p16/Ki-67 dual stained cytology, and viral and host methylation 
markers.[47][48][49][50] Methylation biomarkers would additionally enable to primary screen 
and triage self-collected samples. However, evidence from large head-to-head comparisons of 
biomarkers is needed to fully assess their utility as part of HPV primary screening 
algorithms.[51]  
Novel programmes are expected to move towards a comprehensive and integrated approach 
to screening and vaccination, including the transition to HPV primary testing and appropriate 
triage, the expansion of self-sampling, and exploring options for screening vaccinated 
cohorts.[52][41] 
Mathematical	modelling	
Mathematical models have been widely used to assess the impact of one or several of the 
multiple technologies available in distinct roles within strategies for the prevention of cervical 
cancer.[53][54] The range of options for preventing cervical cancer has rapidly increased, 
making the process of determining optimal algorithms for cervical screening increasingly 
complex. Mathematical models have allowed synthesising evidence from an extensive range of 
sources and simulating setting-specific scenarios that would be unfeasible or unethical in 
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clinical practice. Often assumptions are incorporated to overcome particular limitations of the 
evidence available and sensitivity analysis is used to explore their impact on model results.  
Recent examples of epidemiological and economic modelling used to help inform policy 
decisions concerning cervical screening include cost-effectiveness analyses of HPV primary 
screening and can comprise vaccinated cohorts besides unvaccinated ones.[55][56] Recently 
revised screening policies in Australia and New Zealand, for instance, where HPV primary 
screening with partial genotyping for both unvaccinated and vaccinated women has been 
introduced, made use of mathematical models to study the epidemiologic and economic 
impact of primary HPV protocols compared to cytology-based ones.[56–58] Cost-effectiveness 
analyses of integrated approaches to cervical cancer prevention have found vaccination and 
HPV primary screening with cytology triage of HPV-positive women optimal compared to 
cytology-based approaches and likely to allow for a prolonged screening interval in vaccinated 
cohorts.[59]  
Although screening based on vaccination status is likely more cost-effective than a uniform 
strategy (given the lower risk of cervical cancer of vaccinated cohorts than unvaccinated ones), 
the accurate identification of who has been vaccinated will be challenging and dependent on 
the linkage of screening and vaccination registries. A uniform screening strategy may be the 
only possible option or may become cost-effective as the number of vaccinated women of 
screening age and the subsequent herd immunity effect increase over time. Primary HPV 
screening will facilitate the monitoring of HPV 16/18 prevalence among unvaccinated women 
and mathematical models have been used to identify the level of herd immunity at which 
reducing the screening intensity of unvaccinated women may be safe and cost-effective.[60]  
 Thesis	outline		
1.2.1. Rationale	
Despite having a similar healthcare system, Portugal has almost 50% higher cervical cancer 
incidence than the United Kingdom and twice that of its neighbouring country Spain.[61] This 
disparity is particularly noteworthy in the European context, where countries who have 
invested in organised screening have seen significant reductions of the burden of cervical 
cancer and have started the transition to a molecular-based assessment of risk for progression 
to cancer enabled by emergent technologies, with growing concern for women at high risk of 
cervical cancer who do not regularly participate in screening programmes.[62][38]  
In 2008, thirty years after the introduction of opportunistic screening in Portugal, HPV 
vaccination of girls was included in the National Immunization Plan and the implementation of 
regional cytology-based organised programmes with distinct protocols began. Since then, 
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efforts towards the expansion of the existing protocols and their merger into a uniform 
national programme (including Lisbon and Tagus Valley where organised screening has just 
been introduced in some areas) have been made.[31] 
The emerging pertinence of adopting HPV DNA testing for primary cervical screening was 
highlighted in the last report by the Portuguese Directorate-General of Health, and HPV 16/18 
genotyping with cytology triage of positive results for other high-risk HPV types (being piloted 
in the North region) has recently been endorsed as primary test by the Portuguese Ministry of 
Health.[31,63] HPV primary screening can enable the extension of the screening interval, 
tailoring screening protocols to women’s risk of cervical cancer (increasingly relevant as the 
first vaccinated cohorts reach the age of first screen), and improving attendance of women 
who do not usually engage with screening via self-sampling.[23,64] 
The outstanding burden of cervical cancer in Portugal alongside the current transition from the 
regional diversity of regimes and protocols for cervical screening to a joined HPV-based 
approach calls for an investigation of the potential impact of a uniform well-organised 
programme.  
Hence, it is timely to investigate the key factors driving the relatively high burden of cervical 
cancer in Portugal and the potential effectiveness of alternative screening strategies, including 
an evaluation of their economic implications.    
1.2.2. Aims	and	objectives	 	
The overall aim of this thesis was to evaluate the cost-effectiveness of alternative cervical 
screening strategies in Portugal. For this purpose, the following intermediate main objectives 
were set: 
1. To characterise the current state of HPV infection and cervical cancer epidemiology in 
Portugal and identify the key factors determining the disease burden   
2. To identify existing evaluations based on mathematical models of cervical screening in 
Portugal and review the methods currently used to model cervical screening in distinct settings 
3. To investigate the impact of distinct screening policies in Portugal, via the adaptation of an 
existing mathematical model of HPV infection and disease progression to the Portuguese 
context 
4. To evaluate the cost-effectiveness of alternative cervical screening protocols in Portugal 
These objectives were met by undertaking the research described in the individual chapters of 
this thesis. 
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1.2.3. Structure	of	the	thesis	
Chapter 2 meets objective 1 of this thesis providing a comparative analysis of the time trends 
of the burden of cervical cancer, risk factors, and preventive interventions in Portugal and 
England. While investigating the epidemiology of cervical cancer in Portugal (aiming at 
characterising it as best as one could in the parameterisation of our mathematical model) and 
adapting a model originally developed for the English context, England emerged as a pertinent 
comparator given its successful experience with organised screening in reducing the burden of 
cervical cancer. Hence, evidence from a range of data sources was gathered to analyse the 
elements that could have affected cervical cancer incidence and mortality in both countries. 
Chapter 3 presents the results of a systematic review of the literature on mathematical models 
of cervical screening conducted to address objective 2. It gives a comprehensive overview of 
model-based effectiveness and cost-effectiveness analyses of cervical screening strategies, 
covering epidemiological and economic studies of the full range of technologies available in 
different settings, including screening of vaccinated populations.  
Chapter 4 gives a detailed description of the adaptation of an existing mathematical model of 
HPV infection and progression to cervical cancer, including the analyses performed for model 
parameterisation, calibration, and to assess the effectiveness of distinct screening algorithms. 
This piece of work meets objective 3.  
Chapter 5 provides a cost-effectiveness analysis of cervical screening protocols in Portugal, 
addressing objective 4. It includes a comparison of the impact of cervical screening strategies 
in terms of predicted cost, cancers prevented, and life years and quality-adjusted life years 
saved, together with details on the methods used for the economic analyses performed and a 
discussion of the results obtained. 
Chapter 6 discusses the main findings of the work presented in all previous chapters and areas 
of further research. 
1.2.4. Contribution	of	the	candidate	to	the	thesis	
The candidate conducted the investigations involved in the four research papers presented in 
this thesis, including literature review, analysis, and preparation of all drafts. Hence, the 
candidate is the first author of the four research papers. The first two have already been 
published and the last two are in preparation for submission. The co-authors’ contribution to 
the manuscripts is detailed at the start of each chapter of this thesis, consisting mostly of 
comments on the drafts prepared by the candidate. 
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2. Chapter	2.	Determinants	of	burden	of	cervical	cancer	in	
Portugal	and	England	
 Preamble	to	research	paper	1		
As the introduction chapter indicates, identifying the key drivers for the relatively high burden 
of cervical cancer in Portugal was motivated by two reasons: (i) to better understand current 
cervical cancer epidemiology in Portugal, as well as identify factors driving current morbidity 
and mortality, and (ii) to gather the best available evidence to properly parameterise a 
mathematical model used to investigate the impact of alternative screening policies in 
Portugal.  
A comparison of cervical cancer epidemiology between Portugal and England was conducted, 
motivated by the need to adapt an existing mathematical model developed by Bains and 
colleagues (detailed in the Appendix to this thesis) to help inform decisions on cervical 
screening policies in England, to the Portuguese context.  
The burden of cervical cancer among Western European countries has been higher in the 
North than in the South[1]. Portugal and England were exceptions to this trend, so comparing 
them allowed identifying the country-level differences that caused Portugal and England to 
differ from each other as well as from their regional counterparts. 
Research paper 1 demonstrates how the 20-year time lag in the adoption of widespread 
organised cervical screening is highly likely to be the key driver of these differences. Key 
lessons for cervical cancer surveillance and prevention relevant throughout Europe can also be 
drawn from this investigation. 
Data for a wider region such as England and Wales, Great Britain, or the United Kingdom was 
used when data for England only was not available. Despite the existing differences in HPV 
prevalence[2]and cervical screening policies[3-6] between the different nations of the UK, 
cervical cancer incidence has been similar over time in the 4 constituent countries, and at 8.2, 
9.6, 11.1, and 12.1  cases per 100,000 women (EASR) in 2007 in England, Northern Ireland, 
Wales, and Scotland, respectively[7].    
The overall crude HPV prevalence among women with normal cytology in England and the UK 
was 0.12 [0.09-0.15] and 0.12 [0.10-0.14], respectively[2]. Nonetheless, Wales had the lowest 
crude estimate 7% [95% CI 6.5-7.5%] and Northern Ireland had the highest 13% [95% CI 12-
14%], with 12% [5-22%] in Scotland[2].  
Screening policies have also differed slightly in target ages and frequency over time between 
UK nations[3-6]. Although a centrally organised NHS Cervical Screening Programme and a 
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national call/recall system were introduced in England and Wales since 1988 (where women 
aged 20-64 years were invited for cervical screening at least once every 5 years), Cervical 
Screening Wales was formed in 1999 and introduced its own programme targeting women 
aged 20-64 every 3 years. In Northern Ireland, by 1993 all women aged 20-64 were invited 
every 5 years as part of a call/recall system, and in Scotland, women aged 20-60 years were 
invited for cervical screening at least once every 3 to 5 years since 1989. In 2004, the age range 
and frequency of cervical screening changed to 3 yearly from age 25 and 5 yearly from age 50 
to 64 in England ,and this policy was adopted only more recently by Northern Ireland (2011), 
Wales (2013), and Scotland (2016).  
Despite these policy differences, 5-year cervical screening coverage in England and Wales 
(women aged 25-64), and Scotland (aged 20-60) has been similar and slightly decreasing over 
time - from 80% to 77% in England and 79% to 78% in Wales (2005-2015), and 84% to 77% in 
Scotland (2006-2015), whilst in Northern Ireland 5-year coverage increased from 69% in 2000 
to 77% in 2011[3-6]. 
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2.2.1. Abstract	
Background: Cervical cancer incidence has decreased over time in England particularly 
after the introduction of organised screening. In Portugal, where opportunistic 
screening has been widely available with only slightly lower coverage than that of the 
organised programme in England, rates of cervical cancer have been higher than in 
England. We compared the burden of cervical cancer, risk factors, and preventive 
interventions over time in both countries, to identify elements hindering the further 
decline in incidence and mortality in Portugal.  
Methods: We used joinpoint regression to identify significant changes in rate time-
trends. We also analysed individual-level Portuguese data on sexual behaviour and 
human papillomavirus prevalence, and recent aggregate data on organised and 
opportunistic screening coverage. We compared published estimates of survival, risk 
factors, and historical screening coverage for both countries. 
Results: Despite stable incidence, cervical cancer mortality has declined in both 
countries in the last decade. The burden has been 4 cases and 1 death per 100,000 
women annually higher in Portugal than in England. Differences in human 
papillomavirus prevalence and risk factors for infection and disease progression do not 
explain the difference found in cervical cancer incidence. Significant mortality declines 
in both countries followed the introduction of different screening policies, although 
England showed a greater decline than Portugal over nearly 2 decades after 
centralising organised screening. 
Conclusion: The higher rates of cervical cancer in Portugal compared to England can be 
explained by differences in screening quality and coverage. 
Keywords: human papillomavirus; cervical cancer; screening; incidence trends; 
mortality trends 
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2.2.2. Introduction	
Portugal has had higher burden of cervical cancer than England. Several multi-country 
comparisons have shown that European countries with poor cervical screening 
coverage have a higher cervical cancer burden[1–4]. Reasons for the difference are not 
obvious because cervical cancer development is multi-factorial and depends on 
infection with high-risk human papillomavirus (HPV), the rate of progression of pre-
cancerous lesions, and the existence of preventive interventions such as screening and 
vaccination[5]. 
Opportunistic screening has reduced cervical cancer mortality in some countries; 
however, it is characterised by unnecessarily frequent screening, heterogeneous 
quality, and poor coverage of underserved women who may be at highest risk. Well 
organised programmes enable high coverage of the target population, adequate 
follow-up, and equity of access with more efficient resource use but has yet to be 
implemented in many European countries[6].  
Like most western European countries, England has seen a decline in the burden of 
cervical cancer following the introduction of cytological screening in 1964, particularly 
since screening was centrally organised in 1988[6].  
In Portugal, cervical screening was introduced in 1978 but only on an opportunistic 
basis, although more recently regional organised programmes with varying coverage 
have been initiated. Each mainland regional health administration (RHA) and the 
regional health systems of Azores and Madeira are autonomously responsible for the 
provision of any programme. Partially-organised screening was introduced in 1990 in 
the Centre region. Fully-organised programmes have been introduced post-2008 with 
varied regional coverage in Alentejo, Algarve, Azores, and the North. Lisbon and Tagus 
Valley and the Autonomous Region of Madeira have not implemented such a 
programme yet[7].  
Here we investigate the extent to which screening and other factors may have driven 
differences in cervical cancer incidence between Portugal and England by analysing 
estimates and time-trends in multiple data sets including HPV prevalence, cervical 
cancer incidence and mortality, screening coverage, sexual behaviour and other 
potential risk factors. We then explore the implications of our results for policy making 
across Europe. 
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2.2.3. Methods	
Cervical	cancer	incidence	and	mortality	
European age-standardised rates (EASR) were estimated using the 1976 European 
Standard Population. Age-standardised incidence was estimated from individual case 
data provided for 1998-2010 by all four Portuguese population-based regional 
registries (Azores, Centre, North, and South), covering 100% of the population. 
National estimates were pooled by weighting the regional age-specific number of 
cases by the respective proportion of the population. For the UK, we used estimates 
from EUREG and national statistics databases[8,9].  
Cervical (and other uterine) cancer mortality and female population sizes for both 
countries were obtained from the WHO mortality database[10] and Statistics 
Portugal[11]. Inaccuracies in death certification were adjusted by reallocating deaths 
from non-otherwise specified uterine cancers to cervical cancer[1].  
We performed segmented regression to analyse rate trends and identify trend 
joinpoints (i.e., calendar years where the slopes of two linear trends changed). The 
annual percentage change (APC) was estimated for each segment fitting a log-linear 
model with the Joinpoint software[12]. 
Case-fatality	risk	
Annual case-fatality risk (CFR) was calculated from incidence and mortality estimates, 
as its complement (1-Mortality/Incidence) has been considered a valid approximation 
of the 5-year relative survival for most cancers[13]. The two-proportion z-test was 
used to test whether these populations’ risks differ significantly. 
Cervical	cancer	survival	
We used published 5-year survival estimates from the CONCORD-2[14]  and the 
EUROCARE[15] studies based on cancer registries data. 
HPV	prevalence	
We estimated age-standardised prevalence of 13 high-risk HPV types (16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, and 68) from the CLEOPATRE Portugal study which 
recruited 2,165 unvaccinated women aged 18-64 attending National Health Service 
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(NHS) gynaecology, obstetrics, and sexually transmitted disease services in 2008/9.[16]  
Age-specific and overall crude prevalence estimates of high-risk HPV in women 
attending cervical screening in England were sourced from a systematic review and 
meta-analysis of the main pre-vaccination studies.[17] 
Sexual	behaviour	
Behavioural risk indicators for HPV infection were estimated from individual-level data 
of the 2007 survey on sexual behaviour and HIV/AIDS in mainland Portugal[18] (1,860 
valid questionnaires from sexually active women aged 16-65 years). We compared 
these estimates with those published from the British National Surveys of Sexual 
Attitudes and Lifestyles (Natsal-2 in 1999-2000 16-44 years old, and Natsal-3 in 2010-
2012 16-74 years old).[19] Definitions were standardised across the two surveys 
(additional information is available on request). 
Other	risk	factors	
Published estimates were obtained for risk factors for HPV infection acquisition, 
persistence, and cervical cancer progression: smoking[20], contraception use[21], 
fertility[22], male circumcision[23] and other sexually transmitted infections 
(STIs)[24,25]. We compared outcomes from European Union surveillance of human 
immunodeficiency virus (HIV), chlamydia, syphilis, and gonorrhoea in both countries. 
Data on these risk factors were only found for the UK. 
Cervical	screening	
Cervical screening coverage in Portugal prior to the introduction of organised 
programmes (2008) was obtained from the literature[26,27]. Coverage post-2008 was 
estimated from aggregate data provided by RHAs in mainland Portugal. Coverage of 
opportunistic screening was derived from the number of conventional cytology tests 
reimbursed to contracted laboratories in 2010-2014. For England, we used published 
screening coverage estimates[28]. 
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2.2.4. Results	
Cervical	cancer	incidence		
Annual incidence of cervical cancer in Portugal in 1998-2010 ranged from 11.6 (10.8-
12.5) to 14.3 (13.4-15.3) per 100,000 women; the negative linear trend over that time 
period was not significant (Supplementary Table 2-1 and Figure 2-1). In England over 
the same period, incidence varied between 8.0 (7.7-8.3) and 9.7 (9.4-10.1) and was 
similarly stable in the 2000s. We estimated a positive APC in 1977-1988 followed by a 
negative APC in 1988-1998, but no evidence of a change in incidence in 1999-2011.  
In England, the peak age of cervical cancer incidence has shifted from after 45 years in 
the early 1980s to around 30-45 years in the late 1990s. In Portugal, it peaked at 40-49 
year olds in 1998-2010 (Supplementary Figure 2-1).  
Cervical	cancer	mortality	
For Portugal (1955-2013), we estimated 2 joinpoints in cancer mortality at 1970 and 
1982. There was no evidence of a change in mortality until 1970, with a decline 
thereafter (Figure 2-1 and Supplementary Table 2-1). Three trend periods were 
estimated for England with joinpoints in 1964, 1988, and 2006. The APC has declined 
since 1950, with the steepest decline in 1988-2006. 
In 1998-2010, average cervical cancer incidence in Portugal exceeded that in England 
by 4 cases per 100,000 women. However, cervical cancer mortality was similar 
between countries (on average 1 more death per 100,000 women annually in Portugal 
than in England). Both countries show a period-specific effect as age-specific rates 
declined similarly in consecutive periods and birth cohorts across all age groups apart 
from the youngest (20-29 and 30-39 years old) (Supplementary Figure 2-2 and 2-3). 
Case-fatality	risk	and	survival	
Cervical cancer CFR was higher in England (mean 0.33, range 0.24-0.40, 1998-2010) 
compared to Portugal (mean 0.30, range 0.25-0.34, 1998-2010) but the difference was 
not statistically significant (p>0.5 every year) (Supplementary Figure 2-4). Also, CFR 
declined in England throughout 1996-2011 but not in Portugal (Supplementary Table 
2-1). 
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Allemani and colleagues[14] found that 5-year net survival improved from 54% (50-
58%) to 62% (60-63%) in Portugal (1998-2009) and from 58% (57-59%) to 60% (59-
62%) in England (1995-2009) (Supplementary Table 2-2). Similarly, the EUROCARE 
database shows a greater improvement of 5-year relative survival in Portugal [from 
56.5 (54.4-58.5) to 61.3 (59.5-63.1)] than in England [from 59.1 (58.6-59.6) to 
59.6 (58.7-60.5)] between 1995-1999 and 2000-2007[15]. 
Although similar estimates were found for both countries, slightly greater survival 
improvement was reported for Portugal in both EUROCARE and CONCORD-2 studies, 
while we found a steeper decline in CFR for England (Supplementary Table 2-1). Given 
that population-based survival estimates from high data quality are available, our CFR 
estimates must be considered cautiously and their complement should not be used 
instead of 5-year relative survival estimates.  
Human	papillomavirus	prevalence	
High-risk HPV prevalence among unvaccinated women with normal cytology was 5.5% 
(95% CI: 3.6-8.9%) in Portugal and 10.4% (4.5-18.7%) in the UK. The age distribution 
was similar in both countries, with peak prevalence at 20-24 years of age, followed by 
a decline until age 40 (Supplementary Figure 2-5). The overall crude high-risk HPV 
prevalence was similar in England and the UK.  
Sexual	behaviour	
Women’s median age of first heterosexual intercourse was higher in Portugal (19 
years) than in Great Britain (17 years) (Supplementary Table 2-3). The age difference 
between partners at start of the relationship was smaller in Portugal compared with 
that in Great Britain, with 76% and 63% being ≤5 years, respectively.  
Portuguese women had fewer lifetime partners than British women, but the number 
of partners over the last year and the proportion of women with ³1 new partner last 
year were similar in both countries.  Portuguese women reported 8% of relationships 
lasting less than 1 month, whereas in Great Britain these account for 51% of the 
relationships. In both countries, over 30% of reported relationships overlapped. 
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Overall, Portuguese women were at lower behavioural risk of acquiring HPV from their 
partners given their later sexual debut, fewer number of lifetime partners per year and 
fewer short-term relationships.  
Other	risk	factors	
Smoking, the number of full-term pregnancies, the use of oral hormonal 
contraceptives, and exposure to other STIs have been associated with cervical cancer. 
Conversely, there is robust evidence of inverse association between male circumcision 
and HPV acquisition and consequent development of cervical cancer[5].  
Both Portugal and the UK have shown a decreasing trend in tobacco use over the last 
decade[20], with the prevalence of smoking lower in Portugal than in the UK 
(Supplementary Table 2-4). The Portuguese fertility rate was lower in the early 2000s 
than in the UK[22]. However, Portugal has higher hormonal contraceptive use, lower 
condom use and lower prevalence of male circumcision compared to the UK [21,23]. 
The UK has higher gonorrhoea and syphilis incidence, whilst Portugal has higher HIV 
incidence [24,25]. Portugal has no organised Chlamydia surveillance system so 
Chlamydia prevalence cannot be compared with the UK[25]. 
Cervical	screening	
Cervical screening in Portugal and England differ both in quality and coverage. There is 
a 20-year lag between countries in the introduction of fully-organised programmes 
(Figure 2-2).  
In Portugal, cervical screening remains mainly opportunistic with lower coverage than 
in England (Figure 2-3).  The proportion of eligible women aged 25-64 screened 
between 2012 and 2014 in Portugal was lower than in England between 1995 and 
2015 (average 3-year coverage 60% versus 69%, respectively). Despite the introduction 
of organised screening post-2008 in Portugal, 3-year coverage of resident women in 
2012-2014 (55%) was lower than in 2002-2003 (58%). In England, 5-year coverage also 
decreased over time.  
Organised programmes in Portugal 2012-2014 covered at most for 40% of resident 
women aged 25-64; however, the proportion of eligible women invited for screening 
via a call/recall system varied from 6% (the North) to 60% (Alentejo), assuming 10% of 
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resident women are excluded for clinical reasons[7] (Supplementary Table 2-5).Over 
the same period, the English NHS Cervical Screening Programme was available to all 
resident women aged 25-64, all eligible women (94% of resident) were invited to 
participate, and 91% of these were adequately screened.[28]  
Prior to 2008, in both countries, younger women had the lowest participation rates 
among women eligible for cervical screening (aged from 20/25 to 60/64, depending on 
the country) (Supplementary Figure 2-6).  
2.2.5. Discussion	
Since 1998, cervical cancer incidence and mortality has declined in both Portugal and 
England, but has been consistently higher in Portugal[1,29] despite lower prevalence 
for high-risk HPV and risk factors for cervical cancer (such as sexual activity, smoking 
and other STIs besides HIV) in Portugal. Indeed, HPV prevalence in England exceeds 
that in Portugal, with the age distributions of HPV prevalence in the two countries 
resembling those for Southern and Northern Europe in 1995-2009[30]. HPV 
vaccination was introduced in both countries too recently to have had an effect on 
cervical cancer incidence as the first vaccinated cohorts reached the screening age of 
25 in 2015. Hence, the higher incidence in Portugal can only be explained by 
differences in screening. 
Cervical cancer survival in England is similar to that in Portugal, despite lower 
incidence. This may be due to screening selectively preventing the less invasive cancers 
and to differences in access and effectiveness of cancer treatment between 
countries[31]. 
Registration inaccuracies have hindered trend analyses of cervical cancer[29]. More 
recently, Allemani and colleagues[14] used individual patient data from all four 
Portuguese regional cancer registries (1998-2009) who reported 100% coverage of the 
national population and higher overall quality compared to the European average. We 
assumed similar quality for the data available to us (1998-2010). We corrected for 
inaccuracies in deaths certification following Arbyn and colleagues’  approach[1]. We 
reproduced their results for Portugal, the Netherlands, and the UK, and extended the 
analysis to 2013. The reliability of these adjustments is debatable, particularly for 
Portugal where the Netherlands have been used as reference country, and further 
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methodological research is needed. Consequently, our mortality (and CFR) estimates 
for Portugal may be underestimates, and the gap between countries could be even 
greater. These data limitations highlight the importance of high-quality registry data 
(which may reduce the number of deaths classified as being from uterine cancer not 
otherwise specified) and effective collaboration between cancer and screening 
registries to enable monitoring and evaluating the effectiveness of preventive 
interventions. 
Our findings support existing recommendations for investment in well-organised 
cervical screening programmes[6]. Opportunistic screening may have somewhat 
reduced cervical cancer mortality in Portugal but not to the extent seen in England. 
Time-trends suggest cervical cancer rates in Portugal would have declined more 
sharply had screening been organised. In the UK, incidence and mortality only declined 
post-central organisation of screening.  England (in contrast to Portugal) has seen 
reductions in the peak age of cervical cancer incidence[32]. 
These findings are likely generalizable to other European countries – most of which 
have or are implementing organised programmes, as previous studies showed that the 
increasing cohort-specific risk of cervical cancer in Europe (after the 1930-40s) was 
overridden earlier and more pronouncedly in Northern Europe by the decreasing 
period-specific risk due to effective screening[2]. Encouraging trends are seen in the 
Baltic countries where organised screening has been initiated and incidence is 
stabilising, whilst in Bulgaria and Romania (where screening is fairly opportunistic) 
incidence trends are still increasing[33]. 
Widespread opportunistic screening might also be hindering the extension of coverage 
of the recently implemented programmes in Portugal[6,7]. Other European countries 
also in transition to organised screening (including Belgium, France, Greece, Italy, 
Spain and many Eastern European countries) may face similar challenges. Hence, 
countries with no screening yet (eg. Albania, Azerbaijan) may benefit from thorough 
planning and implementation of organised programmes.  
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2.2.8. Key	points	
• Cervical cancer incidence and mortality have been higher in Portugal than in 
England.  
• High-risk HPV prevalence, sexual behavioural risk, and the prevalence of other 
risk factors for cervical cancer, such as smoking and other STIs (apart from HIV), 
have been lower in Portugal than in England. 
• Differences in cervical screening are likely to explain the higher burden of 
cervical cancer in Portugal compared to England. 
• Cervical cancer rates in Portugal are likely to have declined more rapidly had 
cervical screening been organised earlier. 
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2.2.10. Figures		
 
Figure 2-1. Age-standardized Cervical Cancer Incidence and Mortality by calendar period, 
EASR. 
EASR, European age-standardised rate using the 1976 European Standard Population; dots represent 
annual incidence estimates; squares represent annual mortality estimates; solid lines represent lines 
represent linear time-trends obtained by joinpoint regression; dashed lines represent 95% confidence 
intervals; *Incidence data pertain to England and mortality data pertain to England and Wales 
 
 
 
Figure 2-2. Timeline of main cervical cancer preventive interventions in Portugal and 
England. 
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Figure 2-3. Screening coverage in women aged 25-64 in Portugal[26,27]and England[28]. 
For England, coverage is defined as the proportion of eligible women aged 25-64 who were screened 
adequately within the previous 3.5 or 5 years. For Portugal, white dots represent coverage as the 
proportion of resident women aged 25-64 screened within the previous 3 or 5 years, and black dots 
represent coverage as the proportion of eligible women aged 25-64 screened within the previous 3 
years (assuming 10% of resident women are excluded for clinical reasons[7]). 
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 Supplementary	material	
Supplementary Table 2-1. Joinpoints and annual percentage changes in cervical cancer 
incidence and mortality over time, EASR 
Country (Time period) Joinpoint(s) (95%CI) Trend period(s) APC (95%CI) 
Incidence  
Portugal (1998-2010) None 1998-2010 -0.9 (-1.9; 0.2) 
England (1971-2011) 1977 (1973-1991) 
1988 (1985-2001) 
1998 (1994-2008) 
1971-1977 
1977-1988 
1988-1998 
1998-2011 
-1.1 (-2.9; 0.7) 
1.2 (0.4; 2.0) 
-5.7 (-6.8; -4.7) 
-0.3 (-1.2; 0.5) 
Mortality 
Portugal (1955-2013) 1970 (1966-1973) 
1982 (1975-1985) 
1955-1970 
1970-1982 
1982-2013 
-0.2 (-1.0; 0.5) 
-4.9 (-6.1;-3.8) 
-2.6 (-2.9; -2.4) 
England & Wales  
(1950-2013) 
1964 (1958-1971) 
1988 (1987-1990) 
2006 (2002-2009) 
1950-1964 
1964-1988 
1988-2006 
2006-2013 
-0.7 (-1.1;-0.3) 
-1.4 (-1.6;-1.2) 
-5.0 (-5.2; -4.7) 
-1.7 (-2.8; -0.6) 
Case-fatality risk 
Portugal (1998-2010) None 1998-2010 -1.4 (-2.9; 0.1) 
England (1998-2010) 1989 (1984-1993) 
1996 (1991-2001) 
1971-1989 
1989-1996 
1996-2011 
-1.6 (-2.0;-1.2) 
  0.9 (-1.6;3.4) 
-3.1 (-3.8;-2.4) 
APC, annual percentage change; EASR, European age-standardised rate using the 1976 European 
Standard Population; 95% CI, 95% confidence interval (the range of values within which the population 
mean may lie with 95% confidence level) 
Sources:  
Regional Cancer Registries from Azores, Centre, North, and South of Portugal: 
[Registo Oncologico Regional Norte] Regional Cancer Registry North - RORENO [Internet]. Available from: 
http://www.roreno.com.pt/; [Registo Oncologico Regional Centro] Regional Cancer Registry Centre - ROR-Centro 
[Internet]. Available from: http://www.rorcentro.com.pt/; [Registo Oncologico Regional Sul] Regional Cancer 
Registry South [Internet]. Available from:http://www.ror-sul.org.pt/ContactosLinks/Pages/default.aspx; [Registo 
Oncologico Regional Acores] Regional Cancer Registry Azores - RORA [Internet].Available from: 
http://estatistica.azores.gov.pt/conteudos/Relatorios/lista_relatorios.aspx?idc=29&idsc=3570&lang_id=1 
Office for National Statistics. Cervical Cancer Incidence, mortality and survival, England, 1971-2011 [Internet]. 2011 
[cited 2016 Apr 21]. Available from: 
http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/vsob1/cancer-
statistics-registrations--england--series-mb1-/no--42--2011/sty-cervical-cancer.html 
Steliarova-Foucher E, O’Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, et al. European Cancer Observatory: 
Cancer Incidence, Mortality, Prevalence and Survival in Europe [Internet]. 2012 [cited 2016 Apr 25]. Available from: 
http://eco.iarc.fr 
World Health Organization. WHO Mortality Database [Internet]. [cited 2015 Oct 29]. Available from: 
http://apps.who.int/healthinfo/statistics/mortality/whodpms/ 
Instituto Nacional de Estatistica, IP [Statistics Portugal] [Internet]. [cited 2016 Apr 15]. Available from: www.ine.pt 
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Supplementary Figure 2-1. Age-specific cervical cancer incidence in Portugal and England, 
EASR 
Sources:  
Regional Cancer Registries from Azores, Centre, North, and South of Portugal;  
National Cancer Registration and Analysis Service, Number of new cervical cancer cases by year and age 
group in England 1971-2014, Public Health England, 2016;  
Office for National Statistics. Population estimates for UK, England and Wales, Scotland and Northern 
Ireland, mid-1971 to mid-2014, 2015, 
http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/pop-
estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/index.html 
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Supplementary Figure 2-2. Age-specific incidence by period and birth cohort, EASR 
Sources:  
Regional Cancer Registries from Azores, Centre, North, and South of Portugal;  
National Cancer Registration and Analysis Service, Number of new cervical cancer cases by year and age 
group in England 1971-2014, Public Health England, 2016;  
Office for National Statistics. Population estimates for UK, England and Wales, Scotland and Northern 
Ireland, mid-1971 to mid-2014, 2015, 
http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/pop-
estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/index.html 
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Supplementary Figure 2-3. Age-specific mortality by period and birth cohort, EASR 
Source: World Health Organization. WHO Mortality Database [Internet]. [cited 2015 Oct 29]. Available 
from: http://apps.who.int/healthinfo/statistics/mortality/whodpms/ 
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Supplementary Figure 2-4. Case-fatality risk, % 
Sources: Regional Cancer Registries from Azores, Centre, North, and South of Portugal 
Office for National Statistics. Cervical Cancer Incidence, mortality and survival, England, 1971-2011 
[Internet]. 2011 [cited 2016 Apr 21]. Available from: 
http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/vsob1/ca
ncer-statistics-registrations--england--series-mb1-/no--42--2011/sty-cervical-cancer.html 
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Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe [Internet]. 2012 [cited 2016 
Apr 25]. Available from: http://eco.iarc.fr 
World Health Organization. WHO Mortality Database [Internet]. [cited 2015 Oct 29]. Available from: 
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Supplementary Table 2-2. Cervical cancer survival by country 
 England Portugal 
5-year age-standardised  Net Survival*, %[95%CI][14]  
1995-99 
2000-04 
2005-09 
58.2[57.2-59.1] 
59.2[58.2-60.2] 
60.4[59.4-61.5] 
54.0[50.0-58.0] 
60.3[58.4-62.1] 
61.5[59.7-63.2] 
5-year age-standardised Relative Survival*, %[95%CI][15] 
1990-94 
1995-99 
2000-07 
60.8[59.8-61.9] 
59.1[58.6-59.6] 
59.6[58.7-60.5] 
54.4[48.2-61.4] 
56.5[54.4-58.5] 
61.3[59.5-63.1] 
*For adults (aged 15-99 years) after diagnosis with cervical cancer; using the International Cancer 
Survival Standard age distributions; Net survival, cumulative probability that the cancer patients would 
have survived a given time after diagnosis in the hypothetical situation that the cancer was the only 
possible cause of death; Relative survival, ratio of the measured survival of patients to the expected 
survival in the general population 
Sources: [14]Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of 
cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-
based registries in 67 countries (CONCORD-2). Lancet [Internet]. Allemani et al. Open Access article 
distributed under the terms of CC BY; 2015;385(9972):977–1010. Available from: 
http://dx.doi.org/10.1016/S0140-6736(14)62038-9; [15] EUROCARE. EUROPEAN CANCER REGISTRY 
BASED STUDY ON SURVIVAL AND CARE OF CANCER PATIENTS [Internet]. [cited 2016 Oct 17]. Available 
from: http://www.eurocare.it/Database/tabid/77/Default.aspx 
 
 
Supplementary Figure 2-5. Age-specific high-risk HPV prevalence in the UK and Portugal 
Dots- mean estimates, shaded areas-95%CI; Sources: Pista A, Oliveira C, Cunha MJ, Paixão T, Real O, 
Group CPS. Prevalence of Human Papillomavirus Infection in Women in Portugal - The CLEOPATRE 
Portugal Study. Int J Gynecol Cancer [Internet]. 2011;21(6):1150–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21792018; Anderson L, O’Rorke M, Jamison J, Wilson R, Gavin A. 
Prevalence of Human Papillomavirus in Women Attending Cervical Screening in the UK and Ireland: New 
Data From Northern Ireland and a Systematic Review and Meta-Analysis. J Med Virol [Internet]. 
2013;85:295–308. Available from: http://onlinelibrary.wiley.com/doi/10.1002/jmv.23459/abstract  
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Supplementary Table 2-3. Sexual behaviour indicators 
 
Great Britain,  
Natsal 2 (1999-2000) 
Great Britain,  
Natsal 3 (2010-2012) 
Portugal, 
2007  
Age of sexual debut, years, median[IQR]1,2  
All ages 
16-17  
18-19 
20-24 
16-24 
25-34 
35-44 
45-54 
55-64 
65-74 
 
17 [16-18]  
17 [15-18]  
16 [15-18]  
16 [15-18]  
nr  
17 [16-18] 
 17 [16-19]   
nr  
nr  
nr  
 
17 [15-22] 
nr 
nr 
nr 
16 [15-18] 
17 [15-18] 
17 [16-19] 
17 [16-19] 
18 [17-20]  
19 [17-21] 
 
19 [17-21] 
14.79[14-16.36] 
16[15-17] 
18[16-19] 
17 [16-18] 
18 [17-20] 
19 [17-21] 
19 [18-22] 
20 [18-24] 
na 
Age difference of the new partner, years, 
mean [95%CI]3 
All ages 
16-24 
25-34 
35-44 
45-54 
55-64 
Age difference with partner, % [95%CI] of 
new partnerships: 2 
Male 5+ years older than female 
Male within 5 years of female’s age 
Male 5+ years younger than female 
 
 
2.0 [1.8;2.1]  
nr 
nr 
nr 
nr 
nr 
 
 
24.9 [21.6 – 28.6]  
62.8 [59.2 – 66.2]  
12.3 [10.3 – 14.6]  
 
 
nr 
nr 
nr 
nr 
nr 
nr 
 
 
nr 
nr 
nr 
 
 
0.9 [-9.7;10.0] 
1.9 [-2.4;11.3] 
1.3 [-5.0; 10.6] 
0.6 [-8.7;9.9] 
-0.5 [-23.1;17.2] 
-0.0 [-7.9;10] 
 
 
15.4 [12.4-18.3] 
76.4 [73.0-79.9] 
9.3 [6.9-11.7] 
Number of lifetime partners, % [95%CI] 1,2,4 
0 
1 
2 
3-4 
5-9 
>=10 
Mean [SD], Median [IQR]2, 4 
All ages 
16-17  
18-19 
20-24 
16-24 
25-34 
35-44 
45-54 
55-64 
65-74 
 
5.3 [nr]  
18.3 [nr]  
10.9 [nr]  
19.6 [nr]  
26.5 [nr]  
19.4 [nr]  
 
6.5 [9.7], 4 [39]ϯ    
1.8 [11.6], 1 [16]ϯ  
4.9 [41.1], 3 [30]ϯ  
6.4 [78.5], 4 [33]ϯ  
nr  
7.3 [94.4], 5 [42] ϯ  
6.8 [115.8], 4 [41] ϯ  
nr 
nr 
nr 
 
4.2 [3.8-4.6] 
22.4 [21.3-23.5] 
11.1 [10·3–11·9] 
19.2 [18·2–20·2] 
23.2 [22·2–24·3] 
19.9 [19·0–20·9] 
 
7.1 [32.1], 4 [1-8] 
nr 
nr 
nr 
 5.2 [8.1], 3 [1-7] 
 8.9 [17.2], 5 [2-10] 
 8.5 [19.7], 5 [3-10] 
 6.8 [11.8], 4 [2-7] 
 6.1 [38.3], 3 [1-5] 
 6.3 [73.9], 2 [1-4] 
 
2.2 [1.5-3.1] 
53.9 [51.3-56.5] 
15.8 [13.9-17.8] 
16.0 [14.1-18.0] 
8.7 [7.3-10.3] 
3.4 [2.5-4.5] 
 
2.6 [4.6], 1 [1-3] 
1.8[1.6],2[1.7-
2.2] 
2.3[2.4],2[1-3] 
3.1[5.7],2[1-3] 
2.9 [5.1], 2 [1-3] 
3.0 [4.7], 2 [1-4] 
2.6 [4.1], 1 [1-3] 
2.3 [4.1], 1 [1-3] 
2.2 [5.4], 1 [1-1] 
na 
Number of partners in past year,       
%[95%CI]1,2 
0 
All ages 
16-17  
18-19 
20-24 
16-24 
25-34 
35-44 
45-54 
55-64 
65-74 
 
1 
All ages 
16-17  
18-19 
20-24 
 
 
 
10.7 [nr] 
50.0 [nr] 
17.4 [nr] 
10.1 [nr] 
nr 
5.3 [nr] 
8.4 [nr] 
nr 
nr 
nr 
 
 
76.0 [nr] 
33.7 [nr] 
50.8 [nr] 
65.9 [nr] 
 
 
 
22.3 [21·3–23·3] 
nr 
nr 
nr 
23.0 [21.0-25.1] 
8.2 [7.0-9.5] 
9.2 [7.5-11.2] 
15.0 [13.1-17.2] 
36.3 [33.0-39.6] 
57.9 [54.0-61.7] 
 
 
68.4 [67·2–69·5] 
nr 
nr 
nr 
 
 
 
18.2 [16.2-20.3] 
20.7[18.6-22.9] 
8.3[6.9-9.9] 
8.1[6.8-9.7] 
8.4 [7.0 – 10.0] 
8.0 [6.7-9.6] 
10.3 [8.8-12.0] 
22.1 [20.0-24.4] 
42.0 [39.4-44.6] 
na 
 
 
75.8 [73.5-78.0] 
50.0[47.3-52.6] 
67.5[65.0-69.9] 
70.3[67.8-72.7] 
 58 
16-24 
25-34 
35-44 
45-54 
55-64 
65-74 
 
≥2 
All ages 
16-17  
18-19 
20-24 
16-24 
25-34 
35-44 
45-54 
55-64 
65-74 
 
At least 1 new partner last year, % [95%CI]1 
All ages 
16-24 
25-34 
35-44 
45-54 
55-64 
65-74 
nr  
83.0 [nr] 
84.3 [nr] 
nr 
nr 
nr 
 
 
13.3 [nr] 
16.3 [nr] 
31.8 [nr] 
24 [nr] 
nr 
11.6 [nr] 
7.2 [nr] 
nr 
nr 
nr 
 
 
nr 
nr 
nr 
nr 
nr 
nr 
nr 
50.3 [47.8 – 52.7] 
79.1 [77.1-80.9] 
82.9 [80.5-85.1] 
80.5 [78.1-82.6] 
62.3 [58.9-65.5] 
41.4 [37.7-45.3] 
 
 
9.3 [8·7–10·0] 
nr 
nr 
nr 
26.7 [24.5-29.0] 
12.8 [11.3-14.3] 
7.9 [6.5-9.6] 
4.5 [3.5-5.8] 
1.5 [0.9-2.3] 
0.7 [0.3-1.7] 
 
 
14.5 [13·8–15·4] 
38.3 [35.9-40.7] 
19.6 [17.9-21.5] 
11.2 [9.5-13.2] 
8.9 [7.4-10.8] 
4.4 [3.3-5.9] 
2.1 [1.2-3.6] 
69.2 [66.7-71.6] 
85.2 [83.2-86.9] 
85.7 [83.8-87.5] 
74.8 [72.5-77.1] 
58.0 [55.4-60.6] 
na 
 
 
6.0 [4.9-7.4] 
29.3[27.0-31.8] 
24.4[22.0-26.6] 
21.6[19.5-23.8] 
22.3 [20.2-24.6] 
6.9 [5.7-8.4] 
4.0 [3.0-5.1] 
3.0 [2.2-4.1] 
0 [0-0.3] 
na 
 
 
10.4 [8.8-12.1] 
39.4 [36.9-42.1] 
14.3 [12.5-16.3] 
7.3 [6.0-8.8] 
2.8 [2.0-3.9] 
0 [0-0.3] 
na 
Number of occasions of sexual intercourse 
in past 4 weeks,  
Mean [SD], Median [IQR] 1,2,4 
All ages 
16-17  
18-19 
20-24 
16-24 
25-34 
35-44 
45-54 
55-64 
65-74 
 
 
6.5 [6.6], 4 [28]ϯ  
nr [nr],  0 [0-3] 
nr [nr],  4 [0-10] 
nr [nr],  4 [1-10] 
nr 
nr [nr],  4 [2-8] 
nr [nr],  4 [1-8] 
nr 
nr 
nr 
 
 
4.0 [4.9], 3 [1–6] 
nr 
nr 
nr 
5.8 [6.6], 4 [1-8] 
4.9 [5.1], 4 [1-7] 
4.0 [4.6], 3 [1-5] 
3.5 [4.2], 2 [1-5] 
2.5 [3.4], 2 [0-4] 
1.4 [2.3], 1 [0-2] 
 
 
8.4 [12.2], 5 [3-
10] 
na  
na  
na 
10.5 [22.5], 5 [2-
12] 
9.5 [8.2], 8 [4-12] 
9.5 [13.1], 6 [4-
12] 
6.6 [5.6], 5[3-9.2] 
3.8 [3.1], 3 [1.5-5]   
na 
Proportion of relationships lasting < 1 
month, %[95%CI]5  
50.5 [nr]  nr 7.5 [5.0-10.2] 
Proportion overlap between last two 
relationships, %[95%CI]6 
35 [nr]  nr 31.1 [25.8-36.8] 
na, not applicable; nr, not reported; ϯ 99th percentile; Sources: 1 Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg 
P, Clifton S, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings 
from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet [Internet]. Mercer et al. Open Access 
article distributed under the terms of CC BY; 2013 Nov 30 [cited 2014 Dec 12];382(9907):1781–94. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3899021&tool=pmcentrez&rendertype=abstract 
2 Erens B, McManus S, Prescott P, Field J, Johnson A, Wellings K, et al. Natsal - The National Survey of Sexual 
Attitudes and Lifestyles [Internet]. 2003 [cited 2016 Apr 12]. Available from: http://natsal.ac.uk/natsals-12/results-
archived-data.aspx; 3 Mercer CH, Copas AJ, Sonnenberg P, Johnson AM, McManus S, Erens B, et al. Who has sex 
with whom? Characteristics of heterosexual partnerships reported in a national probability survey and implications 
for STI risk. Int J Epidemiol [Internet]. 2009 Feb [cited 2014 Dec 12];38(1):206–14. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19001667; 4 Johnson A, Mercer C, Erens B, Copas A, McManus S, Wellings K, 
et al. Sexual behavior in Britain: Partnerships, practices, and HIV risk behaviours. Lancet. 2001;358:1835–42.  
5 Althaus C. Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three 
individual-based models and empirical data. J … [Internet]. 2011 [cited 2014 Dec 12];(June 2011):136–46. Available 
from: http://rsif.royalsocietypublishing.org/content/early/2011/06/03/rsif.2011.0131.short; 6 Schmid B V, 
Kretzschmar M. Determinants of sexual network structure and their impact on cumulative network measures. PLoS 
Comput Biol [Internet]. 2012 Jan [cited 2014 Dec 12];8(4):e1002470. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3343090&tool=pmcentrez&rendertype=abstract 
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Supplementary Table 2-4. Risk factors for HPV infection and cervical cancer progression 
Risk Factor Portugal United Kingdom* 
Age-standardised smoking prevalence among women 
aged ≥15 years, %[95%CI][21]                      
2000 
2005 
2010 
 
 
15.7 [10.8-20.9] 
14.9 [10.6-19.4] 
14.2 [9.4-18.5] 
 
 
28.9 [22.7-35.1] 
24.7 [20.5-29.8] 
21.4 [17.1-26.5] 
Percentage of women using contraception among those 
aged 15 to 49 who are married or in union [22] 
i. Oral contraceptive 
ii. Male Condom 
2005/06 
 
58.9 
11.2 
2008/09 
 
28 
27 
Total fertility rate, births per woman[23]     
1990 
2000 
2007 
2008 
2009 
2010 
2011 
2012 
2013 
 
1.6 
1.6 
1.4 
1.4 
1.3 
1.4 
1.4 
1.3 
1.2 
 
1.8 
1.6 
1.9  
1.9 
1.9 
1.9 
1.9 
1.9 
1.8 
Proportion of circumcised men aged 15–64 years 
(2015),%[24] 
0.61 20.1 
Number of HIV cases per 100,000 population[25] 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
2013 
2014 
 
21.2 
21.6 
20.6 
21.2 
19.3 
18.3 
15.9 
15.2 
14.0 
8.8 
 
13.1 
12.3 
12.0 
11.7 
10.7 
10.2 
9.8 
9.8 
9.4 
9.5 
Number of Gonorrhoea cases per 100,000 population[26]  
2004 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
2013 
 
0.3 
0.5 
0.5 
0.7 
0.6 
1.1 
0.8 
1.1 
1.1 
1.1 
 
37.2 
31.9 
31 
30.5 
26.7 
28.5 
29.9 
37 
45.3 
50.7 
Number of Syphilis cases per 100,000 population[26]  
2004 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
2013 
 
1 
1 
1.2 
1.1 
0.9 
1.4 
1.7 
1.5 
2.5 
1.8 
 
4.9 
5.8 
5.8 
5.8 
5.4 
5.1 
4.7 
5.2 
5.2 
5.6 
*data not reported exclusively for England; Sources: [21] United Nations, Department of Economic and Social Affairs 
PD. World contraceptive use 2011 [Internet]. 2011. Available from: 
http://www.un.org/esa/population/publications/contraceptive2011/wallchart_front.pdf ; [22] The World Bank. 
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World Bank Data [Internet]. [cited 2016 Apr 11]. Available from: 
http://data.worldbank.org/indicator/SP.DYN.TFRT.IN; [23]  Morris BJ, Wamai RG, Henebeng EB, Tobian AAR, 
Klausner JD, Banerjee J, et al. Estimation of country-specific and global prevalence of male circumcision. Popul 
Health Metr [Internet]. Population Health Metrics; 2016;14(1):1–4. Available from: 
http://dx.doi.org/10.1186/s12963-016-0080-6; [24]Amato-Gauci AJ, Donoghoe M, Emiroglu N, Rodier G, Lazdina V, 
Catchpole M, et al. HIV/AIDS surveillance in Europe  2013 [Internet]. 2014. Available from: 
http://ecdc.europa.eu/en/publications/publications/hiv-aids-surveillance-report-europe-2013.pdf; [25]European 
Centre for Disease Prevention and Control. Sexually transmitted infections in Europe 2013. 2015.[26]World Health 
Organization. World Health Survey - Portugal [Internet]. 2003. Available from: 
http://www.who.int/healthinfo/survey/en/ 
61 
 
Supplementary Table 2-5. Opportunistic and organised cervical screening in mainland Portugal, 2010-2014 
 Region Screening 2010-2012 2011-2013 2012-2014 
Proportion of women registered 
with the NHS aged 25-64 who 
were screened, % 
Alentejo Opportunistic 3.6 1.8 0.9 
Organised  44.6 46.5 41.0 
Algarve a Opportunistic  36.5 31.6 25.4 
Organised  11.7 16.7 16.5 
Centre Opportunistic 12.1 10.1 8.6 
Partly-
organised 
41.3 47.7 46.8 
Lisbon & Tagus Valley b Opportunistic  33.9  33.9 33.9 
Organised  0 0 0 
North Opportunistic 67.2 62.7 64.3 
Organised  5.5 5.5 4.7 
Portugal (mainland) Opportunistic 42.9 40.5 40.7 
Organised  13.3 14.5 13.7 
Proportion of eligiblec women 
invited by letter within 
programme,% 
Alentejo Organised 60.5 63.5 60.0 
Algarve 17.4 27.5 25.4 
Centre 0 0 0 
Lisbon & Tagus Valley 0 0 0 
North 6.9 7.1 6.4 
Opportunistic cervical screening in Portugal consists of eligible women being invited by their general practitioner (GP) when they visit their practice for any reason. Women who accept 
the invite undergo a conventional Pap smear cytology and are asked to take the smear to a contracted laboratory in their residential area and to bring back the result once available.   
Partly-organised cervical screening in the Centre means that eligible women are invited for screening opportunistically by their GP who performs the smear and sends it for analysis to 
a regional reference laboratory that informs the GP back when results become available. Based on the cytological result, women are notified by phone or letter of their following 
screening appointment.  
Organised or fully-organised cervical screening means that all eligible women are invited under a call/recall system by their GP who performs the smear and sends it for analysis to a 
regional reference laboratory that informs the GP back when results become available. 
a Algarve did not report on the proportion opportunistically screened; this was estimated assuming same overall coverage as Alentejo (RHA with lowest coverage among regions with 
organised screening); likely to be an underestimate as in 2005/6 5-year coverage was 30% and 70% in Alentejo and Algarve, respectively. [28] 
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b Lisbon and Tagus Valley RHA reported 33.93% of women aged 25-64 who had cytology within last 3 years (opportunistic screening, 2013); source: Administração Regional de Saúde 
de Lisboa e Vale do Tejo [Regional Health Administration Lisbon and Tagus Valley]. Relatório anual de atividades 2013 [Annual Activity Report].2014. 1-130 p. Available from: 
http://www.arslvt.min-saude.pt/uploads/document/file/1478/Relat_rio_de_Atividades_2013__07_07_2014_.pdf 
c assuming 10% of resident women would be excluded (non-eligible) for clinical reasons[4] 
Sources: Regional health administrations with fully-organised (Alentejo, Algarve, and North) or partly-organised (Centre) screening programmes provided the number of women aged 
25-64 years registered with the NHS, invited for screening by letter (except Centre), and who attended screening within the implemented programmes. Opportunistic screening data 
provided by Alentejo, Centre, and North. 
 
 
 
Supplementary Figure 2-6. Age-specific 3-year screening coverage (%) of women aged 25-64 in Portugal and 20-69 in England, 2002/3 and 2005/6 
Sources:  
World Health Organization. World Health Survey - Portugal [Internet]. 2003. Available from: http://www.who.int/healthinfo/survey/en/ 
Couceiro L, Alves I, Almendra R. Plano Nacional de Saúde em Foco - Doenças Oncológicas em Portugal - Boletim Informativo no. 4 [National Health Plan under focus - Cancer Diseases in 
Portugal - Informative Bulletin nr.4]. Alto Comissariado da Saúde [High Commissariat for Health Portugal]. 2009. 
Health and Social Care Information Centre. Cervical Screening Programme, England 2004-2005 [Internet]. 2005. [cited 2016 Apr 15]. Available from: 
http://content.digital.nhs.uk/article/2021/Website-Search?productid=1481&infotype=13367&sort=Title&size=10&page=7 
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Supplementary Table 2-6. Type-specific high-risk HPV prevalence among invasive cervical 
cancer cases in Portugal and the UK 
 HPV Prevalence, % (95%CI) 
High-risk HPV types Portugal  UK  
16 71.4 (64.2-77.7) 61.4 (59.7-63.1) 
18 10.1 (6.4-15.6) 17.6 (16.3-19.0) 
31 0.9 (0.2-5.1)  3.6 (3.0-4.3) 
33 9.3 (5.1-16.2) 3.9 (3.3-4.7) 
35 1.9 (0.5-6.5) 1.0 (0.7-1.4) 
39 0.0 (0.0-3.4) 1.2 (0.9-1.7) 
45 3.7 (1.4-9.1) 4.4 (3.7-5.2) 
51 1.6 (0.3-8.3) 0.8 (0.5-1.2) 
52 0.9 (0.2-5.1) 2.1 (1.6-2.7) 
56 1.9 (0.5-6.5) 0.5 (0.3-0.8) 
58 2.8 (0.9-7.9)  1.1 (0.7-1.5)  
59 0.9 (0.2-5.1) 1.0 (0.7-1.5) 
Sources: Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information 
Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Portugal. 
Summary Report 10 December 2018. [Accessed 05/02/2019] Available from 
http://www.hpvcentre.net/statistics/reports/PRT.pdf; Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, 
Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human 
Papillomavirus and Related Diseases in the United Kingdom. Summary Report 10 December 2018. [Accessed 
05/02/2019] Available from http://www.hpvcentre.net/statistics/reports/GBR.pdf 
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3. Chapter	3.	Systematic	review	of	model-based	cervical	
screening	evaluations	
 Preamble	to	research	paper	2		
Chapter 1 introduced the key role that mathematical and economic models play in 
synthesising evidence from epidemiological studies to project long-term outcomes of a range 
of potential choices about cervical screening.  
Previous model-based studies on cervical screening provided useful insights towards the main 
aim of this thesis, i.e. the evaluation of the effectiveness and cost-effectiveness of alternative 
cervical screening strategies in Portugal.  
The literature on cervical screening models has grown rapidly and several reviews have been 
conducted in this field. Since 2005, two systematic reviews were conducted and both focused 
on model-based economic studies of primary HPV screening[1,2]. Other (non-systematic) 
reviews also concentrated on a particular technology[3,4] or on particular settings[5]. 
However, the full range of epidemiological and economic studies using mathematical models 
to quantify the impact and cost-effectiveness of cervical screening (with any technology) had 
never been systematically reviewed.  
Research paper 2 is the first systematic review of the literature to provide an overview of (i) 
how model-based studies (both epidemiological and economic) have informed cervical 
screening policy in distinct settings, (ii) what methods have been applied and how they have 
evolved alongside the development of cervical screening technologies, and (iii) what the 
current trends and gaps are to address present and emergent challenges in this field. 
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3.1.1. Abstract	
Background: Optimising population-based cervical screening policies is becoming more 
complex due to the expanding range of screening technologies available and the interplay with 
vaccine-induced changes in epidemiology. Mathematical models are increasingly being applied 
to assess the impact of cervical cancer screening strategies.  
Methods: We systematically reviewed MEDLINE®, Embase, Web of Science®, EconLit, Health 
Economic Evaluation Database, and The Cochrane Library databases in order to identify the 
mathematical models of human papillomavirus (HPV) infection and cervical cancer progression 
used to assess the effectiveness and/or cost-effectiveness of cervical cancer screening 
strategies. Key model features and conclusions relevant to decision-making were extracted.  
Results: We found 153 articles meeting our eligibility criteria published up to May 2013. Most 
studies (72/153) evaluated the introduction of a new screening technology, with particular 
focus on the comparison of HPV DNA testing and cytology (n = 58). Twenty-eight in forty of 
these analyses supported HPV DNA primary screening implementation. A few studies analysed 
more recent technologies - rapid HPV DNA testing (n=3), HPV DNA self-sampling (n=4), and 
genotyping (n=1) - and were also supportive of their introduction. However, no study was 
found on emerging molecular markers and their potential utility in future screening 
programmes. Most evaluations (113/153) were based on models simulating aggregate groups 
of women at risk of cervical cancer over time without accounting for HPV infection 
transmission. Calibration to country-specific outcome data is becoming more common, but has 
not yet become standard practice. 
Conclusions: Models of cervical screening are increasingly used, and allow extrapolation of 
trial data to project the population-level health and economic impact of different screening 
policy. However, post-vaccination analyses have rarely incorporated transmission dynamics. 
Model calibration to country-specific data is increasingly common in recent studies.  
Keywords: systematic review; human papillomavirus; cervical cancer; screening; mathematical 
models; economic evaluations 
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3.1.2. Background	
Cytological screening for cervical cancer is recognized as having substantially reduced cervical 
cancer incidence and mortality in many high-income countries (HIC). However, recent 
technological developments are prompting a paradigm shift in cervical cancer prevention.[1] 
Human papillomavirus (HPV) DNA testing has greater sensitivity for high-grade lesions than 
cytology when used as a primary screening method,[2] while a panoply of other biomarkers, 
such as p16, Ki-67, mRNA, and methylation markers, have been investigated for their potential 
role in primary screening, triage of borderline cytological outcomes, and triage of HPV-positive 
results that could enable a fully molecular-based approach to screening.[3] Moreover, where 
introduced, HPV vaccination is expected to eventually reduce the incidence of cervical cancer 
and therefore reduce the absolute impact of existing screening programmes, necessitating 
their reassessment for future unvaccinated and vaccinated cohorts.[4] 
Hence the choice of optimum cervical screening strategies in future will be highly complex due 
to the number of technological choices available, combined with epidemiological changes in 
the target population. Mathematical models offer a way to combine different types of 
evidence about the choices available (together with their associated uncertainty) to predict 
the impact of alternative prevention strategies unlikely to be tested in clinical trials due to the 
enormous time and resource requirements.[5] However, the type of analysis used, the health 
technologies assessed, and the modelling methods applied may have an important impact on 
decision-making.  
This is the first systematic review encompassing all model-based effectiveness and/or cost-
effectiveness analyses of cervical cancer screening strategies.  Initial reviews in this area [6, 7] 
only examined cervical cancer models analysing exclusively cytology-based  strategies, while 
those published after 2005[5, 8–10] focused only on economic (and not epidemiological) 
models. There have been three reviews of HPV DNA testing and cytology for primary 
screening,[8–10] but only two[9, 10] were systematic. Other reviews have also examined HPV 
DNA testing as triage for equivocal cytological outcomes in high-income settings and visual 
inspection in low-resource countries,[5] as well as a range of technologies in the USA and in 
low-resource settings.[11] The limited geographical scope of these reviews and the recent 
technological development justify a systematic review of the literature, including 
epidemiological evaluations, over the full range of technologies available in any kind of setting. 
The aims of this review are to (i) provide an overview of results from all model-based 
evaluations of cervical screening, in order to inform comprehensive policy making on 
secondary prevention of cervical cancer, and (ii) identify trends and gaps in these models in 
order to inform future work.  
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3.1.3. Methods	
Search	strategy	
This review was conducted following guidance of the Centre for Reviews and Dissemination  
for systematic reviews[12] and Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA).[13]  We searched the following electronic databases for studies published 
up to May 2013: MEDLINE®; Embase; Web of Science®; EconLit; the Health Economic 
Evaluations Database; and The Cochrane Library including the NHS Economic Evaluation 
Database  and the Health Technology Assessment database using the searches strategies in 
Additional material 1.  
Selection	criteria	
We included original research articles that met the following criteria: 
1. Based on mathematical modelling of HPV infection and/or cervical disease progression 
2. Estimated the impact of at least one cervical screening technology/strategy 
3. Estimated either clinical outcomes alone (epidemiological models) or both clinical and 
economic outcomes (economic models) 
Studies modelling women of any age at risk of infection, infected, or who had been previously 
infected with HPV were included, as well as studies on women with concomitant infections 
(e.g. human immunodeficiency virus (HIV)) or who had been treated for cervical lesions. We 
included models of HPV vaccination where different cervical screening strategies are 
compared to each other. Economic evaluations (specifically cost-effectiveness analyses, cost-
utility analysis, and cost-benefit analyses) were included if they reported both costs and 
benefits expected for each strategy of the analysis. Full texts for abstracts and conference 
presentations identified as potentially relevant in searches were sought, including initiating 
contact with the corresponding authors when details were otherwise unobtainable. Research 
articles published in any language in peer-reviewed journals; and abstracts or conference 
presentations from 2012 onwards published with sufficient details to allow full completion of 
the pre-established data extraction form were included.  
Studies only comparing the costs of different strategies were excluded, as well as publications 
that were neither (i) archived by the British Library[14] nor (ii) published in a journal included 
in the Thompson Reuters Impact Factor list.[15] 
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Study	selection	
Study selection was performed independently by two reviewers (DM and IB). Initially, the titles 
and abstracts of the references retrieved in the searches were screened according to the 
inclusion criteria defined above to identify potentially relevant studies. All titles and abstracts 
were screened by at least one reviewer; 20% were independently screened by both reviewers. 
Where initial assessments differed, reviewers’ decisions and disagreements were compared 
and discussed. Full papers of references identified as potentially relevant in the initial 
screening were then assessed for eligibility (ten per cent independently assessed by both 
reviewers). The reviewers again compared results and discussed any differences. A third 
reviewer (MJ) was consulted where consensus was not reached in any of the screening stages. 
Data	Extraction	
Data extracted included name of first author, year of publication, country of study, type of 
analysis, type of model, calibration method, strategies/technologies assessed, and main 
findings. Additional material 2 provides a list of the data extracted. The included studies were 
grouped by World Health Organization (WHO) region [16] and level of income of the analysed 
countries, as per the World Bank 2014 income levels.[17] Studies referring to their region of 
interest as ‘developing countries’ were assumed to relate to all WHO regions. 
3.1.4. Results		
The searches conducted identified 2,644 studies that potentially met the inclusion criteria set 
out above. A PRISMA[13] flow diagram of the selection of the included studies is given below 
(Figure 3-1) and a completed PRISMA checklist is provided as Additional material 3 . From 
screening titles and abstracts, 392 records were retrieved for full screening, and 153 articles 
met the inclusion criteria.  
Seventy-eight of the 153 publications included in this review explicitly acknowledged that they 
were adaptations or alternative applications (i.e. without changes to the model assumptions) 
of previously published models. 
The main characteristics of the studies included are summarised in Figure 3-2 and are 
discussed further below. Greater detail is provided in Additional materials 4 and 5 that present 
the characteristics of studies that focused on screening alone and on combined screening and 
vaccination interventions, respectively, by year of publication. 
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Countries	
Most included studies (n=135) were based on a single country. Additional material 6 shows the 
number of single- and multiple-country studies by country. Forty-five countries were 
addressed individually (either in single- or multiple-country publications), ten of which – 
Argentina, Barbados, Belgium, Chile, France, Finland, France, Iceland, Ireland, Kenya, 
Mozambique, Tanzania, Uganda, and Zimbabwe - were only analysed as part of multiple-
country studies. Figure 3-3 shows the distribution of the included single-country studies on the 
world map. Over half (80/153) of the studies focused on either the USA (n=44), the UK (n=14), 
the Netherlands (n=13), or Canada (n=9). The Americas, Europe, and/or Western Pacific 
regions accounted for 86% of the studies. 
Most studies focused exclusively on HIC (n=117), whereas 35 studies analysed low- and/or 
middle-income countries, with 28 analysing only middle-income settings and only 2 studies 
focusing entirely on low-income ones.[18, 19] One study analysed 6 regions of different 
income-level.[20]		
Type	of	Analysis	
Most studies (n=129) included a cost-effectiveness analysis. Of these, 10 presented health 
outcomes in terms of disease-specific measures only, 79 in terms of lives saved or life years 
gained, and 40 in terms of the generic health utility measure quality-adjusted life years 
(QALYs). Quality-adjusted life years were particularly common among studies assessing 
vaccination alongside screening compared to those which assessed screening alone (42% 
compared to 21%). There were no cost-benefit analyses (i.e. studies in which both costs and 
outcomes were expressed in monetary terms). 
Figure 3-4 shows the distribution of studies by year according to the type of analysis outcome 
(epidemiological or economic) and the type of prevention strategies assessed (screening alone 
or screening combined with vaccination). Post-vaccination economic analyses have become 
more common in the last decade and economic analyses in general have become dominant 
compared with studies analysing health outcomes only.   
Type	of	intervention		
The included studies estimated the incremental effectiveness or cost-effectiveness of three 
types of interventions: (a) introduction of a new screening programme where none existed 
before (n=34), (b) changes to existing screening algorithms without the introduction of a new 
technology (n=47), and (c) introduction of a new screening technology (n=72).  
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a) Studies on the impact of introducing a new screening programme (n=34) were mostly 
economic evaluations (n=30). Most were set in middle-income (n=14) or high-income 
(n=13) countries. Several (n=12) investigated screening strategies post-HPV vaccine 
introduction. All 34 studies recommended introducing screening.  
b) Studies exclusively analysing changes to existing screening programmes examined 
alternative cytology-based strategies (n=47, 42 in HIC). Most (18/23) studies making 
recommendations on screening intervals or frequency endorsed an interval of 3 years 
or more. Recommended starting ages ranged between 20-35 years old, while 
recommended stopping ages ranged between 60-73 years old. Three studies looked at 
rescreening cytology negative outcomes, and had mixed results. One study examined 
follow-up of women post-hysterectomy and recommended against screening women 
over 40 years.[21]  
c) Seventy-two studies analysed the introduction of a new screening technology to an 
existing programme. All compared the new technology to cytology apart from one 
study that compared visual inspection with acetic acid (VIA) to HPV DNA testing. The 
findings of these comparisons are detailed in the following subsections.  
Technologies	assessed 
Publications focused on cytology (n=150), HPV DNA (n=77), and VIA (n=12). Overall, the studies 
analysed 8 screening techniques: cytology (n=150, of which 34 referred to liquid-based 
cytology (LBC)), cytology automated reading (e.g. Papnet© and AutoPap©, n=7), speculoscopy 
as adjunct to cytology (n=1), HPV DNA (n=76), self-sampled HPV DNA testing (n=4), HPV 16/18 
genotyping (n=1), and VIA (n=12).  
The main technological comparisons made were between (a) alternative cytology-based 
strategies (n=77), (b) HPV DNA versus cytology (n=69), (c) VIA versus cytology and/or HPV DNA 
(n=11). Additional material 7 summarises the findings on comparisons of technologies.  
Alternative	cytology-based	strategies	
Liquid-based cytology was recommended in 18/26 economic analyses and in one 
epidemiological analysis comparing it with conventional cytology. The remaining studies 
recommended conventional cytology (8/27) or were equivocal (1/27).  
Automated reading of cytological results was found to be cost-effective when compared to 
manual reading in all (n=6) economic studies. One epidemiological study on adding automated 
reading to LBC concluded that evidence was still insufficient to recommend it relative to 
manual reading.[22] One economic analysis found  the addition of speculoscopy to biennial 
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conventional cytology cost saving and health improving compared with annual conventional 
cytology alone.[23] 
HPV	DNA	testing	versus	cytology	alone	
Several studies examined replacing cytology with HPV DNA testing as the primary screening 
technique (n=17) and 15/17 studies found HPV DNA more cost-effective. Twenty-four studies 
compared co-testing with cytology and HPV DNA (n=17), or with cytology primary screening 
only (n=7). Co-testing was supported in 6/7 studies comparing it with cytology; however, HPV 
DNA testing was the most supported technology among studies comparing it with co-testing 
and cytology (10/17), whilst 8/17 were favourable to co-testing, and 6/17 to cytology alone for 
primary screening (some studies supported more than one technology). Overall, HPV DNA 
primary screening was supported in 26/34 studies comparing it to cytology alone and/or co-
testing. 
The introduction of HPV DNA testing to triage minor cytological abnormalities was supported 
in 9/10 studies comparing it with repeat cytology and immediate referral to colposcopy (7/8), 
immediate treatment (1/1), or co-testing (1/1) in high- and middle-income countries.   
Rapid and relatively-inexpensive HPV DNA testing (careHPV™, n=3) was found cost-effective in 
China compared with VIA[24] or cytology,[25] as well as when performed twice a lifetime 
alongside vaccination compared with once a lifetime, provided affordable vaccination cost.[26] 
Most (3/4) economic analyses of post-treatment screening[21, 27–29] investigated the 
introduction of HPV DNA testing. Two of these recommended its introduction,[27, 28] whereas 
one study found conventional cytology the most cost-effective approach compared to HPV 
DNA testing or LBC.[29] 
 The introduction of self-sampled HPV DNA primary screening  instead of clinic-based HPV DNA 
testing or conventional cytology was found cost-effective in 2/4 studies that looked at it.  
One study on HPV 16/18 genotyping found it cost-effective in the USA for triage of equivocal 
results of co-testing (HPV DNA and LBC) compared with co-testing alone, HPV DNA with LBC 
triage, LBC with HPV DNA triage, or LBC alone.[30] 
VIA	versus	HPV	DNA	and/or	cytology	
All studies comparing VIA with HPV DNA and/or cytology for primary screening (n=11) were 
economic analyses and most comparing HPV DNA testing and VIA(6/9)recommended HPV DNA 
testing (n=2)[19, 31] or either (n=4)[18, 20, 32, 33]. 
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One study compared VIA with HPV DNA, cytology, and self-sampling in South Africa and 
concluded that 1-visit HPV DNA  testing was the most effective strategy, slightly more costly 
than 1-visit VIA.[32] 
One study only comparing VIA and HPV DNA testing found the latter cost-effective in low 
resource settings,[19] and all studies comparing VIA with cytology only (n=2) supported VIA in 
MIC,[33, 34] with one finding cytology cost-effective to screen women over 50 years old every 
5 years in Thailand.[35] 
Screening	and	vaccination	
Studies analysing screening strategies in vaccinated populations (n=35) assessed (a) the 
introduction of screening strategies where non-existent (n=12), (b) changes to existing 
cytology-based screening strategies (n=12), and (c) the introduction of new screening 
technologies in existing programmes (n=11). 
a) Introducing screening (using any technology) alongside vaccination was preferred over 
screening alone by 10/12 studies (8 regarding low- and/or middle-resource settings).  
b) Most studies analysing changes to existing cytology-based screening alongside 
vaccination (10/12, 10 in high- and 2 in middle-income countries) recommended 
combined screening and vaccination interventions. Half of these studies highlighted 
the importance of high coverage of screening and immunization programmes. 
Recommendations on cytology screening target age and interval varied among HIC 
studies (n=4).  
c) Studies on the introduction of screening technologies post-vaccination looked largely 
at HPV DNA testing and cytology (9/11, 2 in low and middle income countries (LMIC)). 
HPV DNA testing alone was found more cost-effective than cytology in 5/5 studies 
focused on primary screening with these technologies alone. Studies comparing these 
with co-testing as well (n=3) concluded favourably regarding co-testing.[36–38]  One 
study explored only the introduction of HPV DNA in triage of cytological results, and 
supported it in the Netherlands, Taiwan, and USA, but not in Canada or the UK.[39] 
Table 3-1 summarises the findings and recommendations of the studies included in this review.  
3.1.5. Modelling	methods	
The modelling approaches used in the included studies were classified according to the 
following dimensions:[40]  
(a) Randomness (stochastic versus deterministic): In deterministic models, events such as HPV 
acquisition and clearance occur at a pre-determined rate. Stochastic models incorporate 
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randomness (stochasticity) in the occurrence of these events, so the outcomes of a model are 
not exactly the same each time it is run. 
(b) Level (individual versus aggregate): Individual-based models simulate and record the events 
that occur in each modelled individual’s lifetime, so that each individual has unique 
characteristics. In contrast, aggregate models group individuals with similar characteristics into 
compartments, eliminating their variability within each compartment. Hence individual-based 
models capture population heterogeneity more easily.  
(c)  Interaction (static versus dynamic): If the rate at which people get infected with HPV (i.e. 
the force of infection) is likely to change, such as following population-based vaccination, then 
herd immunity (i.e. indirect protection of susceptible individuals by a significant proportion of 
immune individuals in the population) is likely to affect the model results greatly. Dynamic 
models account for herd immunity as the risk of infection is modelled as dependent on the 
number of infectious individuals rather than assumed to be constant over time (static models). 
The models found were mainly static (149/153), deterministic (113/153) and aggregate 
(113/153); all aggregate models were deterministic. Only 4 studies were dynamic and all of 
these were deterministic and modelled individuals at an aggregate level. Three of the four 
dynamic models found were used to assess screening strategies alongside vaccination. 
Similarly to models of screening interventions alone, the models used for post-vaccination 
analyses were mainly static (32/35), and deterministic aggregate (19/35). Stochastic individual-
based models were more common among post-vaccination analyses (16/35; 46%) than amid 
those analysing screening interventions alone (24/118; 20%).  
Many models require values of parameters that are difficult to measure directly, such as the 
rate of progression from CIN3 to invasive cancer. Such values can be estimated by calibrating 
the model, that is, adjusting its internal parameters until model outputs (such as cancer 
incidence) match observational data. The extent to which the outputs can match data is often 
quantified using a goodness-of-fit measure. Commonly used quantitative goodness-of-fit 
measures and tests include the sum of squared residuals, the chi-squared statistic and the 
likelihood of the model parameters given the data. [41]  
Most studies (n=83) did not report having calibrated their models at all. Of those that reported 
calibration (n=70), 21 did not specify the goodness-of-fit measure used and 30 only assessed 
model fit to data visually without using any quantitative goodness-of-fit measure. The 
remaining studies (n=19) explicitly reported using a formal goodness-of-fit measure. A greater 
proportion of models used for the assessment of screening strategies alongside vaccination 
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were calibrated (23/35; 66%) compared with those of models only assessing screening 
strategies (47/117; 40%).  
3.1.6. Discussion	
Many studies addressing a wide range of questions met our inclusion criteria compared to that 
in other cervical cancer-related reviews.[42, 43] This may reflect the substantial global burden 
of cervical cancer, the recent development of new screening methods and technologies, as 
well as the role mathematical modelling has played regarding context-specific policy questions 
that only very large long term trials would address.[43, 44] 
Results	from	model-based	evaluations	of	cervical	screening	
Most studies included a cost-effectiveness analysis (129/153) and investigated the 
introduction of new screening technologies (72/153), with fewer focusing exclusively in 
alternative strategies using already-adopted technologies (47/153), and even fewer on the 
introduction of screening programmes where non-existent (34/153). Evaluations of the 
introduction of a screening technology were generally favourable to its adoption, with LBC 
recommended over conventional cytology (18/27), HPV DNA recommended over cytology for 
primary screening (15/17), rapid HPV DNA (3/3) or self-sampling (2/4) recommended for 
primary screening, and HPV DNA (9/10) or genotyping (1/1) recommended for triage of 
equivocal results. 
Overall, our findings are in line with those of previous reviews of cost-effectiveness analyses[5, 
8–11] and post-vaccination analyses in the context of developed countries with existing 
screening programs[40], which mostly recommend the introduction of HPV DNA primary 
screening in high-resource settings and the revision of screening policies towards the 
introduction of HPV DNA primary testing.  
As Nahvijou and colleagues also found,[10] there is a discrepancy between guidelines and 
model-based evaluations regarding more recent technologies. Generally, current HIC screening 
guidelines ( Summary of cervical screening guidelines provided in Additional material 8) are 
aligned with the overall findings of evaluations of cytology-based strategies; however, most 
concluded lacking sufficient evidence on the effectiveness of HPV DNA testing for primary 
screening to support its implementation,[45] with only a few countries, such as Australia, the 
Netherlands and the USA, recommending it at the moment.  
Trends	and	gaps	identified	
Most of the global cervical cancer burden lies in low- and middle-income countries without 
organised screening programmes [46] However, as noted in previous reviews, [5, 11] only a 
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small proportion of studies in our review (34/153) addressed these settings, with the vast 
majority (33/34) supporting the existence of a screening programme. Indeed, over half the 
studies (80/153) were set in just 4 HIC – the USA, the UK, the Netherlands, or Canada. More 
evaluations focused on the regions with the greatest cervical cancer burden may have greater 
influence in driving adoption of screening technologies where they are most needed. 
Currently several molecular biomarkers are being investigated for their potential to be 
integrated alongside cytology and HPV DNA testing in screening algorithms. However, no 
model-based study was found in this review on these emerging screening technologies.  Only a 
few studies analysed more recent technologies as rapid HPV DNA testing, self-sampled HPV 
DNA testing, or HPV 16/18 DNA genotyping. No study on rapid HPV DNA testing was found in a 
low-income setting either.  
Some molecular-based tests are thought to have the potential to improve cytology’s accuracy 
and reproducibility (e.g. p16 immunostaining), while other are thought to be promising 
alternatives to cytology (e.g. HPV DNA testing, HPV mRNA testing,  p16/ki-67 dual 
immunostaining, or methylation markers) as they can be subject to automated 
quantification.[47] The clinical utility of HPV DNA testing has been shown,[2] and it has 
recently been introduced in primary screening in a few HIC, e.g. the Netherlands and 
Ontario.[48] These recent developments in screening technologies may suggest a transition to 
a fully molecular-based screening approach. However, the population-level effectiveness and 
cost-effectiveness behind many of the molecular technologies is still unexplored. For most 
biomarkers there is currently only cross-sectional evidence of their potential accuracy.[3] HPV 
mRNA testing for instance was approved by the U.S. Food and Drug Administration for 
screening women over 30 years in combination with cytology, despite there being no evidence 
at that time from longitudinal trials of its improved accuracy compared to primary cytology or 
co-testing for HPV DNA  in the detection of CIN2+ lesions who do not regress.[49] 
Mathematical models are a key tool to allow results from trials and observational studies of 
these technologies to be extrapolated to explore their long-term impact in population-based 
screening programmes. 
Another aspect of research that can be explored via mathematical modelling is the interaction 
between vaccination and screening. Vaccinating adolescent girls has been found likely to be 
cost-effective even in settings with existing screening programmes.[40, 50] However, 
vaccination is expected to decrease the incidence of cervical abnormalities and eventually 
cancer.[51] Hence the positive predictive value of cytology will decrease, as will the 
effectiveness of most screening modalities. [43, 52] In order to assist in population level policy 
making, future analyses in settings with vaccination will need to account for its impact on 
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existing and prospect screening programmes. This is particularly true if a 9-valent HPV vaccine 
is successful in trials, as it is projected to ultimately prevent 90% of invasive cervical 
cancers.[53]  
Also, most models of screening in post-vaccination settings relied on a static infection 
structure. This may be suitable for comparing alternate screening strategies in a setting in 
which disease prevalence is constant, but would not capture the long-term changes in HPV 
prevalence, in settings with successful national HPV vaccination programmes[54] such as the 
UK, Australia and Portugal. Dynamic transmission models are particularly important now that a 
9-valent HPV vaccine has shown high immunogenicity and efficacy in clinical trials.[55] This will 
have further implications on cervical screening since vaccinated girls will have a very low risk of 
infection with an oncogenic HPV type and hence risk of cervical cancer. The few dynamic 
models compared alternative cytology-based strategies[56, 57] or strategies with rapid HPV 
DNA testing versus vaccination only or alongside vaccination.[26] Their overall results were 
consistent with those of static models in that screening strategies alongside vaccination 
maximise health outcomes. However, it can take many years for the direct and indirect impact 
of vaccination to be observed in surveillance data, so dynamic models will be increasingly 
important to explore changes to screening as the first vaccinated cohorts enter the age of 
screening eligibility. 
Model calibration to observed setting-specific data has become more common; however it is 
still not routinely used. As most natural history parameters governing the progress of cervical 
abnormalities are very difficult to measure directly, model calibration enables their estimation 
based on observable outcomes such as abnormal screening results. This is generally a more 
reliable approach than making assumptions on parameters based on limited studies, often in 
unrepresentative populations.[41, 58]  Even the studies reporting having calibrated these 
parameters to outcome data often gave few details about the goodness-of-fit measure used 
and very rarely provided details on other aspects of calibration, such as the selection of 
calibration targets, parameter search strategies, and convergence criteria used. Detailed 
reporting of the calibration process should be common practice for reproducibility 
purposes.[59] Also, there should be an indication of uncertainty in the parameter estimates 
used and how it is incorporated to judge the sensitivity of model predictions to the data 
sources used.  
This review is subjected to limitations. We focused on models used to assess the impact of 
alternative screening strategies, and excluded model-based studies assessing vaccination 
strategies, including those modelling screening strategies alongside vaccination that did not 
compare different screening strategies. Because of the volume and diversity of the relevant 
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modelling literature, we did not critically appraise the quality of individual studies, but instead 
focused on providing an overview of the main approaches and conclusions of the models. 
Further work is needed to critically review modelling literature that addresses specific 
questions (such as the choice between cytological and DNA-based screening methods) in more 
detail. The main strength of our work lies in providing a broad overview of the vast literature 
over a long time period, and in identifying key conclusions that are common across models as 
well as gaps in the methodology and scope of current models. 
3.1.7. Conclusions	
The main questions addressed over time by models used to assess cervical cancer screening 
strategies focused on high-income settings analysing matters relevant to LMIC as well, such as 
the introduction of HPV DNA testing and more recently the most appropriate post-vaccination 
screening strategy. Despite the increasingly large number of publications, few studies 
investigated the utility of HPV DNA self-sampling and genotyping in future screening 
programmes, and none explored the potential role of emergent molecular markers. 
Transmission dynamics have rarely been incorporated and model calibration is not standard 
practice yet. Dynamic models fitted to country-specific data could be helpful tools to 
investigate future post-vaccination screening strategies. 
3.1.8. Abbreviations	
DNA – deoxyribonucleic acid, HIC - high-income countries, HIV - human immunodeficiency 
virus, HPV - human papillomavirus, LBC - liquid-based cytology, LMIC – low- and middle-
income countries, mRNA – messenger ribonucleic acid, PRISMA - Preferred Reporting Items for 
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3.1.13. Figures	
 
Figure 3-1. PRISMA Flow diagram of study selection process 
*Articles published in journals not included in the British Library catalogue or Thompson 
Reuters Impact Factor (IF) list 
 
 
Figure 3-2. Characteristics of included studies 
*exclusively these technologies; AFR, African Region; Auto; automated cytology; HPV, HPV 
DNA testing; LMIC, low and middle income countries; VIA, VIA vs HPV DNA testing and cytology 
; WPR, Western Pacific Region 
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Figure 3-3. Number of single-country studies per country 
 
 
Figure 3-4. Number of studies by analysis and prevention type over time 
Dark blue, Economic Screening; Light blue, Economic Screening & Vaccination; Orange, 
Epidemiological Screening; Yellow, Epidemiological Screening &Vaccination    
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Table 3-1. Summary of findings and recommendations 
Type of intervention 
- Screening should be introduced (34/34, 100%) 
- Cytology-based screening should have screening intervals ≥3 years (18/23, 78%), 
starting age ≥25 years old (9/10, 90%), and stopping age ≥60 years old (5/5, 100%) 
- No post-hysterectomy screening follow-up should be given to women >40 years old 
(1/1, 100%) 
Technologies assessed 
- Liquid-based cytology is recommended over conventional cytology (18/27, 67%) 
-  Automated reading should be introduced (6/7, 86%)  
- HPV DNA testing for primary screening is more cost-effective than cytology (15/17, 
88%) 
- Co-testing is more cost-effective than cytology in HIC (6/7, 86%) 
- HPV DNA testing is supported over co-testing and cytology alone (10/17, 59%) 
- HPV DNA to triage minor cytological abnormalities is endorsed over (i)repeat 
cytology and immediate colposcopy (7/8), (ii)immediate treatment (1/1), or (iii)co-
testing (1/1) (9/10, 90%)  
- HPV DNA testing for post-treatment screening should be introduced (2/3, 67%) 
- Rapid HPV DNA testing should be introduced in China (3/3, 100%) 
- Self-sampled HPV DNA testing as primary screening in HIC is cost-effective versus 
clinic-based HPV DNA or conventional cytology alone(2/2, 100%); however, in 
upper-middle income countries, it is not cost-effective versus other technologies, 
such as clinic-based HPV DNA (2/2, 100%) 
- HPV 16/18 genotyping should be introduced for triage of equivocal results of co-
testing versus co-testing alone, HPV DNA with LBC triage, LBC with HPV DNA triage, 
or LBC alone (1/1, 100%) 
- HPV DNA is more cost-effective than VIA in LMIC (1/1; 100%) 
- VIA is more cost-effective than cytology in LMIC (2/2; 100%) 
Screening and Vaccination 
- Screening should be introduced even in a post-vaccination setting (10/12, 83%)  
- Screening should be continued after vaccination is introduced (10/12, 83%) 
- Post-vaccination HPV DNA primary screening is cost-effective compared to cytology 
alone in HIC (5/5, 100%) 
Figures in parentheses show the proportion (x/y) and percentage (%) of relevant studies supporting 
each recommendation. 
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 Additional	Material	
3.2.1. Additional	material	1.		
Supplementary Table 3-1. Search strategies for each database consulted 
Database and search 
date 
Search strategy 
Medline  
1946 to May Week 5 
2013 (OvidSP) 
11/06/2013 (updated - 
extended headings) 
1. exp Uterine Cervical Dysplasia/ or exp Uterine Cervical Diseases/ or exp Cervical Intraepithelial Neoplasia/ or exp Uterine Cervical Neoplasms/ 
2. (cervix or cervical or cervico*) (tw) 
3. cancer* (tw) or carcinoma.mp. or adenocarcinoma.mp. or neoplas* (tw) or dysplas* (tw) or dyskaryos* (tw) or squamous (tw) or CIN (tw) or CINII* 
(tw) or CIN2* (tw) or CINIII* (tw) or CIN3* (tw) or SIL (tw) or HSIL (tw) or H-SIL (tw) or LSIL (tw) or L-SIL (tw) or ASCUS (tw) or AS-CUS (tw) [mp=title, 
abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
4. 2 and 3 
5. 1 or 4 
6. HPV.mp. or Tumor Virus Infections/ or Papillomavirus Infections/ or Oncogene Proteins, Viral/ or Papillomaviridae/ or human papilloma.mp. or 
Alphapapillomavirus/ 
7. (cytolog* or liquid based cytology) (tw) 
8. (hybrid capture or (HC2 or HCII or HC 2 or HC II)).mp. 
9. (pap or papanicolaou or vagina* or cervical or cervix or cervico*) (tw) or Vaginal smears/ 
10. smear*.mp. or test (tw) or tests (tw) or testing (tw) or tested (tw) or swab*.mp. or scrap*.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] 
11. 9 and 10 
12. Early Detection of Cancer/ 
13. DNA, Viral/ 
14. PCR.mp. or Polymerase Chain Reaction/ 
15. colposcopy.mp. or Colposcopy/ or visual inspection.mp. 
16. (oncogene mRNA or methylation or proliferation or integration).mp. or immunohistochemistry/ or Tumor Markers, Biological/ or Ki-67 Antigen/ or 
ki67.mp. or Tumor Suppressor Protein p53/ or Antibodies, Monoclonal/ or Cyclin-Dependent Kinase Inhibitor p16/ or p16.mp. or E6.mp. or E7.mp. or 
3q.mp. or 5p.mp. or MCM?.mp. or Top2A.mp. or CDC6.mp. or DAPK1.mp. or CADM1.mp. or RARB.mp. 
17. Enzyme-Linked Immunosorbent Assay/ 
18. antibod*.mp. or Antibod*/ 
19. models, theoretical/ or models, biological/ or exp models, statistical/ or likelihood functions/ or linear models/ or logistic models/ or exp models, 
economic/ or nomograms/ or proportional hazards models/ or nonlinear dynamics/ or Cost-Benefit Analysis/ or Epidemiologic methods/ or 
mathematical concepts/ or health care evaluation mechanisms/ 
20. 5 or 6 
21. 7 or 8 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
22. screen*.mp. or Mass Screening/ or Triage/ or management.mp. or follow up.mp. or marker.mp. or biomarker.mp. 
23. 21 or 22 
24. 19 and 20 and 23 
91 
 
25. limit 24 to humans 
Embase Classic+Embase  
1947 to 2013 May 9 
(OvidSP) 
10/05/2013 
 
1. papilloma*.mp. or exp Papilloma virus/ or HPV.mp. or Wart virus/ or alphapapillomavirus/ 
2. cervical cancer.mp. or exp uterine cervix carcinoma in situ/ or exp uterine cervix tumor/ or exp uterine cervix cancer/ or exp uterine cervix dysplasia/ 
or exp uterine cervix hypertrophy/ or exp uterine cervix disease/ or exp uterine cervix carcinoma/ or ((cervic*.mp. or exp cervix/) and (exp squamous 
cell carcinoma/ or exp cancer/ or exp carcinoma/ or exp neoplasia/ or exp neoplasm/ or exp dysplasia/)) or CIN.mp. or SIL.mp. or ASCUS.mp. 
3. exp vagina smear/ or exp uterine cervix cytology/ or exp Papanicolaou test/ or cervical cancer screening.mp. 
4. screen*.mp. or Mass Screening/ or triage.mp. or management.mp. or follow up.mp. or marker.mp. or biomarker.mp. 
5. DNA/ or PCR.mp. or Polymerase Chain Reaction/ or colposcopy.mp. or Colposcopy/ or Visual inspection.mp. or (oncogene mRNA or methylation or 
integration or proliferation).mp. or immunohistochemistry/ or Tumor Markers, Biological/ or Ki-67 Antigen/ or ki67.mp. or Tumor Suppressor Protein 
p53/ or Antibodies, Monoclonal/ or Cyclin-Dependent Kinase Inhibitor p16/ or p16.mp. or E6.mp. or E7.mp. or 3q.mp. or 5p.mp. or MCM?.mp. or 
Top2A.mp. or Enzyme-Linked Immunosorbent Assay/ or CDC6.mp. or DAPK1.mp. or CADM1.mp. or RARB.mp. or antibod*.mp. or Antibod*/ 
6. computer model/ or statistical model/ or stochastic model/ or loglinear model/ or biological model/ or theoretical model/ or process model/ or 
hidden Markov model/ or mathematical model/ or proportional hazards model/ or population model/ or compartment model/ 
7. 1 or 2 
8. 3 or 5 
9. 4 and 8 
10. 6 and 7 and 9 
11. limit 10 to human 
Econlit  
1961 to April 2013 
(OvidSP) 
10/05/2013 
1. cervi*.mp. [mp=heading words, abstract, title, country as subject] 
2. HPV.mp. [mp=heading words, abstract, title, country as subject] 
3. papilloma*.mp. [mp=heading words, abstract, title, country as subject] 
4. (papanicol* or smear or cytolog* or liquid?based cytolog*).mp. [mp=heading words, abstract, title, country as subject] 
5. (screen* or test* or inspection or colposcop* or DNA or triage or biomarker* or RNA or methilation or integration or proliferation or p16 or 
antibod*).mp. [mp=heading words, abstract, title, country as subject] 
6. 1 or 2 or 3 
7. 4 or 5 
8. 6 and 7 
9. model*.mp. [mp=heading words, abstract, title, country as subject] 
10. 8 and 9 
HEED 
10/05/2013 
AX= 'HPV' 
AX= 'CERVICAL'  Or  'CERVICAL-CANCER'  Or  'CERVICAL-CANCER-SCREENING'  Or  'CERVICAL-VAGINAL'  Or  'CERVICAL/VAGINAL'  Or  'CERVICO-VAGINAL'  
Or  'CERVICOVAGINAL' 
AX= 'SCREEN'  Or  'SCREEN-ALL' 
AX= 'MODEL'  Or  'MODEL-BASED'  Or  'MODEL-CALCULATED'  Or  'MODEL-DERIVED'  Or  'MODEL-ESTIMATED'  Or  'MODEL-GENERATED'  Or  'MODEL-
PREDICTED'  Or  'MODEL-PROJECTED'  Or  'MODEL-SIMULATED'  Or  'MODELLING-TECHNIQUES'  Or  'MODELLING/DECISION-ANALYTIC'  Or  
'MODELLING'  Or  'MODELS-STATISTICAL' 
CS= 1 OR 2 
CS= 3 AND 4 AND 5 
Cochrane Library 
(all databases apart from 
CENTRAL, no limits) 
10/05/2013  
 
ID Search  
#1 MeSH descriptor: [Uterine Cervical Neoplasms] explode all trees 
#2 MeSH descriptor: [Papillomaviridae] explode all trees 
#3 HPV  
#4 MeSH descriptor: [Mass Screening] explode all trees 
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#5 model*  
#6 {or #1-#3}  
#7 {and #4-#6} 
Web of Science 
14/05/2013 
Topic=(Cervi*) AND Topic=(cancer or carcinoma or neoplas*or dysplas* or tumor or tumour or hypertrophy or disease or squamous or CIN or SIL or 
ASCUS) 
OR 
Topic=(HPV or human papilloma*) 
AND 
Topic=(screen* or test*) AND Topic=(smear or pap* or cytology or visual inspection or VIA or marker or DNA or colposcopy or RNA or methylation or 
integration or proliferation or immunohistochemistry or Ki-67 antigen or p53 or antibod* or p16 or E6 or E7 or 3q or 5p or MCM? or Top2a or CDC6 or 
DAKP1 or CADM1 or RARB) 
AND 
Topic=(model*) AND Topic=(math* or computer or statistic* or likelihood or linear or logistic or economic) 
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3.2.2. Additional	material	2.		
Supplementary Table 3-2. List of the types of data extracted and categorisation used 
Administrative variables 
RefID Reference identification number 
Status 
Retrieved; 
unretrieved   
PubType Journal article; review; comment; Reviewer’s 
Reviewer name   
Decision  
Include; 
exclude; 
unclear   
Reviewer comments     
Variables     
Author First author   
Year     
Title     
Language     
Country     
Population Gender, age, comorbidities  
HIV y/n   
Technologies     
Intervention Strategies assessed  
Comparator Baseline strategy  
Model type     
Study Aim     
Outcomes     
Results Main conclusion (1-2 sentences)  
Calibration     
Form drop-down lists by category  
Technologies   Study Aim 
Unspecified   Effectiveness of screening strategies/interventions 
Cytology   Effectiveness of vaccination strategies/vaccines 
 - Conventional cytology Effectiveness of treatment strategies/interventions 
 - LBC   Cost-effectiveness of screening strategies/interventions 
 - Automated reading   Cost-effectiveness of vaccination strategies/vaccines 
HPV DNA   Cost-effectiveness of treatment strategies/interventions 
Self-sampled HPV DNA   Parameter estimation 
VIA   Other 
VILI     
Colposcopy   Outcomes* 
Vaccine   HPV Prevalence 
    Number of cervical cases 
Model type   Number of deaths avoided 
Deterministic   Cost per cervical case 
Stochastic   Cost per death avoided 
Aggregate   Cost per life year gained 
Individual-based   Cost per QALY gained 
Static   Cost per DALY averted 
Transmission dynamic   Incidence of cervical cases 
Hybrid   Net Benefit 
Compartmental/state transition/Markov Cost and Lys 
Decision tree   Cost per vaccinated girl (CVG) 
    Number of tests/repeats 
Calibration   Life years saved 
Not reported   Smears per LYG 
Visual inspection   DALYs averted 
Least squares   Risk reduction 
Chi-squared     
Likelihood     
Other     
Unspecified method     
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3.2.3. Additional	material	3.		
Supplementary Table 3-3. Completed PRISMA 27-item checklist for current systematic review 
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
Not 
applicable 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4-5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 and  
Additional 
material 1 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Additional 
material 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Additional 
material 2 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
Not 
applicable 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Counts 
and 
proportions 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
Not 
applicable 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
Not 
applicable 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
Not 
applicable 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Additional 
material 4 
and 5 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Not 
applicable 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Additional 
material 4 
and 5 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  6-13 
 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Not 
applicable 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Additional 
material 6 
and 7 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
13-16 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
13-16 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  17 
FUNDING   
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Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
18 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 
6(6): e1000097. doi:10.1371/journal.pmed1000097  
3.2.4. Additional	material	4.		
Supplementary Table 3-4. Main characteristics of studies focused on screening interventions alone (n=118)1 
First Author  Year Country Econ/
Epid 
Aim Technologies Main findings Type of model Calibration 
Agorastos[1] 2010 Greece Econ TechIntro Cyt vs HPV HPV/(Cyt&Colp)+ Static, Deterministic, Aggregate Not reported 
Anderson[2] 2008 Australia Econ Algorithm Cyt vs Cyt Current 2y(20-69);25-; 
74-;1y-;3y? 
Static, Deterministic, Aggregate Visual inspection 
Andres-
Gamboa[3] 
2008 Colombia Econ TechIntro Cyt vs HPV HPV/Pap5y+ Static, Deterministic, Aggregate Not reported 
Atashili[4] 2011 Cameroo
n 
Epid ScreenIntr
o 
Cyt vs Cyt HAART+Cyt1x+ Static, Deterministic, Aggregate Not reported 
Balasubramanian
[5] 
2010 USA Econ TechIntro Cyt vs HPV vs 
SS 
OrgScreen+;HPV-; 
SS/LBC3y+ 
Static, Deterministic, Aggregate Not reported 
Berkhof[6] 2006 Netherlan
ds 
Econ TechIntro Cyt vs HPV ConvC-, LBC/HPV+ Static, Deterministic, Aggregate Not reported 
Berkhof[7] 2010 Netherlan
ds 
Econ TechIntro Cyt vs HPV HPV/Pap+ Static, Stochastic, Individual Formal method 
Bidus[8] 2006 USA Econ TechIntro Cyt vs HPV LBC/HPV2y+ Static, Deterministic, Aggregate Unspecified 
method 
Bistoletti[9] 2008 Sweden Econ TechIntro Cyt vs HPV OrgPap+, Pap/HPV9y+ Static, Deterministic, Aggregate Not reported 
Boyd[10] 1989 UK Epid Algorithm Cyt vs Cyt OrgScreen+, >=3y+ Static, Stochastic, Individual Formal method 
Brown[11] 1999 USA Econ TechIntro Cyt vs Auto ConvC&Auto3y+ Static, Deterministic, Aggregate Not reported 
Burger[12] 2012 Norway Econ TechIntro Cyt vs HPV HPV/LBC >=34+ Static, Stochastic, Individual Formal method 
Campos[13] 2012 USA Econ TechIntro Cyt vs HPV LBC/LBC-, 
LBC/Colp(<21, >25)+, 
LBC/HPV(21-24)+ 
Static, Deterministic, Aggregate Not reported 
Canfell[14] 2004 UK Epid Algorithm Cyt vs Cyt 3y(25-50)5y(50-64)+ Static, Deterministic, Aggregate Visual inspection 
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Chow[15] 2010 Taiwan Econ TechIntro Cyt vs HPV HPV/Cyt5y+ Static, Deterministic, Aggregate Not reported 
Chuck[16] 2010 Canada Econ TechIntro Cyt vs HPV Pap/HPV/Pap(>30)+; 
LBC- 
Static, Deterministic, Aggregate Unspecified 
method 
Coppleson[17] 1976 USA Epid Algorithm Cyt vs Cyt Screen(34-73)10x+ Static, Deterministic, Aggregate Not reported 
Coupe[18] 2007 Netherlan
ds 
Econ TechIntro Cyt vs HPV HPV6mth + 
HPV&Pap24mth+ 
Static, Deterministic, Aggregate Not reported 
Creighton[19] 2010 Australia Econ Algorithm Cyt vs Cyt 3y+ Static, Deterministic, Aggregate Unspecified 
method 
de Bekker-
Grob[20] 
2012 Netherlan
ds 
Econ TechIntro Cyt vs HPV LBC>ConvC +/- Static, Stochastic, Individual Visual inspection 
de Kok[21] 2012 European 
Union 
Econ TechIntro Cyt vs HPV HPV/Cyt+ Static, Stochastic, Individual Not reported 
Dewilde[22] 2004 UK, USA, 
Australia, 
Japan 
Econ Algorithm Cyt vs Cyt 3y+ Static, Deterministic, Aggregate Visual inspection 
Eddy[23] 1987 USA, 
Canada, 
Europe 
Epid Algorithm Cyt vs Cyt 3y+ Static, Deterministic, Aggregate Visual inspection 
Fennessy[24] 2002 Australia Econ TechIntro Cyt vs Cyt LBC- Static, Deterministic, Aggregate Not reported 
Fetters[25] 2003 USA Econ Algorithm Cyt vs Cyt ScreenPostHyst- Static, Deterministic, Aggregate Not reported 
Flores[26] 2011 Mexico Econ TechIntro Cyt vs HPV vs 
SS 
HPV+;HPV&Cyt+; SS- Static, Deterministic, Aggregate Unspecified 
method 
Frame[27] 1998 Europe 
and North 
America 
Epid Algorithm Cyt vs Cyt IncCov+;>=3y+; IncFreq- Static, Deterministic, Aggregate Not reported 
Goldie[28] 2004 USA Econ TechIntro Cyt vs HPV ConvC-, LBC+, 
LBC/HPV=HPV&LBC(>30
)3y+ 
Static, Deterministic, Aggregate Visual inspection 
Goldie[29] 2001 USA Econ TechIntro Cyt vs HPV HPV&Cyt+ Static, Deterministic, Aggregate Not reported 
Goldie[30] 2005 India, 
South 
Africa, 
Kenya, 
Econ ScreenIntr
o 
Cyt vs HPV vs 
VIA 
Pap-, HPV+, VIA+ Static, Deterministic, Aggregate Visual inspection 
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Peru, 
Thailand 
Goldie[31] 2001 South 
Africa 
Econ ScreenIntr
o 
Cyt vs HPV vs 
SS vs VIA 
VIA+, 1-visit HPV+, 
SS+vsNoScreen 
Static, Deterministic, Aggregate Unspecified 
method 
Goldie[32] 1999 USA Econ Algorithm Cyt vs Cyt HIV:Cyt1y+ Static, Deterministic, Aggregate Unspecified 
method 
Gustafsson[33] 1992 Sweden, 
Canada, 
USA, UK, 
Barbados 
Epid Algorithm Cyt vs Cyt OrgScreen+; (30-60)or 
(31-67)5x+ 
Static, Deterministic, Aggregate Not reported 
Gutierrez-
Aguado[34] 
2011 Peru Econ ScreenIntr
o 
Cyt vs Cyt ScreenAlone+ Static, Deterministic, Aggregate Not reported 
Gyrd-Hansen[35] 1995 Denmark Econ ScreenIntr
o 
Cyt vs Cyt 4y(25-59)+ Static, Deterministic, Aggregate Unspecified 
method 
Hadwin[36] 2008 UK Econ Algorithm Cyt vs Cyt Pap/Colp(1mth)+ Static, Deterministic, Aggregate Not reported 
Helfand[37] 1992 USA Epid Algorithm Cyt vs Cyt Improve Pap quality+ 
(reduce false-negative 
rate)  
Static, Deterministic, Aggregate Not reported 
Hughes[38] 2005 USA Econ TechIntro Cyt vs HPV LBC+, LBC/HPV+ Static, Deterministic, Aggregate Not reported 
Hutchinson[39] 2000 USA Econ TechIntro Cyt vs Auto ConvC-, Auto+, LBC+ Static, Deterministic, Aggregate Unspecified 
method 
Karnon[40] 2004 UK Econ TechIntro Cyt vs Cyt LBC+ Static, Deterministic, Aggregate Not reported 
Kim[41] 2004 Hong 
Kong 
Econ ScreenIntr
o 
Cyt vs Cyt LBC+, OrgScreen+ Static, Deterministic, Aggregate Not reported 
Kim[42] 2013 USA Econ Algorithm Cyt vs Cyt >=3y+ Static, Stochastic, Individual Formal method 
Kim[43] 2005 UK, Italy, 
Netherlan
ds, France 
Econ TechIntro Cyt vs HPV Cyt_HPV&Cyt>30+, 
Cyt/HPV+ 
Static, Deterministic, Aggregate Visual inspection 
Kim[44] 2002 USA Econ TechIntro Cyt vs HPV LBC+, LBC/HPV+ Static, Deterministic, Aggregate Unspecified 
method 
Knox[45] 1976 UK Epid Algorithm Cyt vs Cyt 25-;30-;(35-80)10x+ Static, Deterministic, Aggregate Not reported 
Koong[46] 2006 Taiwan Econ ScreenIntr
o 
Cyt vs Cyt 3y+ Static, Stochastic, Individual Not reported 
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Koopmanschap[4
7] 
1990 Netherlan
ds 
Econ ScreenIntr
o 
Cyt vs Cyt OrgPap+, every6y+,37-
73 
Static, Stochastic, Individual Visual inspection 
Koopmanschap[4
8] 
1990 Netherlan
ds 
Econ ScreenIntr
o 
Cyt vs Cyt OrgPap+, (37-73)6y+ Static, Stochastic, Individual Not reported 
Krahn[49] 2008 Canada Econ TechIntro Cyt vs HPV Pap=LBC, HPVtriage+ Static, Deterministic, Aggregate Formal method 
Kulasingam[50] 2006 USA Econ TechIntro Cyt vs HPV LBC/HPV+ Static, Deterministic, Aggregate Not reported 
Kulasingam[51] 2006 USA Econ Algorithm Cyt vs Cyt (<30)2-3y(>30)3y+ Static, Deterministic, Aggregate Not reported 
Kulasingam[52] 2009 Canada Econ TechIntro Cyt vs HPV HPV/Cyt>25+ Static, Deterministic, Aggregate Unspecified 
method 
Kulasingam[53] 2013 USA Econ TechIntro Cyt vs HPV Cyt3y_HPV&Cyt5y>30+ Static, Deterministic, Aggregate Not reported 
Lazaar[54] 2010 Tunisia Econ Algorithm Cyt vs Cyt 3y-;5y-;10y+ Static, Deterministic, Aggregate Not reported 
Legood[55] 2012 UK Econ TechIntro Cyt vs HPV HPVtestCure+ Static, Deterministic, Aggregate Visual inspection 
Legood[56] 2006 UK Econ TechIntro Cyt vs HPV LBC&HPV>35+ Static, Deterministic, Aggregate Not reported 
Levin[57] 2010 China Econ ScreenIntr
o 
Cyt vs HPV LBC+, CareHPV+ Static, Deterministic, Aggregate Unspecified 
method 
Mandelblatt[58] 2002 Thailand Econ ScreenIntr
o 
Cyt vs HPV vs 
VIA 
OrgScreen+, VIA5y(35-
55)+,Pap&HPV5y(20-
70)+ 
Static, Deterministic, Aggregate Visual inspection 
Mandelblatt[59] 1997 USA Econ Algorithm Cyt vs Cyt ERscreen+ Static, Deterministic, Aggregate not reported 
Mandelblatt[60] 2002 USA Econ TechIntro Cyt vs HPV HPV&Pap2y+ Static, Stochastic, Individual Visual inspection 
Mandelblatt[61] 1988 USA Econ Algorithm Cyt vs Cyt Screen1x(>65)+ Static, Deterministic, Aggregate not reported 
Mandelblatt[62] 2004 USA Econ TechIntro Cyt vs HPV HPV&Pap2y+ Static, Deterministic, Aggregate Not reported 
Matsunaga[63] 1997 Japan Econ ScreenIntr
o 
Cyt vs Cyt Pap+ Static, Deterministic, Aggregate Not reported 
Maxwell[64] 2002 USA Econ TechIntro Cyt vs HPV LBC+, LBC/HPV+ Static, Deterministic, Aggregate Not reported 
McCrory[65] 1999 USA Econ TechIntro Cyt vs Auto LBC+/-Auto3y+ Static, Deterministic, Aggregate Visual inspection 
Melnikow[66] 2010 Canada Econ TechIntro Cyt vs HPV Pap+, LBC-, HPV- Static, Deterministic, Aggregate Visual inspection 
Mittendorf[67] 2003 Germany Econ TechIntro Cyt vs HPV HPV/Colp+, HPV&Cyt+ Static, Deterministic, Aggregate Not reported 
Montz[68] 2001 USA Econ TechIntro Cyt vs Cyt LBC+ Static, Deterministic, Aggregate Not reported 
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Myers[69] 2000 USA Epid Algorithm Cyt vs Cyt n.a. Static, Deterministic, Aggregate Not reported 
Myers[70] 2000 USA Econ Algorithm Cyt vs Cyt IncFreq-; IncSE&SP+ Static, Deterministic, Aggregate Not reported 
Neville[71] 2005 Australia Econ TechIntro Cyt vs Cyt LBC+ Static, Deterministic, Aggregate Not reported 
Novoa-
Vazquez[72] 
2004 Portugal Econ ScreenIntr
o 
Cyt vs Cyt LBC+, OrgScreen+ Static, Deterministic, Aggregate Not reported 
Ostensson[73] 2010 Sweden Econ TechIntro Cyt vs HPV Pap/HPV+ Static, Deterministic, Aggregate Not reported 
Ostensson[74] 2013 Sweden Econ TechIntro Cyt vs SS SS(>35)5y+, 
ConvCyt<35+ 
Static, Deterministic, Aggregate Visual inspection 
Parkin[75] 1985 UK Epid Algorithm Cyt vs Cyt Screen+ Static, Stochastic, Individual Not reported 
Parkin[76] 1986 UK Econ Algorithm Cyt vs Cyt <35-;(>35)5y+ Static, Stochastic, Individual Not reported 
Perkins[77] 2010 Honduras Econ ScreenIntr
o 
Cyt vs VIA VIA+, Pap- Static, Deterministic, Aggregate Not reported 
Philips[78] 2001 UK Econ TechIntro Cyt vs HPV Pap = Pap/HPV; 
EarlyWithdrawal- 
Static, Deterministic, Aggregate Unspecified 
method 
Raab[79] 1999 USA Econ TechIntro Cyt vs Cyt Pap+, newTech- Static, Deterministic, Aggregate Not reported 
Raab[80] 1997 USA Econ Algorithm Cyt vs Cyt PapRescreen+/- Static, Deterministic, Aggregate Not reported 
Raab[81] 1999 USA Econ Algorithm Cyt vs Cyt PapRescreenHigh-risk+ Static, Deterministic, Aggregate Not reported 
Raab[82] 1998 USA Econ Algorithm Cyt vs Cyt ASCUS: Colp-,Treat-, 
Pap1y+ 
Static, Deterministic, Aggregate Not reported 
Radensky[83] 1998 USA Econ TechIntro Cyt vs Auto Auto+ Static, Deterministic, Aggregate Not reported 
Raffle[84] 2003 UK Epid Algorithm Cyt vs Cyt SceenIntro+ Static, Deterministic, Aggregate Not reported 
Sato[85] 1999 Japan Econ ScreenIntr
o 
Cyt vs Cyt ScreenIntro+ Static, Deterministic, Aggregate Not reported 
Sawaya[86] 2003 USA Epid Algorithm Cyt vs Cyt 30-64:1-3y-;1-1-3y-;1-1-
1-3y+ 
Static, Deterministic, Aggregate Not reported 
Schechter[87] 1996 USA Econ TechIntro Cyt vs Auto Auto+,2y+ Static, Deterministic, Aggregate Not reported 
Sheriff[88] 2007 Germany Econ TechIntro Cyt vs HPV Pap/HPV+, Pap/Pap-, 
Pap/Colp- 
Static, Deterministic, Aggregate Not reported 
Sherlaw-
Johnson[89] 
2004 UK Econ TechIntro Cyt vs HPV LBC+, HPV&LBC5y+ Static, Deterministic, Aggregate Not reported 
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Sherlaw-
Johnson[90] 
2000 Eastern 
Europe 
Econ TechIntro Cyt vs HPV HPV/Colp+ Static, Stochastic, Individual Unspecified 
method 
Sherlaw-
Johnson[91] 
1997 Developin
g 
countries 
Econ ScreenIntr
o 
Cyt vs HPV HPV1x(30-59)+ Static, Stochastic, Individual Unspecified 
method 
Sherlaw-
Johnson[92] 
1999 UK Econ Algorithm Cyt vs HPV Stop50,55,60-;65+, 
HPV&Cyt=Cyt 
Static, Stochastic, Individual Unspecified 
method 
Sherlaw-
Johnson[93] 
1994 Latin 
America, 
Finland, 
Iceland 
Epid Algorithm Cyt vs Cyt ASCUS:Colp-
Cyt6mth+;IncCov+ 
Static, Stochastic, Individual Not reported 
Shi[94] 2011 China Econ ScreenIntr
o 
HPV vs VIA CareHPV+, VIA- Dynamic, Deterministic, 
Aggregate 
Not reported 
Shun-Zhang[95] 1982 Canada Epid ScreenIntr
o 
Cyt vs Cyt Screen+; Pap(25-52)3y 
OR (25-40)3y+(40-
60)5y+  
Static, Deterministic, Aggregate Not reported 
Siebert[96] 2006 Germany Epid Algorithm Cyt vs Cyt 2y+ Static, Deterministic, Aggregate Visual inspection 
Smith[97] 1999 USA Econ TechIntro Cyt vs Auto Auto+ Static, Deterministic, Aggregate Not reported 
Sroczynski[98] 2011 Germany Econ TechIntro Cyt vs HPV HPV/Cyt2yOlder+ Static, Deterministic, Aggregate Visual inspection 
Stout[99] 2008 USA Epid TechIntro Cyt vs HPV LBC/HPV+_HPV/LBC(>3
0)+ 
Static, Stochastic, Individual Formal method 
Straughn[100] 2004 USA Econ TechIntro Cyt vs HPV LBC/HPV2y+ Static, Deterministic, Aggregate Not reported 
Suba[101] 2001 Vietnam Econ ScreenIntr
o 
Cyt vs Cyt ScreenIntro+ Static, Deterministic, Aggregate Not reported 
Taylor[102] 2000 USA Econ TechIntro Conv+/-Spec 2y+ Static, Deterministic, Aggregate Not reported 
van 
Ballegooijen[103] 
2000 UK, Italy, 
Netherlan
ds, 
Germany, 
France, 
Spain, 
Portugal, 
Greece, 
Denmark, 
Finland, 
Epid Algorithm Cyt vs Cyt n.a. Static, Stochastic, Individual Not reported 
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Sweden, 
Belgium, 
Ireland 
van 
Ballegooijen[104] 
1992 Netherlan
ds 
Epid ScreenIntr
o 
Cyt vs Cyt OrgScreen+,Pap(30-
60)5y+ 
Static, Stochastic, Individual Not reported 
van 
Ballegooijen[105] 
1997 Netherlan
ds 
Econ TechIntro Cyt vs HPV HPV&Pap = Pap Static, Stochastic, Individual Not reported 
van den Akker-
van Marle[106] 
2002 Netherlan
ds 
Econ Algorithm Cyt vs Cyt >=3y+ Static, Stochastic, Individual Visual inspection 
van 
Oortmarssen[107
] 
1992 Canada Epid Algorithm Cyt vs Cyt Pap(35-64)5y+ Static, Deterministic, Aggregate Unspecified 
method 
van 
Rosmalen[108] 
2012 Netherlan
ds 
Econ TechIntro Cyt vs HPV LBC-, 
Pap_HPV/Pap(>32)+ 
Static, Stochastic, Individual Visual inspection 
Vanni[109] 2011 Brazil Econ TechIntro Cyt vs HPV HPV/Cyt1y+ Static, Deterministic, Aggregate Formal method 
Vanni[110] 2011 Brazil Econ TechIntro Cyt vs HPV Cyt/HPV(>30)+ Static, Deterministic, Aggregate Formal method 
Vijayaraghavan[1
11] 
2009 South 
Africa 
Econ TechIntro Cyt vs HPV HPV/Pap+ Static, Deterministic, Aggregate Not reported 
Vijayaraghavan[1
12] 
2010 Canada Econ TechIntro Cyt vs HPV Pap-, Pap/HPV+, 
HPV/Pap+, HPV&Pap+ 
Static, Deterministic, Aggregate Not reported 
Vijayaraghavan[1
13] 
2010 USA Econ TechIntro Cyt vs HPV vs 
GT 
HPV&LBC/GT+ Static, Deterministic, Aggregate Visual inspection 
Voko[114] 2012 Hungary Econ Algorithm Cyt vs Cyt Improve Cov+ Static, Deterministic, Aggregate Visual inspection 
Willis[115] 2005 UK Epid TechIntro Cyt vs Auto Cyt+, Auto- Static, Stochastic, Individual Not reported 
Woo[116] 2007 China Econ ScreenIntr
o 
Cyt vs Cyt 4y+ Static, Deterministic, Aggregate Not reported 
Woo[117] 2005 Hong 
Kong 
Epid ScreenIntr
o 
Cyt vs Cyt OrgScreen+ Static, Deterministic, Aggregate Visual inspection 
Wu[118] 2011 Hong 
Kong 
Econ TechIntro Cyt vs HPV HPV&Cyt3y+ Static, Stochastic, Individual Visual inspection 
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3.2.5. Additional	material	5.		
Supplementary Table 3-5. Main characteristics of studies focused on screening interventions alongside vaccination (n=35) 
First Author  Year Country Econ/Epid Aim Technologies Main findings Type of model Calibration 
Accetta[1] 2010 Italy Econ TechIntro Cyt vs HPV HPV/Cyt5y +/-Vac+ Static, Deterministic, 
Aggregate 
Formal 
method 
Campos[2] 2012 Kenya, Eastern Africa, 
Mozambique, Tanzania, 
Uganda, Zimbabwe 
Econ TechIntro HPV vs VIA HPV3x+, Vac&HPV+ Static, Stochastic, 
Individual 
Formal 
method 
Canfell[3] 2011 China Econ ScreenIntro HPV vs HPV Vac&CareHPV2x(30-59)+ Dynamic, Deterministic, 
Aggregate 
Visual 
inspection 
Chen[4] 2011 Taiwan Econ TechIntro Cyt vs HPV Pap+; HPV&Cyt+ Static, Stochastic, 
Individual 
Not reported 
Coupe[5] 2012 Netherlands Econ TechIntro Cyt vs HPV Vac&HPV/Cyt+ Static, Stochastic, 
Individual 
Visual 
inspection 
Coupe[6] 2009 Netherlands Econ TechIntro Cyt vs HPV Vac&HPV/Cyt=Vac&Cyt/HP
V>30 
Static, Stochastic, 
Individual 
Unspecified 
method 
Coupe[7] 2009 Netherlands Econ Algorithm Cyt vs Cyt Vac&Cyt+ Static, Stochastic, 
Individual 
Formal 
method 
Crowcroft[8] 2012 Canada Epid Algorithm Cyt vs Cyt Vac&Cyt+ Static, Deterministic, 
Aggregate 
Not reported 
de Blasio[9] 2012 Norway Epid Algorithm Cyt vs Cyt Vac&Screen+; 30-;59-; 5y-; 
(25-69)3y+ 
Dynamic, Deterministic, 
Aggregate 
Visual 
inspection 
Diaz[10] 2008 India Econ ScreenIntro Cyt vs HPV vs 
VIA 
Vac&2visitHPV3x(35,40,45)
+ 
Static, Stochastic, 
Individual 
Formal 
method 
Diaz[11] 2010 Spain Econ ScreenIntro Cyt vs HPV Screen+; Vac&HPV/Cyt>30+ Static, Stochastic, 
Individual 
Formal 
method 
Ezat[12] 2010 Malaysia Econ Algorithm Cyt vs Cyt Screen&QVvac+ Static, Deterministic, 
Aggregate 
Not reported 
Ginsberg[13] 2012 Sub-Saharan Africa, South 
East Asia 
Econ ScreenIntro Cyt vs HPV vs 
VIA 
Vac-, Cyt or VIA+ Static, Deterministic, 
Aggregate 
Not reported 
Ginsberg[14] 2009 EMRO, SEARO, AMRO, 
WPRO, AFRO, Eastern Europe 
Econ ScreenIntro Cyt vs HPV vs 
VIA 
HIC:Vac&anyScreen+; 
LMIC:Vac&Pap3or5y+ 
Static, Deterministic, 
Aggregate 
Not reported 
Ginsberg[15] 2007 Israel Econ ScreenIntro Cyt vs HPV vs 
VIA 
HPV-, VIA-, Vac&Pap5y+ Static, Deterministic, 
Aggregate 
Not reported 
Goldhaber-
Fiebert[16] 
2008 USA Econ TechIntro Cyt vs HPV HPV/Cyt(>30)+Cyt/HVP(<30
)+/-Vac+ 
Static, Stochastic, 
Individual 
Formal 
method 
Goldhaber-
Fiebert[17] 
2007 USA Epid Algorithm Cyt vs Cyt Vac&Screen+; (18-70)5y+ Static, Stochastic, 
Individual 
Formal 
method 
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Goldie[18] 2004 USA Econ TechIntro Cyt vs HPV Vac&ConvC(>25)3y+ Static, Deterministic, 
Aggregate 
Unspecified 
method 
Goldie[19] 2011 USA Econ TechIntro Cyt vs HPV Vac&HPV/Cyt>30+ Static, Stochastic, 
Individual 
Unspecified 
method 
Goldie[20] 2008 Latin America, Caribbean 
(Argentina, Chile, Colombia, 
Mexico, Peru) 
Econ ScreenIntro Cyt vs HPV Vac&2-visit HPV3x(>30)+ Static, Stochastic, 
Individual 
Formal 
method 
Goldie[21] 2007 Brazil Econ ScreenIntro Cyt vs HPV Vac&Cyt+ Static, Stochastic, 
Individual 
Formal 
method 
Goldie[22] 2008 Developing countries Econ ScreenIntro Cyt vs HPV Vac&HPV+ Static, Stochastic, 
Individual 
Not reported 
Gutierrez-
Delgado[23] 
2008 Mexico Econ TechIntro Cyt vs HPV Vac&HPV&Cyt+ Static, Deterministic, 
Aggregate 
Not reported 
Kim[24] 2008 Vietnam Econ ScreenIntro Cyt vs HPV Vac&HPV5y+ Static, Stochastic, 
Individual 
Visual 
inspection 
Kim[25] 2009 USA Econ TechIntro Cyt vs HPV Vac>30-; HPV&Cyt-; HPV- Static, Stochastic, 
Individual 
Formal 
method 
Kulasingam[26] 2003 USA Econ Algorithm Cyt vs Cyt Vac&Screen(>24)2y+;3-5y-
;18- 
Static, Deterministic, 
Aggregate 
Not reported 
McLay[27] 2010 USA, Western Europe Epid Algorithm Cyt vs Cyt Vac&Screen+; >3y+ Static, Deterministic, 
Aggregate 
Visual 
inspection 
Praditsitthikorn
[28] 
2011 Thailand Econ ScreenIntro Cyt vs VIA VIA(30-45)Pap(50-60)5y+ Static, Deterministic, 
Aggregate 
Not reported 
Reynales-
Shigematsu[29] 
2009 Mexico Econ Algorithm Cyt vs Cyt Vac+, Vac&Cyt- Static, Deterministic, 
Aggregate 
Visual 
inspection 
Rogoza[30] 2008 Canada, Netherlands, 
Taiwan, UK, USA 
Econ TechIntro Cyt vs HPV Vac&Cyt/HPV-;Vac&Cyt+ Static, Deterministic, 
Aggregate 
Unspecified 
method 
Sharma[31] 2012 Thailand Econ ScreenIntro Cyt vs HPV vs 
VIA 
Vac&HPV5x(>35)+ Static, Stochastic, 
Individual 
Formal 
method 
Sopina[32] 2011 New Zealand Econ Algorithm Cyt vs Cyt Vac&Screen(30-60)5y+; 20-; 
69-; 3y- 
Static, Deterministic, 
Aggregate 
Not reported 
Tully[33] 2012 Canada Econ Algorithm Cyt vs Cyt CatchUp+; 25+; 18-;21- Dynamic, Deterministic, 
Aggregate 
Visual 
inspection 
Wong[34] 2009 Australia Econ Algorithm Cyt vs Cyt Vac-;LBC-;ConvCyt 1y+ Static, Deterministic, 
Aggregate 
Not reported 
Yamamoto[35] 
 
2012 Japan Econ Algorithm Cyt vs Cyt Vac&Cyt+ Static, Deterministic, 
Aggregate 
Unspecified 
method 
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3.2.6. Additional	material	6.		
Supplementary Table 3-6. Number of single- and multiple-country studies per country 
Country Single-country 
studies 
Multiple-country 
studies 
Total 
Argentina - 1 1 
Australia 5 1 6 
Barbados - 1 1 
Belgium - 1 1 
Brazil 3 - 3 
Cameroon 1 - 1 
Canada 9 3 12 
Chile - 1 1 
China 4 - 4 
Colombia 1 1 2 
Denmark 1 1 2 
Germany 4 1 5 
Greece 1 1 2 
France - 2 2 
Finland - 2 2 
Honduras 1 - 1 
Hong Kong 3 - 3 
Hungary 1 - 1 
Iceland - 1 1 
India 1 1 2 
Ireland - 1 1 
Israel 1 - 1 
Italy 1 2 3 
Japan 3 1 4 
Kenya - 2 2 
Malaysia 1 - 1 
Mexico 3 1 4 
Mozambique - 1 1 
Netherlands 13 3 16 
New Zealand 1 - 1 
Norway 2 - 2 
Peru 1 2 3 
Portugal 1 1 2 
South Africa 2 1 3 
Spain 1 1 2 
Sweden 3 2 5 
Taiwan 3 1 4 
Tanzania - 1 1 
Thailand 3 1 4 
Tunisia 1 - 1 
Uganda - 1 1 
UK 14 5 19 
USA 44 5 49 
Vietnam 2 - 2 
Zimbabwe - 1 1 
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3.2.7. Additional	material	7.		
Supplementary Table 3-7. Summary of findings on comparisons of screening technologies 
Intervention/ 
Comparison 
No. of studies,  
Type of analysis 
Recommended technology  (no. of studies, 
country) 
Cytology 
Conventional Cytology 
vs LBC 
 
27 (26 Economic, 1 
Epidemiological[59]) 
LBC (n=18; Australia[60], China[25], Hong 
Kong[61], Netherlands[62, 63], 
Portugal[64], UK[65–67], USA[68–
75, 59])  
Conventional (n=8, Australia[76][77]†, 
Canada[29, 78], Netherlands[79], 
Sweden[80], USA[81, 82]†)  
Conventional or LBC (n=1, Canada)[78]  
Cytology +/- 
Automation 
7 (6 Economic, 1 
Epidemiological[22]) 
Automated cytology (n= 6, USA)[74, 75, 81, 
83–85]  
Cytology alone (n=1, UK)[22]  
Cytology +/- 
Speculoscopy 
1 Economic Cytology + Speculoscopy (n=1, USA)[23]  
HPV DNA 
Cytology vs HPV  
 
   
                 
17 Economic HPV (n=15; Brazil[86]a, Canada[87], 
Caribbean and Latin America[88]†, 
Colombia[89], unspecified 
developing countries[90, 91]†, 
Eastern Europe[92], European 
Union[93], Italy[94]†, 
Netherlands[79]† [95]†, 
Norway[96], USA[97]†[98]†, 
Vietnam[99]†)  
HPV/cytology triage or Cytology/HPV triage 
≥30y (n=1, Netherlands)[100] 
Cytology (n=1, Canada)[101] 
Co-testing vs Cytology 
vs HPV  
17 (16 Economic, 1 
Epidemiological[59]) 
HPV (n= 6; Canada[102], Germany[103, 
104],  Netherlands[105], 
Taiwan[106], USA[59]) 
Co-testing (n=2; USA[107], Mexico[36]†) 
Co-testing or HPV (n=3, UK[66], South 
Africa[108], USA[38]†)  
Co-testing or Cytology (n=2, UK, Italy, 
Netherlands, and France[109], 
Taiwan[37]†) 
Co-testing or HPV or Cytology (n=1, 
Netherlands)[110]  
Cytology (n= 3; Brazil[111]†, Sweden[112], 
Spain[113]†) 
Co-testing vs Cytology  7 Economic Co-testing (n=6; Hong Kong[114], UK[67], 
USA[115–117] [82]a 
Cytology/HPV triage (n=1, USA)[118]  
Triage of cytological 
abnormalities 
  
Repeat Cytology vs 
HPV vs Co-testing   
1 Economic HPV triage (n=1, Netherlands)[62] 
Repeat Cytology vs 
HPV vs Immediate 
treatment 
1 Economic  HPV triage  (n=1,Germany[119]) 
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Repeat Cytology vs 
HPV vs Immediate 
colposcopy 
8 Economic Colposcopy with biopsy (n=1, Sweden)[120] 
HPV triage  (n=7; Brazil[121], Canada[78], 
UK[122], USA[39, 71, 123, 124], 
Netherlands and Taiwan[39]†)  
Cytology triage(n=1, Canada and UK)[39]†  
Rapid HPV 
Rapid HPV(2x) vs Rapid 
HPV (1x) 
1 Economic Rapid HPV (2x) (n=1, China)[26]  
Rapid HPV vs VIA 1 Economic Rapid HPV (25-49, triennial; 50-64, 
quinquennial)(n=1, China)[24]  
Rapid HPV vs HPV vs 
Cytology 
1 Economic Rapid HPV (3x) (n=1, China)[25]  
Self-sampling 
Cytology vs HPV vs SS 
vs VIA 
1 Economic VIA or HPV; SS vs No screening (n=1, South 
Africa) [32]   
Cytology vs HPV vs Co-
testing vs SS 
1 Economic HPV alone or Co-testing (n=1, Mexico)[125]  
Cytology  vs HPV vs SS 1 Economic SS (n=1, USA)[126]  
Cytology vs SS 1 Economic SS (≥35y) and cytology (<35y) (n=1, 
Sweden)[80]  
HPV 16/18 genotyping 
Cytology vs HPV vs  
Co-testing vs  
Co-testing+Genotyping 
1 Economic Co-testing with HPV 16/18 genotyping 
triage (n=1, USA)[30] 
VIA 
Cytology vs HPV vs SS 
vs VIA 
1 Economic VIA or HPV (n=1, South Africa)[32]  
Cytology vs HPV vs VIA 7 Economic VIA or HPV (n=2, India[18]†, Kenya, Peru, 
Thailand, and South Africa)[33] 
VIA or Cytology (n=1, Sub-Saharan Africa 
and South East Asia)[127]† 
VIA or Co-testing (n=1, Thailand)[128]  
VIA in LMIC, any in HIC (n=1, developing 
countries)[20]† 
HPV (n=1, Thailand[31]†)  
Cytology (n=1, Israel)[129]†  
Cytology vs VIA 2 Economic VIA (n=1, Honduras)[34] 
VIA (30-45y) and Cytology (50-60y) (n=1, 
Thailand)[35]† 
HPV vs VIA 1 Economic HPV (n=1; Kenya, Mozambique, Tanzania, 
Uganda, Zimbabwe[19]†)  
aHIV-positive women; †screening & vaccination study; Co-testing, combined cytology and HPV DNA 
testing; HPV, HPV DNA testing; LBC, liquid-based cytology; SS, self-sampling HPV DNA testing; VIA, visual 
inspection with acetic acid; y, years; 1x, once a lifetime; 2x, twice a lifetime 
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3.2.8. Additional	material	8.		
Supplementary Table 3-8. Summary of cervical screening guidelines 
Country and Year 
of publication 
Recommendation for primary screening 
Australia 2015[130] Currently, conventional cytology 2-yearly for women aged ≥18 or 
20, or 1-2 years after sexual debut, whichever is later. 
In 2016, HPV DNA testing 5-yearly to women aged 25-74 
Canada 2013[45] Cytologya 3-yearly to women aged 25-69 
Ireland 2011[131] LBC 3-yearly to women aged 25-44; 5-yearly to women aged 45-
60 
Japan 2010[132]  Cytologya recommended  2-yearly to women aged ≥20 
Free screening offered 5-yearly to women aged 20–40 
Latvia 2009[133] Cytologyb 3-yearly to women aged 25-69 
Netherlands 
2011[134] 
Conventional cytology 5-yearly to women aged 30-60 
In 2016, HPV DNA testing 5-yearly to women aged 30-60  
New Zealand 
2010[135] 
Cytology a 3-yearly to women aged 20-69 
 
Norway 2005[136]  Cytology a 3-yearly to women aged 25–69 
Planning to start introducing HPV DNA primary screening for 
women aged 34 – 69 in four counties in 2015[137, 138] 
Portugal 2014[139] Cytologya 3-yearly to women aged 25-65 or HPV DNA primary 
testing 5-yearly for women aged 30-65 
Singapore 
2010[140] 
Cytologya 3-yearly to women aged 25–69 
South Korea 
2012[141] 
Cytologya yearly to women aged 20–70  
 
Sweden 2010[142] LBC 3-yearly to women aged 23-49; 5-yearly to women aged 50-
60 
Switzerland 
2004[143] 
Conventional cytology yearly from sexual debut 
  
Taiwan 1995[144] Conventional cytology yearly to women aged ≥30 
UK 2012 [145][146] England, Northern Ireland and Wales:  
LBC to 25-64; 3-yearly to women aged 25-49; 5-yearly to 50-64  
Scotland: 
LBC 3-yearly to women aged 20-60 
In 2016, to change to same schedule as rest of UK  
USA 2012[147] 
 
Cytologya 3-yearly to women aged 21-65  
Optional, Co-testing  5-yearly to women aged 30-65 
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a Conventional or liquid-based; b Giemsa stain in Leishman modification; Co-testing, combined cytology 
and HPV DNA testing; LBC, liquid-based cytology  
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4. Chapter	4.	Model-based	evaluation	of	the	effectiveness	of	
primary	HPV	testing	versus	cytology-based	cervical	screening	
in	Portugal	
 Preamble	to	research	paper	3		
In research paper 1[1], the burden of cervical cancer, risk factors, and preventive interventions 
in place in Portugal were characterised. Its findings suggest that the incidence of cervical 
cancer is likely to decrease with improvements on screening coverage and quality.   
The overall aim of this thesis was to investigate the effectiveness and cost-effectiveness of 
distinct screening policies in Portugal. The systematic review of previous model-based 
evaluations of cervical screening  (research paper 2[2], Chapter 3) demonstrated how similar 
mathematical models have yielded insight in other countries. The two studies[3,4] found on 
Portugal analysed the impact of cytology-based strategies in the 2000s. Since then, HPV 
vaccination has been introduced in the Portuguese National Immunisation Plan[5], organised 
screening has been introduced in several Portuguese regions[6], and primary HPV testing has 
proven its superiority to prevent cervical cancer compared to primary cytology in large 
European clinical trials[7]. The questions to address in this context now concern mainly the 
integration of primary HPV screening into a countrywide organised programme, including the 
appropriate triage of HPV positive women. 
In order to investigate how alternative screening protocols are likely to impact cervical cancer 
incidence in Portugal, we adapted an existing model of HPV acquisition and progression to 
cervical cancer to Portugal. Research paper 3 in this chapter shows how we parameterised the 
model using Portuguese data and the methods applied to circumvent data constraints to 
predict the effectiveness of cytology- and HPV-based protocols.  
While research paper 1[1] facilitated identifying crucial data sources for the parameterisation 
of our model, research paper 2[2]  improved our understanding of the methodology used in 
the field and showed that model calibration to country-specific data is rarely but increasingly 
conducted to more robustly characterise the setting regarding parameters non-directly 
measurable.  
We used individual-patient data from the latest Portuguese population-based sexual health 
survey[8] to parameterise the HPV acquisition component of our model and calibrated it to 
Portuguese age- and type-specific HPV prevalence[9] and incidence of cervical cancer[10]. The 
characterisation of opportunistic screening was based on the Portuguese National Health 
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Survey 2005/6 individual-patient data[11], before the introduction of regional organised 
programmes in 2008. 
Research paper 3 provides the first model-based evaluation of primary HPV screening in 
Portugal and shows that such a nationwide organised programme is likely more effective in the 
prevention of cervical cancer than cytology-based protocols. 
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4.2.1. Abstract	
Background: Portugal has shown higher incidence of cervical cancer than England, despite its 
relatively low overall prevalence of human papillomavirus (HPV) and behavioural risk factors 
for HPV infection prior to the introduction of HPV vaccination. Publicly-funded opportunistic 
cervical screening is ubiquitous and recently implemented organised regional programmes 
vary in coverage, protocols, and technologies used. Primary HPV screening is being piloted in 
preparation for a uniform countrywide organised approach, but this has not been formally 
assessed. Our aim was to compare the effectiveness of alternative cervical screening strategies 
in Portugal. 
Methods: We projected the effectiveness of possible cervical screening strategies in Portugal 
using a static, stochastic, individual-based mathematical model of HPV infection and cervical 
disease progression adapted to the Portuguese context. The acquisition of HPV infection was 
parameterised with data from a population-based Portuguese sexual health survey. Rates of 
HPV acquisition and clearance were fitted to pre-vaccination HPV prevalence from a 
population-based cross-sectional Portuguese study, and disease progression to national 
cervical cancer incidence. Screening currently in place was characterised based on published 
estimates of cytology uptake and data from the organised programmes. The calibrated model 
was used to quantify the impact of alternative cervical screening strategies. 
Results: Our results indicate that opportunistic screening has decreased cervical cancer 
incidence by over 30% and organised screening may lead to a further 35% reduction. Protocols 
incorporating HPV triage of minor abnormalities detected during cytological screening would 
require fewer tests while detecting similar numbers of cervical intraepithelial neoplasia (CIN) 
2+ lesions compared to repeat cytology. However, as part of a national coordinated strategy, 
primary HPV DNA testing every 3 years is likely to prevent more cervical cancer cases with 
fewer tests than most primary cytology-based strategies. Extending the screening interval to 5 
years would achieve comparable reduction in cervical cancer incidence as 3-yearly strategies 
and require fewer tests, with an average annual number of tests similar to what is predicted 
for opportunistic screening.   
Conclusions: A countrywide organised HPV-based cervical screening programme with a 5-year 
screening interval may help identify a substantial number of neoplasias and potentially 
prevent more cervical cancers without increasing the burden of testing.  
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4.2.2. Introduction		
Cytology-based cervical screening has reduced cervical cancer incidence more pronouncedly 
where organised programmes have been implemented, as shown by several time trend and 
age-period-cohort analyses of incidence and mortality in Europe[1–3] and worldwide[4]. For 
instance, in England and Wales, opportunistic screening had reduced cervical cancer deaths by 
40% in young women by 1987[5] and a further decline in mortality to less than a third 
projected was seen in the decade following the organisation of a national screening 
programme[3]. 
Several countries with organised programmes (e.g. the Netherlands and Australia) are now 
transitioning from using cytology to using human papillomavirus (HPV) DNA testing as the 
primary screening[6,7] on the basis of the emergent evidence of greater protection against 
high-grade pre-malignant lesions and invasive cervical cancer and safe extension of the 
screening interval conferred by HPV DNA testing compared to cytology as primary screening 
test. The higher sensitivity and slightly lower specificity to high-grade precancerous lesions of 
HPV testing compared to cytology (whether used for primary testing alone or as adjunct to 
cytology-based screening) has been demonstrated in several European and North American 
split-sample studies[8] and randomised controlled trials (RCTs)[9–13]. The lower incidence of 
cervical cancer following primary HPV screening compared to cytology was shown in the 
follow-up analysis of four large European RCTs as well as the safety of prolonging the screening 
interval to at least 5 years[14]. Several large trials in Europe[14,15] and North America[16–18] 
also demonstrated the lower risk of cervical cancer following a negative HPV result compared 
to that after a negative cytology, with Gage and colleagues’ analysis[17] of Kaiser Permanente 
North California data (largest and longest experience with routine HPV screening) estimating a 
lower risk of high-grade precancer with 5-yearly HPV screening than with 3-yearly cytology.   
Other advantages of HPV-based screening include the high reproducibility and better quality 
assurance of an automated test, its potential to improve coverage of non-attenders with 
implementation of self-sampling, and its potential to be less affected by the foreseen 
reduction on prevalence of cervical lesions due to vaccination than cytology[19].  
Primary HPV screening entails effective management of HPV-positive results given the greater 
sensitivity of primary HPV DNA testing compared to primary cytology. As cytology has been 
widely used in cervical screening and is more specific for cervical intraepithelial neoplasia 
(CIN)2+ than HPV testing[20], it can safely reduce the high colposcopy referral rates expected 
when used in triage of HPV-positive women compared to immediate referral of HPV-positives 
for colposcopy[21]. Alternative triage tests have not yet been approved[19].  
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Portugal is likely to benefit from improvements in screening quality and coverage conveyed by 
organised screening to reduce incidence and mortality of cervical cancer further[22]. Publicly-
funded opportunistic cervical screening is ubiquitous but has recently been supplemented by 
organised cytology-based regional programmes that have extended screening to different 
populations, with distinct protocols and technologies[23]. Additionally, the Portuguese 
Ministry of Health now  recommends HPV testing for primary screening of women aged 25-60 
every 5 years[24].  There may be benefits in moving to a HPV-based uniform countrywide 
organised approach, but this has not been formally assessed.  
Mathematical models of HPV infection and cervical disease progression have been widely used 
internationally to inform cervical screening policies.  While large long-term trials are necessary 
to collect primary evidence on the impact of screening protocols on cancer incidence in a 
particular context, mathematical models are a  useful tool to combine the existing evidence 
and predict the impact of different screening algorithms involving alternative technologies in 
varied populations from those in trials[25].  
Given the mix of screening efforts currently in place, we investigated the impact of the 
transition from an exclusively opportunistic approach using conventional cytology to an 
organised programme using liquid-based cytology (LBC) or HPV DNA testing as primary 
screening technology. 	
4.2.3. Methods		
We adapted an existing model of HPV acquisition and progression of cervical disease 
previously developed by Bains and colleagues (described in the Appendix to this thesis).  Our 
main aim was to compare the effectiveness of alternative screening protocols in Portugal in 
terms of cervical cancer cases and related deaths prevented. 
The static, stochastic, individual-based model developed by Bains and colleagues consists of 
three main components: (1) acquisition of HPV infection, (2) natural progression to cervical 
cancer in HPV-positive women, and (3) detection and treatment of cervical high-grade lesions 
and cancer.   
In Bains and colleagues’ model, HPV type-specific acquisition is simulated accounting for 
individuals’ age and level of sexual activity. HPV-positive women can then develop cervical 
lesions which may progress to cancer or regress spontaneously at any stage of disease 
progression. We used country-specific inputs for each component and calibrated Bains and 
colleagues’ model to Portuguese data on HPV prevalence and cervical cancer incidence. 
Subsequently the impact of alternative screening strategies was predicted by overlaying a 
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screening component to the natural history of the disease. Figure 4-1 provides a schematic 
diagram of our adaptation of the Bains and colleagues model.  
Infection	acquisition	model	
We parameterised Bains and colleagues’ model of infection acquisition with Portuguese data 
to generate a modelled cohort of women representative of Portuguese women in terms of 
age- and type-specific HPV prevalence. Details on the parameterisation and calibration of the 
HPV acquisition component of the model are provided in Supplementary material 4.3.1. 
In Bains and colleagues’ model of HPV infection, the number of infected women over time was 
determined by their risk of acquisition and clearance of HPV infection. Women were assumed 
to become susceptible after clearing the infection, given the unclear protection from re-
infection conferred by naturally acquired immunity[26,27]. The risk of HPV acquisition was 
modelled as a function of women’s sexual behaviour, the number of infectious male partners, 
and the transmissibility of HPV. The probability of sexual contact with an infected partner by 
age and activity level was determined by HPV male prevalence and the age mixing matrix. HPV 
infection acquisition was dependent on the number of sex acts and the transmissibility per 
sexual act rate. Eight types of HPV were modelled: 16, 18, 31, 33, 45, 51, 52, 58. Simultaneous 
infections by multiple HPV types were assumed independent. 
We modified this model by characterising Portuguese women’s sexual behaviour with 
distributions for age of sexual debut, partner acquisition rate, age of new partner, duration of 
relationship, and frequency of sex acts obtained from individual-patient data of a 2007 
Portuguese population-based sexual health survey[28].  
The number of infectious male partners was assumed constant over the lifetime of each 
modelled cohort of women. We derived age- and type-specific male HPV prevalence in 
Portugal from Portuguese female HPV prevalence adjusted by the ratio of male and female 
HPV prevalence in England (Supplementary material 4.3.1). 
Women’s HPV type-specific clearance parameters and transmissibility per sexual act, and  
men’s seroconversion and clearance rates were calibrated by fitting the model's predicted pre-
vaccination HPV type-specific prevalence to data from the population-based cross-sectional 
Cervical Lesions Observed by Papillomavirus Types – A Research in Europe (CLEOPATRE) study 
in Portugal[29,30]. The posterior distributions for the fitted parameters, used to run our 
analyses, were found via an adaptive Metropolis algorithm using Markov Chain Monte Carlo 
simulation implemented in R[31]. We incorporated deviance of the model output to the 
observed HPV prevalence (-2*log(likelihood))  in Bains and colleagues’ functions to measure 
goodness-of-fit, using the likelihood function of the binomial distribution. We used the priors 
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defined by Bains and colleagues for male and female HPV clearance rates, and non-informative 
priors for transmissibility per sexual act and male seroconversion rate.  
Disease	progression	model	
Bains and colleagues modelled progression from HPV infection to pre-malignant cervical 
lesions via a set of conditional probability functions, where cytological outcomes are 
interdependent, generating time-dependent HPV type-specific probabilities of the different 
cytological outcomes (described in the Appendix to this thesis). Progression rates for 
cytological outcomes fitted to English data on LBC and HPV DNA test outcomes by Bains and 
colleagues were used for Portugal, based on the assumption that disease progression following 
HPV infection is independent from women’s country of origin and the performance of cytology 
is comparable between the two countries (Supplementary material 4.3.2). Consequently, the 
eight most prevalent high-risk HPV types in England were modelled: 16, 18, 31, 33, 45, 51, 52, 
and 58. We also used Bains and colleagues’ estimates for the probabilities of the distinct 
colposcopy outcomes conditional on women’s cytological outcome (based on data from the 
cervical screening programme in England), assuming the same diagnostic performance for 
colposcopy in both countries.  Our model uses the British Society for Clinical Cytology 
terminology for cytological outcomes (normal, borderline change, low-grade dyskaryosis 
(mild), high-grade dyskaryosis (moderate), or high-grade dyskaryosis (severe)) adopted in 
England for histological results[32].  
Bains and colleagues modelled the incidence of HPV type-specific cervical cancer as a function 
of time since HPV infection (detailed in the Appendix to this thesis). Progression from HPV 
infection to cervical cancer was modelled independently for squamous and adenocarcinomas. 
For squamous cell carcinomas, time since infection to cancer clinical detection was modelled 
as a function of time since infection to cancer onset and time since cancer onset to its clinical 
detection, whereas time since infection to clinical diagnosis of adenocarcinomas was modelled 
unabridged using a gamma distribution. Like Bains and colleagues, we used a gamma 
distribution to model time since infection to onset of squamous cell carcinomas for Portugal; 
however, we assumed that time from cancer onset to clinical detection followed a lognormal 
distribution, as it fitted the observed incidence better that the exponential distribution used 
for England. 
Posterior distributions for these non-directly measurable cancer-related parameters were 
calibrated to cervical cancer incidence in Portugal[33–38]. We limited the fitting target to 
incidence in women under 50 years of age as our model cannot capture the cohort effects 
reflected in the observed incidence for older age groups[39]. For HPV 16 and 18 squamous cell 
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carcinomas, we assumed that the gamma parameters modelling time to cancer onset were 
uniformly distributed. We ran the model with several sets of values for the gamma and the 
lognormal parameters and selected the best fitting set by visual inspection of the fit. For the 
remaining HPV types and for adenocarcinomas, we selected among Bains and colleagues’ 
posterior distributions for England those that visually better fit type-specific incidence in 
Portugal. 
Age-at-diagnosis-specific mortality rates for cervical cancer were derived from survival data 
reported by the Portuguese cancer registry of the North region[40] and applied for 5 years 
after diagnosis to women with detected cancer, whose survival was assumed to be the same 
as in the general population from then onwards[41]. Further details on disease progression 
model and its parameterisation and calibration are given in Supplementary material 4.3.2. 
Screening	model	
For each screening strategy, the model was run for 5 cohorts of 10,000 women from age 10 
and followed over their lifetime. The occurrence of events, such as HPV acquisition or 
attendance of a screening appointment, was modelled in months. To capture the uncertainty 
in the fitted parameters, the model was run with 1,000 distinct combinations of parameter 
values randomly drawn from their distributions.  
The screening component was originally structured by Bains and colleagues (in the Appendix 
to this thesis) to model screening frequency as a function of the individual’s age and previous 
screening attendance history. Given the lack of data on Portuguese women’s screening 
attendance, we restructured the screening component to model women’s probability of 
attending subsequent screens and the waiting time to their next screen independently from 
their previous attendance. 
Decision trees for each strategy were developed specifically for the Portuguese context  and 
incorporate the mapping between the Bethesda system used in Portugal (normal, atypical 
squamous cell of undetermined significance (ASC-US), low-grade squamous intraepithelial 
lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL) and that of the British Society 
for Clinical Cytology[42,43] (detailed in Supplementary material 4.3.3). We also adapted the 
relevant model functions to accommodate opportunistic screening and repeat cytology triage 
(which were not modelled for England). 
A no screening strategy and several cervical screening protocols were modelled independently. 
Table 4-1 summarises the characteristics of the cervical screening protocols modelled. Strategy 
1 is intended to represent the widespread opportunistic conventional cytology-based 
screening in Portugal (prior to the introduction of organised programmes and still 
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predominant), where ASCUS is triaged at 6 months with repeat cytology (strategy 1). We also 
modelled the introduction of HPV testing to immediately triage ASCUS and LSIL (strategy 2).   
We then simulated fully organised cytology-based primary screening with repeat cytology 
(strategy 7) and HPV triage (strategy 3), assuming screening frequency and compliance under a 
country-wide organised programme in Portugal would be the same as in the organised cervical 
screening programme in England.  
The screening algorithms recommended by the Portuguese Society of Gynaecology[44] for the 
opportunistic and organised approach were used to characterise strategies 1- 3 and 7. We also 
modelled HPV triage in an organised system following the English cervical screening 
programme protocol[45] (strategy 6), under the same screening frequency and compliance 
assumptions as strategy 3. 
Finally, we modelled the adoption of HPV DNA testing for primary screening following the 
management algorithm by the English cervical cancer screening programme for HPV primary 
screening pilot protocol using a screening interval of 3 and 5 years in strategies 4 and 5, 
respectively[46].  
Opportunistic and organised screening were recreated in our model via use of alternative data 
and assumptions for the proportion of women never screened, the age at first screen, time to 
next screen, and compliance with referrals for colposcopy and screen or post-treatment 
follow-up.  
Screening frequency under opportunistic screening (i.e. the proportion of women never 
screened, the age at first screen, and time to next screen) was characterised using individual-
patient data from the Portuguese National Health Survey 2005/6[47]. The probability of a 
women being lost to follow up was assumed to be 0.50, as this is slightly below the lowest 
compliance rate to screening invitation reported in organised programmes in 2013 (55%). 
Compliance to repeat cytology referral was assumed to be 100% as 99% was reported in the 
Centre region, the only region where repeat cytology has been in place. Compliance with 
colposcopy referral was assumed to be 0.75, the mid-point of 10-40% estimates of non-
adherence to referral by Khanna and Phillips[48], e.g. 40% lost to follow-up in Nottingham, 
England before introduction of an organised programme in 1984, due to lack of Portuguese 
data to inform this parameter.  
To characterise organised screening in Portugal, we assumed that screening frequency would 
be similar to that in England under a similarly organised call-recall cervical screening 
programme; hence we used Bains and colleagues’ model of age at first screen  for women 
aged over 24.5 years in England, and the distribution of time since last adequate test reported 
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for women aged 25-64 in the NHS Cervical Screening Programme, England (2012-2013)[49]. 
We also assumed 10% of women would never be screened based on a population-based study 
on cytology attendance in the Manchester Health Authority Area (2004)[50].  
As the average screening attendance in Portuguese regional organised programmes was 82% 
(range: 55-86% in Algarve and Alentejo, respectively) in 2013, we assumed that 20% of women 
are lost to follow-up following identification of a cytological lesion, under organised screening. 
Colposcopy attendance was assumed to be 88%, the average in Portugal organised 
programmes (range: 59-92%, in Alentejo and North, respectively). 
Conventional cytology is the primary screen used in Portugal in areas not covered by an 
organised programme. For our analyses, we assumed conventional cytology and LBC had 
equivalent performance based on Arbyn and colleagues’ meta-analysis[51]. Potential 
advantages of LBC compared to conventional cytology, such as reduction of unsatisfactory 
samples and inter-laboratory discordance, are not accounted for in out model. The 
performance of the screening tests modelled was implicitly captured by our disease 
progression rates. The number of treatments performed in each strategy was estimated 
assuming that all CIN2+ cases were treated. The parameterisation of the screening model for 
each of these strategies is described in detail in Supplementary material 4.3.3. 
4.2.4. Results		
The predicted age-specific crude incidence of squamous cell carcinomas and adenocarcinomas 
in women undergoing the different strategies is shown on Figure 4-2.  Under a hypothetical 
scenario of no screening performed, cervical cancer incidence would be 11.7 and 11.0 per 
100,000 women using the 1976 and 2013 European Standard Population, respectively.  
If entirely cytology-based opportunistic screening had continued in place in the same way as 
prior to 2008 (strategy 1), the predicted  annual European age-standardised incidence (EASR) 
of squamous cell carcinoma and adenocarcinoma attributable to the modelled high-risk HPV 
types would be 7.5 and 7.2 per 100,000 women (EASR 1976 and 2013, respectively). In 
Portugal between 1998 and 2010, annual cervical cancer incidence varied between 11.6 and 
14.3 cases per 100,000 women (EASR 1976, including all HPV and histological types)[22] and 
we estimate 8.9-11.0 cases attributable to the modelled high-risk HPV types per 100,000 
women (EASR 1976). For squamous cell carcinoma, our predicted 5.5 incident cases per 
100,000 women attributable to the 8 high-risk HPV types modelled with opportunistic 
cytology-based screening (strategy 1) is just under our estimated 6.6 incidence per 100,000 
women (EASR 1976) based on data from the National Cancer Registry (2001-2010)[33–38].  
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An opportunistic programme with HPV triage of equivocal cytological results (strategy 2) is 
predicted to reduce cancer incidence similarly to strategy 1 (repeat cytology), whereas 
organised cytology- or HPV-based programmes (strategies 3-7) would reduce incidence to 3.6-
3.8 cases per 100,000 women (EASR 2013). 
Table 4-2 presents our model results in terms of number of tests and cervical cancer cases 
predicted, assuming the 2016 Portuguese population aged 10-89. The number of tests by age 
group is shown in Figure 4-3.  The average annual 640,000 primary cytologies predicted for 
opportunistic screening with repeat cytology (strategy 1) is comparable to our estimate of 
675,000 and 630,000 primary tests if 65% the Portuguese 2016 female population aged 20-64 
and 25-64, respectively, were screened every 3 years. Our estimates for the proportion of 
women never screened [35.5%, 95%CI 33.8%- 37.2% and 23.3% (95%CI 7.4%, 39.2%) aged over 
20 and 25-64, respectively] from data of the Portuguese National Health Survey 2005/6 are 
similar to Oliveira and colleagues estimates[52]. 
We predict that current practice (strategy 1) has prevented 30% of cervical cancer cases (220 
cases per year) compared to no screening at a cost of 680,000 annual cytologies and 20,000 
colposcopies.  A fully organised programme with repeat cytology (strategy 7) would reduce an 
additional 34% of cases compared to no screening requiring over 50% more tests than 
opportunistic repeat cytology.  
An opportunistic programme with HPV triage of ASCUS and LSIL approach with lesions 
followed by annual co-testing (strategy 2) would reduce a similar number of cancer cases to 
opportunistic repeat cytology despite 45% fewer colposcopies, given the greater proportion of 
cervical intraepithelial neoplasias among colposcopies performed in strategy 2 compared to 
strategy 1. Overall, HPV triage would involve 4% more tests due to a greater number of 
additional HPV DNA tests despite the fewer cytologies (3% of the total number of cytologies) 
and colposcopies required, but substantially lower burden for women by averting unnecessary 
colposcopies.  
If an organised strategy was adopted instead of an opportunistic strategy, then the greatest 
proportion of cervical intraepithelial neoplasias detected would occur among 25-29 year olds 
instead of among 35-39 year olds (Figure 4-3). 
A fully-organised HPV- or cytology-based screening programme (strategies 3 to 7) would 
reduce cancer cases by over 65% compared to no screening. On average, primary HPV 
screening every 3 years with cytology triage of HPV positive women (strategy 4) was the most 
effective protocol in reducing the incidence of cervical cancer and would entail similar total 
number of tests as a less follow-up intensive organised HPV triage programme (strategy 6), 
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and about 10% less than intense follow-up cytology-based strategies 3 and 7 compared to 
opportunistic repeat cytology (strategy 1). Primary 3-yearly HPV testing (strategy 4) would 
detect a similar number of CIN2+ cases with 38% fewer colposcopies, given the greater 
proportion of severe outcomes among colposcopies with strategy 4 (0.45 no CIN, 0.15 CIN1, 
and 0.41 CIN2+) than strategy 3 (0.65 no CIN, 0.12 CIN1, and 0.24 CIN2+). 
Extending the interval of primary HPV screening to 5 years (strategy 5) would lead to a similar 
reduction of cervical cancer incidence compared to organised programmes with a 3-yearly 
interval screening. However, strategy 5 would yield 34% fewer tests than HPV primary every 3 
years (strategy 4) and 40% less than the most screening intense programme (organised repeat 
cytology, strategy 7).  
Our model also shows that at age 35-39 the proportion of CIN2+ lesions detected was greatest 
under opportunistic cytology-based screening (strategies 1 and 2). The proportion of CIN2+ 
detected was higher in younger age groups with HPV triage (strategy 2) than with repeat 
cytology (strategy 1), and with organised screening (strategies 3 ,6, and 7) the proportion of 
CIN2+ lesions detected was greatest 10 years earlier (age 25-29).	
4.2.5. Discussion		
Primary HPV screening with cytology triage of HPV-positive women is likely to be more 
effective reducing cervical cancer incidence than most cytology-based strategies modelled. 
However, primary HPV testing with a 5-year screening interval would involve fewer tests than 
organised programmes based on 3-yearly screening and similar numbers of tests to that with 
opportunistic screening protocols despite the higher coverage, lesions follow-up, and 
adherence to screening.  
Our findings on the average effectiveness of HPV-based programmes relative to cytology 
primary screening  are consistent with the lower rates of cervical cancer with primary HPV 
than cytology in four large European randomised clinical trials[14], and also support the safe 
extension of the screening interval to 5 years. 
We also found that introducing HPV triage testing of ASCUS and LSIL would require fewer 
colposcopies than repeat cytology while preventing a similar number of cancers. Although the 
HPV triage protocol (triage referral for ASCUS or LSIL) involved more triage tests than repeat 
cytology (triage referral for ASCUS), the proportion of HPV-positive women would be smaller 
than that of women with repeat cytological result of ASCUS or worse, and the severity of 
lesions among women referred to colposcopy after HPV triage greater than among those 
referred after repeat cytology. Berkhof and colleagues[53] also predicted HPV triage of 
borderline or mild lesions (with immediate referral of HPV-positive women to colposcopy) to 
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require fewer cytologies and colposcopies than repeat cytology but preventing slightly more 
cancers, in their economic evaluation for the Netherlands. 
Our analysis predicts a change in the ages at which the detection of CIN2+ lesions is most 
frequent towards younger age groups with the transition from opportunistic to organised 
screening. A similar shift was found for the age of cervical cancer incidence in England 
between the early 1980s and the late 1990s, where age-at-diagnosis decreased accompanying 
the decline in incidence[22,54].  
Strengths	and	limitations	
Our model strengths include the integrated microsimulation of HPV infection and progression 
to cervical cancer with calibration to Portuguese age- and type-specific HPV prevalence and 
cervical cancer incidence, which provides a detailed representation of the population at risk of 
HPV infection and cervical cancer.  The simulation of individual women eligible for screening 
over a lifetime also facilitates a thorough characterisation of the screening eligible population 
(e.g., capturing the heterogeneity of screening attendance patterns), and it would have 
allowed investigating as well the impact of additional protocols targeting particular risk groups, 
such as that of self-sampling HPV testing, shown to be superior to re-invitation in attracting 
typical non-attendees[55]. For instance, we could have incorporated screening attendance 
dependent on women’s previous screening history, where the time to next screen would be a 
function of the time between previous screens. However, the limited data available on 
screening participation and outcomes of Portuguese women has hindered our use of the 
model full potential. Several methodological and data-driven limitations must be kept in mind.  
We modelled HPV types 16, 18, 31,33,45,51,52, and 58 because these were the types for 
which age-specific disease progression was available from the model fitted by Bains and 
colleagues to English data; hence, we are possibly missing some of the most prevalent types 
for cervical cancer in Portugal. According to the latest meta-analysis by the International 
Agency for Research on Cancer[56] ( which included 3 studies of Portuguese women with 
invasive cervical cancer, n=168), we may be missing 3.8% of cases due to HPV types 35 and 56 
(more prevalent than HPV 31,51, and 52 which were present in 3.6% of cases). A more recent 
retrospective study of 714 samples (1928-2005)[57] suggests that HPV 35 and 39 are more 
prevalent than HPV 51, which account in total for 2.6% of cases, 1.5% and 1.3%, respectively.   
Because of the lack of data on screening and colposcopy outcomes in Portuguese women, we 
used Bains and colleagues’ distributions for progression rates from HPV infection to 
precancerous lesions and for the distribution of colposcopy outcomes by cytological outcome, 
assuming disease progression and test performance to be independent of the 
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population/setting studied. However, Portuguese and English women may differ in exposure 
to risk factors for pre-malignant lesions. We found that Portuguese women are likely at lower 
risk for progression to cervical cancer than their English counterparts, e.g. in terms of smoking 
and contraception prevalence[22]. Hence, a slower progression to precancerous lesions among 
Portuguese women is likely. Also, we are possibly overestimating the performance of 
screening tests; particularly for cytology as the objective nature and automation of HPV DNA 
testing makes its inter-laboratory reproducibility more likely than for cytology. Although  
similar performance for conventional and LBC has been found in a meta-analysis[51] and two 
more recent randomised clinical trials in Italy[58] and the Netherlands[59], cytology’s 
performance varied noticeably among 15 European countries[60]. Ronco and colleagues’ 
analysis of key performance indicators showed that the performance of cytology-based 
screening programmes can vary substantially between settings and is generally better where 
screening has been organised for longer given the long-term monitoring and quality 
assurance[60]. Our model also does not capture potential benefits from using LBC compared 
to conventional cytology, such as faster interpretation and greater reproducibility[61].  
Our characterisation of opportunistic screening in Portugal was restricted by the scarcity of 
available data on screening frequency and attendance. The distribution for age of first screen 
and proportion of women never screened were estimated from the Portuguese National 
Health Survey 2005/6 data[47] (when cervical screening was exclusively opportunistic). 
However, given the lack of data on the actual time interval between screens, we also used data 
on the self-reported year of last cytology from the Portuguese National Health Survey 2005/6 
to derive age-specific screening intervals, by assuming that women’s next screen occurred 
within the year that followed the survey; hence, our average screening interval of 2.97 (95% CI 
0.83, 3.08) years under opportunistic screening is likely an overestimate. We also lacked the 
data to characterise long-term attendance patterns, as the time to next screen has been 
reported dependent on the previous screen interval in England (Bains and colleagues in 
Appendix to this thesis).  
We took a pragmatic but potentially suboptimal approach to calibrate the progression to 
cancer model to the observed incidence of cervical cancer in Portugal. For HPV 16 and 18, we 
only explored a narrow range of the parameter space with a limited number of proposed 
parameter values selected based on the posterior distributions found by Bains and colleagues 
for England. We also did not use an optimization algorithm to search for parameter values nor 
used an objective statistical measure of goodness-of-fit for the selection of the best fitting 
parameter sets. Instead of visually inspecting the fit of each proposal and using this to choose 
the next one, we could have used an automated method to more effectively search the 
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parameter space and objectively identify sets of values that better fit the target[62]. For 
instance, for the calibration of the HPV acquisition model, we used an adaptive Metropolis 
algorithm to search the parameter space and identify those that better match the target based 
on their likelihood to result in output that best fits the observed incidence. This approach 
would have led to a better match between predicted and observed incidence, more accurate 
estimates of the fitted parameters, and more reliable model outcomes, as illustrated by 
Morina and colleagues study of the impact of alternative calibration methods[63].  
For the remaining HPV types and for adenocarcinomas, we attempted to approximate the 
predicted incidence to the observed data by selecting the best matching posterior distributions 
fitted by Bains and colleagues for England. However, our predicted incidence overestimates 
the observed incidence of adenocarcinomas in Portugal. Hence, re-calibration with more 
efficient methods would be necessary to obtain appropriate country-specific estimates of 
these unmeasurable parameters and a better representation of the Portuguese setting. 
Type-specific HPV prevalence in Portuguese men was derived from prevalence in Portuguese 
women using Bains and colleagues’ models for English male seroprevalence and 
seroconversion, as we did not find Portuguese male prevalence estimates in the literature. We 
adjusted for differences in sexual behaviour between populations by applying the age- and 
type-specific HPV prevalence ratios between English and Portuguese women to men. Previous 
static models[64,65] modelled HPV incidence (the rate at which women become infected per 
unit of time) as a function of age but not of sexual activity or HPV prevalence over time, thus 
not capturing the heterogeneity in sexual behaviour (and subsequent risk of HPV acquisition) 
across women in a population.  
Parsimoniously, we did not explicitly model natural immunity to re-infection. Despite evidence 
of modest naturally acquired immunity (of unknown duration) to subsequent HPV infections in 
seropositive women[26,66], other modelling studies[67,68] have assumed an SIS structure. 
Baussano and colleagues’[69] model-based estimation of the probability of developing life-
long immunity after clearance suggests this is a likely pattern for HPV 16 (responsible for the 
majority of cervical cancers) but may not be valid for the remaining types.  
We modelled an unvaccinated population, and so do not capture the indirect protection 
conferred by vaccinated individuals to unvaccinated ones. Vaccination of girls is expected to 
diminish the incidence of HPV infection and cervical lesions in future screening cohorts, as 
vaccinated women are not susceptible to the vaccine HPV-types and not infectious to 
susceptible men. Also, the reduction in prevalence of precancerous lesions is also expected to 
diminish substantially the positive predictive value of cytological screening tests. Primary HPV 
DNA screening with cytology triage of HPV-positive women is then likely to be a more 
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adequate approach as the prevalence of high-risk cytological lesions will be higher among HPV-
positive women and hence so will the positive predictive value of cytology be.[70] HPV 
vaccination was introduced for thirteen-year old girls in Portugal in 2008 with a catch-up 
campaign for 17-year olds, who have now reached the age of screening. However, older 
cohorts of women have not been vaccinated, so our model results provide important evidence 
to inform screening algorithms for those cohorts. 
Moreover, we have not exhaustively explored all the alternative strategies for screening that 
are currently available in Portugal. A particularly relevant alternative is HPV16/18 genotyping. 
The impact of strategies where women positive to HPV16/18 are immediately referred to 
colposcopy should be investigated, as this is the most recent recommendation from the 
Portuguese Ministry of Health and is being piloted in the North of Portugal. 
Policy	implications	
Our findings support the adoption of primary HPV screening with cytology triage of positive 
results under a well organised programme with high coverage and adherence similar to those 
in the English Cervical Screening Programme. Widespread screening is one of the main 
challenges to the successful implementation of organised programmes[71,72] and such 
transition will require the creation an effective invitation system, the adjustment of services 
and integration of information systems between primary care centres and hospitals, as well as 
between screening and cancer registries, with intensive monitoring and high-quality assurance 
in the different stages of the screening process[60,73,74].  
In the context of an organised HPV-based programme, HPV testing offers additional 
advantages for cervical cancer prevention compared to cytology, such as the potential to 
deploy self-collected HPV testing in parallel to the clinic-based programme to improve 
adherence of under-screened women, necessarily at higher risk of cervical cancer. 
As more women vaccinated for HPV 16 and 18 become screening eligible in Portugal, it is 
important to also note that prevalence monitoring can be facilitated by primary HPV testing 
and used to adapt future screening protocols[75]. 
Although our model was parameterised and calibrated to Portugal, the main findings of this 
study are likely generalisable to other European countries, such as Spain and France, with 
similar cervical cancer epidemiology and who are also transitioning from opportunistic to 
organised primary HPV screening.  
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4.2.8. Tables	
Table 4-1. Main characteristics of the screening strategies modelled 
 Strategy 1 Strategy 2 Strategy 7 Strategy 3 Strategy 6 Strategy 4 Strategy 5 
Screening system Opportunistic Opportunistic Organised Organised Organised Organised Organised 
Primary test Cytology Cytology Cytology Cytology Cytology HPV DNA HPV DNA 
Triage test Repeat 
cytology  
HPV DNA Repeat 
cytology  
HPV DNA HPV DNA Cytology Cytology 
- threshold for referral  
(assumed wait time for 
triage) 
- ASCUS  
(6 months) 
- ASCUS or 
LSIL  
(immediate) 
- ASCUS  
(6 months) 
- ASCUS or 
LSIL 
(immediate) 
- ASCUS or 
LSIL 
(immediate) 
- HPV positive 
(immediate) 
- HPV positive 
(immediate) 
Diagnosis test Colposcopy  Colposcopy  Colposcopy  Colposcopy  Colposcopy  Colposcopy  Colposcopy  
- threshold for referral        
following primary test >=LSIL HSIL >=LSIL HSIL HSIL   
triage test >=ASCUS >=ASCUS >=ASCUS >=ASCUS >=ASCUS HPV positive & 
>=ASCUS 
HPV positive & 
>=ASCUS 
- follow-up test for normal 
colposcopy 
Cytology Co-testing* Cytology Co-testing*  Cytology HPV DNA HPV DNA 
Treatment    Conisation Conisation Conisation Conisation Conisation Conisation Conisation 
- threshold for referral - CIN2+ 
- Persistent 
CIN1 (24 
months)  
- Post-
treatment 
CIN1+ 
- CIN2+ 
- Persistent 
HSIL (12 or24 
months) 
- Post-
treatment 
CIN1+ 
- CIN2+ 
- Persistent 
CIN1 (24 
months)  
- Post-
treatment 
CIN1+ 
- CIN2+ 
- Persistent 
HSIL (12 or24 
months) 
- Post-
treatment 
CIN1+ 
- CIN2+ 
 
- CIN2+ 
 
- CIN2+ 
 
- follow-up test Cytology & 
Colposcopy 
Cytology & 
Colposcopy 
Cytology & 
Colposcopy 
Cytology & 
Colposcopy 
Cytology HPV DNA HPV DNA 
Proportion of women 
never screened 
0.355 α 0.355 α 0.1[50] 0.1[50] 0.1[50] 0.1[50] 0.1[50] 
Screen age range, 
minimum – maximum 
19-66 (85 if 
follow-up) 
19-66 (85 if 
follow-up) 
24-66 (85 if 
follow-up) 
24-66 (85 if 
follow-up) 
24-66 (85 if 
follow-up) 
24-66 (85 if 
follow-up) 
24-66 (85 if 
follow-up) 
Age at first screen, 
median, mean (IQR) years 
33.00, 32.37 
(28.88, 36.67)α 
33.00, 32.37 
(28.88, 36.67)α 
26.12, 28.09 
(25.18, 28.29)β 
26.12, 28.09 
(25.18, 28.29)β 
26.12, 28.09 
(25.18, 28.29)β 
26.12, 28.09 
(25.18, 28.29)β 
26.12, 28.09 
(25.18, 28.29)β 
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Screening frequency, θ  
median, mean (IQR) years 
1.67, 2.97 
(0.83, 3.08)α  
1.67, 2.97 
(0.83, 3.08)α 
2.08, 3.02 
(1.00, 3.42)δ 
2.08, 3.02 
(1.0, 3.42) δ 
2.08, 3.02 
(1.0, 3.42) δ 
2.08, 3.02 
(1.0, 3.42) δ 
4.08, 4.72 
(2.33, 6.25) σ 
Probability of loss to 
follow-up of cytological 
abnormality or treatment 
0.5 0.5 0.2 0.2 0.2 0.2 0.2 
Probability of complying 
with repeat cytology 
referral 
1 n.a. n.a. n.a. n.a. n.a. n.a. 
Probability of complying 
with colposcopy referral 
0.75 0.75 0.88 0.88 0.88 0.88 0.88 
Probability of complying 
with treatment referral 
0.97 0.97 0.97 0.97 0.97 0.97 0.97 
Lesions follow up waiting 
time, months 
Post-triage: 
- ASCUS & normal 
cytology 
- ASCUS & HPV-negative 
- HPV-positive & normal 
cytology  
Post-colposcopy: 
- normal colposcopy 
 
 
- CIN1 
 
Post-treatment  
 
 
 
 
6 (for 1 yr) 
 
- 
- 
 
 
6 (for 1 yr) 
 
 
6 (for 2 yrs) 
 
6 (for 2 yrs, 
annually 
afterwards) 
 
 
 
 
-  
 
routine 
-  
 
 
12 (for 2 
yrs**) 
 
12 (for 2 yrs) 
 
12 (for 2 yrs, 
routine 
afterwards) 
 
 
 
6 (for 1 yr) 
 
- 
- 
 
 
6 (for 1 year) 
 
 
6 (for 2 yrs) 
 
6 (for 2 yrs, 
annually 
afterwards) 
 
 
 
 
-  
 
routine 
-  
 
 
12 (for 2 
yrs**) 
 
12 (for 2 yrs) 
 
12 (for 2 yrs, 
routine 
afterwards) 
 
 
 
- 
 
routine 
- 
 
 
routine 
(minor) /12 
(high-grade) 
12  
 
6 (once, 
routine 
afterwards) 
 
 
 
- 
 
- 
12 (for 2 yrs) 
 
 
routine  
 
 
12 (for 2 yrs) 
 
12 (for 2 yrs, 
routine 
afterwards) 
 
 
 
- 
 
- 
12 (for 2 yrs) 
 
 
routine  
 
 
12 (for 2 yrs) 
 
12 (for 2 yrs, 
routine 
afterwards) 
Note: Recommended screening ages & interval by the Portuguese Society of Gynaecologists: 20-64 every 3 years (opportunistic cytology-based strategies), 25-64 
every 3 years (organised cytology-based strategies), 30-64 every 5 years (organised HPV-based strategies alongside cytology every 3 years for women aged 25-
29)[44] n.a., not applicable; *Co-testing corresponds to testing with cytology and HPV DNA testing ; **follow-up of LSIL/HPV-negative or normal colposcopy following 
ASCUS/HPV-positive or HSIL results at 12 and 24 months, or follow-up of normal colposcopy following LSIL at 12 and 36 months; α individual patient data from the 
Portuguese National Health Survey 2005/6[47]; β obtained using Bains and colleagues[76] model of age at first screen derived from NHS CSP England data; δ derived 
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from NHS CSP England report (2012-2013)[49]; σ assumed 2 additional years for each age category of the distribution reported by NHS CSP England (2012-2013)[49] 
where women aged 25-49 and 50-64 are invited for screening every 3 and 5 years, respectively. θ Screening frequency in England was based on cross-sectional data 
on time since last screen, rather than actual screen interval data. Consequently, the organised screening strategies modelled have a shorter median interval than 
that expected (for 3-yearly strategies, 2.1 years versus 3 years, respectively), being effectively simulations of 2-yearly and 4-yearly organised screening strategies. 
This error – to be corrected in subsequent publication - has affected the health outcomes predicted for each strategy and the results of this analysis. 
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Table 4-2. Predicted total number of tests and cancers by strategy, mean (95%CI) 
 
No 
Screening 
S1  
(OPP Repeat 
Cytology) 
S2  
(OPP HPV 
triage) 
S5  
(ORG HPV 5y) 
S6  
(ORG HPV 
triage ENG) 
S7  
(ORG Repeat 
Cytology) 
S3  
(ORG HPV triage 
PT) 
S4  
(ORG HPV 3y) 
Primary 
cytologies 
- 639000 
(632000; 
646000) 
639000 
(630000; 
649000) 
- 901000 
(893000; 
908000) 
969000 (961000; 
978000) 
913000 (906000; 
920000) 
- 
Triage 
cytologies 
- 17900 (13500; 
22500) 
- 33600 (32500; 
34500) 
- 27000 (21300; 
32200) 
- 41600 (40300; 
42700) 
HPV DNA 
tests 
- 0 (0; 0) 50000 (41000; 
60000) 
592000 
(587000; 
597000) 
50000 (43000; 
57000) 
0 (0; 0) 83000 (72000; 
98000) 
909000 
(901000; 
917000) 
Colposcopies - 19800 (16100; 
23800) 
10800 (9200; 
13100) 
11700 (11300; 
12100) 
14300 (12000; 
16800) 
47000 (40100; 
54500) 
23100 (20000; 
27000) 
14300 (13900; 
14800) 
Treatments - 2200 (1900; 
2600) 
2700 (2500; 
3000) 
5000 (4700; 
5300) 
4800 (4500; 
5400) 
4600 (4100; 5500) 5500 (5200; 6000) 5900 (5600; 
6300) 
Total tests - 676000 
(664000; 
689000) 
700000 
(685000; 
715000) 
637000 
(631000; 
642000) 
965000 
(955000; 
976000) 
1043000 
(1024000; 
1062000) 
1019000 
(1002000; 
1040000) 
965000 
(957000; 
974000) 
SCC 501 (256; 
747) 
329 (267; 419) 325 (265; 405) 172 (132; 220) 153 (115; 200) 148 (108; 195) 146 (110; 191) 145 (109; 189) 
Screen-
detected SCC 
- 69 (47; 97) 67 (44; 93) 58 (37; 84) 49 (31; 70) 46 (27; 68) 44 (27; 63) 45 (27; 65) 
Clinically-
detected SCC 
501 (256; 
747) 
260 (209; 330) 259 (208; 324) 115 (86; 148) 104 (77; 135) 102 (74; 137) 102 (77; 133) 101 (73; 132) 
ADC 134 (20; 
341) 
96 (33; 222) 87 (29; 208) 62 (17; 156) 60 (17; 146) 62 (18; 158) 54 (13; 144) 52 (14; 132) 
Total cancers 634 (309; 
999) 
425 (328; 566) 413 (322; 553) 234 (167; 337) 213 (153; 308) 210 (144; 308) 199 (141; 297) 197 (139; 287) 
Cancer 
reduction*, % 
- 33 35 66 66 67 69 69 
Total tests 
change**, % 
- - 4 -6 43 54 51 43 
For the 2016 Portuguese female population aged 15-89; * compared to no screening; ** compared to strategy 1 
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4.2.9. Figures	
 
Figure 4-1. Diagram of model components, data, and parameters 
Double and simple arrows indicate deterministic and stochastic relationships, respectively 
Ellipses indicate variables, rectangles indicate data 
Double and single circled ellipses indicate unknown or known parameter, respectively  
Double and single lined rectangles indicate calibration target or parameterisation data, respectively 
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A 
 
B 
 
Figure 4-2. Predicted and observed age-specific crude incidence of squamous cell carcinomas 
(A) and adenocarcinomas (B) 
Dots and error bars represent the mean and 95%CI of observed incidence, respectively (fitting target in 
blue and non-targeted in light blue); blue thick line and dotted lines correspond to the mean and 95%CI 
incidence for strategy 1 (fitted to observed incidence); remaining lines correspond to the mean 
incidence predicted for no screening and strategies 2 to7. 
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Figure 4-3. Age-specific number of tests per strategy, mean and 95%CI 
Strategy 1 – Opportunistic repeat cytology   
Cytology primary test Cytology triage test Colposcopy 
   
Strategy 2 – Opportunistic HPV triage of 
ASCUS  
  
Cytology primary test HPV Triage test Colposcopy 
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Strategy 7 – Organised repeat cytology   
Cytology primary test Cytology triage test Colposcopy 
   
Strategy 3 – Organised HPV triage of ASCUS and LSIL – Portuguese Society of Gynaecology 
protocol  
 
Cytology primary test  HPV Triage test Colposcopy 
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Strategy 6 – Organised HPV triage of ASCUS and LSIL – NHS CSP England protocol  
Cytology primary test HPV Triage test Colposcopy 
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Strategy 4 – Organised Primary HPV screening every  3 years  
HPV primary test  
 
Cytology Triage test 
 
Colposcopy 
 
Strategy 5 – Organised Primary HPV screening every  5 years  
HPV primary test  Cytology Triage test Colposcopy 
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 Supplementary	Material	
4.3.1. HPV	acquisition	model	
We re-parameterised the transmission component of Bains and colleagues model (described in 
the Appendix to this thesis) to generate Portuguese age- and type-specific HPV prevalence 
among the modelled women, i.e. the number of infected women over time.  
In Bains and colleagues’ model, prevalence of HPV infection is determined by the risk of 
acquisition of HPV infection and its persistence. The risk of HPV acquisition is a function of (a) 
women’s sexual behaviour, (b) the number of infectious male partners, and the (c) 
transmissibility of HPV, and the persistence of HPV infection depends on (d) women’s natural 
clearance of the infection. We used a susceptible-infected-susceptible model of HPV infection 
in women, where the possible naturally acquired immunity to cervical HPV is not explicitly 
modelled. 
This unusual approach of including sexual behaviour in a static model developed to evaluate 
the impact of screening-only strategies taken by Bains and colleagues has the advantage of 
capturing the heterogeneity in behavioural risk for the acquisition of HPV infection.  
Herein we present the derivation of parameter values used in the HPV acquisition component 
for the Portuguese context: those estimated directly from data on (a) sexual behaviour and (b) 
male prevalence, and (c) not directly observable parameters that were derived by model fitting 
to observed data, namely HPV transmissibility per sex act, female clearance shape parameter 
and rate parameters, male seroconversion rate, and male clearance rate. 
4.3.1.1.	Sexual	behaviour	
The HPV acquisition component of the model requires estimates of the following parameters 
on sexual behaviour that determine women’s risk of acquiring HPV from infected partners: 
1. Age of sexual debut 
2.  Partner acquisition rate 
3. Age of the new partner 
4. Duration of the relationship  
5.   Frequency of sex acts  
We derived distributions for these parameters from individual-level data of the 2007 survey on 
sexual behaviour and HIV/AIDS in mainland Portugal (1,860 valid questionnaires from sexually 
active women aged 18-65 years)[2].   
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1.	Age	of	sexual	debut	
In the model, the age of sexual debut for each individual woman is randomly sampled from the 
empirical cumulative density function of the reported age of sexual debut by Portuguese 
women[2] (Supplementary Figure 4-1), which determines the transition from unsusceptible to 
susceptible to HPV infection.  
  
Supplementary Figure 4-1. Empirical cumulative probability of sexual debut 
2.	Partner	acquisition	
The modelled time to the next partnership is determined by the rate of acquisition of a new 
partner, which was derived from the number of new partners last year. The number of new 
partners is not part of the data collected in the Portuguese survey, hence an approximation 
was estimated from the reported total number of partners last year and reported first time sex 
dates for the last 2 most recent partnerships. For participants reporting more than 2 partners 
last year and providing consistent dates for these relationships, the number of new 
partnerships last year was assumed to be the same as the total number of partners in that 
time period. For those reporting concurrency in last 5 years, we assumed one long-term 
relationship and subtracted that from the total number of partners last year.  
We tested the fit of some statistical models to the number of new partners - Poisson, negative 
binomial, geometric - using the gamlss package (allows estimating parameters using the 
maximum likelihood method for a wide family of distributions) and the zero-inflated Poisson 
(ZIP) model showed lower global deviance (Supplementary Figure 4-2). The ZIP model is a 
mixture of two components: a Binomial distribution, with the value 0 with probability sigma, 
and the Poisson distribution with probability 1-sigma. It lends itself to the interpretation of the 
probability of women being available or not to a new sexual partnership, and among those 
available there is a rate of partner acquisition that follows a Poisson distribution, expressing 
the probability of a given number of new partners last year.  
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Supplementary Figure 4-2. Women’s number of new partners last year (observed and 
modelled) 
According to this model, the baseline proportion of women not available for a new sexual 
partnership is approximately 0.55. For those available, some do not have a new sexual partner 
(0.16), most have 1 new partner (0.30) and the remaining have 2 or more (0.54). The annual 
rate of partner acquisition decreases by approximately 9% with each year of age and the 
average annual rate of partner acquisition for 20-year old women is just over 1 partner per 
year (1.12). 
We stratified risk of infection by age and activity level. We fitted the ZIP model to different 
activity level thresholds and age bands and the best goodness-of –fit (lowest deviance) was 
obtained using 5 age bands [17-19, 20-24, 25-29, 30-39, 40-65] and 3 activity levels [0-
0.51,0.52-0.84,0.85-1] (Supplementary Figure 4-3). 
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Supplementary Figure 4-3. Number of new partners last year by age group and activity level (observed and modelled)
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3.	New	partner	age	
The age mixing matrix used in the model is based on the partners’ age difference and provides 
the cumulative probability distribution of a partner’s age for each woman’s sexually active year 
of age. Partners’ age difference was derived from women’s reported age of most recent 
partner and women’s own age at first time sex with the most recent partner (partners’ ages at 
start of the relationship). Women’s own age at first time sex with the most recent partner was 
estimated from the difference between the reported year of birth and the reported year of 
first time sex with most recent partner. We assumed the partner’s age difference follows a 
Normal distribution and estimated the mean and standard deviation by woman’s year of age 
(Supplementary Figure 4-4). 
 
Supplementary Figure 4-4. Partner’s age difference by women’s age, years	
4.	Partnership	duration	
Relationship duration in the model is randomly generated using the fraction of occasional 
relationships (0.036, n=1,275 relationships) and the mean cumulative probability of 
relationship survival (Supplementary Figure 4-5). Estimates of partnership duration were 
derived from reported year and month of first time and last time sex with previous most 
recent partner, and year and month of first time sex with most recent partner. Last time sex 
with most recent partner was derived from reported categorical question (defining complete 
relationship as last sexual act more than 3 months ago) and the interview date. The interview 
date was not available for each individual, so we used the reported first interview date for 
each borough for right-censoring the data.  
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Supplementary Figure 4-5. Cumulative probability of relationship survival 
5.	Frequency	of	sex	acts	
The number of sex acts per month is randomly generated at each model iteration using the 
respective cumulative probability distribution of x acts (P(X<=x)) obtained from the Portuguese 
survey data (Supplementary Figure 4-6). We used the reported number of sexual acts last 
month by women in an active relationship (defined as less than 3 months since last sexual 
contact).  
 
Supplementary Figure 4-6. Empirical cumulative probability of x number of sex acts 
 
4.3.1.2.	Male	prevalence	
In Bains and colleagues model, the type-specific HPV infection status of partners for women of 
each sexually active age is pre-generated using the age mixing matrix and male prevalence 
curve (Bains and colleagues in the Appendix to this thesis). For each model simulation, a male 
prevalence curve (number of infected men by age) is randomly generated using a male 
infection model developed by Bains and colleagues (male prevalence as a function of age, 
seroprevalence, seroconversion rate, clearance and immunity waning rate, and female inter-
type and inter-country HPV prevalence ratios). The predicted English and Portuguese male 
type-specific HPV prevalence and details of our adaptation are provided herein.  
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Male infection model 
In Bains and colleagues’ model, male HPV prevalence in England is calculated using a 
seroconversion HPV male infection model developed and fitted to the English population by 
Bains and colleagues (in the Appendix to this thesis). English age-specific male HPV 16 and 18 
prevalence is modelled as a function of seroprevalence, seroconversion, clearance, and waning 
rates using a susceptible-infectious-recovered-susceptible model. Immunity waning rate was 
fixed at 0.05 per month for all HPV types (Bains and colleagues in the Appendix to this thesis).  
We used the seroconversion model developed by Bains and colleagues to obtain age- and 
type-specific HPV prevalence in English men. We then derived HPV prevalence for Portuguese 
men from Portuguese female prevalence using our estimates of inter-type and inter-country 
HPV prevalence ratios.  
In Bains and colleagues’ model of male infection, HPV 16 and 18 prevalence among English 
men is calculated using their seroconversion model from the seroprevalence function. The 
observed seroprevalence in English men[3] is assumed to follow the following hill function:  Seroprevalence	(t) = 0∗234563473 	,	with A=18.2117869, B=0.1793239, n= 19.9999864 for HPV 
16,and A=16.56897610, B=0.06720027, n=19.99995364 for HPV18, and male prevalence over 
50 years old was assumed constant (Bains and colleagues in the Appendix to this thesis).  
We used Bains and colleagues’ model to obtain England male HPV 16 and 18 prevalence and 
derived English male prevalence for the remaining HPV types from that for HPV 16 using inter-
type HPV prevalence ratios in English women, assuming the same ratios would be found 
among men (presented below). We also applied the inter-country female prevalence ratios to 
estimate male prevalence in Portugal from male prevalence in England, as outlined in the 
following equations: 
9:;<=>?@ = 	9:;<=?@AB × DEFGHIJK	DEFGHJK	5L	  , where 9:;<=>?@   is	the	prevalence	of		HPV type Q in age 
group R in males (S) in England (T), 9:;<=?@AB	is	that	for	HPV type 16, and U for females; and  9:;<=>?D = 	9:;<=>?@ × 	DEFGHIJVDEFGHIJK 				, where	(9) corresponds to Portugal. 
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Supplementary Figure 4-7. Type-specific predicted male HPV prevalence in Portugal and 
England 
Predicted prevalence for England and Portugal in blue and red, respectively 
Dots and lines or shaded areas represent mean and 95th percentile, respectively 
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Inter-type	HPV	prevalence	ratios	
English male prevalence of the remaining HPV subtypes was derived by applying bootstrapped 
HPVx/HPV16 prevalence ratios among English women (Supplementary Table 4-1) to HPV 16 
male prevalence.  
Supplementary Table 4-1. Summary of the HPVx/HPV16 prevalence ratio distributions 
(yearly 16-39 & 5-yearly 40-64) 
Age  HPV 31 HPV 33 HPV 45 HPV 51 HPV 52 HPV 58 
16 0.061  
(0;0.458) 
0.115 
(0;0.59) 
0.343  
(0.026;1.22) 
0.566  
(0.123;1.74) 
0.241 
 (0;0.83) 
0.353 
(0.033;1.297) 
17 0.448  
(0.051;1.491) 
0.255  
(0;0.718) 
0.302 
 (0;1.066) 
0.669  
(0.148;3.066) 
0.314 
(0;1.12) 
0.586  
(0.071;2.822) 
18 0.345 
(0.02;1.169) 
0.2  
(0;0.585) 
0.251 (0;0.879) 0.596 
(0.171;1.505) 
0.379 
(0.059;1.039) 
0.198 (0;0.753) 
19 0.383 
(0.015;1.809) 
0.162 (0;0.736) 0.296 (0;1.601) 0.541 
(0.074;2.044) 
0.286 (0;1.144) 0.581 
(0.124;1.938) 
20 0.401 
(0.054;1.612) 
0.105 (0;0.877) 0.164 (0;1.194) 0.606 
(0.119;1.889) 
0.295 (0;1.222) 0.346 (0;1.415) 
21 0.352 
(0.014;2.059) 
0.183 (0;0.841) 0.197 (0;1.068) 0.415 (0;1.178) 0.492 
(0.015;1.876) 
0.256 
(0.009;1.067) 
22 0.354 (0;2.967) 0.597 (0;9.081) 0.348 (0;2.844) 0.769 (0;4.942) 0.3 (0;3.8) 0.47 (0;4.242) 
23 0.445 (0;2.935) 0.21  
(0;1.679) 
0.506 (0;3.076) 0.57  
(0;4.459) 
0.952 
(0.066;5.471) 
0.281 (0;1.395) 
24 0.067  
(0;0.53) 
0.069 (0;0.952) 0.528  
(0;4.85) 
0.423 (0;3.207) 0.595 (0;3.295) 0.082 (0;0.724) 
25 0.375 
(0.027;3.222) 
0.228 
(0.001;0.861) 
0.542 (0;4.304) 0.593 
(0.052;4.626) 
0.444 (0;4.847) 0.443 (0;1.013) 
26 0.273 
(0.024;1.121) 
0.166 (0;1.145) 0.643 (0;4.375) 0.997 
(0.093;6.236) 
0.797 (0;5.76) 0.972 
(0.024;5.763) 
27 0.42 
(0.034;3.459) 
0.278 
(0.001;4.101) 
0.542 (0;4.159) 0.162 (0;0.822) 0.086 
(0.005;0.525) 
0.082 (0;0.618) 
28 0.134  
(0;0.56) 
0.258 
(0.001;1.243) 
0.092 (0;0.449) 0.585 (0;5.441) 0.156 (0;0.912) 0.128 (0;2.145) 
29 0.348 
(0.019;1.816) 
0.308 
(0.001;1.553) 
0.641 (0;7.928) 0.884 (0;8.237) 0.164 (0;1.082) 1.234 (0;9.489) 
30 1.804 
(0.062;16.3) 
0.587 (0;7.471) 0.149 (0;1.143) 0.556 (0;6.571) 0.854 (0;8.859) 1.395 
(0.001;13.14) 
31 0.227 (0;1.058) 0.231 (0;0.999) 0.709 (0;6.28) 1.575 (0;9.659) 0.624 (0;6.556) 0.171 (0;0.775) 
32 0.661 
(0.008;11.9) 
0.241 (0;6.765) 0.029 (0;0.392) 0.05 (0;0.757) 0.203 (0;0.937) 0.208 (0;0.949) 
33 0.674 (0;15.18) 0.017 (0;0.501) 0.319 (0;11.85) 0.267 (0;1.492) 0.621 (0;19.54) 0.07 (0;1.568) 
34 0.156 (0;1.994) 0.138 (0;2.612) 0.776 (0;17.9) 0.499 (0;12.42) 0.423 (0;9.822) 0.083 (0;1.532) 
35 0.399 (0;5.116) 0.538 (0;1.839) 0.059 (0;0.856) 1.246 (0;17.17) 0.277 (0;2.816) 1.987 (0;22.43) 
36 3.752 (0;179.9) 0.895 (0;25.51) 0.503 (0;16.42) 1.265 (0;53.01) 0.73 (0;8.503) 0.672 (0;31.13) 
37 0.166  
(0;3.39) 
0.024 (0;0.737) 0.045 (0;1.28) 1.042 (0;19.58) 0.677 (0;21.42) 0.579 (0;13.48) 
38 1.933 
(0.001;15.18) 
0.128 (0;0.811) 0.446 (0;2.154) 0.447 (0;3.456) 0.002 (0;0.196) 0.125 (0;1.507) 
39 0.49 
(0.001;3.959) 
0.265 (0;2.448) 0.08 (0;0.628) 2.511 (0;32.88) 0.158 (0;2.521) 0.378 (0;2.516) 
40-
44 
0.556 
(0.094;2.175) 
0.089 
(0.007;0.343) 
0.39 
(0.016;1.657) 
0.368 
(0.019;1.941) 
0.663 
(0.09;3.654) 
0.23 (0;2.077) 
45-
50 
0.486 
(0.078;2.244) 
0.254 (0;1.857) 0.817 
(0.062;4.111) 
0.836 
(0.087;4.052) 
0.628 
(0.036;3.188) 
0.643 
(0.018;3.931) 
55-
60 
0.587 
(0.028;2.791) 
0.145 
(0.001;1.126) 
0.319 
(0.001;1.549) 
0.236 
(0.02;1.402) 
0.283 
(0.014;1.736) 
0.483 
(0.016;2.505) 
60-
64 
0.666 
(0.002;9.747) 
0.045 (0;0.526) 0.012 (0;0.193) 0.342 (0;6.194) 0.564 
(0.001;12.46) 
0.965 
(0.034;10.67) 
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Inter-country	HPV	prevalence	ratios		
We used bootstrapped type-specific HPV prevalence ratios between Portuguese and English 
women to derive the Portuguese HPV male prevalence from that in England (Supplementary 
Table 4-2).  We assumed the same age- and type-specific proportions would be found between 
men.  
Portugal/England prevalence ratios were randomly generated from prevalence among women 
in both countries, assuming prevalence follows a binomial distribution of probability p 
obtained for each age group by maximum likelihood estimation from the country-specific 
prevalence data available. Maximum likelihood estimates were adjusted using the Wilson 
method to relocate central estimates when prevalence mle(p) is very close to zero (some age 
groups over 40 or less prevalent HPV subtypes)[4]. Also, the binomial distribution was 
truncated to the 95%CI when the randomly sampled English prevalence was zero (less 
prevalent HPV subtypes age groups over 50) to prevent infinite ratios. 
Supplementary Table 4-2. Portugal/ England HPV female prevalence ratios, mean (95%CI) 
HPV 
type 
Age group 
18-19 20-24 25-29 30-39 40-49 50-64 
HPV 
16  
0.681 
(0.338;1.149) 
0.69 
(0.482;0.945) 
0.51 
(0.308;0.761) 
0.351 
(0.071;0.725) 
0.406 
(0;1.129) 
0.432 
(0.087;0.974) 
HPV 
18 
0.498 
(0.185;0.922) 
0.285 
(0.114;0.517) 
0.403 
(0.079;0.88) 
0.908 
(0;2.323) 
0.998   
(0;2.93) 
1.081 
(0;2.921) 
HPV 
31 
0.618 
(0.117;1.444) 
1.347 
(0.785;2.149) 
1.377 
(0.706;2.36) 
0.372 
(0;0.906) 
1.554 
(0.272;3.585) 
0.343 
(0;1.004) 
HPV 
33 
0.964 
(0.142;2.647) 
0.795 
(0.332;1.52) 
0.371 
(0.062;0.88) 
0.69   
(0;2.013) 
2.685 
(0;9.524) 
2.102 
(0;8.034) 
HPV 
45 
0.473 
(0;1.263) 
0.239 
(0.046;0.522) 
0.095 
(0;0.257) 
0.602 
(0;1.776) 
0.775 
(0;2.241) 
1.015 
(0;3.213) 
HPV 
51 
0.707 
(0.256;1.365) 
0.634 
(0.364;1.004) 
0.413 
(0.161;0.741) 
0.917 
(0.275;1.83) 
0.795 
(0;2.344) 
2.169 
(0.402;5.624) 
HPV 
52 
0.636 
(0.124;1.489) 
0.57 
(0.306;0.929) 
1.192 
(0.586;2.052) 
0.368 
(0;1.035) 
1.053 
(0;2.689) 
0.56   
(0;1.674) 
HPV 
58 
0.847 
(0.248;1.82) 
0.657 
(0.298;1.194) 
0.342 
(0.105;0.666) 
1.643 
(0.566;3.179) 
2.305 
(0.331;5.926) 
0.566 
(0;1.506) 
4.3.1.3.	Calibration	of	the	transmission	model	
HPV type-specific posterior distributions of the following not directly observable parameters 
were estimated by calibration of the model to age- and type-specific HPV prevalence in the 
Portuguese population:  
• HPV transmissibility per sex act transprob 
• female clearance shape parameter clearance1 and rate parameter clearance2  
• male seroconversion rate maleseroC 
• male clearance rate maleclear 
We used  the modMCMC function of FME package to implement a Markov Chain Monte Carlo 
(MCMC)  simulation using an adaptive Metropolis algorithm in R[5]. Sixty parallel chains of the 
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model were set to run with different initial parameter values for 20,000 iterations for each 
HPV type.  
To find the best fitting set of parameter values, at each iteration, a new proposal set of 
parameter values was compared with the observational estimates of HPV prevalence using the 
likelihood function of the binomial distribution (i.e. the probability of obtaining the 
observational outcomes given that set of parameter values).  
The fitting algorithm determined the computational steps to find the values for each set of 
parameters which were likely to result in output that best fits the data, i.e. those with which 
the deviance (-2*log(likelihood)) of the model output to the observed HPV prevalence was 
smallest. 
The adaptive Metropolis algorithm was used aiming at a more efficient process by updating 
the proposal distribution every 1,000 iterations tuning it to the target distribution based on the 
process information so far.    
The coda package was used for analysis of the MCMC chains.[6] We visually inspected how the 
accepted values varied within the parameter space over the iterations for each parameter and 
each individual chain.  We selected the chains that presented good exploration of the 
parameter space and removed auto-correlation within each chain by thinning with an interval 
of 50 iterations (i.e. discarding all but the 50th accepted value).   
Convergence was diagnosed using the (1) Geweke test statistic, defining convergence when 
the z-score for the difference in the means of the first 10% of the chain and the final 50% is 
within -2 and 2, and the (2) Gelman diagnostic, that compares the variance of each parameter 
within each chain to its pooled variance (in all chains) and provides an estimate of the 
potential scale reduction factor (PSRF) (i.e. how much variance could be reduced by running 
chains longer)  for each parameter and a multivariate PSRF for multivariate chains , defining 
convergence when the upper limit is close to 1.  
Priors 
We used a Bayesian framework to ensure that different sources of evidence were 
appropriately incorporated. In Bayesian statistics, data and prior information of the 
parameters are combined using Bayes’ rule into a posterior distribution which update the prior 
knowledge using information from the data. In this framework, heterogeneous data sources 
can be easily combined to refine parameter estimation. This allows an optimal use of the 
different data sources and a rigorous treatment of the uncertainty.  
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We used the priors defined by Bains and colleagues (in Appendix to this thesis). A non-
informative prior was used for parameters that are not well defined, specifically the probability 
of transmission of HPV per sexual contact and for the male seroconversion rate. The rate of 
HPV infection clearance in men was assumed to be lognormally distributed based on the 
assumption of a median time to clear of 6 months (i.e. mean log rate 0.134 and variance of 0.2 
of the mean log rate).[7] 
The duration of HPV infection was assumed to follow a Weibull distribution with shape and 
scale parameters (clearance1 and clearance2, respectively). The probability of clearance of 
HPV infection is thought to be initially high, but decreasing over time and right-skewed. Hence, 
the shape parameter (clearance1) was assumed to be less than 1 and follow a beta distribution 
with Beta [2,1] and the rate parameter (clearance2) is in the same unit as time (months) was 
assumed follow a lognormal distribution, ranging from 0 to +∞. The type-specific prior for the 
rate parameter was generated using the median annual clearance rates of initial infection 
predicted by Johnson and colleagues.[8] 
Calibration Target 
As calibration target we estimated the observed type-specific HPV prevalence from individual 
patient data from the Cervical Lesions Observed by Papillomavirus Types – A Research in 
Europe (CLEOPATRE) Portugal study, a cross-sectional study where smears from 18 to 64-year-
old unvaccinated women eligible for screening across the 5 RHAs were taken for LBC and HPV 
DNA genotyping.[9]  
Results 
The sets of parameters that provide best model output fit to the observed data were used to 
run the effectiveness analyses. The posterior distributions found for the fitted parameters 
(summarised in Supplementary Table 4-3, their pairwise densities, and correlation coefficients 
are presented in Supplementary Figure 4-9. 
Our model predicted prevalence and estimates of the observed age- and type-specific 
prevalence are shown in Supplementary Figure 4-8. 
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Supplementary Table 4-3. Summary of the posterior distributions of fitted parameters by HPV type, mean (95%CI) 
 
Transmissibility, 
β 
Clearance 
shape, c1 
Clearance scale, 
c2 
Male 
seroconversion 
Male clearance Fraction 
infected at 
12mths 
Fraction 
infected at 
24mths 
Median time 
to clear 
(months) 
HPV 16  0.49 
(0.028;0.974) 
0.817 
(0.491;0.993) 
25.941 
(3.632;50.759) 
0.043 
(0.019;0.076) 
42.195 
(2.063;96.601) 
0.559 
(0.176;0.767) 
0.374 
(0.085;0.611) 
16.796 
(1.761;33.859) 
HPV 18 0.512 
(0.025;0.975) 
0.771 
(0.396;0.993) 
26.907 
(1.345;79.924) 
0.19 
(0.022;0.521) 
50.131 
(3.596;97.098) 
0.487 
(0.019;0.818) 
0.331 
(0.001;0.689) 
16.586 
(0.694;49.455) 
HPV 31 0.5 (0.022;0.969) 0.828 
(0.511;0.993) 
46.737 
(12.442;88.407) 
0.019 
(0.008;0.032) 
50.334 
(3.011;97.417) 
0.695 
(0.375;0.859) 
0.538 
(0.23;0.744) 
30.257 
(6.754;59.649) 
HPV 33 0.486 
(0.019;0.965) 
0.775 
(0.361;0.99) 
34.403 
(2.579;87.184) 
0.384 
(0.07;0.873) 
48.185 
(1.827;96.344) 
0.569 
(0.081;0.848) 
0.41 
(0.024;0.729) 
21.253 
(0.949;55.728) 
HPV 45 0.494 
(0.031;0.977) 
0.719 
(0.239;0.988) 
24.673 
(1.936;82.465) 
0.639 
(0.156;0.984) 
50.132 
(3.859;97.211) 
0.466 
(0.038;0.805) 
0.314 
(0.006;0.682) 
14.288 
(0.496;48.44) 
HPV 51 0.499 
(0.022;0.982) 
0.76 
(0.372;0.989) 
38.379 
(3.843;90.627) 
0.258 
(0.072;0.515) 
49.566 
(1.013;97.168) 
0.61 
(0.186;0.848) 
0.455 
(0.092;0.73) 
23.84 
(1.701;58.678) 
HPV 52 0.492 
(0.027;0.976) 
0.814 
(0.436;0.992) 
50.941 
(11.651;94.351) 
0.132 
(0.055;0.25) 
50.731 
(2.12;97.214) 
0.703 
(0.362;0.864) 
0.553 
(0.228;0.754) 
32.613 
(5.68;62.261) 
HPV 58 0.587 (0.05;0.97) 0.519 
(0.042;0.957) 
62.58 
(9.125;98.452) 
0.133 
(0.071;0.218) 
49.354 
(1.341;96.687) 
0.628 
(0.336;0.86) 
0.531 
(0.267;0.751) 
29.431 
(0.006;63.229) 
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Supplementary Figure 4-8. Age- and type-specific HPV prevalence (modelled and observed) 
Observed prevalence in orange (dots and lines correspond to mean and 95%CI, respectively); 
modelled prevalence in black and shaded areas (black line, light blue area, and light grey area 
correspond to mean, IQR and 95th percentile, respectively) 
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Supplementary Figure 4-9. Posterior distributions used for calibrated parameters of the 
transmission model 
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4.3.2. 				Disease	progression	
4.3.2.1.	Progression	to	pre-malignant	cervical	lesions	
Several classification criteria have been used to report cytological and histological results (Supplementary 
Table 4-4 provides a summary of these terminologies).  
Both Portugal and England have adopted the cervical intraepithelial neoplasia (CIN) terminology for 
histological results as per European guidelines;[1][2]however, different systems are used for cytology 
reporting. While Portugal has implemented the Bethesda System, England has used the terminology by the 
British Society for Clinical Cytology (BSCC).[3] 
Our model uses the BSCC terminology for cytology outcomes (Bains and colleagues in Appendix to this 
thesis); hence, we adapted the screening decision algorithms to map between systems for Portugal 
(described in detail in Supplementary material 4.3.3).  
Supplementary Table 4-4. Terminologies used for cytological and histological reporting (adapted from 
IARC 2005 and Schiffman and Wentzensen 2013) [4] [5] 
 Histology    Cytology   
Natural history 
model  
Papanicolaou 
class system 
(Papanicolaou 
1954)  
World Health 
Organisation 
(WHO)  
(Riotton et 
al.1973)  
CIN  
(Richart 
1968,1973)  
Bethesda 
System 
(Solomon et al. 
2002)  
BSCC  
(1986,2013)  
 Class I Negative Negative Within normal 
limits 
Negative 
Infection  Class II  Squamous atypia  Squamous 
atypia  
Benign cellular 
changes  
ASCUS  
ASCH  
Borderline 
change  
Precancer  Class III  Mild dysplasia  
 
Moderate 
dysplasia  
Severe dysplasia  
CIN1  
 
CIN2  
 
CIN3 
Low-grade SIL 
(LSIL)  
 
High-grade SIL 
(HSIL) 
LD (mild)  
 
HD (moderate) 
 
HD (severe) 
Cancer Class IV Carcinoma in situ    
 Class V  Microinvasive 
carcinoma  
Invasive 
carcinoma  
Invasive 
carcinoma  
Invasive 
carcinoma  
HD/?invasive  
squamous 
carcinoma  
ASC, atypical squamous cells; CIN, cervical intraepithelial neoplasia; HD, high-grade dyskaryosis; LD, low-grade 
dyskaryosis; SIL, squamous intraepithelial lesions  
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Cytological	outcomes	for	HPV-positive	women	
Bains and colleagues modelled the development of pre-malignant lesions for HPV-positive women as a 
function of time since acquisition of HPV infection (detailed in the Appendix to this thesis). HPV type-
specific progression parameters fitted by Bains and colleagues and their time-dependent probability model 
of the different cytological outcomes were used to randomly generate cytological outcomes as a function 
of time since infection. The probability of a normal outcome was thought to decrease exponentially over 
time since infection and to be less than norm2 at time of cancer onset. Given an abnormality, the 
probability of a severe outcome was modelled to increase over time since infection while the probability of 
the remaining abnormalities was modelled to decrease exponentially over time since infection (Bains and 
colleagues in Appendix to this thesis).  !	($%&'()	, +) = (1 − $%&'2) × 2345678∗: + $%&'2 !	(<%&=2&)>$2, +) = (1 − !	$%&'()) × 23?56@8∗: !	('>)=, +) = (1 − !	$%&'()) ×	A1 − 23?56@8∗:B × 237CD@8∗: !	('%=2&(+2, +) = (1 − !	$%&'()) ×	A1 − 23?56@8∗:B ×	A1 − 237CD@8∗:B ∗ 2375@8∗: !	(E2F2&2, +) = 1 − !$%&'() − !<%&=2&)>$2 − !'>)= − !'%=2&(+2 
Bains and colleagues’ posterior distributions of the five progression parameters used for each HPV type are 
summarised in Supplementary Table 4-5 and the probability of any given cytological outcome over time 
since infection is shown in Supplementary Figure 4-10. 
Supplementary Table 4-5. Posterior distributions of cytological outcomes parameters, by HPV type, mean 
(95%CI) (Bains and colleagues in Appendix to this thesis) 
 norm1 norm2 bord1 mild1 mod1 
HPV 16 0.334 
(0.0798,1.5738) 
0.0006 
(0,0.0037) 
0.723 
(0.0912,1.9066) 
0.6576 
(0.0456,1.9122) 
0.7366 
(0.0484,1.906) 
HPV 18 1.3812 
(0.2335,1.9815) 
0.0052 
(0,0.0377) 
1.0985 
(0.1296,1.9441) 
0.8482 
(0.0448,1.9388) 
0.9542 
(0.0571,1.9387) 
HPV 31 0.1869 
(0.0179,0.9381) 
0.0003 
(0,0.0007) 
0.5748 
(0.03,1.911) 
0.6058 
(0.023,1.8928) 
0.8446 
(0.0368,1.9475) 
HPV 33 0.4209 
(0.1212,1.6706) 
0.0003 
(0,0.0028) 
0.4507 
(0.103,1.6846) 
0.1234 
(0.0214,0.4913) 
0.8384 
(0.0647,1.9446) 
HPV 45 0.0505 
(0.0059,0.2027) 
0.001 
(0,0.0068) 
0.9098 
(0.0387,1.9282) 
0.8605 
(0.031,1.9451) 
0.9369 
(0.0468,1.9392) 
HPV 51 0.144 
(0.0278,0.4301) 
0.0008 
(0,0.0045) 
0.6778 
(0.0388,1.9007) 
0.6771 
(0.021,1.9159) 
0.8406 
(0.0363,1.9422) 
HPV 52 0.144 
(0.0278,0.4301) 
0.0008 
(0,0.0045) 
0.6778 
(0.0388,1.9007) 
0.6771 
(0.021,1.9159) 
0.8406 
(0.0363,1.9422) 
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Supplementary Figure 4-10. Probability of the different cytological outcomes by time since infection 
(Bains and colleagues in Appendix to this thesis) 
Cytological	outcomes	distribution	for	HPV-negative	women	
For HPV-negative women, Bains and colleagues modelled the probability of a given cytological outcome as 
a function of age at time of screen. We used their estimates for 3 age categories derived from the National 
Health Service Cervical Screening Programme England data (Supplementary Table 4-6) (Bains and 
colleagues in Appendix to this thesis).  
Supplementary Table 4-6. Cytological outcomes for HPV negative women, by age group (Bains and 
colleagues in Appendix to this thesis) 
Cytological outcome Age group 
25-29 30-49 50+ 
Normal 0.86767990 0.946778133 0.9714036878 
Borderline 0.06160168 0.031433627 0.0199242190 
Mild 0.04808784 0.015740005 0.0066748133 
Moderate 0.01224573 0.003267666 0.0010578025 
Severe 0.01038485 0.002780570 0.0009394774 
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Colposcopy	outcomes		
We used the probabilities of the different colposcopy outcomes by cytological outcome for HPV-positive 
women under cytology-based and HPV primary screening derived by Bains and colleagues from National 
Health Service Cervical Screening Programme England data (Supplementary Table 4-7) (Bains and 
colleagues in Appendix to this thesis).  
Supplementary Table 4-7. Probability of colposcopy outcomes, by cytological outcome and primary 
screening technology (Bains and colleagues in Appendix to this thesis) 
 Colposcopy outcome 
Cytology primary Normal CIN1 CIN2+ 
- Borderline/Mild 0.4437     0.2805          0.2759 
- Moderate/Severe 0.0259     0.0518          0.9223 
HPV DNA primary    
- Borderline/Mild 0.5883     0.1758          0.2359 
- Moderate/Severe 0.0192     0.0392         0.9415 
4.3.2.2.	Progression	to	cervical	cancer	
Bains and colleagues modelled the incidence of HPV type-specific cervical cancer as a function of time since 
HPV infection (Bains and colleagues in Appendix to this thesis). Squamous cell carcinomas and 
adenocarcinomas were modelled independently. Clinical detection of squamous cell carcinomas was 
modelled as a combination of (1) time since infection to cancer onset and (2) time from cancer onset to 
clinical detection. The first is assumed to follow a gamma distribution with shape and rate parameters, and 
the later an exponential distribution with a clinical detection delay rate decreasing with time. For 
adenocarcinomas, time since infection to clinical detection modelled using a single gamma distribution with 
shape and rate parameters, as cervical screening has proven inefficient in their detection and subsequent 
prevention[6]. Incidence of squamous cell carcinomas was modelled separately for screen-detected and 
clinically-detected cancers, so that incident squamous cancers are clinically detected if not yet detected by 
screening.  
Cancer incidence was modelled as a function of women’s infection history and all-cause mortality, where 
being alive and persistent infection were necessary conditions for cancer incidence (Bains and colleagues in 
Appendix to this thesis). Women’s time of death was randomly pre-generated from the cumulative 
probability function derived from Portuguese age-specific mortality (1981-2060)[7].  
We obtained distributions of HPV type-specific time to cancer-related parameters by calibration of our 
model predicted incidence to the observed annual incidence of cervical cancer in Portugal. 
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Calibration	target		
We estimated HPV type-specific incident squamous and adenocarcinoma cases by 5-year age group to use 
as calibration target of this component of the model (Supplementary Table 4-8 and Supplementary Table 4-
9, respectively). These estimates were derived from (1) the number of incident cases, (2) the histological 
distribution of cervical cancers, and (3) HPV type-specific prevalence in cervical cancers.  
The proportion of HPV 16 and HPV 18 is 68% and 11% of squamous cases and 52% and 37% of 
adenocarcinoma cases, similar to the proportions reported by Tjalma and colleagues.[8] The total number 
of incident cases and their distribution by histological type and age group obtained (Supplementary Table 
4-10) is also in line with the data reported by the Portuguese National Cancer Registry[9–14], e.g. the total 
squamous and adenocarcinoma cases account on average for 65% and 16% of the total number of cases.  
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Supplementary Table 4-8. Number of HPV type-specific incident SCC cases by age group, mean(95%CI) Portugal 
 
HPV 16 HPV 18  HPV 31 HPV 33 HPV 45 HPV 51 HPV 52 HPV 58 
0-4 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
5-9 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
10-14 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
15-19 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0.1 (0.1 ; 0.1) 0 (0 ; 0) 0.1 (0 ; 0.1) 0 (0 ; 0) 
20-24 1.8 (1.4 ; 2.1) 0.3 (0.2 ; 0.3) 0.1 (0 ; 0.1) 0.1 (0 ; 0.1) 0.9 (0.6 ; 1.1) 0.1 (0.1 ; 0.1) 0.3 (0.2 ; 0.4) 0.3 (0.2 ; 0.3) 
25-29 5.8 (4.2 ; 7.7) 1.8 (1.2 ; 2.3) 0.7 (0.5 ; 0.9) 0.8 (0.6 ; 1) 1.5 (1.1 ; 1.9) 0.1 (0.1 ; 0.1) 0.5 (0.3 ; 0.6) 0.5 (0.3 ; 0.6) 
30-34 20.7 (14.6 ; 25.8) 3 (2.1 ; 3.8) 1.3 (0.9 ; 1.6) 1.8 (1.3 ; 2.3) 1.9 (1.4 ; 2.5) 0.2 (0.1 ; 0.2) 0.7 (0.5 ; 0.9) 0.6 (0.4 ; 0.7) 
35-39 30.1 (21.6 ; 37.7) 5.1 (3.7 ; 6.5) 1.5 (1 ; 1.8) 2.3 (1.6 ; 2.9) 2.9 (2.1 ; 3.6) 0.3 (0.2 ; 0.3) 1.3 (0.9 ; 1.6) 1 (0.7 ; 1.3) 
40-44 40 (28.6 ; 50.3) 6.6 (4.7 ; 8.3) 2.6 (1.8 ; 3.2) 2.7 (1.9 ; 3.3) 3.2 (2.2 ; 4) 0.3 (0.2 ; 0.3) 1.5 (1.1 ; 1.9) 0.8 (0.6 ; 1) 
45-49 35.5 (25.1 ; 44.7) 6.9 (4.9 ; 8.7) 2.3 (1.6 ; 2.9) 2.9 (2.1 ; 3.7) 3.2 (2.2 ; 4) 0.2 (0.2 ; 0.3) 1.3 (0.9 ; 1.6) 0.8 (0.6 ; 1) 
50-54 35.1 (25.1 ; 44) 6 (4.3 ; 7.6) 2.3 (1.7 ; 2.9) 2.8 (2 ; 3.5) 1.9 (1.4 ; 2.4) 0.2 (0.1 ; 0.2) 0.9 (0.6 ; 1.1) 0.6 (0.5 ; 0.8) 
55-59 27 (18.9 ; 33.6) 4.1 (2.9 ; 5.2) 1.8 (1.3 ; 2.2) 2.3 (1.6 ; 2.9) 1.7 (1.2 ; 2.1) 0.1 (0.1 ; 0.2) 0.8 (0.5 ; 0.9) 0.4 (0.3 ; 0.5) 
60-64 21.6 (15.3 ; 27.2) 3.9 (2.8 ; 4.9) 1.7 (1.2 ; 2.1) 1.9 (1.3 ; 2.3) 1.9 (1.3 ; 2.4) 0.2 (0.1 ; 0.2) 0.8 (0.6 ; 1) 0.7 (0.5 ; 0.8) 
65-69 27.5 (19.5 ; 34.8) 4 (2.9 ; 5.1) 1.4 (1 ; 1.8) 2.2 (1.6 ; 2.8) 1.5 (1.1 ; 1.9) 0.1 (0.1 ; 0.2) 0.5 (0.4 ; 0.7) 0.4 (0.3 ; 0.5) 
70-74 20.7 (14.7 ; 25.8) 3.3 (2.4 ; 4.2) 1.8 (1.3 ; 2.3) 1.9 (1.3 ; 2.4) 1.4 (1 ; 1.7) 0.1 (0.1 ; 0.1) 0.6 (0.4 ; 0.7) 0.4 (0.3 ; 0.5) 
75-79 18.4 (13.2 ; 23) 2.5 (1.8 ; 3.2) 1.2 (0.8 ; 1.5) 1.5 (1 ; 1.8) 1.2 (0.9 ; 1.5) 0.1 (0.1 ; 0.1) 0.4 (0.3 ; 0.5) 0.3 (0.2 ; 0.4) 
80-84 20.2 (14.6 ; 25.2) 1.4 (1 ; 1.8) 1 (0.7 ; 1.2) 1.4 (1 ; 1.7) 0.7 (0.5 ; 0.9) 0.1 (0 ; 0.1) 0.2 (0.1 ; 0.3) 0.2 (0.1 ; 0.2) 
85+ 9.5 (7 ; 11.9) 1.7 (1.2 ; 2.1) 0.5 (0.3 ; 0.6) 0.8 (0.6 ; 1) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
Total 314 (223.8 ; 393.7) 50.8 (36.2 ; 64) 20 (14.3 ; 25.2) 25.2 (17.8 ; 31.7) 23.9 (17.1 ; 30.1) 2 (1.4 ; 2.5) 9.8 (6.9 ; 12.3) 6.9 (4.9 ; 8.7) 
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Supplementary Table 4-9. Number of HPV type-specific incident ADC cases by age group, mean(95%CI)Portugal 
 
HPV 16 HPV 18  HPV 31 HPV 33 HPV 45 HPV 51 HPV 52 HPV 58 
0-4 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
5-9 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
10-14 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
15-19 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
20-24 0.5 (0 ; 1) 0.2 (0 ; 0.4) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0.1) 0 (0 ; 0) 0 (0 ; 0) 0 (0 ; 0) 
25-29 2.1 (0.5 ; 4.1) 1.5 (0.4 ; 3) 0 (0 ; 0) 0 (0 ; 0.1) 0.2 (0.1 ; 0.4) 0 (0 ; 0.1) 0 (0 ; 0) 0 (0 ; 0) 
30-34 3.3 (1 ; 6.2) 3.2 (1.1 ; 6.3) 0.1 (0 ; 0.2) 0.1 (0 ; 0.2) 0.6 (0.2 ; 1.3) 0.1 (0 ; 0.2) 0 (0 ; 0) 0 (0 ; 0) 
35-39 6.5 (2.1 ; 12.9) 4.4 (1.5 ; 8.6) 0.1 (0 ; 0.2) 0.1 (0 ; 0.3) 0.8 (0.2 ; 1.6) 0.1 (0 ; 0.2) 0 (0 ; 0) 0 (0 ; 0) 
40-44 6.9 (2.1 ; 13.9) 4.4 (1.5 ; 8.6) 0.1 (0 ; 0.3) 0.2 (0.1 ; 0.4) 1.3 (0.4 ; 2.6) 0.1 (0 ; 0.3) 0 (0 ; 0) 0 (0 ; 0) 
45-49 9.2 (3.1 ; 18.1) 5.8 (1.9 ; 11.6) 0.1 (0 ; 0.3) 0.2 (0.1 ; 0.4) 1 (0.3 ; 1.9) 0.2 (0.1 ; 0.3) 0 (0 ; 0) 0 (0 ; 0) 
50-54 5.6 (1.6 ; 11.3) 4.2 (1.1 ; 8.2) 0.1 (0 ; 0.2) 0.1 (0 ; 0.2) 1.3 (0.4 ; 2.5) 0.2 (0 ; 0.3) 0 (0 ; 0) 0 (0 ; 0) 
55-59 5 (1.6 ; 9.8) 4.1 (1.1 ; 8.2) 0.1 (0 ; 0.3) 0.1 (0 ; 0.3) 0.7 (0.2 ; 1.3) 0.1 (0 ; 0.3) 0 (0 ; 0) 0 (0 ; 0) 
60-64 3.8 (1 ; 7.3) 2 (0.7 ; 3.7) 0.1 (0 ; 0.2) 0.1 (0 ; 0.2) 0.6 (0.2 ; 1.1) 0.1 (0 ; 0.2) 0 (0 ; 0) 0 (0 ; 0) 
65-69 4.9 (1.6 ; 9.8) 3.6 (1.1 ; 7.1) 0.1 (0 ; 0.2) 0.1 (0 ; 0.2) 0.8 (0.3 ; 1.6) 0.1 (0 ; 0.2) 0 (0 ; 0) 0 (0 ; 0) 
70-74 4 (1 ; 7.8) 1.9 (0.7 ; 3.7) 0.1 (0 ; 0.1) 0.1 (0 ; 0.2) 0.6 (0.2 ; 1.1) 0.1 (0 ; 0.2) 0 (0 ; 0) 0 (0 ; 0) 
75-79 3.7 (1 ; 7.3) 3 (1.1 ; 6) 0.1 (0 ; 0.1) 0.1 (0 ; 0.1) 0.4 (0.1 ; 0.9) 0.1 (0 ; 0.2) 0 (0 ; 0) 0 (0 ; 0) 
80-84 2.9 (1 ; 5.7) 2.1 (0.7 ; 4.1) 0.1 (0 ; 0.1) 0.1 (0 ; 0.1) 0.3 (0.1 ; 0.6) 0.1 (0 ; 0.1) 0 (0 ; 0) 0 (0 ; 0) 
85+ 1.4 (0.5 ; 2.6) 1.6 (0.4 ; 3.3) 0 (0 ; 0.1) 0 (0 ; 0.1) 0.3 (0.1 ; 0.6) 0 (0 ; 0.1) 0 (0 ; 0) 0 (0 ; 0) 
Total 59.9 (18.1 ; 118) 42 (13.4 ; 82.9) 1.2 (0.4 ; 2.4) 1.4 (0.4 ; 2.8) 8.9 (2.7 ; 17.6) 1.4 (0.4 ; 2.7) 0 (0 ; 0) 0 (0 ; 0) 
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1)	Number	of	incident	cases	
We estimated the annual total number of incident cervical cancer cases (Supplementary Table 
4-10)  from the total number of incident cases (ICD-10 code C53 – Malignant neoplasm of 
cervix uteri[18]) and total number of women by 5-year age bands from National Cancer 
Registry data for 2001, 2005, 2006, 2007, 2008, and 2010.[9–14] The age-specific annual rate 
of invasive cervical cancer in the Portuguese population was estimated fitting a Poisson 
distribution to the data. 	
Supplementary Table 4-10. Number of incident cases and women by age group and 
histological category, Portugal 
Age 
group 
Total number of 
cervical cancer 
cases  
(mean, 95%CI) 
Squamous 
carcinoma cases 
(mean, 95%CI) 
Adenocarcinoma 
cases  
(mean, 95%CI) 
Number of women  
(mean, 95%CI) 
0-4 0 (0 ; 3.7) 0 (0 ; 0) 0 (0 ; 0) 257258.2 (250919.7 ; 
263596.7) 
5-9 0 (0 ; 3.7) 0 (0 ; 0) 0 (0 ; 0) 265435 (258814.3 ; 272055.7) 
10-14 0 (0 ; 3.7) 0 (0 ; 0) 0 (0 ; 0) 270559.7 (268169.9 ; 
272949.5) 
15-19 0 (0 ; 3.7) 0 (0 ; 0) 0 (0 ; 0) 290800.8 (276755.2 ; 
304846.5) 
20-24 4 (1.1 ; 10.2) 2.6 (2 ; 3) 0.7 (0 ; 1) 324572.7 (298279.1 ; 
350866.3) 
25-29 21 (13 ; 32.1) 13.6 (10 ; 17) 3.4 (1 ; 7) 374194.2 (354475.9 ; 
393912.5) 
30-34 44 (32 ; 59.1) 28.4 (20 ; 36) 7.1 (2 ; 14) 408155.8 (392381.3 ; 
423930.3) 
35-39 66 (51 ; 84) 42.5 (30 ; 54) 10.6 (3 ; 21) 399400 (388100.3 ; 410699.7) 
40-44 86 (68.8 ; 106.2) 55.5 (39 ; 70) 13.8 (4 ; 27) 392457.7 (380169.8 ; 
404745.5) 
45-49 94 (76 ; 115) 60.6 (43 ; 76) 15.1 (5 ; 30) 379612.7 (363698.6 ; 
395526.8) 
50-54 80 (63.4 ; 99.6) 51.5 (36 ; 65) 12.9 (4 ; 26) 355066.5 (341817.6 ; 
368315.4) 
55-59 66 (51 ; 84) 42.5 (30 ; 53) 10.6 (3 ; 21) 334738.8 (318213.1 ; 
351264.6) 
60-64 55 (41.4 ; 71.6) 35.4 (25 ; 45) 8.8 (3 ; 18) 309607 (297364.5 ; 321849.5) 
65-69 55 (41.4 ; 71.6) 35.4 (25 ; 45) 8.9 (3 ; 18) 285553.8 (281699.7 ; 289408) 
70-74 47 (34.5 ; 62.5) 30.3 (22 ; 38) 7.6 (2 ; 15) 273568.7 (264761.1 ; 
282376.2) 
75-79 40 (28.6 ; 54.5) 25.8 (18 ; 32) 6.4 (2 ; 13) 240000.5 (232715.8 ; 
247285.2) 
80-84 33 (22.7 ; 46.3) 21.3 (15 ; 27) 5.3 (2 ; 11) 172872.3 (166290.3 ; 
179454.2) 
85+ 22 (13.8 ; 33.3) 14.2 (10 ; 18) 3.5 (1 ; 7) 134678.3 (124192.2 ; 
145164.3) 
Total 713 (538.8 ; 
944.7) 
459.5 (325 ; 579) 114.8 (35 ; 229) 5468532.5 (5258818.3 ; 
5678246.7)  
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2)	Histological	distribution	of	cervical	cancer	cases	
The proportion of each histological type was derived from the type-specific annual total 
number of squamous, adeno, and other type of cervical carcinoma cases reported for 2001, 
2005, 2007, 2008, and 2010.[9,10,12–14] We fitted a Dirichlet-Multinomial distribution to the 
data to estimate the maximum likelihood estimator (MLE) of the probability of having 
squamous cell carcinoma (SCC), adenocarcinoma (ADC), or other histological type 
(Supplementary Table 4-11).  
Supplementary Table 4-11. Maximum likelihood estimators for histological type-specific 
probability of cancer 
Histological type  p (SE) 
squamous carcinoma 0.645 (0.0413)  
adenocarcinoma  0.161 (0.0336)  
other  0.194 (0.0311)  
theta 0.036 (0.0159)  
3)	HPV	type-specific	prevalence	in	cervical	cancer	cases	
The proportion of each modelled HPV type was derived from estimates of high-risk HPV 
prevalence among women with high grade CIN or invasive cervical cancer by histological 
diagnosis from two studies: (i) a meta-analysis of data (n= 2,715 ICC) from17 European 
countries between 2001 and 2008 and (ii) a cross-sectional study of Portuguese women with 
CIN2+ lesions or cervical cancer (n=64 ICC) attending NHS obstetrics/gynaecology 
services.[8,19] We combined both studies data and fitted a Dirichlet –multinomial distribution 
to obtain the MLE of the probability of infection in incident cases for each HPV type by 
histological category (Supplementary Table 4-12).  
Supplementary Table 4-12. Maximum likelihood estimators for HPV type-specific probability 
of infection by cancer histological type 
HPV type  Squamous carcinoma 
 p (SE) 
Adenocarcinoma 
p (SE) 
16 0.658 (0.01)  0.511 (0.0267)  
18 0.106 (0.0065)  0.369 (0.0258)  
31 0.04 (0.0041)  0.011 (0.0057)  
33 0.053 (0.0047)  0.011 (0.0057)  
35 0.012 (0.0023)  - 
39 0.012 (0.0023)  0.011 (0.0057)  
45 0.049 (0.0046)  0.074 (0.014)  
51 0.004 (0.0013)  0.011 (0.0057)  
52 0.02 (0.0029)  - 
56 0.01 (0.0021)  - 
58 0.014 (0.0025)  - 
59 0.006 (0.0017)  - 
66 0.002 (0.0009)  - 
68 0.014 (0.0025)  - 
Theta 0 (0) 0 (0) 
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Calibration	
We tried obtaining posterior distribution for time to cancer-related parameters using MCMC 
simulation and the adaptive Metropolis algorithm method used to calibrate the HPV 
acquisition component of the model to Portuguese HPV prevalence (described in 
Supplementary material 4.3.1). We used Bains and colleagues’ type-specific distributions for 
England as priors (in Appendix to this thesis) and introduced the Poisson likelihood function to 
calculate the deviance between predicted and observed incidence used to measure goodness-
of-fit. The model was run for HPV 16 and 18 with alternative sets of starting values, lower and 
upper bounds, jumps (proposal covariance matrix), and weights for the prior distributions. 
However, many attempts failed to explore the parameter space and none of those reached 
convergence. 
We then took on a manual approach to fit progression to squamous cell carcinomas 
attributable to HPV 16 and 18 based on the assumption that the gamma distribution 
parameters used to model time from infection to cancer onset follow a uniform distribution. 
We also changed Bains and colleagues’ model of time to clinical detection by using a lognormal 
distribution with location and shape parameter as it seemed to fit Portuguese incidence 
better. Alternative several value sets for these distributions parameters were chosen to run 
the model with, based on the posterior distributions reported by Bains and colleagues for 
progression to cancer in English women and the output of attempts to fit the model using 
MCMC simulation. The best fitting set of parameter values were selected by visual inspection 
of the fit to the observed incidence. For HPV 16, we used the "L-BFGS-B" optimisation method 
of the optim function in R stats package[15] - to refine the fit of the three best visually fitting 
parameter sets and selected the one with least sum of squared residuals to run our model 
with.  
For HPV 18, we assumed the gamma shape and rate parameters for time to squamous cell 
carcinoma onset were uniformly distributed and ran the model using different ranges for these 
parameters (minimum and maximum values for those uniform distributions). We selected the 
best fitting set of values by visual comparison of the fit. For squamous cell carcinomas caused 
by the remaining HPV types and for adenocarcinomas, we used Bains and colleagues’ posterior 
distributions of gamma parameters for England (in Appendix to this thesis), selecting for each 
HPV type the distribution that visually better fit its incidence in Portugal.  
We used as calibration target the observed incidence of cervical cancer under 50 years of age 
as our model does not capture incidence in older women. This difference between predicted 
199 
 
and observed incidence in older age groups has been described for England and it is likely 
explained by cohort effects as in practice older women did not benefit from cervical screening 
available in the more recent decades to younger women and this is not captured in our 
model[16].  
Supplementary Table 4-13 summarises the distributions used for our cancer-related 
parameters and observed and model predicted age- and type-specific incidence is shown in 
Supplementary Figure 4-11 and Supplementary Figure 4-12.  
Supplementary Table 4-13. Posterior distributions of fitted parameters by HPV type 
 Squamous carcinomas Adenocarcinomas 
 Gamma shape 
min – max / 
mean (95%CI)  
Gamma rate  
min – max / 
mean 
(95%CI) 
Lognormal 
location 
Lognormal 
shape  
Gamma shape  
min – max / 
mean (95%CI) 
Gamma rate 
min – max / 
mean 
(95%CI)   
HPV 
16 
205.04   1.29 5.086 0.477 6.049 (4.1,7.9) 0.012 
(0.008,0.015) 
HPV 
18 
30-60 0.1-0.3 5.406 0.385 6.777 
(2.896,38.832) 
0.017 
(0.003,0.119) 
HPV 
31 
6.222 
(2.896,34.483) 
0.015 
(0.003,0.112) 
5.086 0.477 5.194 
(3.943,8.115) 
0.005 
(0.003,0.011) 
HPV 
33 
5.298 (2.7,12.9) 0.015 
(0.003,0.055) 
5.086 0.477 5.194 
(3.943,8.115) 
0.005 
(0.003,0.011) 
HPV 
45 
5.298 (2.7,12.9) 0.015 
(0.003,0.055) 
5.086 0.477 5.194 
(3.943,8.115) 
0.005 
(0.003,0.011) 
HPV 
51 
45.338 
(4.082,175.676) 
0.008 
(0.003,0.026) 
5.086 0.477 44.952 
(4.102,175.676) 
0.007 
(0.003,0.026) 
HPV 
52 
45.338 
(4.082,175.676) 
0.008 
(0.003,0.026) 
5.086 0.477 5.194 
(3.943,8.115) 
0.005 
(0.003,0.011) 
HPV 
58 
5.229 
(3.943,8.115) 
0.005 
(0.003,0.011) 
5.086 0.477 5.194 
(3.943,8.115) 
0.005 
(0.003,0.011) 
 
  
Supplementary Figure 4-11. Age-specific cervical cancer incidence (modelled and observed) 
for squamous cell carcinomas and adenocarcinomas (total, all HPV types modelled) 
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Supplementary Figure 4-12. Age- and HPV type-specific cervical cancer incidence (modelled 
and observed) for squamous cell carcinomas and adenocarcinomas 
SCC, squamous cell carcinomas; ADC, adenocarcinomas; Observed incidence in orange (the fitting target 
in dark orange and incidence in women >50 years in light orange), dots and lines correspond to mean 
and 95%CI, respectively; modelled incidence in black and grey shaded area correspond to mean  and 
95th percentile, respectively. 
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4.3.2.3.	Cervical	cancer	survival	
Cervical cancer survival was derived from survival data reported by the Portuguese cancer 
registry of the North region[17]. A model assuming survival exponentially decreasing over time 
was calibrated to age-group specific 1- and 5-year net survival of patients diagnosed in 2007/8 
(Supplementary Table 4-14). The fitted yearly rates were used to predict post-treatment 
survival in our model. Age-at-diagnosis-specific mortality rates (1-survival) were applied for 5 
years after diagnosis to women with detected cancer, whose survival was assumed to be the 
same as in the general population from then onwards. 
Supplementary Table 4-14. Cervical cancer survival 
Survival (%), 1year,  5 year Mean  Sources 
   15-44 93.3, 80.8 IPO Porto[17] 
   45-54 88.9, 76.0  
   55-64 91.7, 65.2  
   65-74 87.5, 62.2  
   75+ 72.5, 32.2  
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4.3.3. Screening	
This component simulates implementing a screening strategy alongside the natural disease 
progression, where women can be tested to detect cervical pre-malignant lesions or cancer 
and be referred to follow-up screen, colposcopy, or treatment according to the severity of the 
screening test outcome. The screening strategies modelled are defined by their target age 
groups, screening frequency, technologies used, and thresholds for lesions follow-up, 
colposcopy, or treatment referral. 
The screening component of Bain and colleagues’ model was developed and parameterised to 
inform decisions for the National Health Service Cervical Screening Programme England (in 
Appendix to this thesis). It was structured so that screening frequency was modelled as a 
function of the individual’s age and previous screening attendance history. Given the lack of 
data on Portuguese women’s screening attendance, we restructured the screening component 
of the model. We modelled women’s probability of attending subsequent screens and the 
waiting time to their next screen independently from their previous attendance. 
4.3.3.1	Description	of	the	screening	model	developed	by	Bains	and	colleagues	
(detailed	in	the	Appendix	to	this	thesis)	
In Bains and colleagues model, the probability of an individual woman being ever screened is 
randomly generated by sampling with replacement in each model iteration. For those who 
ever get screened, a month of first screen is randomly generated from the cumulative 
distribution function of first screen age. The month of first screen is hence determined by 
vector of 10,000 months of age at first screen that is updated thereafter at each screen with 
the age at next screen for that particular individual. 
If the date of screen is over the maximum screening age of 66 then no screen occurs. 
Otherwise, the woman’s cytological and HPV infection status at date of screen are assigned 
(based on the infection history of the individual) as well as whether cancer is detected at that 
screen. The outcome of each screen for a given woman depends on her current screening 
recall status and the cytological outcome and HPV status. The recall status determines the 
applicable primary and triage tests and whether there’s referral to immediate colposcopy or 
not before the next screen based on the cytological and HPV status.  
The cytological outcome is extracted from previously randomly generated vectors of outcomes 
according to time since infection at date of screen or according to the woman’s age if HPV 
negative (detailed in Supplementary material 4.3.2. Disease progression).  For each infection 
persistent at that particular screen, time since infection is normalised to a period of10 years 
204 
 
waiting time to cancer, proportional to the waiting time to cancer for that infection. The worse 
cytological outcome among the existing infections is then assigned. 
Squamous cell carcinomas are detected by screening if there’s a persistent infection and the 
current date of screen is at or after the onset date of cancer and before the date of clinical 
detection. If detection occurs at that screen, that individual’s age at screen detection is 
updated for all existing infections.  
The outcome of referral to colposcopy depends on the HPV infection status and worse 
cytological outcome. The probability of attending colposcopy varies according to the 
cytological outcome. If the HPV status is negative (false referral), the colposcopy outcome is 
normal, if attended. If there’s an HPV infection, the colposcopy outcome depends on the 
cytological outcome (Supplementary material 4.3.2). 
A new screening recall status is assigned to the individual based on the cytological, triage, and 
colposcopy results. If the colposcopy appointment was missed, the woman is assumed to go 
back to the standard recall status.  
The waiting time to next screen is then assigned based on the new recall status. If she goes 
back to standard recall, the date of next screen is dependent on the woman’s age and the 
previous screen waiting time. If cancer is detected, there’s no further screens (the next screen 
for that individual is set over the maximum screening age). If not, the woman is assumed to 
attend the follow-up visit at the scheduled waiting time, provided she is not lost to follow up. If 
she does miss her appointment, her next time of screen is assigned based on her previous 
screening waiting time. 
If the woman is treated, the infection history record for that individual is updated depending 
on whether the lesion and/or the HPV infection were successfully treated/ cleared. If 
treatment was unsuccessful in treating the lesion, the individual’s infection record remains 
unchanged. If both lesion and HPV infection are treated, the age at end of infection is updated 
for all current infections that have not yet progressed to cancer to the current date of screen. 
If the lesion was treated but HPV infection remains, the date of infection is updated to the 
current date of screen, the age at cancer onset updated to the current date of screen plus a 
randomly extracted time to cancer, and the age at clinical detection updated to increase by the 
same amount that the age at cancer was delayed. 
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4.3.3.2	Adaptation	of	the	screening	model	to	Portugal	
We developed decision trees for each strategy modelled for the Portuguese context based on 
Bains and colleagues design and adapted all the relevant model functions to accommodate 
opportunistic screening and repeat cytology triage (not modelled for England). We also 
adapted the functions involved in summarising the screening strategies output. 
Women’s waiting time to next screen was modelled as dependent on women’s age but not on 
women’s previous screening history, given the lack of Portuguese data.  
The maximum screening age of 66 used by Bains and colleagues for standard routine screening 
was adopted as well and the maximum screening age of 85 for follow-up of cytological 
abnormalities or treatment was introduced. 
Due to the paucity of data on screening and colposcopy attendance, we assumed the 
probability of attending colposcopy did not vary according to the cytological outcome, and that 
women who miss their appointments for lesions follow-up have the same probability of 
attending a next screen at the next scheduled screening age as women of that age attending 
standard routine screens. 
4.3.3.2.3.	Screening	strategies	
Flowcharts for each strategy are shown in Supplementary Figure 4-13 and the decision trees 
used for the different strategies and respective recall waiting times to next screen are shown 
in section 4.3.3.2.4. The mapping between the Bethesda system used in Portugal and that of 
the British Society for Clinical Cytology is incorporated in the decision trees, where borderline 
changes, low-grade dyskaryosis (mild), and high-grade dyskaryosis (moderate or severe) are 
followed-up according to the recommendations for atypical squamous cell of undetermined 
significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), and high-grade 
squamous intraepithelial lesion (HSIL), respectively. Atypical squamous cells cannot exclude 
HSIL (ASC-H) in Portugal are followed up as HSIL just as borderline changes, high-grade 
dyskaryosis not excluded are managed as high-grade dyskaryosis in England.  Despite the 
general overlap of the two terminologies, our model does not account for the fact that 
borderline changes may include low-grade squamous intraepithelial lesions and some 
moderate dyskaryosis can be read as LSIL in Portugal[1,2].  
Opportunistic screening in Portugal has been based on conventional cytology until the present 
day. Liquid-based cytology was introduced in 2008 (alongside HPV DNA testing for triage of 
ASCUS and LSIL lesions) and has been confined to areas where organised programmes have 
been implemented. We assumed the same performance for conventional and liquid-based 
cytology in our analyses[3]. 
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The different cervical screening strategies studied in this thesis were selected based on 
discussions with the co-ordinators of screening programmes for the mainland Regional Health 
Administrations at the Portuguese General-Directorate for Health. It is important to note that 
many other possible strategies with varying screening intervals, screening ages, and pathways 
were not included. 
Strategies 1 and 2 simulate different management protocols deployed opportunistically (the 
same screening frequency and compliance parameters were applied to these strategies), 
whereas strategies 3- 7 model alternative protocols implemented as part of a fully call-recall 
organised programme. The data and assumptions used to characterise these programmes are 
detailed in Parameterisation below.     
Strategy	1	
In Strategy 1, we assumed women were screened and followed up according to the 
Portuguese Gynaecology Society guidelines, where ASCUS were triaged by repeating cytology 
at 6 months and LSIL+ lesions were referred to immediate colposcopy (Supplementary Figure 
4-13A). Those with abnormal triage cytology were referred to immediate colposcopy and those 
with normal triage cytology were followed up in 6 months.  
Normal colposcopy results were also followed up by cytology at 6 months. If normal cytology 
at 6 months, the next cytology was at 12 months, and given both results were normal, women 
went back to standard routine screening. If any abnormality was detected they were referred 
to immediate colposcopy and followed up accordingly. CIN1 lesions were followed by cytology 
and colposcopy 6-monthly until 24 months if normal or CIN1. If normal at 24 months, women 
went back to standard routine screening. Persistent CIN1 at 24 months or any CIN2+ detected 
were referred to immediate treatment.  
Post-treatment follow up consisted of cytology and colposcopy 6-monthly for 2 years. CIN1+ 
lesions were referred to immediate treatment. If normal for 2 years women entered a yearly 
follow-up with cytology. Cytology abnormalities were checked by immediate colposcopy. 
Normal colposcopy results were followed up in 12 months, whereas CIN1+ were referred to 
immediate treatment.  
Strategy	2	
Strategy 2 replicates the introduction of HPV DNA testing to triage ASCUS and LSIL lesions at 12 
months and yearly co-testing with cytology and HPV DNA testing to follow-up <CIN1 lesions, as 
per the Portuguese Gynaecology Society guidelines (Supplementary Figure 4-13B). Women 
with normal cytology or ASCUS HPV-negative went back to standard screening.  LSIL HPV-
negative women were followed up with co-testing at 12 months and went back to standard 
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routine screening if normal. HPV-positive or HSIL women were referred to immediate 
colposcopy. 
Normal colposcopy results after ASCUS were followed by co-testing at 12 months and went 
back to standard routine screening if normal cytology & HPV-negative. Normal colposcopy 
results after LSIL were followed by co-testing at 12 months and 36 months and went back to 
standard routine screening if normal cytology & HPV-negative. Normal colposcopy results after 
HSIL and any CIN1 colposcopy were followed by co-testing at 12 months and 24 months and 
went back to standard routine screening if normal cytology & HPV-negative. CIN2+ results 
were referred to immediate treatment. 
After treatment, women were followed up at 6, 12, and 24 months. At 6 months, all women 
had cytology and colposcopy. If normal colposcopy, they had co-testing with cytology and HPV 
DNA at 12 months, and HPV-positive women or women with abnormal cytology had 
colposcopy and were followed accordingly (as described above). Women with normal cytology 
and HPV negative at 12 months had co-testing of cytology and HPV DNA at 24 months and 
were sent to standard routine screening if all negative, whereas HPV-positive or women with 
any abnormalities had colposcopy and were followed accordingly. 
Strategies	3	and	7	
Strategy 3 and 7 used the same decision trees for management of lesions as strategies 2 and 1, 
respectively (Supplementary Figure 4-13). Hence, both approaches were simulated under 
organised screening using the age at first screen and screening interval reported for women in 
the NHS Cervical Screening Programme, England (Bains and colleagues, Appendix in this 
thesis).  
Strategy	6	
We also modelled HPV triage in an organised system following the National Health Service 
Cervical Screening Programme England protocol[4] (Strategy 6, Supplementary Figure 4-13D), 
under the same screening frequency and compliance assumptions as Strategy 3. 
The main differences between the lesions management algorithm used in strategy 6 compared 
to the one used for strategies 2 and 3 are: 
- Women with normal colposcopy after ASCUS or LSIL go back to standard recall (instead 
of followed in 12 months) 
- HPV-negative women after LSIL go back to standard recall (instead of followed in 12 
months) 
- 12 months lesions follow-up is done by cytology alone with HPV triage of ASCUS & LSIL 
(instead of co-testing everyone) 
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- At co-testing at 12 months follow-up, women with normal cytology or HPV-negative 
with ASCUS/LSIL go back to standard recall (instead of only HPV-negative women with 
normal cytology (both negative) go back to standard recall; everyone else has 
colposcopy in S2 & S3). 
- Post-treatment 6 months follow-up by co-testing normal/ASCUS/LSIL. HSIL are 
referred to immediate colposcopy (instead of cytology & colposcopy to everyone). 
HPV-negative women with normal/ASCUS/LSIL go back to routine recall (instead of 
normal colposcopy with normal/ASCUS/LSIL go to 12 month follow-up by co-testing). 
Post-treatment Normal colposcopy with HSIL go back to standard recall and CIN1 (any 
cytology outcome) are followed up by cytology in 12 months (instead of everyone with 
HSIL or CIN1 post-treatment being referred to treatment again).  
Strategy	4	
In strategy 4, HPV DNA test was the primary screening test and HPV-positive women were 
triaged with cytology (Supplementary Figure 4-13C). HPV-positive women with normal triage 
cytology were referred to HPV testing in 12 months. If negative at 12 months, they went back 
to standard routine screening, whereas if HPV positive, cytology was used for triage and any 
cytological abnormality resulted in referral to colposcopy. HPV-positive women with normal 
cytology were followed-up in 12 months. HPV-positive women at 12 months had cytology 
triage and referred to colposcopy regardless of the cytological outcome.  
Women with normal colposcopy went back to standard routine screening. Those with CIN1 
were followed up at 12 and 24 month, those with CIN2+ were referred to immediate 
treatment. 
Post-treatment follow-up with HPV DNA testing occurred at 6 months. HPV negative women 
went back to routine screening, while HPV positive results were triaged by cytology and 
referred to colposcopy regardless of the cytological outcome. Colposcopy results were 
managed accordingly. 
Strategy	5	
We used the same decision trees for strategy 4 and 5, but assumed an extended screening 
interval of 5 years for the latter. 
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A) Strategies 1 & 7 – Repeat cytology 
 
B) Strategies 2 & 3 – HPV triage (PT algorithm) 
[5] 
 
C) Strategies 4 & 5 – Primary HPV testing 
 
D) Strategy 6 – HPV triage (EN algorithm)[4] 
 
Supplementary Figure 4-13. Screening strategies flowcharts 
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4.3.3.2.4.	Decision	trees	
Supplementary Table 4-15. Decision Trees and assumed time to next screen 
Decision tree Decision tree description  Time to next 
screen (months) 
Strategy 1 and 7 
  
1 Standard routine 36 
2 Normal colposcopy 6 months follow-up  6 
3 Post-treatment 6 months follow-up 6 
4 Normal colposcopy 12 months follow-up  6 
5 CIN1 6 months follow-up  6 
6 CIN1 12 months follow-up 6 
7 CIN1 18 months follow-up 6 
8 CIN1 24 months follow-up 6 
9 Post-treatment 12 months follow-up 6 
10 Post-treatment 18 months follow-up 6 
11 Post-treatment 24 months follow-up 6 
12 Post-treatment >24 months follow-up 12 
Strategy 2 and 3 
  
21 Standard routine 36 
22 LSIL&HPV-negative or Normal colposcopy  
12 months follow-up  
12 
23 Post-treatment 6 months follow-up 6 
24 Post-treatment 12 months follow-up 12 
25 Post-treatment 24 months follow-up 12 
26 LSIL 12 months follow-up  12 
27 LSIL 36 months follow-up 24 
28 HSIL 12 months follow-up  12 
29 HSIL 24 months follow-up 12 
30 CIN1 12 months follow-up  12 
31 CIN1 24 months follow-up 12 
Strategy 4 and 5 
  
41 Standard routine 36 
42 HPV-positive normal cytology 12 months follow-up  12 
43 Post-treatment 6 months follow-up 6 
44 HPV-positive normal cytology 24 months follow-up 12 
45 CIN1 12 months follow-up 12 
46 CIN2 24 months follow-up  12 
Strategy 6   
61 Standard routine 36 
62 CIN1 and HSIL/Normal colposcopy follow-up 12 
63 Post-treatment 6 months follow-up 6 
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Supplementary Table 4-16. Strategies 1 and 7 – Repeat conventional cytology algorithm 
 
The first row indicates the number of the decision tree; Column names: C, primary cytology; CT, repeat cytology (triage); H, HPV test; K, colposcopy; A, action (next follow-
up decision tree); each row represents a set of potential outcomes in a given follow-up path (columns C, CT, H, and K) and the number of the decision tree for the next 
follow-up (column A); Cytological outcomes: 1, normal; 2, borderline; 3, mild; 4, moderate; 5, severe dyskaryosis; HPV test outcomes: 1, negative; 2, positive; Colposcopy 
outcomes: 1, normal; 2,CIN1; 3, CIN2+; 0, represents test not performed. 
 
 
  
1 2 4 3 5 6 7 8 9 10 11 12
C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A
1 0 0 0 1 1 0 0 0 4 1 0 0 0 1 1 0 0 1 9 1 0 0 1 6 1 0 0 1 7 1 0 0 1 8 1 0 0 1 1 1 0 0 1 10 1 0 0 1 11 1 0 0 1 12 1 0 0 0 12
2 1 0 0 2 2 0 0 1 2 2 0 0 1 2 1 0 0 2 3 1 0 0 2 6 1 0 0 2 7 1 0 0 2 8 1 0 0 2 3 1 0 0 2 3 1 0 0 2 3 1 0 0 2 3 2 0 0 1 11
2 2 0 1 2 2 0 0 2 5 2 0 0 2 5 1 0 0 3 3 1 0 0 3 3 1 0 0 3 3 1 0 0 3 3 1 0 0 3 3 1 0 0 3 3 1 0 0 3 3 1 0 0 3 3 2 0 0 2 3
2 2 0 2 5 2 0 0 3 3 2 0 0 3 3 2 0 0 1 9 2 0 0 1 6 2 0 0 1 7 2 0 0 1 8 2 0 0 1 5 2 0 0 1 10 2 0 0 1 11 2 0 0 1 12 2 0 0 3 3
2 2 0 3 3 3 0 0 1 2 3 0 0 1 2 2 0 0 2 3 2 0 0 2 6 2 0 0 2 7 2 0 0 2 8 2 0 0 2 3 2 0 0 2 3 2 0 0 2 3 2 0 0 2 3 3 0 0 1 11
2 3 0 1 2 3 0 0 2 5 3 0 0 2 5 2 0 0 3 3 2 0 0 3 3 2 0 0 3 3 2 0 0 3 3 2 0 0 3 3 2 0 0 3 3 2 0 0 3 3 2 0 0 3 3 3 0 0 2 3
2 3 0 2 5 3 0 0 3 3 3 0 0 3 3 3 0 0 1 9 3 0 0 1 6 3 0 0 1 7 3 0 0 1 8 3 0 0 1 5 3 0 0 1 10 3 0 0 1 11 3 0 0 1 12 3 0 0 3 3
2 3 0 3 3 4 0 0 1 2 4 0 0 1 2 3 0 0 2 3 3 0 0 2 6 3 0 0 2 7 3 0 0 2 8 3 0 0 2 3 3 0 0 2 3 3 0 0 2 3 3 0 0 2 3 4 0 0 1 3
2 4 0 1 2 4 0 0 2 5 4 0 0 2 5 3 0 0 3 3 3 0 0 3 3 3 0 0 3 3 3 0 0 3 3 3 0 0 3 3 3 0 0 3 3 3 0 0 3 3 3 0 0 3 3 4 0 0 2 3
2 4 0 2 5 4 0 0 3 3 4 0 0 3 3 4 0 0 1 9 4 0 0 1 6 4 0 0 1 7 4 0 0 1 8 4 0 0 1 3 4 0 0 1 10 4 0 0 1 11 4 0 0 1 12 4 0 0 3 3
2 4 0 3 3 5 0 0 1 2 5 0 0 1 2 4 0 0 2 3 4 0 0 2 6 4 0 0 2 7 4 0 0 2 8 4 0 0 2 3 4 0 0 2 3 4 0 0 2 3 4 0 0 2 3 5 0 0 1 3
2 5 0 1 2 5 0 0 2 5 5 0 0 2 5 4 0 0 3 3 4 0 0 3 3 4 0 0 3 3 4 0 0 3 3 4 0 0 3 3 4 0 0 3 3 4 0 0 3 3 4 0 0 3 3 5 0 0 2 3
2 5 0 2 5 5 0 0 3 3 5 0 0 3 3 5 0 0 1 9 5 0 0 1 6 5 0 0 1 7 5 0 0 1 8 5 0 0 1 3 5 0 0 1 10 5 0 0 1 11 5 0 0 1 12 5 0 0 3 3
2 5 0 3 3 5 0 0 2 3 5 0 0 2 6 5 0 0 2 7 5 0 0 2 8 5 0 0 2 3 5 0 0 2 3 5 0 0 2 3 5 0 0 2 3
3 0 0 1 2 5 0 0 3 3 5 0 0 3 3 5 0 0 3 3 5 0 0 3 3 5 0 0 3 3 5 0 0 3 3 5 0 0 3 3 5 0 0 3 3
3 0 0 2 5
3 0 0 3 3
4 0 0 1 2
4 0 0 2 5
4 0 0 3 3
5 0 0 1 2
5 0 0 2 5
5 0 0 3 3
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Supplementary Table 4-17. Strategies 2 and 3 – Primary liquid-based cytology and HPV triage algorithm as per Portuguese guidance[5] 
 
The first row indicates the number of the decision tree; Column names: C, primary cytology; CT, repeat cytology (triage); H, HPV test; K, colposcopy; A, action (next 
follow-up decision tree); each row represents a set of potential outcomes in a given follow-up path (columns C, CT, H, and K) and the number of the decision tree for 
the next follow-up (column A); Cytological outcomes: 1, normal; 2, borderline; 3, mild; 4, moderate; 5, severe dyskaryosis; HPV test outcomes: 1, negative; 2, 
positive; Colposcopy outcomes: 1, normal; 2,CIN1; 3, CIN2+; 0, represents test not performed. 
 
  
21 22 23 24 25 26 27 28 29 30 31
C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A C CT H K A
1 0 0 0 21 1 0 1 0 21 1 0 0 1 24 1 0 1 0 25 1 0 1 0 21 1 0 1 0 27 1 0 1 0 21 1 0 1 0 29 1 0 1 0 21 1 0 1 0 31 1 0 1 0 21
2 0 1 0 21 1 0 2 1 22 1 0 0 2 23 1 0 2 1 22 1 0 2 1 22 1 0 2 1 22 1 0 2 1 22 1 0 2 1 22 1 0 2 1 22 1 0 2 1 22 1 0 2 1 22
2 0 2 1 22 1 0 2 2 30 1 0 0 3 23 1 0 2 2 30 1 0 2 2 30 1 0 2 2 30 1 0 2 2 30 1 0 2 2 30 1 0 2 2 30 1 0 2 2 30 1 0 2 2 30
2 0 2 2 30 1 0 2 3 23 2 0 0 1 24 1 0 2 3 23 1 0 2 3 23 1 0 2 3 23 1 0 2 3 23 1 0 2 3 23 1 0 2 3 23 1 0 2 3 23 1 0 2 3 23
2 0 2 3 23 2 0 1 1 22 2 0 0 2 23 2 0 1 1 22 2 0 1 1 22 2 0 1 1 22 2 0 1 1 22 2 0 1 1 22 2 0 1 1 22 2 0 1 1 22 2 0 1 1 22
3 0 1 0 22 2 0 1 2 30 2 0 0 3 23 2 0 1 2 30 2 0 1 2 30 2 0 1 2 30 2 0 1 2 30 2 0 1 2 30 2 0 1 2 30 2 0 1 2 30 2 0 1 2 30
3 0 2 1 26 2 0 1 3 23 3 0 0 1 24 2 0 1 3 23 2 0 1 3 23 2 0 1 3 23 2 0 1 3 23 2 0 1 3 23 2 0 1 3 23 2 0 1 3 23 2 0 1 3 23
3 0 2 2 30 2 0 2 1 22 3 0 0 2 23 2 0 2 1 22 2 0 2 1 22 2 0 2 1 22 2 0 2 1 22 2 0 2 1 22 2 0 2 1 22 2 0 2 1 22 2 0 2 1 22
3 0 2 3 23 2 0 2 2 30 3 0 0 3 23 2 0 2 2 30 2 0 2 2 30 2 0 2 2 30 2 0 2 2 30 2 0 2 2 30 2 0 2 2 30 2 0 2 2 30 2 0 2 2 30
4 0 0 1 28 2 0 2 3 23 4 0 0 1 23 2 0 2 3 23 2 0 2 3 23 2 0 2 3 23 2 0 2 3 23 2 0 2 3 23 2 0 2 3 23 2 0 2 3 23 2 0 2 3 23
4 0 0 2 30 3 0 1 1 26 4 0 0 2 23 3 0 1 1 26 3 0 1 1 26 3 0 1 1 26 3 0 1 1 26 3 0 1 1 26 3 0 1 1 26 3 0 1 1 26 3 0 1 1 26
4 0 0 3 23 3 0 1 2 30 4 0 0 3 23 3 0 1 2 30 3 0 1 2 30 3 0 1 2 30 3 0 1 2 30 3 0 1 2 30 3 0 1 2 30 3 0 1 2 30 3 0 1 2 30
5 0 0 1 28 3 0 1 3 23 5 0 0 1 23 3 0 1 3 23 3 0 1 3 23 3 0 1 3 23 3 0 1 3 23 3 0 1 3 23 3 0 1 3 23 3 0 1 3 23 3 0 1 3 23
5 0 0 2 30 3 0 2 1 26 5 0 0 2 23 3 0 2 1 26 3 0 2 1 26 3 0 2 1 26 3 0 2 1 26 3 0 2 1 26 3 0 2 1 26 3 0 2 1 26 3 0 2 1 26
5 0 0 3 23 3 0 2 2 30 5 0 0 3 23 3 0 2 2 30 3 0 2 2 30 3 0 2 2 30 3 0 2 2 30 3 0 2 2 30 3 0 2 2 30 3 0 2 2 30 3 0 2 2 30
3 0 2 3 23 3 0 2 3 23 3 0 2 3 23 3 0 2 3 23 3 0 2 3 23 3 0 2 3 23 3 0 2 3 23 3 0 2 3 23 3 0 2 3 23
4 0 1 1 28 4 0 1 1 28 4 0 1 1 28 4 0 1 1 28 4 0 1 1 28 4 0 1 1 23 4 0 1 1 23 4 0 1 1 28 4 0 1 1 28
4 0 1 2 30 4 0 1 2 30 4 0 1 2 30 4 0 1 2 30 4 0 1 2 30 4 0 1 2 23 4 0 1 2 23 4 0 1 2 30 4 0 1 2 30
4 0 1 3 23 4 0 1 3 23 4 0 1 3 23 4 0 1 3 23 4 0 1 3 23 4 0 1 3 23 4 0 1 3 23 4 0 1 3 23 4 0 1 3 23
5 0 1 1 28 5 0 1 1 28 5 0 1 1 28 5 0 1 1 28 5 0 1 1 28 5 0 1 1 23 5 0 1 1 23 5 0 1 1 28 5 0 1 1 28
5 0 1 2 30 5 0 1 2 30 5 0 1 2 30 5 0 1 2 30 5 0 1 2 30 5 0 1 2 23 5 0 1 2 23 5 0 1 2 30 5 0 1 2 30
5 0 1 3 23 5 0 1 3 23 5 0 1 3 23 5 0 1 3 23 5 0 1 3 23 5 0 1 3 23 5 0 1 3 23 5 0 1 3 23 5 0 1 3 23
4 0 2 1 28 4 0 2 1 28 4 0 2 1 28 4 0 2 1 28 4 0 2 1 28 4 0 2 1 23 4 0 2 1 23 4 0 2 1 28 4 0 2 1 28
4 0 2 2 30 4 0 2 2 30 4 0 2 2 30 4 0 2 2 30 4 0 2 2 30 4 0 2 2 23 4 0 2 2 23 4 0 2 2 30 4 0 2 2 30
4 0 2 3 23 4 0 2 3 23 4 0 2 3 23 4 0 2 3 23 4 0 2 3 23 4 0 2 3 23 4 0 2 3 23 4 0 2 3 23 4 0 2 3 23
5 0 2 1 28 5 0 2 1 28 5 0 2 1 28 5 0 2 1 28 5 0 2 1 28 5 0 2 1 23 5 0 2 1 23 5 0 2 1 28 5 0 2 1 28
5 0 2 2 30 5 0 2 2 30 5 0 2 2 30 5 0 2 2 30 5 0 2 2 30 5 0 2 2 23 5 0 2 2 23 5 0 2 2 30 5 0 2 2 30
5 0 2 3 23 5 0 2 3 23 5 0 2 3 23 5 0 2 3 23 5 0 2 3 23 5 0 2 3 23 5 0 2 3 23 5 0 2 3 23 5 0 2 3 23
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Supplementary Table 4-18. Strategies 4 and 5 – Primary HPV testing with liquid-based cytology triage algorithm 
 
The first row indicates the number of the decision tree; Column names: H, HPV test; CT, cytology (triage); K, colposcopy; A, action (next follow-up decision tree); each 
row represents a set of potential outcomes in a given follow-up path (columns C, CT, H, and K) and the number of the decision tree for the next follow-up (column A); 
Cytological outcomes: 1, normal; 2, borderline; 3, mild; 4, moderate; 5, severe dyskaryosis; HPV test outcomes: 1, negative; 2, positive; Colposcopy outcomes: 1, 
normal; 2,CIN1; 3, CIN2+; 0, represents test not performed. 
41 42 43 44 45 46
H H CT K A H H CT K A H H CT K A H H CT K A H H CT K A H H CT K A
1 0 0 0 41 1 0 0 0 41 1 0 0 0 41 1 0 0 0 41 1 0 0 0 41 1 0 0 0 41
2 0 1 0 42 2 0 1 0 44 2 0 1 1 41 2 0 1 1 41 2 0 1 0 46 2 0 1 0 41
2 0 2 1 41 2 0 2 1 41 2 0 1 2 45 2 0 1 2 45 2 0 2 1 41 2 0 2 1 41
2 0 2 2 45 2 0 2 2 45 2 0 1 3 43 2 0 1 3 43 2 0 2 2 45 2 0 2 2 45
2 0 2 3 43 2 0 2 3 43 2 0 2 1 41 2 0 2 1 41 2 0 2 3 43 2 0 2 3 43
2 0 3 1 41 2 0 3 1 41 2 0 2 2 45 2 0 2 2 45 2 0 3 1 41 2 0 3 1 41
2 0 3 2 45 2 0 3 2 45 2 0 2 3 43 2 0 2 3 43 2 0 3 2 45 2 0 3 2 45
2 0 3 3 43 2 0 3 3 43 2 0 3 1 41 2 0 3 1 41 2 0 3 3 43 2 0 3 3 43
2 0 4 1 41 ? 2 0 4 1 41 2 0 3 2 45 2 0 3 2 45 2 0 4 1 41 2 0 4 1 41
2 0 4 2 45 2 0 4 2 45 2 0 3 3 43 2 0 3 3 43 2 0 4 2 45 2 0 4 2 45
2 0 4 3 43 2 0 4 3 43 2 0 4 1 41 2 0 4 1 41 2 0 4 3 43 2 0 4 3 43
2 0 5 1 41 ? 2 0 5 1 41 2 0 4 2 45 2 0 4 2 45 2 0 5 1 41 2 0 5 1 41
2 0 5 2 45 2 0 5 2 45 2 0 4 3 43 2 0 4 3 43 2 0 5 2 45 2 0 5 2 45
2 0 5 3 43 2 0 5 3 43 2 0 5 1 41 2 0 5 1 41 2 0 5 3 43 2 0 5 3 43
2 0 5 2 45 2 0 5 2 45
2 0 5 3 43 2 0 5 3 43
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Supplementary Table 4-19. Strategy 6 - Primary liquid-based cytology and HPV triage 
algorithm as per NHS CSP, England[4] 
 
 
The first row indicates the number of the decision tree; Column names: C, primary cytology; CT, repeat 
cytology (triage); H, HPV test; K, colposcopy; A, action (next follow-up decision tree); each row 
represents a set of potential outcomes in a given follow-up path (columns C, CT, H, and K) and the 
number of the decision tree for the next follow-up (column A); Cytological outcomes: 1, normal; 2, 
borderline; 3, mild; 4, moderate; 5, severe dyskaryosis; HPV test outcomes: 1, negative; 2, positive; 
Colposcopy outcomes: 1, normal; 2,CIN1; 3, CIN2+; 0, represents test not performed. 
 
	
4.3.3.2.5.	Parameterisation	
Individual patient data from the Portuguese National Health Survey 2005/6[6] was used to 
parameterise our model on screening frequency under opportunistic screening. The variables 
of interest were derived from the self-reported year of last cytology and the year the survey 
was taken (n=3,368 valid answers). 
To characterise screening frequency in the context of organised screening, we used an Bains 
and colleagues model for the distribution of age at first screen derived from data of the NHS 
CSP, England (2011/12) (Bains and colleagues, Appendix in this thesis). We also used the 
distribution of time since last adequate test reported for women aged 25-64 in the NHS 
Cervical Screening Programme, England (2012-2013)[7], and an estimate of loss to follow-up 
from a population-based study on cytology attendance in the Manchester Health Authority 
Area (2004)[8]. 
61 62 63
C CT H K A C CT H K A C CT H K A
1 0 0 0 61 1 0 0 0 61 1 0 1 0 61
2 0 1 0 61 2 0 1 0 61 1 0 2 1 61
2 0 2 1 61 2 0 2 1 61 1 0 2 2 62
2 0 2 2 62 2 0 2 2 62 1 0 2 3 63
2 0 2 3 63 2 0 2 3 63 2 0 1 0 61
3 0 1 0 61 3 0 1 0 61 2 0 2 1 61
3 0 2 1 61 3 0 2 1 61 2 0 2 2 62
3 0 2 2 62 3 0 2 2 62 2 0 2 3 63
3 0 2 3 63 3 0 2 3 63 3 0 1 0 61
4 0 0 1 62 4 0 0 1 62 3 0 2 1 61
4 0 0 2 62 4 0 0 2 62 3 0 2 2 62
4 0 0 3 63 4 0 0 3 63 3 0 2 3 63
5 0 0 1 62 5 0 0 1 62 4 0 0 1 61
5 0 0 2 62 5 0 0 2 62 4 0 0 2 62
5 0 0 3 63 5 0 0 3 63 4 0 0 3 63
5 0 0 1 61
5 0 0 2 62
5 0 0 3 63
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Proportion	never	screened	
Under opportunistic screening (strategies 1 and 2), 35.5% of women never attend screening 
over a lifetime. Out of the 3,368 valid answers, 1,588 women reported never having been 
screened (47.15% (95%CI 45.5%, 48.9%) and 35.5% (95%CI 33.8%, 37.2%) crude and weighted 
estimate, respectively).   
For organised screening strategies, we assumed 10% of women were never screened based on 
an analysis of screening records in the Manchester Health Authority Area estimating that 11% 
of women aged 30-64 (n=72,613) never attended NHS screening[8]. 
Age	at	first	screen	
To model opportunistic screening, we derived the age at first screen from the proportion of 
women ever screened stratified by age group, as the actual age at first screen was not 
reported in the Portuguese National Health Survey 2005/6. The probability of having been 
screened at a given age was obtained by fitting a binomial distribution by maximum likelihood 
estimation. The maximum age at first screen was then assumed to be the last year within the 
age group with highest probability of having been screened, i.e. 39 years old Supplementary 
Figure 4-14).  
 
Supplementary Figure 4-14. Proportion of women ever screened by 5-year age group 
As the individual age at the survey participants was not available, we assume they were evenly 
distributed across the age group and randomly sampled the individual years and months of 
age. The empirical cumulative distribution function of first screen age was then used to 
randomly sample the age at first screen from for each individual woman modelled 
(Supplementary Figure 4-15), mean 32.58,median 33.42, 95%CI [21.25, 39.67]). 
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Supplementary Figure 4-15. Predicted age at first screen (opportunistic screening), 
cumulative probability distribution (left) and histogram (right) 
To model organised screening, we used Bains and colleagues’ distribution function of age at 
first screen for women aged over 24.5 years in England, where the age at first screen is 
assumed to be at least 24.5 years of age plus a lognormally distributed time interval whose 
logarithm has mean and standard deviation of 0.47389 and 1.26237, respectively (Appendix in 
this thesis). Supplementary Figure 4-16 shows the predicted age at first screen distribution 
used for modelled strategies of organised screening (mean 28.09, median 26.13, 95%CI [24.64, 
43.54]). 
Age at first screen ~ 24.5 + LogNormal[0.47389, 1.26237] 
 
 
 
Supplementary Figure 4-16. Predicted age at first screen (organised screening), cumulative 
probability distribution (left) and histogram (right) 
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Time	to	next	screen	
To model opportunistic screening, we derived time since last cytology from individual-patient 
data of the Portuguese National Health Survey 2005/6 by subtracting the self-reported year of 
last cytology from the reported year of the survey data. For each year of age, we sampled the 
time since last cytology of the respective age group with replacement and added a randomly 
generated month within a year, assuming the time of next cytology to be within a year’s time 
from completion of the survey. Supplementary Table 4-20 shows the summary statistics for 
the reported time since last cytology and for our modelled screening interval under 
opportunistic screening. 
Supplementary Table 4-20. Time since last cytology and opportunistic screening interval by 
age group 
Age 
group 
Time since last cytology 
mean, median (IQR), years 
Screening interval 
mean, median (IQR), years 
20-24 1, 1.19 (0, 2) 1.42, 1.8 (0.67, 2.58) 
25-29 1, 1.4 (0, 2) 1.42, 1.69 (0.75, 1.92) 
30-34 1, 1.71 (0, 2) 1.33, 2.04 (0.58, 2.25) 
35-39 1, 1.94 (0, 2) 1.42, 2.39 (0.67, 2.75) 
40-44 1, 2.36 (0, 3) 1.67, 2.69 (0.92, 3.33) 
45-49 1, 2.31 (0, 2) 1.58, 2.2 (0.83, 2.67) 
50-54 1, 2.83 (1, 3) 1.75, 3.38 (1, 3.42) 
55-59 2, 3.08 (1, 4) 2, 3.46 (0.92, 4.5) 
60-64 3, 5.44 (1, 9) 3.17, 6.15 (1.33, 10.17) 
65-69 4, 7.9 (1, 10) 3.92, 7.4 (1.75, 10.5) 
70-74 5, 9.18 (2, 13) 5.25, 9.18 (2.17, 12.92) 
75-79 8, 12.38 (2, 20) 7.5, 12.62 (4.83, 20.42) 
80-84 10, 10.39 (3, 16) 5.92, 8.84 (1.83, 10.92) 
For organised screening, we used the distribution of time since last adequate test reported for 
women aged 25-64 in the NHS Cervical Screening Programme, England (2012-2013), assuming 
similar screening frequency would take place in Portugal under a similarly organised call-recall 
cervical screening programme.[7] The proportion of women who had their last adequate test 
within a given period of time was used (categories: <1.5 , 1.5-3, 3-3.5, 3.5-5, 5-10,10-15, 15-20 
years). We sampled the time since last cytology with replacement (in months) for each year of 
age, assuming this variable was uniformly distributed within each time category.  
For the extended screening interval of 5 years (strategy 5), we used the organised screening 
distribution of time to next screen but added 2 years to each category: <3.5 , 3.5-5, 5-6.5, 6.5-
7, 7-12, 12-17, 17-22 years. 
Supplementary Table 4-21 summarises the primary screen intervals used as inputs to model 
screening strategies under opportunistic and organised regimes. 
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Supplementary Table 4-21. Screening interval by age group, mean, median (IQR), years 
Age group Opportunistic screening 
(3 yearly) 
Organised screening   
(3 yearly) 
Organised screening  
(5 yearly) 
20/25-65 1.67, 2.97 (0.83, 3.08) 2.08, 3.02 (1, 3.42) 4.08, 4.72 (2.33, 6.25) 
20-24 1.42, 1.8 (0.67, 2.58) - - 
25-29 1.42, 1.69 (0.75, 1.92) 2.08, 3.03 (1, 3.42) 4.08, 4.7 (2.33, 6.25) 
30-34 1.33, 2.04 (0.58, 2.25) 2.08, 3.02 (1, 3.42) 4.08, 4.69 (2.33, 6.17) 
35-39 1.42, 2.39 (0.67, 2.75) 2.08, 3.01 (1, 3.42) 4.08, 4.72 (2.33, 6.25) 
40-44 1.67, 2.69 (0.92, 3.33) 2.08, 3.03 (1, 3.5) 4.08, 4.74 (2.33, 6.33) 
45-49 1.58, 2.2 (0.83, 2.67) 2.08, 3.02 (1, 3.42) 4.08, 4.71 (2.33, 6.17) 
50-54 1.75, 3.38 (1, 3.42) 2.08, 3.02 (1, 3.5) 4.08, 4.73 (2.25, 6.25) 
55-59 2, 3.46 (0.92, 4.5) 2.08, 3.02 (1, 3.42) 4.08, 4.73 (2.33, 6.25) 
60-64 3.17, 6.15 (1.33, 10.17) 2.08, 3 (1, 3.42) 4.08, 4.73 (2.33, 6.33) 
65-69 3.92, 7.4 (1.75, 10.5) 2.08, 2.98 (1, 3.42) 4.08, 4.73 (2.33, 6.33) 
70-74 5.25, 9.18 (2.17, 12.92) 2.08, 3.02 (1, 3.5) 4.08, 4.72 (2.33, 6.25) 
75-79 7.5, 12.62 (4.83, 20.42) 2.08, 3.03 (1, 3.42) 4.08, 4.71 (2.25, 6.27) 
80-84 5.92, 8.84 (1.83, 10.92) 2.08, 3.02 (1, 3.42) 4.08, 4.71 (2.25, 6.25) 
Compliance	with	follow-up,	diagnostic,	and	treatment	referrals	
Opportunistic	screening	
The probability of a women being lost to follow up of a cytological abnormality (including 
vigilance of minor abnormalities and post-treatment follow-up) was assumed to be 0.50, as 
this is slightly under the lowest compliance to screening invitation reported by one of the 
Regional Health Administrations in 2013 (55%).  
Compliance to repeat cytology referral was assumed to be 100% as 99% was reported in the 
Centre region, where repeat cytology has been in place.  
Compliance with colposcopy referral was assumed to be 0.75, the mid-point of 10-40% 
estimates of non-adherence to referral by Khanna and Phillips[9], e.g. 40% loss FU in 
Nottingham pre-1984 when screening was opportunistic.  
Organised	screening	
For organised screening strategies, we assumed only 20% of women being lost to follow-up of 
a cytological lesion given the 82% (range: 55-86%, in Algarve and Alentejo respectively) 
average attendance to screening reported in organised programmes (2013).  
Colposcopy attendance was assumed to be 88%, the average in Portugal organised 
programmes (range: 59-92%, in Alentejo and North, respectively). 
We assumed 100% compliance to referrals to treatment of CIN2+ lesions and that only 24-
month persistent CIN1 lesions were treated, for both opportunistic and organised screening 
strategies. 
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Treatment	effectiveness	
As per Bains and colleagues (in the Appendix to this thesis), in our model, the proportion of 
lesions successfully treated was 95% and the probability of treatment successfully clearing HPV 
infections was 88.4%, as 16% of all women treated are HPV positive.[10] 
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5. Chapter	5.	Economic	evaluation	of	primary	HPV	DNA	screening	
in	Portugal	
 Preamble	to	research	paper	4		
The systematic review of previous model-based evaluations of cervical screening  in research 
paper 2[1] (Chapter 3) showed that cost-effectiveness analyses have become more common in 
this area than studies of effectiveness only. The economic impact of screening interventions 
has been proposed as a key criteria for the comprehensive evaluation and selection of 
screening strategies for clinical practice[7,8].   
Over two thirds of the studies reviewed in research paper 2[1] quantified health outcomes 
only in terms lives or life-years saved and a third in quality-adjusted life-years (QALYs) gained 
(particularly common among analyses of vaccination and screening).  In research paper 4, we 
performed a cost-effectiveness evaluation, measuring economic efficiency in terms of life-
years and QALYs in the base-case analysis and health-related quality of life in scenario 
sensitivity analyses.  
One[2] of the  two studies[2,3] previously published on modelling screening in Portugal 
included economic outcomes taking the perspective of the health care system on costs to 
analyse the cost-effectiveness of organised primary screening with conventional cytology or 
liquid-based cytology compared to opportunistic screening in euros (€) per life-year gained 
over an horizon of 10 years.  
In research paper 4, the cost-effectiveness of organised programmes with conventional or 
liquid-based cytology was compared to opportunistic screening (which is still commonly 
practiced in parts of Portugal) as well as to no screening and strategies including HPV DNA 
testing, either as a primary screening test or as triage of minor cytological lesions. The 
economic implications of extending the screening interval under organised primary HPV 
screening were also investigated. Health and economic outcomes were estimated over the 
lifetime of screened women and a partial societal perspective on costs was adopted, as per 
Portuguese guidelines on economic evaluations of medicines[4], by including the direct costs 
of providing health care for the National Health Service and the indirect costs of paid 
productivity loss by women due to cervical cancer. Other direct and indirect costs to society, 
e.g. costs to patients for attending screening, have not been included though. Cost-utility 
analysis was also performed in two scenarios with alternative assumptions on the impact of 
cervical cancer and cervical screening on women’s health-related quality of life.  
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The overall aim of this thesis was accomplished with the work presented in research paper 4 as 
it presents a fully incremental analysis of the cost-effectiveness of cytology- and HPV-based 
protocols compared to no screening.  
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5.2.1. Abstract	
Background: Portugal is moving towards a nationwide organised HPV-based cervical screening 
programme. Opportunistic screening is currently still predominant in most parts although 
organised regional programmes have gradually expanded since 2008. A unified organised 
programme is likely to reduce the incidence of cervical cancer more effectively; however, the 
cost-effectiveness of primary HPV- and cytology-based organised cervical screening in Portugal 
has yet to be evaluated. 
Methods: We adapted a static, stochastic, individual-based mathematical model of HPV 
acquisition and cervical disease progression to Portugal, and calibrated it to type-specific 
Portuguese HPV prevalence and incidence of cervical cancer. The cost-effectiveness of 
alternative opportunistic and organised cervical screening strategies, including repeat 
conventional cytology for triage of ASCUS, liquid-based cytology with HPV DNA triage of ASCUS 
and LSIL, and primary HPV DNA testing with liquid-based cytology triage of HPV-positive 
women was compared to no screening. Opportunistic screening was characterised using data 
on screening attendance from the Portuguese National Health Survey 2005/6. Organised 
screening in Portugal was assumed to have the same screening participation, frequency, and 
follow-up of lesions as the organised call-recall programme in England. A partial societal 
perspective was adopted by including direct medical costs to the National Health Service and 
paid productivity loss to patients due to cervical cancer.  
Results: Primary HPV screening every 5 years may be cost-effective at a willingness-to-pay of 
just under €18,000 per life-year saved compared to no screening, assuming the unit cost of 
HPV DNA testing was half of that of liquid-based cytology, followed by organised repeat 
cytology with an additional cost of €33,210 per life-year saved compared to 5-yearly primary 
HPV screening. Probabilistic sensitivity analysis revealed substantial uncertainty in our findings 
with several protocols under organised screening having similar probability of being cost-
effective over a willingness-to-pay of €20,000 per life-year saved. Organised repeat 
conventional cytology is likely optimal over €44,000 per life-year saved given its lower cost in 
Portugal and assumed similar performance to liquid-based cytology in England, with no 
screening having the highest probability of being cost-effective below that threshold.  
Conclusions:  A national HPV-based organised cervical screening programme is likely more 
effective than cytology-based protocols and may be cost-effective if the screening interval is 
extended to 5 years. However, the cost-effectiveness of primary HPV screening is highly 
dependent on the unit cost of HPV DNA testing relative to cytology.	
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5.2.2. Introduction	
Cervical cancer is the second most common cause of cancer mortality in women aged 15-45 in 
Portugal.[1] Opportunistic cervical screening has been offered as part of the National Health 
Service (NHS) in Portugal since 1978, but incidence of cervical cancer has remained stable 
between 1998 and 2010, despite a significant decline in mortality due to cervical cancer since 
the early 1980s.[2]  
Age-period-cohort models[3,4]  and time trend analyses[5] have shown a greater decline in the 
burden of cervical cancer in areas with high-coverage of organised cytological screening than 
where screening is largely opportunistic. Organised screening can also ensure equity of access, 
improved screening quality and more effective use of resources[6]. In Portugal, the 
implementation of regional fully-organised cervical screening programmes began in 2008[7], 
when human papillomavirus (HPV) vaccination of 13-year-old girls was introduced in the 
National Immunisation Plan[8].  
The Portuguese universal, tax-financed NHS is provided by 5 regional health administrations 
(RHAs) each responsible for its own population health strategy and direct management of 
primary care centres, as well as for the implementation of national health programmes and 
the coordination of the several levels of health care provision[9]. On behalf of the Portuguese 
Ministry of Health, the Central Administration of the Health System manages the financial and 
human resources of the Portuguese NHS and is responsible together with the RHAs for 
contracting with hospitals and private care providers for the NHS patients, including services 
implied in cervical cancer prevention.  
Opportunistic cervical screening in Portugal has relied on private providers to examine smears 
collected in NHS primary care centres as part of conventional cytological screening and 
brought in for analysis by patients. The Centre region has offered semi-organised screening 
since the 1990s. In this region, women are offered conventional cytology in primary care 
centres opportunistically, but the transportation and examination of conventional cytology 
samples has been part of the RHA contract with the regional central public hospital. In other 
regions of the country, opportunistic conventional cytological screening coexists alongside fully 
organised programmes where women are offered liquid-based cytology and HPV testing is 
used to triage equivocal cytological results. These organised regional programmes include a 
call-recall invitation system and the transportation and examination of smears are part of the 
contract with the regional central public hospitals.  
National price lists for institutions and services integrated in the Portuguese NHS are based on 
diagnosis-related groups (DRGs) and include the unit costs of services charged to subsystems 
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and private insurers[10] or paid to private care providers assisting the NHS by the Central 
Administration of the Health System[11]. In 2018, the unit cost for all screening, diagnosis, and 
treatment activities to support RHAs on cervical cancer prevention became uniform nationally 
as part of contracts with public hospitals[12,13].  
Since 2008, the geographical coverage of existing regional organised cervical screening 
programmes has increased, with the aim of ultimately attaining a centrally coordinated 
nationwide single screening strategy[7]. The implementation of primary HPV screening has 
recently been endorsed by the Portuguese Ministry of Health and HPV 16/18 genotyping with 
cytology triage of women positive to other HPV types is being piloted in the North region of 
Portugal since September 2017[7,12]. 
Other countries where HPV vaccination has also been implemented are evaluating possible 
HPV-based screening protocols[14]. HPV DNA testing has shown to be more sensitive to high-
grade precancerous lesions than cytology while enabling the safe extension of the screening 
interval to at least 5 years[15]. This objective automated test is also more reproducible, 
reliable, and likely more robust to the anticipated impact of vaccination on HPV prevalence 
and cervical lesions than cytology, offering as well the compatibility with self-sampling[16]. 
Primary HPV screening may result in unnecessary referral for colposcopy though, if adequate 
triage is not conducted, given its lower specificity to high-grade cervical intraepithelial 
neoplasia than cytology. The variety of triage algorithms of HPV-positive women 
recommended for or applied in different countries reflects the uncertainty in identifying the 
optimal approach for risk stratification.  
Mathematical models have been helpful in making projections to assist decision making based 
on epidemiological and economic evidence concerning alternative screening technologies and 
algorithms [17]. These models have been used to predict the lifetime health benefits and costs 
associated with different screening protocols and assess the effectiveness and cost-
effectiveness of different options, in vaccinated and unvaccinated cohorts[18,19].    
In this study, we aimed at estimating the expected health effects and costs of alternative 
cervical screening strategies in unvaccinated Portuguese women and their relative cost-
effectiveness. To our knowledge, this is the first cost-effectiveness analysis of HPV- and 
cytology-based cervical screening protocols in Portugal.   
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5.2.3. Methods	
We adapted an existing mathematical model (described in Bains and colleagues in the 
Appendix to this thesis) to simulate HPV acquisition and progression to cervical cancer in 
Portugal. The model was calibrated to Portuguese HPV prevalence and incidence of cervical 
cancer (detailed in research paper 3, Chapter 4) and its effectiveness outcomes together with 
Portuguese cost data were used to project the health and economic outcomes associated with 
alternative screening protocols presented in this chapter.  
We compared the approaches currently available in the Portuguese National Health Service: (i) 
conventional cytology-based screening, the predominant opportunistic countrywide protocol 
also currently available in the partly-organised programme of the Centre region, and (ii) 
organised liquid-based cytology with HPV triage of equivocal cytological results, in place in 
Alentejo, Algarve, and the North region; with alternative primary HPV DNA testing strategies 
and no screening. For each strategy, health outcomes (such as the number of deaths due to 
cervical cancer, life-years lost, and quality-adjusted life years lost due to screening and cervical 
cancer) and costs (in 2018 euros, €) were projected over the lifetime of the screened women. 
Incremental cost-effectiveness ratios (ICERs, i.e. additional cost (€) per additional life-year 
saved) were calculated to evaluate the relative cost-effectiveness of the distinct strategies. We 
adopted a partial societal perspective and discounted future health and costs annually by 5%, 
as recommended in Portugal[20]. Indirect costs to cervical cancer patients due to paid 
productivity loss were included, but other societal costs such as those related to attending 
screening were not. The robustness of our findings to parameter and scenario uncertainty was 
investigated in sensitivity analysis. 
Model	structure	
We adapted an existing static, stochastic, individual-based model developed to assist decisions 
for the National Health Service Cervical Screening Programme in England (described in detail 
by Bains and colleagues in the Appendix to this thesis). The acquisition and clearance of 
infection by 8 HPV types - 16, 18, 31, 33, 45, 51, 52, and 58 - were simulated over women’s 
lifetime in monthly steps. The risk of acquisition was modelled as a function of their age, sexual 
behaviour, the number of infectious men in that cohort of the population, and HPV 
transmissibility per sexual act. The number of infectious men was constant over the cohort 
lifetime. The development of HPV type-specific precancerous lesions and cancer was modelled 
for HPV-positive women depending on the time since acquisition and clearance of the 
infection. Cervical cancer remained undiagnosed if not detected via screening or clinical 
symptoms. 
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Portuguese data were used to parameterise the distinct components of the model, where 
available. Data from the Portuguese 2007 population-based sexual behaviour and HIV/AIDS 
survey[21]  was used to simulate the behavioural risk of HPV acquisition among Portuguese 
women. Type-specific HPV clearance and transmissibility rates were among the parameters 
obtained by calibration to Portuguese age- and type-specific HPV prevalence[22]and cervical 
cancer incidence[23]. Age-specific cervical cancer survival was derived from data reported by 
the Portuguese cancer registry of the North region[24], and mortality from other causes from 
Portuguese life tables (1981-2060)[25]. 
The performance of the screening tests modelled was implicitly captured by the progression 
rates to precancerous lesions used in our model. Given the lack of Portuguese data on 
cytological outcomes, we used the lesions progression rates fitted by Bains and colleagues for 
England on liquid-based cytology (LBC) and HPV DNA test outcomes, as well as their estimates 
for the probabilities of the distinct colposcopy outcomes conditional on women’s cytological 
outcome (based on data from NHS CSP England), assuming progression of cervical lesions to be 
independent of women’s country of origin and the same performance for screening and  
diagnostic tests in both countries. Also, as conventional cytology is the primary test used in 
Portugal in areas not covered by an organised programme, we assumed conventional cytology 
and LBC had equivalent performance[26]. The number of treatments performed in each 
strategy was calculated assuming that all grade 2 or above cervical intraepithelial neoplasia 
(CIN2+) cases were treated.  
Details of the parameterisation and calibration of the model can be found in Chapter 4 of this 
thesis. 
Screening	strategies	
The characteristics of the strategies modelled for cervical screening of unvaccinated women 
are summarised on Table 5-1 (tabulated in greater detail in Research paper 3 Table 4-1, 
Chapter 4). We compared 7 screening protocols to a no screening approach, including the 
currently prevalent opportunistic conventional cytology-based screening with repeat cytology 
for triage of ASCUS (strategy 1) and an organised analogous programme (strategy 7). 
Liquid-based cytology with HPV triage of low-grade lesions (ASCUS and LSIL) was modelled 
under (i) opportunistic screening (strategy 2), and (ii) organised screening according to 
protocols recommended by the Portuguese Society of Gynaecology[27] (strategy 3) and (iii)  
organised screening according to the English National Health Service Cervical Screening 
Programme protocol[28] (strategy 6). 
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An organised programme with primary HPV screening and cytology triage of HPV-positive 
women was also modelled with a screening interval of 3 and 5 years (strategies 4 and 5, 
respectively). 
Screening attendance under opportunistic screening was characterised based on individual-
patient data from the Portuguese National Health Survey 2005/6[25], when screening was 
exclusively opportunistic in Portugal. For organised screening, we assumed the screening 
attendance in Portugal would be similar to that of the organised call-recall National Health 
Service Cervical Screening Programme England[29].  
Cost-effectiveness analysis 
We conducted a cost-effectiveness analysis based on the guidelines for the economic 
evaluation of medicines by the Portuguese National Authority of Medicines and Health 
Products (INFARMED)[21]. Table 5-2 below summarises the methods used.  
Health outcomes were estimated in terms of number of cervical cancers and deaths, life-years 
(LY) lost, and quality-adjusted life years (QALY) lost due to screening and cancer. For each 
screening strategy, the accumulated health outcomes and costs (in 2018 euros, €) were 
estimated for each simulated individual over her lifetime. Future costs, LY, and QALY losses 
were discounted at a rate of 5% per year, according to the guidelines[21]. 
We adopted a partial societal perspective on costs and resource use, including direct costs for 
the Portuguese National Health Service to provide screening, follow-up, diagnosis, and 
treatment for precancerous lesions and cervical cancer as well as indirect cost due to cervical 
cancer patients' productivity loss. Paid productivity costs were calculated by applying the 
workforce engagement rate among women aged 20 to 64 years and the net monthly average 
wage reported for women in mainland Portugal[]25] to the number of life-years lost due to 
cervical cancer. Other direct and indirect costs to social care services, patients, and family, 
such as out-of-pocket fees and productivity loss due to attending screening, were not included.   
The relative cost-effectiveness of the strategies analysed was estimated in terms of 
incremental cost-effectiveness ratios (ICER). Strategies were ranked by increasing cost and the 
incremental costs averted, as well as life-years or QALY saved were calculated relative to the 
immediately less expensive strategy. Strategies that were both less effective and more costly 
were left out of the analysis as these are dominated by the next more effective strategy. The 
ICER for the dominant strategies was then estimated and extendedly dominated strategies 
(with larger ICER than the subsequent more costly strategy) were ruled out as well before the 
final recalculation of the ICER[30]. 
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Scenario and univariate sensitivity analyses were performed to explore the impact of 
alternative input data sets and assumptions on our model results. The model stochasticity and 
the Bayesian method of inferring the transmission parameters inherently enabled estimating 
the impact of joint parameter uncertainty, also known as probabilistic sensitivity analysis.  
Health-related	quality	of	life	
We searched PubMed for studies measuring the impact of screening, diagnosis, and treatment 
of precancerous lesions or cervical cancer on the health-related quality of life (HRQoL) of 
women attending screening or cervical cancer patients using the EQ-5D. The search terms used 
were “EQ-5D cervical cancer screening” and “utility scores cervical cancer screening”. 
No study was found on Portuguese women and only one study in the Netherlands provided 
utility scores for all health states related to cervical screening derived from data reported 
directly by women attending screening and cervical cancer patients using the EQ-5D with 
preference elicited[31].  De Kok and colleagues[31] found no significant association with 
disutility from screening itself, only from cervical cancer and that post-treatment disutility held 
for at least 10 years after diagnosis. 
Among the studies found, a survey by Simonella and colleagues[32] was conducted specifically 
to estimate utility scores for primary HPV screening and subsequent triage and management 
for use in an economic evaluation of primary HPV screening in England by Kitchener and 
colleagues[33]. Simonella and colleagues[32] measured preferences for hypothetical health 
states using a two-stage standard gamble in a sample of women from the general population 
targeted for cervical screening who ranked an HPV-positive result below a low-grade 
cytological outcome. 
We built two scenarios to explore the effect of alternative assumptions on the impact of 
cervical screening of women’s HRQoL on our cost-effectiveness results. In scenario 1, we 
assigned no disutility to screening events, accounting only for the impact of cervical cancer 
diagnosis and treatment, and assumed lifetime post-treatment disutility as per de Kok and 
colleagues[31]. In scenario 2, disutility from screening, colposcopy, and treatment for CIN2+ 
was incorporated, as well as that from cervical cancer, similarly to the approach taken by 
Kitchener and colleagues[33] in their economic evaluation of primary HPV screening in 
England. Women surviving cancer for at least 5 years were assumed to recover to full health in 
this scenario[33].  
Table 5-3 below summarised the utility estimates used as inputs. Disutility for each health 
state was calculated by subtracting the utility score (drawn from a beta distribution) for that 
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health state from that of the general population (scenario 1) or from 1 (scenario 2). We 
assumed utility scores to follow a beta distribution. 
The distribution of cervical cancer cases by stage reported for the largest oncology hospital in 
the North region (2010-2014, Table 5-4) was used to apply stage-specific disutility from cancer, 
based on the age at which the cancer was diagnosed[34].  
Costs	and	resource	use	
In our systematic review of model-based studies of cervical screening strategies[18] (Chapter 
3), we found one cost-effectiveness analysis of cervical screening  in Algarve, Portugal by 
Novoa-Vazquez[35]. We accounted for similar resource use and used the latest Portuguese 
NHS price lists[10,11,13], assuming that these prices are a reasonable approximation of the 
opportunity cost of health-care resources  in Portugal; however, list prices may not capture the 
actual underlying cost of resources.  
Similarly to Novoa-Vazquez[35], we added the cost of sampling to the laboratory examination 
cost of each primary screening test (conventional cytology, liquid-based cytology, or HPV DNA 
testing) and the cost of a gynaecological visit to each colposcopy. The sampling cost for liquid-
based cytology was also used for HPV DNA testing.  
The unit cost of conventional cytology varied per strategy. For strategy 1, it included the 
examination cost (€5.42) paid by the Portuguese NHS to private providers and the patient’s co-
payment (€3.00)[11] used for the opportunistic screening currently in place throughout the 
country, whereas in strategy 7, representing an organised programme based on repeat 
conventional cytology (resembling that in place in the Centre region), the unit cost of 
conventional cytology consisted of the examination cost (€15.20) charged to the Portuguese 
NHS subsystems[10]. These are list prices for the Portuguese NHS. They are assumed to be a 
reasonable approximation of the opportunity cost of cytology in Portugal. 
We also assumed that 35% of colposcopies involved biopsy[35], that all CIN2+ lesions were 
treated by conisation [27,35], and 97% compliance with treatment referral as per data from 
the organised cervical screening programme in Alentejo (2011-2013)[RHA, personal 
communication].  
The unit cost for an HPV DNA test without genotyping is not catalogued in the Portuguese 
national price lists[10]; however, the unit cost of HPV DNA genotyping is listed as €64.40. In 
England, the unit cost of an HPV DNA test is approximately half of that for liquid-based 
cytology[33]. The relatively high cost of HPV DNA testing in Portugal is likely due to it 
depending on in house specialist technology; hence we assumed that as part of an organised 
programme with the subsequent economies of scale, the cost ratio seen in England would 
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apply to Portugal. This assumption was varied in a scenario where HPV DNA was assumed to 
cost the same as liquid-based cytology.  
A scenario analysis was also conducted to reflect the recent NHS national contract with public 
hospitals to support RHAs on screening activities (2018)[13] by using the unit cost of €67.50 for 
the examination of any cervical screening sample (applicable to primary cytology or HPV test 
and subsequent triage test) by public hospitals. 
The unit costs and resource use applied in our model are presented on Table 5-5 below and 
were assumed lognormally distributed in our model. 
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5.2.4. Results	
Cancer cases and life-years lost 
Table 5-6 presents the predicted annual number of cervical cancer cases, deaths, and years of 
life lost, as well as the total annual number of tests and cost (differentiating screening, 
treatment, and productivity cost) for each simulated strategy.  
Organised programmes based on cytology or HPV DNA testing (strategies 3-7), which are likely 
to achieve higher coverage and improved follow-up of women with positive screening results, 
prevented more cancer cases and saved more life years than protocols in opportunistic 
screening (strategies 1 and 2), and no screening yielded the greatest health loss. Protocols 
under organised 3-yearly screening would have over 70% and 20% of their annual cost due to 
screening activities and productivity losses due to cancer deaths, respectively, whilst nearly 
50% of the annual cost of opportunistic repeat cytology screening is predicted to be due to 
productivity loss.  
On average, primary HPV screening every 3 years (strategy 4) was the most effective protocol 
in preventing more cancer cases and subsequent cancer-related deaths and life-years saved; 
however, its effectiveness is not significantly different from the other HPV- and cytology-based 
protocols under organised screening (strategies 3,5,6,and 7). 
Primary HPV screening every 5 years (strategy 5) was as effective as protocols based on 3-year 
screening intervals, reducing cancer incidence by nearly twice as much than opportunistic 
repeat cytology (strategy 1) relative to no screening, and was the strategy involving the fewest 
tests (on average), similar to those under opportunistic screening (strategies 1 and 2). 
Cost-effectiveness analysis 
Opportunistic repeat cytology was the least expensive protocol, in terms of discounted lifetime 
cost per woman, as the sampling and examination cost of conventional cytology (€7.50 and 
€5.42 plus €3.00 user charge, respectively) is about half of that for liquid-based cytology or 
HPV DNA testing (€15.00 and €15.20, respectively), in the Portuguese national price list[10]. 
The cheaper sampling cost of conventional cytology also contributed to organised 
conventional-cytology based screening (strategy 7, with sampling and examination cost of 
€7.50 and €15.20, respectively) being similarly expensive to opportunistic HPV triage (strategy 
2, with liquid-based cytology sampling and examination cost of €15.00 and €27.40, 
respectively), despite being the strategy requiring the most testing.  
The incremental cost-effectiveness results (Table 5-7) show primary HPV screening every 5 
years (strategy 5) to be cost-effective at a willingness-to-pay of €17,701 per life-years saved, 
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compared to no screening. Organised repeat conventional cytology and 3-yearly primary HPV 
screening (strategies 7 and 4) would follow as cost-effective at €36,822 and €91,979 per life-
years saved, respectively.  
Opportunistic HPV triage (strategy 2) was dominated by organised repeat cytology (strategy 7). 
Organised HPV triage according to either English or Portuguese guidelines (strategies 3 and 6) 
was dominated by strategy 4. Opportunistic repeat conventional cytology (strategies 1) was 
extendedly dominated (more costly per life-year saved than the next more efficient strategy) 
by strategy 5, leaving no screening, 5-yearly primary HPV testing, organised repeat cytology, 
and 3-yearly primary HPV screening on the efficiency frontier of the cost-effectiveness plane 
(Figure 5-1A).  
The results of the probabilistic analysis are presented on Figure 5-1C, where each cost-
effectiveness acceptability curve (CEAC) represents the probability of each protocol or no 
screening being cost-effective over a range of values of willingness-to-pay. The cost-
effectiveness acceptability frontier is also shown on top of the CEACs identifying the optimal 
option (in terms of having the highest expected net benefit) at a given willingness-to-pay. 
Despite not having the highest probability of being cost-effective at €18,000 to €36,000 per 
life-year saved, primary HPV testing every 5 years was the optimal strategy within that range 
of willingness-to-pay with 21% probability of being the most cost-effective option. For 
thresholds between €36,000 and €91,000 per life-year saved, organised repeat cytology 
becomes optimal and over €44,000 per life-year saved it is also the option with highest 
probability of being cost-effective (21-22%).  
HRQoL scenarios 
Under HRQoL scenario 1, assuming disutility only from cervical cancer, strategy 3 (organised 
HPV triage as per Portuguese guidelines) joins the efficiency frontier as the most efficient and 
most costly protocol compared to those in our base case analysis, with organised HPV 
screening every 5 years and repeat cytology being cost-effective at a slightly lower willingness-
to-pay of €17,081 and €24,123 per QALY saved, respectively, compared to no screening (Figure 
5-2A). The cost-effectiveness acceptability curves for this scenario (Figure 5-2C) show a similar 
pattern to that of our base case analysis, with 5-yearly primary HPV screening being optimal at 
thresholds between €18,000 and €24,000 per QALY saved and 21% probability of being cost-
effective, while organised screening with repeat cytology for triage of ASCUS lesions (strategy 
7) became optimal at a lower threshold (€25,000 per QALY saved) having the highest 
probability of being cost-effective (23-25%) from €39,000 to €92,000 per QALY saved.  
237 
 
In a scenario where substantial disutility from screening was assumed, as with the study by 
Kitchener and colleagues[33]  (HRQoL scenario 2), the most effective and least expensive 
strategy was no screening (Figure 5-3A), dominating all screening strategies which would yield 
greater QALY loss. Among protocols under organised screening, 5-yearly primary HPV testing 
had the least QALY loss, as it yielded fewer testing. Table 5-8 provides the detailed incremental 
cost-utility analysis for both scenarios. 
2018 Contract cost scenario 
Under the scenario of a fixed uniform unit cost per screening test (including subsequent triage) 
analysed by laboratories in public hospitals, opportunistic screening with repeat conventional 
cytology (Strategy 1) becomes part of the cost-effectiveness frontier with the lowest ICER of 
€30,052 per life-year saved compared to no screening (Figure 5-4A), given the absence of an 
alternative cheaper organised screening strategy, for instance entailing less frequent 
screening.  The ICER of primary HPV screening every 5 or 3 years increased to €44,989 and 
€134,211 per life-year saved compared to strategy 1 and strategy 5, respectively (Table 5-9). 
Figure 5-4C shows that 5-yearly HPV screening would be optimal over a willingness-to-pay of 
€45,000 per life-year saved with 15% probability of being cost-effective.   
5.2.5. Discussion	
Our findings suggest that primary HPV screening every 5 years may be cost-effective compared 
to no screening with similar cost as opportunistic screening, provided that the unit cost of HPV 
DNA test is sufficiently lower than liquid-based cytology, for instance half as much as is 
reported in England (in our base case analysis). The transition to a countrywide HPV- or 
cytology-based organised cervical screening programme is likely more effective in cancer 
prevention than opportunistic screening, and the total annual cost of 5-yearly primary HPV 
screening is comparable to that of opportunistic repeat cytology screening. Organised 
programmes with primary liquid-based cytology and HPV triage of ASCUS and LSIL were on 
average more costly and less effective preventing cancers than primary HPV testing every 3 
years.   
These results are compatible with those from both modelling studies and trial-based economic 
evaluations in unvaccinated women in other European settings. Primary HPV screening has 
proven more effective than cytology-based screening in cervical cancer prevention in 4 large 
European randomised controlled trials, independently of the diverse protocols used[15]. Other 
model-based economic evaluations of primary HPV testing have also found it cost-effective (in 
the Netherlands using Population-Based SCreening study Amsterdam (POBASCAM) trial 
data[36]), or dominant (cost-saving and more effective, as in our base case analysis based on 
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average discounted cost per life-year saved) compared to HPV triage in countries such as 
England (using data from the A Randomised Trial In Screening To Improve Cytology (ARTISTIC) 
trial[33]), France [37], Italy[38], and Norway[39]. The cost-effectiveness of repeat cytology 
strategies in a low cytology cost European scenario was also reported in the model-based 
study by de Kok and colleagues[40], who also pointed out the importance of organising 
primary HPV screening so that the examination costs of HPV testing are minimised, such as 
having most tests concentrated in a few large laboratories.  
Our probabilistic sensitivity analysis indicated substantial joint parameter uncertainty with 
primary HPV screening every 5 years being the optimal option between €18,000 and €36,000 
per life-year saved with a probability of being cost-effective of only 21-22% at that range of 
willingness-to-pay. This is likely driven by the similar effectiveness predicted for protocols 
under organised screening and the relative cost of the technologies involved. For instance, the 
unit cost of sampling for primary HPV testing (assumed the same as for liquid-based cytology 
in our base case) is twice as much as that for conventional cytology in the Portuguese NHS, 
which is predicted similarly effective as primary HPV testing every 3 years (on average 
prevented slightly more cancers). Our assumption that the performance of conventional 
cytology in Portugal is the same as that of automated liquid-based cytology in England is likely 
overestimating the effectiveness of organised repeat cytology screening. 
Our scenario of a uniform unit cost per examination of screening test (regardless of technology 
used and associated triage) in public hospitals for organised programmes suggests that 
primary HPV screening every 5 years would be cost-effective at a willingness-to-pay of €45,000 
per life-years saved compared to opportunistic repeat conventional cytology, albeit with a high 
uncertainty around this decision, mainly due to the examination cost of conventional cytology 
in opportunistic screening being about 1/8 of its cost in an organised programme.  It is of note 
that cheaper alternative organised screening strategies that could dominate opportunistic 
repeat conventional cytology in this scenario, e.g. every 8 years, have not been analysed. 
We used Bains and colleagues’ distributions for disease progression and test performance 
(given the lack of data on cytology and colposcopy outcomes in Portuguese women), assuming 
the quality of these subjective tests to be the same under opportunistic and organised 
screening in Portugal as in organised screening in England; however, Ronco and colleagues[41] 
found evidence of the variation in cytology performance between countries (generally better 
where cytology-based screening has been organised for longer). Hence, we are likely 
overestimating the performance of opportunistic cytology in Portugal and have not accounted 
for costs associated with quality assurance that are essential to well organised programmes 
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nor eventual economies of scale due to centralisation of testing in major hospital laboratories 
for instance. 
Given the uncertainty on the impact of cervical screening on women’s HRQoL and this being a 
strong determinant of the cost-effectiveness of screening strategies[31,33], our base case 
analysis was founded on life-years saved as primary effectiveness outcome. Primary HPV 
screening every 5 and 3 years became slightly more cost-effective in the HRQoL scenario 1 (as 
de Kok and colleagues[31] found no disutility from screening, only from cervical cancer). In 
HRQoL scenario 2 (derived from Kitchener and colleagues[33]),  disutility from a screening-
positive result is just slightly less detrimental than that from colposcopy and treatment for 
CIN2+. Hence, greater disutility was yield from screening intensive strategies and no screening 
ended up dominating all screening protocols. While screening was found to impose significant 
disutility by Simonella and colleagues[32] who elicited preferences in women in the general 
population targeted for screening but not actually experiencing it, de Kok and colleagues[31] 
found no significant evidence of screening disutility in women attending screening and actually 
experiencing the screening-related health states. This difference can be explained by the 
disability paradox as patients tend to report better quality-of-life than healthy people asked to 
imagine those health states[42].Also, INFARMED’s guidelines[20] recommend patients’ 
valuations for the measurement of HRQoL and the general public as source of preference data 
for weighting changes in health-related quality of life, as done by de Kok and colleagues[31]. 
Hence, we think HRQoL scenario 1 is likely to better reflect national guidelines on capturing 
the impact of screening and cervical cancer on patients’ quality of life than scenario 2 where 
the negative impact of screening was assumed to outweigh its benefit. However, we also find 
important to note that the impact of screening might not be appropriately captured by generic 
measures of HRQoL as the EQ-5D, given that it has been found significant in studies measuring 
condition-specific effects like anxiety and worry[43].       
Despite having adopted a partial societal perspective for cost-effectiveness analyses, including 
productivity loss due to cervical cancer deaths in women participating in the labour market 
aged 20-64 years, it is important to note that direct social care costs and direct patients costs 
such as user charges were not included in our analysis. Also not included were indirect costs, 
such as patients’ paid productivity loss due to attending screening, patients’ unpaid 
productivity loss, or carers’ productivity loss, nor were costs related to the implementation of 
a fully-organised nationwide programme.  
The use of a stochastic model facilitates capturing the joint uncertainty of the parameter 
values used.  However, we used a fixed value for some parameters in our model and the 
uncertainty in those estimates was not accounted for. Using other distributions for these 
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parameters or and performing univariate sensitivity analysis on these to investigate the impact 
of changes to these values on our model results may help to fully capture the parametric 
uncertainty in these values. 
Necessary further work, particularly pertinent to support the transition to a successful well-
organised countrywide programme, includes evaluating the cost-effectiveness of primary HPV 
screening with HPV 16/18 genotyping, currently being piloted in the North region,[7]as per the 
latest recommendation of the Portuguese Ministry of Health[12]. With the increasing number 
of vaccinated women, HPV genotyping is likely a useful tool to monitor HPV 16/18 prevalence 
among unvaccinated women and mathematical models can be used to help identify safe and 
cost-effective screening protocols[44]. 
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5.2.8. Tables	
Table 5-1. Summary of characteristics of cervical screening strategies modelled 
 No 
screening 
Strategy 1 Strategy 2 Strategy 7 Strategy 3 Strategy 6 Strategy 4 Strategy 5 
Organisation of 
screening 
n.a. Opportunistic Opportunistic Organised Organised Organised Organised Organised 
Primary test n.a. Cytology Cytology Cytology Cytology Cytology HPV DNA HPV DNA 
Triage test n.a. Repeat 
cytology  
HPV DNA Repeat 
cytology  
HPV DNA HPV DNA Cytology Cytology 
Screening frequency θ,  
median, mean (IQR) 
years 
n.a. 2, 5.2 (1, 6)α  2, 5.2 (1, 6)α 2.1, 3 (1, 3.4)β 2.1, 3 (1, 3.4)β 2.1, 3 (1, 3.4)β 2.1, 3 (1, 3.4)β 4, 4.7 (2.3, 
6.3) 
Age at first screen, 
median, mean (IQR) 
years 
n.a. 33.00, 32.37 
(28.88, 
36.67)α 
33.00, 32.37 
(28.88, 
36.67)α 
26.12, 28.09 
(25.18, 
28.29)β 
26.12, 28.09 
(25.18, 
28.29)β 
26.12, 28.09 
(25.18, 
28.29)β 
26.12, 28.09 
(25.18, 
28.29)β 
26.12, 28.09 
(25.18, 
28.29)β 
Probability of loss to 
follow-up of cytological 
abnormality or 
treatment 
n.a. 0.5 0.2 
Probability of complying 
with colposcopy/ 
treatment referral 
n.a. 0.75/ 0.97 0.88/ 0.97 
Note: Recommended screening ages and interval by the Portuguese Society of Gynaecologists: 20-64 every 3 years (opportunistic cytology-based strategies), 25-64 every 3 
years (organised cytology-based strategies), 30-64 every 5 years (organised HPV-based strategies alongside cytology every 3 years for women aged 25-29)[27];  n.a., not 
applicable;  α derived from PTNHS2005/6; β derived from the English cervical cancer screening programme (assuming same frequency for all strategies under organised 
screening); θ Screening frequency in England was based on cross-sectional data on time since last screen, rather than actual screen interval data. Consequently, the 
organised screening strategies modelled have a shorter median interval than that expected (for 3-yearly strategies, 2.1 years versus 3 years, respectively), being effectively 
simulations of 2-yearly and 4-yearly organised screening strategies. This error – to be corrected in subsequent publication - has affected the costs and health outcomes 
predicted for each strategy and the results of the cost-effectiveness analysis.
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Table 5-2. Summary of the methods used  
Element of economic 
evaluation 
Description 
Perspective on outcomes All direct health effects on patients were included  
Perspective on costs As per INFARMED’s recommendation, we adopted a partial 
societal perspective on costs, including  the direct costs of 
providing health care for the National Health Service and the 
indirect costs of productivity loss by women due to cervical 
cancer  
Type of economic evaluation Cost-effectiveness and cost-utility analyses with fully 
incremental analysis 
Time horizon Lifetime 
Comparator(s) We compared alternative screening strategies, including that 
in place in Portugal before the introduction of regional 
organised programmes, with no screening. 
Synthesis of evidence on health 
effects 
We used the best evidence available on the clinical 
effectiveness or utility found for each alternative strategy and 
respective technologies 
Measuring and valuing health 
effects 
We estimated health outcomes in life-years (LY) saved and 
quality-adjusted life years (QALY) saved. The estimates used in 
both health-related quality of life scenarios were obtained 
with a validated and standardised HRQoL instrument - the EQ-
5D. 
Source of data for 
measurement of health-related 
quality of life (HRQoL) 
We used estimates derived from data reported directly by 
women undergoing cervical screening and cervical cancer 
patients in the Netherlands[32], as well as data reported 
directly by women from the general population (a sample of 
women targeted for screening living in Sydney, Australia[33]) 
Source of preference data for 
valuation of changes in health-
related quality of life 
Estimates derived from preference data elicited by a 
representative sample of the Portuguese population were not 
available; the estimates used in the HRQoL scenarios 1 and 2 
were derived from data elicited by a sample of the UK and 
Australian population, respectively. 
Evidence on resource use and 
costs 
Unit costs for  the Portuguese National Health Service (NHS) 
were used 
Discounting The same annual rate of 5% was applied to both future costs 
and health effects as recommended for base case analysis by 
INFARMED 
Currency Euros (€) 
Economic analysis outcomes An incremental analysis was conducted to compare mutually 
exclusive strategies and assess their relative cost-effectiveness 
in terms of incremental cost-effectiveness ratios (ICER). 
Characterisation of uncertainty Scenario and probabilistic sensitivity analysis were conducted 
to assess the most relevant types of uncertainty.  
 
  
247 
 
Table 5-3. Health–state utility scores 
Health state Utility score,   
mean (SE) 
Source 
Scenario 1   
General population 0.86 (0.02) De Kok 2018[31] 
Cancer Stage 1 0.79 (0.06) 
Cancer Stage 2+ 0.72 (0.17) 
Post-treatment cancer (any stage) 0.82 (0.03) 
Scenario 2   
Cytology normal / HPV- 0.9967 (0.0026) Simonella 2014* [32]  
LG cytology  0.9735 (0.0231) 
HPV+ with cytology normal 0.9733 (0.0233) 
LG/HG cytology/ HPV+ with colposcopy 
normal or CIN1 
0.9724 (0.0226) 
LG/HG cytology/ HPV+  with CIN2 or 3 0.9704 (0.0233) 
Pre-treatment cervical cancer**  0.8178 (0.0531) 
Cancer (<5 years after diagnosis ) 
Stage 1 
0.76 (nr)  Elbasha 2007*[45]  
Stage 2 0.67 (nr) 
Stage 3 0.56 (nr) Goldie 2004*[46] 
Stage 4 0.48 (nr) 
Cancer survivor (≥5years after diagnosis) 1 (nr) De Kok 2012*[47]  
 
*as used by Kitchener et al[33]; **for all stages assumed the same as early stage cervical cancer 
reported by Simonella et al; nr, not reported -standard error assumed to be 10% of the mean  
 
Table 5-4. Cervical cancer cases distribution by stage and age group [IPO Porto][34] 
FIGO stage <30 30-49 50-69 70+ 
I 8 95 71 16 
II 1 75 93 35 
III 3 40 48 47 
IV 0 15 25 29 
FIGO, International Federation of Gynecology and Obstetrics  
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Table 5-5. Selected model inputs 
Epidemiological parameter Mean  Sources 
General population life expectancy, years 83.3 Statistics Portugal (2014-2016) 
Unit costs (€) and resource use Base case value* Sources 
Screening  
      Sampling for conventional cytology (onto glass slide) 7.50 DRG 48910  Portaria 207/2017[10] 
      Sampling for liquid-based cytology (for “thin-prep”) 15.00 DRG 48900 Portaria 207/2017[10] 
      Examination of conventional cytology sample by private provider 5.42 DRG 30510[11]  
      Patient co-payment for examination of conventional cytology sample by 
private provider 
3.00 DRG 30510[11] 
      Examination of conventional cytology sample  15.20 DRG 30510 Portaria 207/2017[10] 
      Automated examination of liquid-based cytology sample  27.40 DRG 30650 Portaria 207/2017[10] 
      Automated examination of high-risk HPV DNA testing  13.70  not listed; base case assumed half of LBC cost  
      Examination of any cervical screening sample including triage test when 
applicable 
67.5 NHS Contractualisation Reference terms (2018)[13] 
Diagnosis  
      Colposcopy  14.50 DRG 48180 Portaria 207/2017[10] 
      Colposcopy with biopsy 34.40 DRG 48190 Portaria 207/2017[10] 
Treatment 
      Conisationα  2,285 DRG 532  Portaria 207/2017[10] 
      Invasive cervical cancer (first year) 12,023.00 NHS Contractualisation Reference terms (2018)[13] 
      Invasive cervical cancer (second year) 3,551.00 NHS Contractualisation Reference terms (2018)[13] 
Consultation costs 
      Medical visit 34.1 Portaria 207/2017[10] 
Activity rate, women 20-64 years 0.758 Statistics Portugal (2016)[25] 
Net monthly average wage, women  805 Statistics Portugal (2018)[25] 
Discount rate, % 5  INFARMED[20]   
* unit costs were assumed lognormally distributed with a scale=0.1; No inflation-related adjustment was necessary as all the above costs are 2018 prices. 
α The cost used for conisation corresponds to that listed for the average Portuguese NHS patient treated for diagnosis-related group 532 - Disturbances of the female reproductive system, 
which includes cervical conisation[10]. List prices are assumed a reasonable approximation but may not entirely capture the underlying opportunity cost of resources. 
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Table 5-6. Predicted annual number of cervical cancer cases, cancer-related deaths and life-years lost, and total number of tests and cost with and 
without cancer treatment by screening strategy 
Strategy Total 
annual 
cancer 
cases 
Total annual 
cancer 
deaths 
Total life-years 
lost 
Total 
annual 
tests, 
thousands 
Total annual 
screening cost  
(euros, million) 
Total annual 
treatment cost 
(euros, million) 
Total annual 
productivity cost  
(euros, million) 
Total annual cost 
(euros, million) 
No Screening 634 (309; 
999) 
167 (72; 
278) 
4400 (2200; 
7000) 
- 0 (0; 0) 9.9 (4.5; 16.2) 32.7 (15.5; 53.5) 42.6 (20.4; 69.7) 
S1 (OPP Repeat Cytology) 425 (328; 
566) 
101 (72; 
141) 
3100 (2400; 
4300) 
676 (664; 
689) 
16.7 (14.4; 
19.6) 
6.6 (4.6; 9.3) 22.9 (15.9; 32.9) 46.3 (37.3; 58.5) 
S2 (OPP HPV triage) 413 (322; 
553) 
98 (69; 132) 3000 (2300; 
4100) 
700 (685; 
715) 
34.8 (29.6; 
40.5) 
6.5 (4.6; 9.2) 22.4 (15.9; 32.1) 63.6 (53.5; 77.1) 
S5 (ORG HPV primary 5y) 234 (167; 
337) 
52 (33; 79) 1800 (1200; 
2700) 
637 (631; 
642) 
29.8 (26.0; 
34.4) 
3.7 (2.4; 5.4) 13.0 (8.5; 20.3) 46.5 (39.4; 56.3) 
S6 (ORG HPV triage ENG 
algorithm) 
213 (153; 
308) 
47 (28; 72) 1600 (1100; 
2400) 
965 (955; 
976) 
50.6 (43.4; 
58.9) 
3.4 (2.2; 5.0) 11.7 (7.6; 18.4) 65.7 (56.3; 76.8) 
S7 (ORG Repeat Cytology) 210 (144; 
308) 
47 (27; 71) 1600 (1100; 
2400) 
1043 (1024; 
1062) 
36.5 (30.7; 
43.2) 
3.3 (2.1; 5.1) 11.7 (7.3; 18.4) 51.5 (43.4; 61.8) 
S3 (ORG HPV triage PT 
algorithm) 
199 (141; 
297) 
44 (26; 68) 1500 (1000; 
2400) 
1019 (1002; 
1040) 
54.2 (46.3; 
62.7) 
3.1 (2.1; 4.8) 11.1 (7.1; 17.9) 68.4 (59.0; 79.1) 
S4 (ORG HPV primary 3y) 197 (139; 
287) 
43 (26; 66) 1500 (1000; 
2300) 
965 (957; 
974) 
41.5 (36.0; 
47.1) 
3.1 (2.0; 4.7) 11.0 (7.1; 17.2) 55.5 (47.9; 65.1) 
Note: The predicted annual number of screening tests, treatments, and cervical cancer cases was calculated using the age distribution for the 2016 Portuguese female population aged 15-
89[25] 
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Table 5-7. Incremental cost-effectiveness results 
Strategy Discounted  lifetime 
LY lost per woman 
Discounted  lifetime cost 
per woman (euros) 
Incremental LYs 
saved 
Incremental 
Cost, € 
ICER (€/LY gained) 
No Screening 0.010107 95.083659 - -  -  
S1 (OPP Repeat Cytology) 0.008669 138.082697 0.001438 42.999038  Dominated  
S5 (ORG HPV primary 5y) 0.005626 174.405110 0.003044 36.322413                   17,701  
S7 (ORG Repeat Cytology) 0.005170 191.202782 0.000456 16.797671                   36,822  
S2 (OPP HPV triage) 0.008510 192.025791 -0.003340 0.823009  Dominated  
S4 (ORG HPV primary 3y) 0.004979 208.765954 0.003531 16.740163                   91,979  
S6 (ORG HPV triage ENG algorithm) 0.005215 234.270417 -0.000236 25.504464  Dominated  
S3 (ORG HPV triage PT algorithm) 0.005031 249.173233 0.000184 14.902816  Dominated  
LY, life years; ICER, incremental cost-effectiveness ratio; incremental cost and LY saved calculated relative to the immediately less expensive strategy; OPP, opportunistic 
screening; ORG, organised screening 
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Table 5-8. Incremental cost-utility results  
Strategy Discounted  
lifetime QALY 
lost per woman 
Discounted  lifetime 
cost per woman 
(euros) 
Incremental 
QALYs saved 
Incremental 
Cost, € 
ICER (€/QALY 
gained) 
HRQoL scenario 1      
No Screening 0.011014 94.754033 - - - 
S1 (OPP Repeat Cytology) 0.009758 137.87197 0.001256 43.117937 Dominated 
S5 (ORG HPV primary 5y) 0.006349 174.429877 0.003409 36.557907                17,081  
S7 (ORG Repeat Cytology) 0.005672 190.778158 0.000677 16.348281                24,123  
S2 (OPP HPV triage) 0.009658 191.826097 -0.003986 1.047939  Dominated  
S4 (ORG HPV primary 3y) 0.005545 208.764662 0.004113 16.938565              141,692  
S6 (ORG HPV triage ENG algorithm) 0.005669 234.906234 -0.000124 26.141572  Dominated  
S3 (ORG HPV triage PT algorithm) 0.005474 248.487972 0.000195 13.581738              565,806  
HRQoL scenario 2      
No Screening 0.01278 95.083659 - - - 
S1 (OPP Repeat Cytology) 0.021024 138.082697 -0.008245 42.999038 Dominated 
S5 (ORG HPV primary 5y) 0.01805 174.40511 0.002974 36.322413 Dominated 
S7 (ORG Repeat Cytology) 0.025331 191.202782 -0.007281 16.797671 Dominated 
S2 (OPP HPV triage) 0.021819 192.025791 0.003512 0.823009 Dominated 
S4 (ORG HPV primary 3y) 0.021701 208.765954 0.000118 16.740163 Dominated 
S6 (ORG HPV triage ENG algorithm) 0.022221 234.270417 -0.00052 25.504464 Dominated 
S3 (ORG HPV triage PT algorithm) 0.026315 249.173233 -0.004095 14.902816 Dominated 
QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; incremental cost and LY saved calculated relative to the immediately less expensive strategy; 
OPP, opportunistic screening; ORG, organised screening 
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Table 5-9. Incremental cost-effectiveness results for 2018 fixed uniform unit cost scenario 
Strategy Discounted  lifetime 
LY lost per woman 
Discounted  lifetime cost 
per woman (euros) 
Incremental LYs 
saved 
Incremental 
Cost, € 
ICER (€/LY gained) 
No Screening 0.010107 95.031387 - - - 
S1 (OPP Repeat Cytology) 0.008669 138.235300 0.001438 43.203913              30,052  
S2 (OPP HPV triage) 0.008510 265.761499 0.000160 127.526198  Dominated  
S5 (ORG HPV primary 5y) 0.005626 275.164990 0.002884 9.403491              44,989  
S6 (ORG HPV triage ENG algorithm) 0.005215 347.435703 0.000411 72.270713  Dominated  
S7 (ORG Repeat Cytology) 0.005170 359.198447 0.000045 11.762744  Dominated  
S3 (ORG HPV triage PT algorithm) 0.005031 361.229121 0.000139 2.030674  Dominated  
S4 (ORG HPV primary 3y) 0.004979 362.017520 0.000052 0.788399           134,211  
LY, life years; ICER, incremental cost-effectiveness ratio; incremental cost and LY saved calculated relative to the immediately less expensive strategy; OPP, opportunistic 
screening; ORG, organised screening 
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5.2.9. Figures		
Figure 5-1. Cost-effectiveness plane (A) and 95%confidence ellipses (B), cost-effectiveness 
acceptability curves and cost-effectiveness acceptability frontier (C) – base case analysis 
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C  
 
LY, life years; ICER, incremental cost-effectiveness ratio; Cost-effectiveness acceptability curves 
(CEACs) are shown in thin lines for no screening (NS) and the distinct screening protocols modelled;  
The cost-effectiveness acceptability frontier (CEAF) is presented in thicker line segments on top of 
the corresponding CEAC. 
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Figure 5-2. Cost-effectiveness plane (A) and 95% confidence ellipses (B), cost-
effectiveness acceptability curves and cost-effectiveness acceptability frontier (C) – 
HRQoL scenario 1 
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QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; Cost-effectiveness 
acceptability curves (CEACs) are shown in thin lines for no screening (NS) and the distinct screening 
protocols modelled;  The cost-effectiveness acceptability frontier (CEAF) is presented in thicker line 
segments on top of the corresponding CEAC.  
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Figure 5-3. Cost-effectiveness plane (A) and 95% confidence ellipses (B), cost-
effectiveness acceptability curves and cost-effectiveness acceptability frontier (C) – 
HRQoL scenario 2  
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QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; Cost-effectiveness 
acceptability curves (CEACs) are shown in thin lines for no screening (NS) and the distinct screening 
protocols modelled;  The cost-effectiveness acceptability frontier (CEAF) is presented in thicker line 
segments on top of the corresponding CEAC. 
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Figure 5-4. Cost-effectiveness plane (A) and 95% confidence ellipses (B), cost-
effectiveness acceptability curves and cost-effectiveness acceptability frontier (C) – 2018 
contract cost scenario 
264 
 
A  
 
265 
 
 
B  
 
C 
 
LY, life years; ICER, incremental cost-effectiveness ratio; Cost-effectiveness acceptability curves 
(CEACs) are shown in thin lines for no screening (NS) and the distinct screening protocols 
modelled;  The cost-effectiveness acceptability frontier (CEAF) is presented in thicker line 
segments on top of the corresponding CEAC. 
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6. Chapter	6.	Discussion	
The main objective of this thesis was to evaluate the effectiveness and cost-effectiveness of 
cervical screening strategies in Portugal. This overall aim was achieved by conducting a 
comprehensive analysis of the epidemiology of HPV infection and cervical cancer in Portugal, 
adapting an existing mathematical model of HPV acquisition and progression of cervical cancer 
to the Portuguese context, and carrying out a model-based analysis of the clinical and 
economic impact of cervical screening protocols.      
In this chapter, we summarise (i) the main findings of the work conducted for this thesis, (ii) its 
main contributions for cervical cancer prevention, (iii) its strengths and limitations beyond 
those discussed in previous chapters, and (iv) areas of future work. 
 Summary	of	main	findings	
Our analysis of the burden and risk factors for cervical cancer in Portugal in research paper 1[1] 
(Chapter 2) suggests that improvements in quality and coverage of cervical screening have the 
scope to achieve large reductions in incidence of cervical cancer. We found that despite the 
significant decline in mortality, incidence of cervical cancer in Portugal has been stable in the 
last decade. This contrasts with the decline that several European countries have been 
experiencing in incidence of cervical cancer, particularly where organised cervical screening 
has been introduced, such as in England[2].  
We also found that HPV prevalence and non-screening risk factors for HPV infection and 
cervical cancer (such as lifetime number of sexual partners and smoking) were lower in 
Portugal than in England. Hence, these differences cannot explain the higher incidence in 
Portugal compared to England, but the markedly distinct screening policies that have been in 
place can. We found that cervical screening in Portugal remains mainly opportunistic with 
lower coverage than in England. Fully-organised cervical screening programmes were 
introduced in some Portuguese regions 20 years after the centralisation of organised screening 
in England and covered at most 40% of the resident population in 2014. 
Despite recent developments towards a national HPV-based organised cervical screening 
programme[3,4], to our knowledge , the impact and cost-effectiveness of adoption of HPV 
DNA testing for primary screening has not been studied yet. It is pertinent to compare HPV-
based screening strategies with those currently established on technologies available in the 
Portuguese National Health Service, namely conventional cytology (the most prevalent 
technology for cervical screening used opportunistically throughout the country and as part of 
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the programme in the Centre region) and liquid-based cytology with HPV DNA triage currently 
used in several regional protocols.  
The systematic  review (research paper 2[5]) in Chapter 3 showed that 65% of the included 
model-based evaluations of cervical screening protocols  were published in the last decade 
(2003-2012), and that they were conducted in order to understand the effectiveness (12%) and 
cost-effectiveness (88%) of screening interventions alone (64%) or alongside vaccination (35%), 
particularly with new screening options as new technologies become available and vaccinated 
women reach screening age. The main issues addressed relate to the introduction of new 
technologies to an existing cytology-based programme (particularly the introduction of HPV 
DNA for primary screening or triage of cytological abnormalities), or changes to an existing 
programme (comparing alternative primary cytology protocols). LBC was recommended in 
most studies comparing it with conventional cytology, and HPV DNA primary testing with 
cytology triage was optimal in most comparisons with cytology. 
Most studies found were based on static, deterministic models of groups of women at risk of 
cervical cancer over a lifetime (71%). The number of individual-based models has risen by 64% 
in the last decade. Individual-based models simulate the variability in a population, capturing 
the heterogeneity across individuals (such as different risk factors and previous screening 
history), while modelling policy decisions for the whole population[6].  Also, model calibration 
to observed setting-specific data has become more common as well but only reported in 46% 
of the studies included in our review.   
Only two studies analysed the Portuguese setting - Van Ballegooijen and colleagues (2000)[7] 
and Novoa-Vazquez (2004)[8], in a multiple- and single-country analysis, respectively. Van 
Ballegooijen and colleagues’ static, deterministic, individual-based model predicted up to 77% 
reduction of life-years lost if coverage of the current repeat conventional cytology programme 
of the Centre region in Portugal increased to 80%[7]. Novoa-Vazquez’s[8] cost-effectiveness 
analysis of cervical screening in the Algarve region using a static, deterministic, aggregate 
model, found repeat conventional cytology under organised screening more cost-effective 
than opportunistic or organised screening using liquid-based cytology. Since the publication of 
these studies, HPV DNA testing has been integrated in screening programmes worldwide,  
including as primary screening test in countries such as the Netherlands and Sweden[9]. In 
Portugal, HPV triage of cytological minor lesions has been used in regional organised 
programmes and the Ministry of Health is now recommending the adoption of HPV 16/18 
genotyping for primary screening[3,4]. Hence there is a need for new model-based economic 
evaluations considering options with this technology. 
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In our analysis of the effectiveness of alternative screening protocols (research paper 3 in 
Chapter 4), using a static, stochastic, individual-based model, we compared the introduction of 
HPV DNA as primary screening test in an organised programme with the currently 
predominant opportunistic repeat conventional cytology approach and liquid-based cytology 
with HPV DNA triage of minor abnormalities protocol adopted in some regional organised 
programmes. The impact of the current practices was modelled under organised and 
opportunistic screening, as well as a no screening strategy. We found that organised primary 
HPV screening every 3 years was more effective in preventing cervical cancer than cytology-
based protocols. Extending the interval to 5 years would achieve comparable reduction in 
cancer incidence as organised protocols based on 3-yearly screening and require fewer tests. 
Our economic evaluation of these strategies in research paper 4 (Chapter 5) estimated the 
health outcomes, in terms of cancer-related life-years lost and quality-adjusted life-years lost 
due to cancer and screening procedures, as well as the costs and resource use of the strategies 
described above, from a partial societal perspective. Our results suggest that organised 
primary HPV screening would be cost-effective at an interval of 5 years at a willingness-to-pay 
of just under €18,000 per life-year gained compared to no screening, if the cost of HPV DNA 
testing was half of that for liquid-based cytology. Organised repeat cytology would also be on 
the cost-effectiveness frontier at a willingness-to-pay of nearly €37,000 per life-year saved 
compared to 5-yearly primary HPV screening, given the relative lower cost of conventional 
cytology and the assumed similar effectiveness to liquid-based cytology in England. Primary 
HPV screening every 5 years would be the optimal option at a range of  willingness-to-pay 
between €18,000 and €36,000 per life-years saved and our probabilistic sensitivity analysis 
indicates a 21% probability of this strategy being cost-effective, reflecting the joint parameter 
uncertainty in our model (based on the identification of the strategy with highest net benefit 
at a given threshold in each model iteration) further illustrated by the small differences in the 
probability of being cost-effective of several protocols.  
 Main	contributions	of	the	thesis	
To our knowledge, research paper 1[1] (Chapter 2) is the first original integrated analysis of the 
burden of cervical cancer and the associated risk factors in Portugal, including prevention 
policies in place. While there has been primary research reporting cervical cancer mortality 
trends in Portugal[10,11]  and secondary research on the epidemiology of cervical cancer in 
Portugal[12], we have analysed time trends of incidence and mortality together with the 
developments in cervical screening over the past two decades. 
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By comparing the burden of cervical cancer, risk factors, and preventive measures in Portugal 
and England, we identified screening as the main factor limiting the speed of decline in 
incidence of cervical cancer in Portugal. Research paper 1[1] also provides the first time trend 
analysis of national incidence of cervical cancer in Portugal, the most recent time trend of 
cervical cancer mortality in Portugal, and the first overview of the historical variation of 
cervical screening coverage in Portugal. 
Research paper 2[5] (Chapter 3) is the first systematic review of epidemiological and economic 
model-based evaluations of cervical screening strategies, including the whole range of settings 
and technologies, for a comprehensive overview of the findings and methods employed. 
Previous reviews have restricted their analyses to particular technologies[12–16], 
outcomes[12–14,17], settings[17,18].  
The two model-based studies on cervical screening in Portugal found in this review of the 
literature were conducted in the early 2000s, when the relevant questions for high-income 
countries concerned the impact of organised programmes and alternative cytology-only 
protocols, e.g. conventional versus liquid-based cytology. Research papers 3 and 4  (Chapter 4 
and 5) consist of the first model-based evaluation of the effectiveness and cost-effectiveness, 
respectively, of primary HPV DNA screening, as well as of HPV DNA testing for triage of minor 
cytological lesions, in Portugal.  
Although liquid-based cytology with HPV DNA triage has been implemented from 2008 and is 
currently used to a variable extent in 3 regions of Portugal, its effectiveness and cost-
effectiveness as part of an opportunistic regime (with similar coverage to that currently 
widespread with repeat conventional cytology) or of an extended coverage and improved 
follow-up organised programme have not been investigated either. 
Also for the first time for Portugal, we used a model calibrated to Portuguese HPV prevalence 
and cancer incidence, quantified health outcomes of cervical screening protocols in quality-
adjusted life years, and performed probabilistic sensitivity analysis to capture the joint 
parameter uncertainty in our cost-effectiveness estimates. 
Our analyses of alternative primary HPV- and cytology-based protocols are particularly 
pertinent now as (i) primary HPV testing has been recently endorsed  for the Portuguese 
National Health System by the Portuguese Ministry of Health[3] and is being piloted in the 
North region[4], (ii) the implementation of organised HPV-based screening is being prepared in 
Lisbon and Tagus Valley, and (iii) vaccinated women have reached screening ages prompting 
the revision of the screening protocols in place, which will be required as well over time by the 
gradual decline in HPV prevalence subsequent  to the increasing proportion of vaccinated 
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women among the screening-eligible population[19]. Although the impact of vaccination has 
not been investigated in our studies, a clinic-based primary HPV programme can potentially 
facilitate monitoring HPV prevalence, its performance is less likely to be diminished by the fall 
in prevalence, and its coverage can be extended by self-collected HPV testing which has shown 
effective in improving the adherence of typical non-attendees[20] (whose cost-effectiveness 
we have not studied either).  
We quantified the benefits and costs associated to each algorithm and their relative cost-
effectiveness, and our findings can support evidence-based decision making and help refining 
screening protocols. Research paper 4 (Chapter 5) also includes scenarios on the impact of 
alternative sets of HRQoL assumptions on the relative cost-effectiveness of the different 
strategies, making it the first cost-utility analysis of cervical screening programmes in Portugal. 
Additionally, our analyses highlight the relevance of the length of the screening interval and 
the unit cost of HPV testing relative to that of cytology to the affordability of primary HPV 
programmes. 
 Strengths	and	limitations	
In research paper 1[1], we identified inadequate screening quality and coverage as the most 
likely factor that has prevented a further decline in incidence of cervical cancer in Portugal 
over the last 20 years, as seen in countries such as England. This was based on the comparison 
of risk factors and changes in burden and screening policies over time between Portugal and 
England. However, this was an ecological analysis (inherently prone to biases due to 
differences in ascertainment of disease and exposure between countries and within countries 
over time), even though we investigated the role of both (i) non-screening risk factors, such as 
HPV prevalence and sexual behaviour (we assumed a constant ratio between countries over 
time as we lacked historical data), and (ii) cervical screening coverage over time, particularly 
for Portugal.  
This work also provided the first time trend analysis of cervical cancer incidence in Portugal 
and our estimates of national age-standardised incidence in Portugal were based on individual 
case data provided for 1998-2010 by all four Portuguese population-based regional registries 
(Azores, North, Centre, and South]), covering 100% of the population. However, we were not 
able to make any correction for registration inaccuracies that may be present. Coverage 
estimates and quality indicators of the Portuguese regional cancer registry data made available 
for our analysis (covering 1998-2010) were not provided; however, Allemani and colleagues 
(2015)[21] also used individual patient-data from the four Portuguese population-based 
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regional registries (1998-2009) and reported full population coverage and generally higher 
quality for Portuguese registry data compared to the European average.  
In research paper 2[5], we reviewed, summarised findings, and identified trends and gaps in 
the voluminous literature about models used to evaluate the epidemiological and economic 
impact of cervical screening strategies, alone or alongside vaccination against HPV. This 
improved our knowledge of the features of existing models and the recent methodological 
developments emerging alongside new technologies. However, conclusions regarding findings 
on the impact of technologies must be drawn cautiously from our summary of the findings as 
we did not critically appraised the model-based studies included in our review nor listed the 
data sources and assumptions made on particular protocols and settings. Also, our systematic 
review included studies up to May 2013; it is possible that an update of the searches could find 
studies recently conducted for the Portuguese context, that were not captured in our more 
recent search in PubMed for research paper 4 (Chapter 5). 
In research paper 3 and 4 (Chapters 4 and 5), we predicted the effectiveness and cost-
effectiveness of several cervical screening protocols in Portugal by adapting a model previously 
developed by Bains and colleagues for England (detailed in the Appendix to this thesis).  
We used Portuguese age- and type-specific HPV prevalence data to calibrate the model, 
making the modelled cohorts more likely to represent the Portuguese female population at 
risk of HPV infection. However, it is debatable whether the participants of CLEOPATRE Portugal 
study are a representative sample of the Portuguese population. Although this is the only 
population-based epidemiological study conducted in the 5 regions of mainland Portugal to 
determine age- and type-specific HPV cervical prevalence in the general population aged 18-64 
years, the participants (n=2326) consisted of women attending gynaecology/ obstetrics or 
sexually transmitted disease clinics of the National Health Service. These women can 
potentially be at lower or higher risk than the general population, as they might be attending 
NHS appointments for compliance with cervical screening or routine medical checks for other 
clinical reason or for having or being at high-risk of a sexually transmitted infection. We 
compared the behaviour risk indicators reported by the participants of the CLEOPATRE 
Portugal study and by those of the 2007 survey on sexual behaviour and HIV/AIDS in mainland 
Portugal (n=1860 sexually active women aged 16-65 years) and found similar distributions for 
the lifetime number of sexual partners and age of sexual debut. 
Our predictions for organised screening are based on the (potentially optimistic) assumption 
that a national cervical screening programme in Portugal would achieve similar adherence to 
screening as that in England, in terms of age at start of screen, screening frequency, and 
proportion never screened. Elfstrom and colleagues showed how widely programmes 
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implemented in the European Union varied in coverage in 2012/2014 (from less than 10% in 
Hungary to 78% in Sweden)[22]. In 2016 mainland Portugal, coverage of organised cervical 
screening varied from 0% in Lisbon and Tagus Valley to 97% in the Centre region, and 
compliance to screening invitation by letter in the existing organised programmes ranged from 
73% to 96% in Alentejo and Algarve, respectively[4]. Also, the effectiveness of primary HPV 
screening is dependent on a well-organised programme to safely allow for the extension of the 
screening interval[23].  
 Areas	of	further	research	
An obvious future step in our work would be to consider strategies involving other tests and 
biomarkers besides HPV positivity and cytology. For instance, this could include a strategy with 
primary HPV 16/18 genotyping of women aged 25-60 years every 5 years, with cytology triage 
of women positive to other HPV types, as recommended by the Portuguese Ministry of 
Health.[3] Another potentially useful analysis would be that of the adoption of self-sampled 
HPV DNA testing as complement of a countrywide clinic-based programme.[20] 
Also, future incidence and mortality from cervical cancer in Portugal will be determined by 
HPV vaccination. Vaccination against HPV 16, 18, 11, and 6 has been part of the Portuguese 
National Immunisation Plan since 2008 with high uptake[24] and the first cohorts of vaccinated 
Portuguese women reached the screening age of 25 in 2015. We would have to include 
transmission dynamics in our model to capture the full impact of vaccination on HPV 
prevalence and subsequently on the effectiveness of screening strategies[25]. A transmission 
dynamic, stochastic, individual-based model would be useful to model the lower prevalence of 
cervical cancer and the heterogeneity in sexual behaviour and screening attendance of the 
population at risk for future analyses of the health and economic combined impact of 
screening and vaccination policies. 
A transmission dynamic model could also be used to address relevant questions concerning 
vaccination strategies, such as the effectiveness and cost-effectiveness of vaccinating boys and 
older women in Portugal, as well as estimating the impact of the adoption of the 9-valent 
vaccine (for which the impact on several other HPV-related cancers should be considered as 
well). 
We adapted the screening component of Bains and colleagues’ model to the Portuguese 
context, using country-specific screening algorithms and data on screening frequency and 
attendance. However, several data constraints limited our characterisation of opportunistic 
screening in Portugal, particularly regarding screening frequency, and modelling screening and 
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colposcopy outcomes in Portuguese women, as well as the clinical performance of screening 
tests in Portugal, as discussed in detail in Chapter 4.  
The establishment of a national organised cervical screening programme in the near future is 
likely to enable the collection of data on screening outcomes and adherence, including 
individual women’s history of attendance, which would allow capturing the heterogeneity in 
attendance patterns (as per Bains and colleagues, detailed in the Appendix of this thesis).  
Further research is also needed on the effectiveness and cost of interventions and policy 
measures to improve adherence to and compliance with screening programmes, respectively. 
Organised screening  is also likely to improve inter-laboratory concordance, the quality of 
lesions follow-up, and equality of access; however, it will also bring challenges such as 
changing existing screening patterns where opportunistic screening is frequently used.[23] 
Inequalities in access and frequency of screening have been reported in Portugal. For instance 
in the urban area of Porto, under opportunistic screening (2005-2008), over 85% of women 
aged 30-49 reported being screened more often than every 3 years and only 7% of women 
reported having cervical cytology in 3- to 5-year intervals.[26]    
The linkage of screening and diagnosis databases is also fundamental to obtain data on the 
distribution of histological outcomes according to cytological ones and study the impact of 
alternative screening protocols (with distinct age groups and screening intervals) on the 
severity of lesions and cancers detected.  
As found by De Kok and colleagues[27] and demonstrated in our research paper 4 (Chapter 5), 
findings on the cost-effectiveness of cervical screening strategies are highly sensitive  to 
estimates and assumptions used for HRQoL. Further research is needed on the measurement 
and valuation of the impact of cervical screening and cervical cancer on HRQoL. According to 
INFARMED’s guidance[28], this should be measured in Portuguese women undergoing cervical 
screening and cervical cancer patients using  a validated and standardised preference-based 
instrument, like the EQ-5D, with the valuation of the health states elicited by a representative 
sample of Portuguese population.  Although the latter is available[29], to our knowledge, 
HRQoL in Portuguese women screened for or suffering from cervical cancer has not been 
measured yet. It is important to note that, as a general measure, the EQ-5D may not fully 
capture condition-specific changes in the HRQoL of these women, such as anxiety and 
worry.[27] Also, HRQoL instruments based on one-time questionnaire may not capture 
changes in quality of life over time, e.g. the period of time women’s quality of life might be 
compromised for by undertaking screening tests. 
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Finally, having a specific willingness-to-pay threshold for health interventions as an indicator of 
the preferences of the Portuguese population would be helpful for decision making and future 
economic evaluations. 
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7. Appendix	
The clinical impact and cost-effectiveness of primary cytology compared to primary human 
papillomavirus testing for cervical cancer screening: a model-based analysis 
 
Iren Bains1, Yoon Hong Choi1, Kate Soldan1, Mark Jit1,2 
1National Infections Service, Public Health England, London, UK; 2Department of Infectious 
Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK 
 
Abstract 
Background: Using human papillomavirus (HPV) testing as a primary cervical screen has been 
shown in trials to offer better cancer protection compared to cytology. In England, HPV testing 
is planned to replace cytological screening by 2019. Model-based economic evaluations offer 
the possibility of projecting the long term clinical impact and cost-effectiveness of such 
screening strategies. 
Methods: A stochastic, individual-based model of HPV acquisition, natural history and cervical 
cancer screening was used to compare primary cytological screening and primary HPV testing 
with cytology triage (with either 3 or 5 year screening intervals for women under 50 years). 
The model was fitted to data from England's Cervical Screening Programme. 
Results: Primary HPV testing is likely to decrease primary screen frequency, cervical cancer 
incidence and health system costs. It may increase the number of colposcopies, although this 
can be reduced without leading to more cancers compared to primary cytology, by increasing 
the interval between screens to 5 years. The impact in terms of quality adjusted life years 
(QALYs) depends on the quality of life weight given to colposcopies vs cancer.  
Conclusion: England's move from primary cytology to primary HPV screening will likely be life-
saving and cost-effective. Cost-effectiveness can be improved further by extending the interval 
between screens or using alternative triage methods (like partial or full genotyping). 
Introduction 
Persistent infection with a high-risk type of human papillomavirus (HPV) is a necessary 
condition for cervical cancer. Cervical cancer prevention has traditionally focused on detecting 
and removing cervical neoplasms with abnormal cytology before they progress to cancer. The 
development of rapid and sensitive tests for HPV now offer an alternative means of screening 
for risk of developing cervical cancer.  Clinical trials of HPV testing as a primary cervical screen 
suggest that   it provides 60-70% greater protection against cervical cancer compared to 
cytology (Ronco Lancet 2014). However, trial results need to be extrapolated to project likely 
impact of different screening algorithms across varied settings, as well as to investigate the 
cost-effectiveness of each option. A model-based assessment of the potential costs and 
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benefits of different screening algorithms can synthesise available knowledge on HPV 
acquisition risk, cervical disease progression, cancer incidence and screening effectiveness. 
In England, secondary prevention of cervical cancer has been based on cytological testing to 
detect cervical abnormalities since the introduction of the National Health Service Cervical 
Screening Programme (NHSCSP) in 1988. Testing for high risk human papillomavirus (HR-HPV) 
to determine management of women with borderline or low-grade abnormalities, and as a 
test-of-cure for recently treated women, has been used since 2011. In 2013, a pilot study of 
implementing screening in which the primary assessment is a test for HR-HPV was initiated at 
several sites across England. The National Screening Committee has agreed to replace 
cytological testing with HPV testing as the primary England-wide by 2019, following a review of 
evidence including cost-effectiveness.  
However, additional considerations surround the introduction of primary HPV testing. HPV 
testing has higher sensitivity for high-grade lesion detection (Kelly et al., 2011) and provides 
stronger negative predictive power than cytology (K. et al., 2010), leading the health care 
community to discuss the extension of the screening interval following a negative primary HPV 
testing. Additionally, concern that primary HPV screening may lead to over-testing in young 
women, in whom there is a high prevalence of HPV infection, and increased burden on 
colposcopists, has led to discussions surrounding the introduction of additional triage tests 
prior to colposcopy. 
Here we present a model-based evaluation of the potential clinical impact and cost-
effectiveness of switching from primary cytology to primary HPV testing across the NHSCSP, as 
well as increasing the standard screening interval associated with primary HPV testing from 3 
to 5 years for women under 50. This work was conducted by Public Health England in order to 
inform decision making by the NHSCSP. 
Methods 
Model overview 
A stochastic, individual-based simulation model was developed to evaluate primary HPV 
testing and the current primary cytology protocol. The key model components are: (a) 
acquisition of HPV infection as a necessary pre-condition for cervical pathogenesis; (b) natural 
progression of HPV infection, cervical intraepithelial neoplasia (CIN) and cervical cancer; and 
(c) detection and treatment of women with cervical abnormalities through cervical screening. 
The model generates a cohort of women and simulates their history of partner acquisition, 
HPV infection, disease progression, and screening attendance and outcomes over their 
lifetime. Women can acquire multiple HPV infections, possibly simultaneously with different 
strains, and each infection follows its own timeline to clearance or emergence of a pre-invasive 
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cancer lesion, adenocarcinoma or squamous cell carcinoma. Women are categorised according 
to HPV infection status, as illustrated in Figure 1. Following this, women undergo screening and 
the life history is changed according to any treatment undertaken (screening algorithms 
illustrated in Figures 2-3). 
Screening Interventions 
Three alternative strategies were considered:  
(a) primary cytological screening with HPV testing to determine further management of 
cytology abnormals (“primary cytology protocol”), with a 3 year (or 5 year for women over 50 
years old) recall interval following a negative primary screen, which is current screening 
practices in England;  
(b) primary HPV testing (“primary HPV protocol”), with cytology testing to determine further 
management of HR HPV positives, with a 3 year (or 5 year for women over 50 years old) recall 
interval following a negative primary screen; 
(c) primary HPV testing (“5 year primary HPV protocol”) with an extended 5 year recall interval 
following a negative primary HPV screen, for all women regardless of age. 
Economic parameters 
The cost and utility implications of cervical screening and cancer outcomes were estimated 
from the literature, and are summarised in Tables 1 and 2. 
Table1: Model inputs: economic parameters and sources. 
 Parameter Costs 95 % range Source 
Screening 
   
Sample collection 15.31 (12.5, 18.63) Karnon (2003), 
Moss (04), Kitchner 
(2011), LeGood 
(2012); Kitchner 
(2014) 
HPV test per sample (includes consumables, 
equip,ment, staff time & other overheads) 
9.75 (7.23, 13.03) LeGood (2012); 
Kitchner (2014); 
NHS supplier chain 
(2014); Primary 
HPV pilot site 
(2014) 
Cytology test per slide (includes consumables, 
equip,ment, staff time, other overheads) 
18.15 (14.95, 22.02) Karnon (2003), 
Moss (2004), 
Kitchner (2011), 
LeGood (2012); 
Kitchner (2014) 
Treatment of pre cancer and cancers 
   
Colposcopy 151.18 (124.18, 184.08) Martin-Hirsch 
(2007) 
Biopsy  79.84 (65.35, 97.71) Sherlaw-Johnson  
(2004) 
Excision 382.6 (313.89, 468.41) Martin-Hirsch 
(2007) 
Hysterectomy 2583.5 (2222.28, 3039.77) Martin-Hirsch 
(2007) 
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Chemotherapy 5089 (4203.03, 6188.00) Salter (2014)  
Trachalectomy 5485.67 (4500.32, 6646.50) Salter (2014)  
Radiography 19078 (15709.73, 23126.39) Salter(2014)  
Stage 1 4,619 (4105.25, 5156.03) Salter (2014); 
Cervical Cancer 
Audit (2010) 
Stage2 20,704 (17927.10, 23509.72) Salter (2014); 
Cervical Cancer 
Audit (2010) 
Stage 3 20,387 (17638.43, 23509.18) Salter (2014); 
Cervical Cancer 
Audit (2010) 
Stage 4 17,320 (14953.77, 20008.25) Salter (2014); 
Cervical Cancer 
Audit (2010) 
 
Table 2: Model inputs: utility loss due to screening 
  Utility loss 
per 
episode 
95 % range Sources 
Screening outcomes     Simonella (2014); 
Routine screen 0.0001 (0.00002, 
0.00023) 
Simonella (2014); 
Gold (1998) as used 
by Mandelblatt 
(2002) and de Kok 
(2014); Myers 
(2007) as used in 
Elbasha (2007) and 
Kitchner (2014); 
Insigna (2007); 
TOMBOLA (2007) 
Negative cytology; Negative HPV 
Abnormal result with routine recall 0.0011 (0.00023, 
0.002) Low grade cytology & negative HPV; 
Abnormal result with 12 month follow up 0.004 (0.00023, 
0.0089) Positive HPV & normal cytology 
Normal outcome at colposcopy 0.0147 (0.0015, 
0.04) Low grade cytology, positive HPV & normal 
colposcopy; 
High grade cytology & normal colp; 
Positive HPV, abnormal cytology & normal 
colposcopy 
CIN1 outcome at colposcopy 0.0618 (0.005, 
0.11) Low grade cytology, positive HPV & CIN1; 
High grade cytology & CIN1; 
Positive HPV, abnormal cytology & CIN1 
CIN2 outcome at colposcopy 0.0783 (0.003, 
0.13) Low grade cytology, positive HPV & CIN2 or 
worse; 
High grade cytology & CIN2 or worse; 
Positive HPV, abnormal cytology & CIN2 or worse 
Cancer     Gold (1998), 
Stratton(2000) and 
Wolfson(1996) 
as used in Goldie 
(2004), Kahn(2008), 
deKok (2014) and  
Kitchener (14); 
Myers (2004) as 
used by Elbasha 
(2007) and Jit 
(2011); Klee (2000) 
and Korfage (2009) 
stage 1 0.295 (0.19, 0.51) 
stage 2 0.385 (0.33, 0.58) 
stage 3 0.44 (0.44, 0.58) 
stage 4 0.52 (0.4, 0.64) 
Post treatment     
stage 1 0.03 (0.01, 0.27) 
stage 2 0.065 (0.02, 0.32) 
stage 3 0.065 (0.02, 0.32) 
stage 4 0.205 (0.031, 
0.53) 
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Results 
 
Primary HPV testing   
 
The model and best fitting disease progression parameters are used to evaluate a change to 
the national cervical screening programme in England from primary cytology, the current 
protocol, to primary HPV testing, under the algorithm which is currently being rolled out 
nationally. 
Increased number of tests carried out under primary HPV testing. A summary of clinical 
outcomes under the primary HPV and cytology protocols is shown in Table 4. The annual 
number of primary screening tests carried out is expected to increase by 5% under the 
standard primary HPV protocol from 3.14 million to 3.31 million per annum (Table 4); the 
largest increase is expected in women aged 25 to 35 and represents additional 73,000 tests 
carried on women that are followed up following a HPV positive result (Figure 5).  Inevitably, a 
switch to the primary HPV protocol resulted in a large reduction in the number of women 
undergoing cytological testing, from 3.14 to 0.38 million tests annually. While the proportion 
of women with non-negative cytology outcomes increased from 8.8% under primary cytology 
protocol to 35% under primary HPV protocol (Figure 6). A more detailed breakdown of number 
of tests and outcomes is shown for each screening strategy in Tables 5 and 6.  
Improved efficiency of screening under primary HPV testing. The model predicts a 25% 
increase in the number of women referred to colposcopy through the screening programme. 
The model does not consider women referred to colposcopy following a clinical indication. The 
number of cases of CIN 2 or worse identified annually is expected to increase by 44%; 
reflecting ~22,000 additional cases detected per year through the screening programme 
(Tables 6 and 7; Figure 7).  The referral value, that is the number of women referred to 
colposcopy, by way of the screening programme, per detection of one CIN 2 or worse lesion, is 
projected to decrease from 2.6 to 2.3.  In addition to the increased ‘efficiency’ of colposcopy, 
the total number of primary screens required  to identify a single case of CIN2 or worse is also 
predicted to drop from 158 using the primary cytology protocol, to 104 under the primary HPV 
protocol. 
Reduced cancer incidence and cancer-related-deaths under primary HPV testing. Best fitting 
model simulations cover a wide range of scenarios for cancer incidence when we combine 
cases of squamous cell carcinoma and adenocarcinoma for HPV types 16,18, 31, 33, 51, 52 and 
58 . The model predicts that a switch to primary HPV testing will result in a statistically 
significant decrease in the mean annual incidence of cervical cancer of 14.5%; equivalent to a 
reduction in 290 cases per year in individuals aged 10 to 79 years (95% CI=(195, 370)) (Table 4). 
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The number of cases detected in women aged 35 years and over is expected to experience the 
largest drop, while the number of cases in women below the age of 30 was not found to be 
significantly different between the two protocols (Figure 2). This corresponds to a mean 
reduction in cervical cancer-related deaths of 15.5%; 56 fewer deaths (95% CI=(38, 75)) are 
predicted under primary HPV testing protocol. In terms of the ‘efficiency of primary screening’, 
we find that primary HPV protocol requires an additional 587 primary screens per cancer case 
avoided.  
Cost savings. A switch from primary cytology to the primary HPV protocol, would lead to a 
total health-care cost saving of £13 million (2.9m, 22.8m). The annual screening costs are 
expected to be £120.5 million. The discounted lifetime cost saving per women is estimated to 
be £14 (1,27). 
QALY changes. We do not identify a significant change in QALY outcome associated with a 
switch from primary cytology to a primary HPV protocol. The modelling predicts a median 
discounted per-woman lifetime QALY gain of (i) -0.0026 (95%CI=(-0.0064, 0.013)) under a 
mixed, (ii) 0.0005 (95%CI=(-0.0013, 0.0026)) under the Simonella, and (iii) -0.0033 (95%CI=(-
0.0004, 0.0064)) under the Insigna basis. 
Extended screening interval 
We consider the impact of increasing the recall interval, following a negative primary HPV 
screen, to 5 years for all women regardless of age (5 year primary HPV protocol). This fixed 
interval compares to current practise whereby women under 50 years are recalled at 3 year 
intervals, and women over 50 are recalled at 5 year intervals. 
As we might expect, the model predicts, a switch from primary cytology to primary HPV testing 
with a 5 year interval for all women, will lead to a 17% decrease in the number of primary tests 
carried out (from 3.1 to 2.6 million tests per year) (Table 4). The model does not predict a 
significant difference in the number of colposcopies with a move from primary cytology to 
primary HPV with 5 year recall; however, the model predicts that ~7000 additional cases of 
CIN2 or worse cases will be detected per year.  The increased ‘rate’ of detection per 
colposcopy under a 5 year protocol arises from the increased proportion of women attending 
colposcopy following a moderate or severe cytological referral. Overall, the increased 
detection and subsequent treatment of precancerous lesions results in a drop in cancer 
incidence of 145 (95%CI=(82, 246)) cases per year under the 5 year primary HPV protocol, 
saves 47 (95%CI=(27, 67))  lives per year, and leads to a discounted per-woman lifeyear saving 
of 0.0008 compared to primary cytology protocol (Table 4). 
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Moving from primary cytology to primary HPV testing, in combination with a regular 5 year 
screening interval, would lead to a substantial total health-care cost saving of £33 million 
(23.7m, 44.1m). The annual screening costs are expected to be £97.7 million. The discounted 
lifetime cost saving per women is estimated to be £38 (25,49). 
Using 3 alternative basis for screening-associated QALYs, our mixed weighting, the Simonella 
and the Insinga bases, we do not identify a significant change in QALY outcome associated with 
a switch to a 5 year primary HPV protocol. The modelling predicts a median discounted per-
woman lifetime QALY gain of (i) -0.001 (95%CI=(-0.0047, 0.0028)) under a mixed, (ii) 0.0004 
(95%CI=(-0.0018, 0.0025)) under the Simonella, and (iii) -0.0009 (95%CI=(-0.004, 0.002)) under 
the Insigna basis. 
Discussion 
The modelling work presented here predicts that a move from the current primary cytology to 
a primary HPV screening protocol will be both life-saving and cost-saving, while no significant 
difference was predicted in terms of QALY gains. 
In terms of clinical outcomes, moving from the current cervical screening protocol to one 
employing primary HPV testing is expected to: (i) increase the number of primary screening 
tests carried out; (ii) increase the number of women referred to colposcopy; and (iii) increase 
the number of lesions of grade 2 or worse identified and treated through colposcopy. The 
model projects a positive impact on cervical cancer incidence and cancer-related mortality.  
The impact of increasing the standard recall interval, following a negative primary HPV screen, 
to 5 years for all women, regardless of age, is also considered within the primary HPV protocol. 
The switch from a primary cytology to 5 year primary HPV protocol is expected to: (i) reduce 
cancer incidence; (ii) reduce cancer-related deaths; and (iii) reduce costs. As above, the model 
does not predict a significant change in QALYs.  
The model predicts a sizable total health-care cost saving of £35 million (22.4m, 47.2m) with a 
switch from the current practise primary cytology protocol to the 5 year primary HPV protocol, 
compared to a saving of £15.8 million (2.7m, 27m) associated with a switch to the standard 
primary HPV protocol. The median reduction in cervical-cancer related deaths is predicted to 
be 56 and 47, respectively, following a switch to the 5 year- and standard-, primary HPV 
protocols. Despite the smaller life-years saving, the trade-off between screening- and cancer- 
related QALY losses means that a switch to a 5 year primary HPV protocol is more favourable 
in terms of net quality-adjusted life years than a switch to standard primary HPV testing. The 
median QALY loss predicted, using an averaged QALY weighting basis, for a switch from 
 284 
 
current practise to a 5 year recall primary HPV protocol is 0.0010, compared to a QALY loss of 
0.0026 associated with a switch from current practise to the standard HPV protocol. 
Model Limitations 
The model explicitly considers HPV strains 16, 18, 31, 33, 45, 51, 52 and 58, representing the 
most prevalent strains that are associated with cervical cancer in England.  However, 
commercially available test, such as the commonly used HC2 assay, will also detect cases of 
hpv-35, 39, 56, 59 and 68.  There are also reports that HPV testing may react to non HR-HPV 
test, however, the validation of model outcomes against preliminary data from the HPV 
primary pilot give us confidence that we do not underestimate HR-HPV positivity. 
The model is unable to capture a second peak in cancer incidence from 70 onwards; one 
explanation is that cancers in older women are more likely to arise from non-model types. 
Joste et al. [Human Papillomavirus Genotype-Specific Prevalence across the Continuum of 
Cervical Neoplasia and Cancer; Cancer Epi Biomarkers Prev Jan 2015] showed that 100% of 
cancers in under 30s were attributable to strains considered in the model however, this 
dropped to 75% in women over 40. In addition, the age-incidence data represents a combined 
effect of cohort differences in addition to age related changes. The model calibration assumes 
that all women undergo screening according the current protocol from age 25 to 65; however, 
the national screening programme began in 1988 meaning that the cohort of women, aged 70 
and over, in the 2012 dataset would only have benefited from screening from the age of 45 
onwards, rather than the full 40 years. Additionally, for simplicity and viability of 
parameterisation, the model assumes a rate of progression to cancer that is related to time 
since infection, however, there may be age-related factors that result in a more rapid rate of 
progression to cancer in old age, ie. diminished DNA repair.  As part of the Kaiser study, 10 
year follow up of women aged 30 years and over was found to be associated with a higher risk 
of CIN3 and cervical cancer, than in those under 30 (Khan et al. JNCI 05). 
Model projections give a large uncertainty range around cancer incidence. This uncertainty is 
in part explained by the additive uncertainty arising from combining 16 distinct cancer-causing 
processes– eight hpv strains leading to either squamous cell carcinoma or adenocarcinomas. 
The rare nature of non hpv 16/18-related cancers means that the underlying parameters can 
be difficult to constrain for hpv strains other than 16 and 18. Conservatively, the model 
simulations cover a broad range of scenarios for each HPV type.  
In this work, we use the economic costs taken from historical economic analyses of screening 
in England, and inflate to 2014 values. The limitations of inflating historical costs are that we 
do not necessarily capture the reduction in technology costs over time. Economies of scale 
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also suggest that a switch to primary screening is likely to result in a reduction in the per 
sample cost of an HPV test. Overall, this is expected to lead to a further cost saving associated 
with a switch to primary HPV testing. A more detailed study of work flow and costs in the 
context of primary HPV testing is planned by the primary HPV pilot screening committee that 
will provide further insight into the expected changes. 
The utility detriment associated with cervical screening is not well defined, reflected in the 
diverse estimates for QALY loss weights reported in the literature. This is particularly true for 
primary HPV related screening. In this work, we use a sensitivity approach that captures the 
extreme values reported in the literature to show that the choice of published screening-
associated QALY loss values can determine whether an intervention is beneficial or 
detrimental. The work highlights a need for further study of QALY loss associated with 
screening, in order to appropriately judge the increase in colposcopy and treatment of 
precancerous CIN2 lesions we are willing to accept in order to reduce the incidence and death 
related to cervical cancer.   
The current analysis is based on a static model of infection, this means that we are unable to 
incorporate changes in male prevalence that might arise following vaccination due to herd 
immunity; and limits the projections that we can make about the suitability of HPV testing to 
an unvaccinated female population.  The introduction of a national HPV vaccination 
programme, in 2008, means that it is relevant to consider the implications of vaccination on 
HPV prevalence and disease incidence as vaccinated cohorts approach screening age. 
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Figures and Tables 
Table 3: Summary of clinical outcomes and resource usage (mean and 95%CI). Number of tests 
calculated assuming an age distribution as observed by ONS in 2013. 
  Primary cytology protocol 
Primary HPV 
protocol 
with 3 year recall 
for women under 
50, 
and 5 year recall 
otherwise 
Primary HPV 
protocol with 5 
year recall for all 
women  
Number of cytology tests 3,145,825 396,427 325,066 
 (3092564, 3195711) (371807, 397559) (286693, 324171) 
Normal cytology 2,863,609 257,145 206,282 
 (2806087, 2930539) (226971, 276908) (175124, 205872) 
Borderline changes 182,912 107,725 90,947 
 (138567, 218231) (73542, 128330) (66713, 90347) 
Mild dyskariosis 71,910 24,634 21,445 
 (48355, 96806) (15695, 34081) (13485, 20964) 
Moderate dyskariosis 16,576 5,707 5,245 
 (6500, 27929) (3218, 8324) (2730, 5113) 
Severe dyskariosis 10,819 1,216 1,146 
 (2418, 21514) (571, 2117) (478, 1053) 
    
Number of HPV tests 272,228 3,315,913 2,608,628 
 (220774, 313783) (3260003, 3359351) (2551687, 2608256) 
HPV negative 157,739 2,868,372 2,242,651 
 (115711, 196221) (2830218, 2919485) (2192448, 2242518) 
HPV positive 114,489 447,541 365,977 
 (89616, 134687) (419017, 450246) (322009, 365021) 
    
Number of colposcopies 106,931 147,386 123,691 
 (83824, 125307) (127789, 154795) (104117, 123118) 
Normal 63,490 77,693 64,918 
 (47456, 76680) (66514, 82732) (54067, 64602) 
CIN 1 23,627 37,985 31,774 
 (17987, 28133) (32204, 40955) (26133, 31628) 
CIN 2 or worse 19,813 31,708 26,999 
 (15456, 23309) (26483, 34545) (21884, 26856) 
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Table 4: Summary of costs and QALYs (mean and 95%CI) 
  
Primary 
cytology 
protocol 
Primary HPV 
protocol 
with 3 year 
recall for 
women 
under 50, 
and 5 year 
recall 
otherwise 
Saving 
under 
primary HPV 
Primary HPV 
protocol with 
5 year recall 
for all women  
Saving 
under 
primary HPV 
with 5 year 
recall 
Annual screening-associated 
costs (£000) 134,173 120,479 13,078 97,726 33,958 
  
(122855, 
145382) 
(112413, 
130635) 
(2924, 
22814) 
(91366, 
106906) 
(23749, 
44166) 
Annual total health costs 
(£000) 153,391 136,707 15,756 114,196 35,711 
(including cost of cervical 
cancers) 
(139306, 
164510) 
(126156, 
147393) 
(2716, 
27990) 
(104471, 
126831) 
(22381, 
47182) 
       
Discounted lifetime cost per 
women (£) 160 145 14 121 38 
(including cost of cervical 
cancers) (146, 172) (134, 157) (1, 27) (108, 131) (25, 49) 
       
Annual incidence of cervical 
cancer 2123 1828 290 1999 145 
  (1475, 2869) (1016, 2738) (195, 370) (1356, 3022) (82, 256) 
       
Deaths related to cervical 
cancer (/year) 520 461 56 475 47 
  (364, 704) (325, 752) (38, 75) (337, 777) (27, 67) 
Discounted life years lost to 
cervical cancer per women 0.0157 0.0146 0.0018 0.0153 0.0008 
  
(0.0092, 
0.0239) 
(0.0079, 
0.0212) 
(-0.0043, 
0.0082) 
(0.0085, 
0.0224) 
(-0.0063, 
0.0076) 
Discounted quality-adjusted 
life years lost due to cancer 
and screening 0.0136 0.0160 -0.0026 0.0144 -0.0010 
  
(0.0105, 
0.0165) 
(0.0128, 
0.0198) 
(-0.0064, 
0.0013) 
(0.0113, 
0.0179) 
(-0.0047, 
0.0028) 
Discounted quality-adjusted 
life years lost due to cancer 
and screening, using Simonella 
basis for screening-related 
QALY detriment 0.0060 0.0055 0.0005 0.0052 0.0004 
  
(0.0037, 
0.0080) 
(0.0033, 
0.0073) 
(-0.0013, 
0.0026) 
(0.0032, 
0.0076) 
(-0.0018, 
0.0025) 
 288 
 
 
 
 
Figure 1: Number of women tested and predicted outcome under primary HPV protocol and 
primary cytology protocol, assuming age distribution in England as in 2013. 
 
Figure 2: Cervical cancer incidence as predicted by model outcomes under primary cytology 
and primary HPV protocols. Boxes represent the interquartile prediction interval (primary 
cytology =blue; primary HPV= red). 
0
100000
200000
300000
400000
500000
25
-29
30
-34
35
-39
40
-44
45
-49
50
-54
55
-59
60
-64
65
-69
Nu
m
be
r o
f t
es
ts
Age (years)
Primary cytology
protocol
Severe dyskariosis
Moderate dyskariosis
Mild Dyskariosis
Borderline cytology
Normal cytology
0
100000
200000
300000
400000
500000
25
-29
30
-34
35
-39
40
-44
45
-49
50
-54
55
-59
60
-64
65
-69
Nu
m
be
r o
f t
es
ts
Age (years)
Primary HPV
protocolSevere dyskariosis
Moderate dyskariosis
Mild Dyskariosis
Borderline cytology
Normal cytology
HPV Negative
Discounted quality-adjusted 
life years lost due to cancer 
and screening, using Insigna 
basis for screening-related 
QALY detriment 0.0195 0.0225 -0.0033 0.0199 -0.0009 
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(-0.0004, 
0.0064) 
(0.0.0162, 
0.0237) 
(-0.0040, 
0.0020) 
 289 
 
References 
Carter, J.J., Koutsky, L. a, Hughes, J.P., Lee, S.K., Kuypers, J., Kiviat, N., Galloway, D. a, 2000. J. 
Infect. Dis. 181, 1911–1919. 
Ho, G.Y.F., Studentsov, Y., Hall, C.B., Bierman, R., Beardsley, L., Lempa, M., Burk, R.D., 2002. J. 
Infect. Dis. 186, 737–42. 
Howell-Jones, R., Bailey, A., Beddows, S., Sargent,  a, de Silva, N., Wilson, G., Anton, J., Nichols, 
T., Soldan, K., Kitchener, H., 2010. Br.J.Cancer 103, 209–216. 
Howell-Jones, R., de Silva, N., Akpan, M., Oakeshott, P., Carder, C., Coupland, L., Sillis, M., 
Mallinson, H., Ellis, V., Frodsham, D., Robinson, T.I., Gill, O.N., Beddows, S., Soldan, K., 
2012. Vaccine 30, 3867–75. 
Insinga, R.P., Glass, A.G., Myers, E.R., Rush, B.B., 2007. Med.Decis.Making 27, 414–422. 
K., L., M.A., R., K.J., S., S.E., G., S.M., S., 2010. Genotype-specific persistence of genital human 
papillomavirus (HPV) infections in women followed for 6 years in the finnish family HPV 
study. J. Infect. Dis. 
Kelly, R.S., Patnick, J., Kitchener, H.C., Moss, S.M., 2011. Br. J. Cancer 105, 983–8. 
Legood, R., Smith, M., Lew, J.-B., Walker, R., Moss, S., Kitchener, H., Patnick, J., Canfell, K., 
2012. Cost effectiveness of human papillomavirus test of cure after treatment for cervical 
intraepithelial neoplasia in England: Economic analysis from NHS Sentinel Sites Study. 
BMJ. 
Safaeian, M., Porras, C., Schiffman, M., Rodriguez, A.C., Wacholder, S., Gonzalez, P., Quint, W., 
Van Doorn, L.J., Sherman, M.E., Xhenseval, V., Lowy, D.R., Hildesheim, A., 2010. J. Natl. 
Cancer Inst. 102, 1653–1662. 
Simonella, L., Howard, K., Canfell, K., 2014. 7, 1–11. 
Sonnenberg, P., Clifton, S., Beddows, S., Field, N., Soldan, K., Tanton, C., Mercer, C.H., Da Silva, 
F.C., Alexander, S., Copas, A.J., Phelps, A., Erens, B., Prah, P., Macdowall, W., Wellings, K., 
Ison, C. a., Johnson, A.M., 2013. Lancet 382, 1795–1806. 
Viscidi, R.P., 2004. Cancer Epidemiol. Biomarkers Prev. 13, 324–327. 
Viscidi, R.P., Snyder, B., Cu-Uvin, S., Hogan, J.W., Clayman, B., Klein, R.S., Sobel, J., Shah, K. V, 
2005. Cancer Epidemiol Biomarkers Prev 14, 283–288. 
 
  
 290 
 
Appendix: The clinical impact and cost-effectiveness of primary cytology 
compared to primary human papillomavirus testing for cervical cancer 
screening: a model-based analysis 
A1 Model and Parameterisation of Sexual Behaviour 
The sexual behaviour characteristics described below are used to generate the age of sexual 
debut and formation and dissolution of subsequent sexual partnerships for a population of 
100,000 women from birth to age sixty five years. Figure A1 illustrates broad model framework 
from sexual debut to HPV transmission, lesion development, and cervical screening and 
treatment.  
Sexual debut 
Entry into the HPV-susceptible population is determined by age of sexual debut as reported in 
the National Survey of Sexual attitudes and Lifestyles 2010 (NATSAL-3). The data allow us to 
directly determine the fraction women that are sexually active from age 16 to 75 years. For 
individuals aged 16 years and under, we use the distribution of reported age at first sex, Sd, (for 
those that report sexual activity before the age of 16 years), and scale this to the known 
fraction of individuals that are active by age 16 years, to determine the probability of sexual 
debut from age 10 onwards (P[Sd=d] = P[Sd=d |Sd<=16]P[Sd <=16]).  A smooth hill function is 
used to fit the empirical cumulative distribution of sexual debut age before and after the age 
of 16 years (shown in Figure A2(A).) 
Partnership acquisition 
The number of new partners acquired in the last year, as reported in NATSAL-3, reveals a trend 
towards decreasing partner acquisition with age with significant variation between individuals 
at the population level. We divide the population into five-year age bands (16-20, 21-25, 26-
30, 31-35, 36-40, 41-45, 46-50, 51-55, 56 an over). A Poisson distribution is used to describe 
the number of partners, LN, acquired over the last 12 months. A Nelder-Mead optimisation to 
identify the rate of partner acquisition, μ, and the size of each sexual behavioural categories, 
Si, where increasing i reflects increasing sexual activity. The Aikake information criterion 
identified a model that divided the population into 4 behavioural categories to be optimal; 
where,  S0 represents 17%,  S1 represents 51%,  S2 represents 26%,  and S3 represents 5% of the 
population, repsectively. An individual within the model remains associated with a given 
behavioural category throughout their lifetime, however, the rate of partner acquisition 
associated with each behavioural category decreases with age.  (Rates of partner acquisition 
shown in Table A1) 
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Partnership duration 
A survival model is used, in combination with the NATSAL-3 dataset, to parameterise the 
cumulative probability of relationship ‘survival’ as a function of time and age of women at the 
start of relationship.  In the natsal survey, individuals reported on the three most recent 
partners with sexual activity within the past 5 years. To counter the bias towards observing 
longer-relationships in a fixed-window sampling scenario, the survival of relationships is 
calculated using a modified Kaplan-Meier estimator that explicitly accounts for truncation (as 
described by Burington and colleagues1) 
!(#) = & 1− )(*+)/-(*+)./01  
where d(yi) represents the number of uncensored events (relationships) of length exactly yi 
;and the denominator R counts the total number of relationship events lasting more than or 
equal to yi months, but excluding events that began more than yi months before the start of 
the sampling window.   
-(*+) =23(45 < *+)5 −23(*5 < *+)5  
where 45   is the time between the start of the relationship and the start of the sampling 
window, measured as 5 years before the date of interview according to the natsal 
questionnaire design, (45 is 0 for partnerships that began after the start of the sampling period), 
and I(x) is the indicator function, value 1 if x is true, 0 otherwise.  
A partnership is defined as complete when there has been no sexual activity for 3 months. 
Data from the first, second and third most recent heterosexual partner is combined. 
Missing partnerships: The sampling of detailed partnership information from the three most 
recent partnerships in the past 5 years can lead to a bias towards longer relationships and 
those with a large gap between relationships as they are most likely to be ‘most recent’ at time 
of interview.  We compare the total number of partners in the past 5 years to the number of 
partners for whom we have detailed information for individual, to determine the number of 
missing partnerships in our data sample.  It is assumed that missing partnerships are complete 
and therefore will be most similar to completed partnerships that have been reported in detail 
by the same individual.  
The detailed information on complete partnerships for individual i can be weighted by W, 7 =1 + 9H;,= − T=?/C=), where H;,= is the number of partnerships reported in the last five years; T= 
is the number of partners for whom detailed partnership data is available; C= is the number of 
complete partnerships for whom data is available for subject i.  
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Relationship survival curves exhibit a biphasic decay; with a large number of short term 
relationships and a smaller number of very long partnerships. The data reveals that the 
fraction of relationships falling into the short-term category increases as a function of age at 
start of relationship; the five year survival for a relationship is 19%, 7% and 3,5% for women 
aged 16 to 20 years, 31 to 35 years, and 51 to 55 years, respectively, at the start of relationship 
(Figure A2(B)).  
Age mixing 
An age-mixing matrix is generated by directly sampling from the age of most recent partners 
reported by female participants in NATSAL-3. We stratify the data according to the age of 
female respondent at the start of relationship to reveal an increasing variance in partner age 
for older women. This approach is preferred to a more traditional approach to partner-
matching that assumes a constant age difference distribution or an approximation of +/- 3 
years, as it better captures the complexities of HPV transmission; in particular, the role of 
novel HPV infections in older women versus long term persistent infection. The shift in age 
difference is illustrated in Figure A2C). 
Frequency of sex acts 
We use data from NATSAL-3 to quantify the number of sex acts per month for individuals in an 
active relationship (defined as those participants who reported a sexual encounter in the last 3 
months with the most recent partner). As above, a weighting is added to response data that 
scales with total 5 year partner count to remove the bias towards reporting of characteristics 
from long term relationships. A small fraction of new relationships are assumed to result in a 
single sexual contact, defined by age according to data reported in NATSAL-3. Relationships in 
the model are generated by randomly sampling from the weighted distribution of sex acts per 
month (Figure A2(D)) and according to the reported probability of a single contact (Figure 
A2(E)).  
A2 Model and Paramterisation of HPV infection 
A static model of transmission was applied in which male prevalence was assumed to be 
constant throughout the duration of model simulation; i.e. the introduction of primary HPV 
testing in cervical screening is assumed to have no effect on the prevalence of HPV in males. 
The probability of transmission of HPV is described as a function of (i) HPV prevalence among 
male partners according to age; and (ii) the probability of transmission per contact with an 
infected individual.  
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The HPV status of a new male partner is randomly generated using the distribution of age of 
new partners, reported in NATSAL-3, according to the age of the woman at start of 
partnership, and the prevalence of HPV among men of the preferred partner age. 
HPV infection is modelled by introducing a per-sex-act probability of transmission of HPV. The 
probability of infection by each strain is assumed to be independent. In this work we consider 
HPV-16, 18, 31, 33, 45, 51, 52 and 58. Rates of clearance and transmission of HPV were 
parameterised using HPV prevalence data in women and sero-prevalence data in males.  
In the interest of parameterisation and model simplicity, we assume that natural immunity 
post-infection is negligible. Approximately half of women seroconvert within 18 months of 
infection (Carter et al., 2000). However, the risk of subsequent infection in women who were 
seropositive, compared to seronegative, has been shown to be (i) reduced between 25-85% for 
HPV 16(Ho et al., 2002; Safaeian et al., 2010); (ii) reduced between 14-75% for HPV 18; and  
(iii) not statistically significantly different(Viscidi, 2004; Viscidi et al., 2005). Epidemiological 
evidence suggests that reinfection is observed in 10-17% of women within 5 years of clearing 
an infection 1,4. There is some evidence to support the hypothesis that the majority of 
infections are rapidly cleared, and these transient infections are cleared by the innate immune 
system which does not result in the creation of a memory response5,6.  
HPV-strain specific prevalence was determined using surveillance data collected by Public 
Health England from residual samples taken from the NHSCSP pre-immunisation for women 
aged 25-65 years2. For women between the ages of 16 and 24 years, HPV prevalence was 
measured in residual samples taken from the national chlamydia screening programme 
(NCSP), pre-HPV-immunisation3. Data from these younger women is important for 
characterising the peak of HPV infection, however, the selective nature of women attending 
the NCSP means that the sample reflects a higher sexual risk group than the general 
population; NCSP data is accompanied by data with number of partners reported in the past 
12 months which is higher than that predicted by NATSAL-3 for women aged 16-24 years. We 
introduce a weighting to resample the NCSP data such that the number of partners reported in 
the past 12 months matches that observed in natsal-3 for women aged 16-24 years, and 
introduce a sub-population of sexually-inactive women in the same age range (as predicted in 
NATSAL-3 but not present in the NCSP dataset) who are expected to be HPV-naïve. HPV 
prevalence is recalculated in this re-weighted population and this new comparable prevalence 
is merged with the NHSCSP predicted prevalence.  
HPV prevalence data was not available for a sufficiently large male population in England. 
Instead, national surveillance data describing male sero-prevalence of HPV-16 and HPV-18 in 
England, collected by PHE4, was used to estimate prevalence of HPV among males. A study of 
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sero-prevalence in the Netherlands revealed that sero-prevalence levels were similar in HPV-
,33, 45 and 52, but approximately two-fold higher in HPV-315 ; a similar result was found in the 
German population6. In the parameterisation that follows, sero-prevalence of hpv 33, 45 and 
52 among males was constrained by observed sero-prevalence of hpv-18, in accord with levels 
of hpv prevalence of these strains observed in women in England. Sero-prevelance of HPV 
strains 31 and 51 was estimates by scaling the observed hpv-18 sero-prevalence according to 
the ratio of hpv prevalence of hpv-31: hpv-18 and hpv-51: hpv-18 observed in women. 
HPV infection in males 
A simple three compartment differential equation model is used to analyse the sero-
prevalence data and extract HPV prevalence for each HPV type. We consider individuals that 
are (i) infected but sero-negative (I); (ii) sero-positive, that is they have detectable HPV 
antibodies (S), and (iii) infected and HPV-DNA positive (H). 3̇ = B(4) − (C + D)3(4) !̇ = D	3(4) − F!(4)	 Ġ = B(4) − CG(4)	 
Where, f(t) is the number of new infections at time t; c is the rate of clearance of male 
infection; k is the rate of sero-conversion; and w is the rate of HPV antibody waning.    
The size of the infected population, H, can be estimated using numerical methods to solve the 
following equation: 
Ġ = !̈D + (F + C + D) !̇D + F(C + D) !D − CG(4)	 
where, the observed sero-prevalence, S[t], can be described by a polynomial, and it is assumed 
that the half life of antibodies is at least 20 years, that is the rate of waning (w) is  constrained 
to be less than 0.05 (/year). 
The rates of sero-conversion and clearance for each male HPV strain are identified, together 
with the rates of female clearance and transmission, using the observed HPV sero-
prevalence in males and prevalence in females. Described in detail below.Clearance of HPV 
infection 
The rate of HPV-clearance is allowed to vary with time post-infection, using a weibull 
distribution, selected due to its generality to allow a constant, increasing or decreasing rate of 
clearance with time.  The clearance rate is proportional to a power of time (tK-1), where t is 
time post-infection and K is the shape parameter; K=1 leads to a constant rate of clearance, 
while K<1 leads to a decreasing clearance rate with time.  
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HPV transmission probability (per-sex act) 
We find that the transmission probability per contact is not well defined. One explanation for 
this is that, according to the sexual behaviour data, the majority of partnerships result in 
multiple contacts; where the probability of contracting HPV from an infected partner, 1-(1- 
Transmission.Probability)^’Sex.Acts’, becomes decreasingly sensitive to the 
Transmission.Probability as the number of Sex.Acts increases. We accept the broad range of 
values suggested for transmission probabilities as they are able to reproduce the observed 
HPV prevalence within the context of known sexual behaviour. 
Parameterisation 
The disease transmission was parameterised independently for each HPV-subtype. In this 
parameterisation we assume that HPV prevalence is not sensitive to screening strategy. The 
reasoning is that (i) the number of women treated for cervical lesions is small relative to the 
number of women that are infected with HR-HPV, ~10% of population at large; and (ii) not all 
treatment of lesions leads to clearance of HPV-infection. As a result, we can identify the rate of 
disease transmission and clearance using a simplified individual-based model without 
screening, in a computationally tractable parameterisation. Best fitting parameters in Table A2 
and model predictions and observed HPV prevalence data in Figure A3.  
A Markov Chain Monte Carlo simulation, using an adaptive Metropolis algorithm, was 
implemented using the FME package in R to simultaneously identify the (i) HPV clearance 
parameters in females and males (c1, c2, cm); (ii) per contact probability of transmission from 
males to females; and (iii) rate of sero-coversion in males. Each chain was run for a length of 
20,000 and 100 parallel chains were generated using randomly generated starting values, for 
each strain of HPV.  
A thinning interval of 50 was used to remove auto-correlation within each chain.  Convergence 
was identified using the Geweke test statistic, a test of equality of the means of the first 10% 
and last 50% of the markov chain. A Gelman convergence diagnostic was then used to confirm 
convergence of the MCMC output in the parallel chains; a comparison of the empirical 
variance of each parameter within each chain should be comparable to the variance from all 
chains combined. The final parameter distribution reflects the joint distribution of the parallel 
chains.  
A3 Model and Parameterisation of Disease Progression 
A nested conditional probability structure is used to generate a model in which the probability 
of a given cytological outcomes varies as a continuous function of time post-infection for each 
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strain of HPV, as opposed to introducing distinct disease states.  The five cytology outcomes, 
normal, borderline, mild, moderate and severe, are characterised by 5 parameters (p_norm1, 
p_norm2, p_bord, p_mild, p-mod), I[KLMNOP, Q = 4] = STUVWX + (1 − STUVWX)YZ[∗]^_`ab I[cLM)YMPdeY, Q = 4] = YZ[]f_`g(1 − I[KLMN, Q = 4]) I[hdP), Q = 4] = (1 − I[KLMNOP, Q = 4])(1 − YZ[∗]f_`g)YZ[∗]a/ig I[hL)YMO4Y, Q = 4] = (1 − I[KLMNOP, Q = 4])(1 − YZ[∗]f_`g)(1 − YZ[∗]a/ig)YZ[∗]a_g I[!YjYMY, Q = 4] = 1 − I[hL)|	hdP)|cLM)|	KLMN, Q = 4]) 
where, the probability of a normal outcome decreases, while the probability of a severe 
outcome increase, with time since infection, and, STUVWX reflects the maximum probability of 
a normal cytology outcome at time of cancer, constrained to lie between 0 and 0.1.   An 
accelerated hazard component is introduced by normalising the time post-infection to an 
individual’s personal timeline to squamous cell carcinoma; T is the cancer-normalised time 
post-infection (= time post-infection/ Time from infection to SCC). Cytology outcomes are 
linked to the progression of squamous cell carcinomas, rather than adenocarcinomas because 
screening is thought to be poor at detecting adenocarcinoma. The introduction of the cervical 
screening programme in 1989 was associated with a ~35% reduction in squamous cell 
carcinoma cases over  a 10 year period, while the number of adenocarcinomas remained 
stable over the same period26.  
Cytology outcome parameters were calibrated using surveillance data collected by PHE, prior 
to the introduction of vaccination in 2008, mapping observed cytological outcomes to HPV 
type, as a function of age, using residual samples (n=2370) collected by the NHSCSP 11. 
Cytology screening outcomes for women who were not infected with HPV were parameterised 
using observed cytology outcomes from samples that tested negative for HPV 11. The model 
was calibrated simultaneously for each HPV-strain, in a simulation that incorporated screening 
and treatment under the existing primary cytology protocol.   
Cancer progression 
The hazard of squamous cell carcinoma and adenocarcinoma incidence are modelled 
independently; the hazard of cancer is assumed to increase as a function of time post-infection 
and modelled by a gamma distribution.  
Cancer incidence within the model was calibrated using cancer registrations in England 
reported by the Office for National Statistics in 2012. A breakdown of squamous cell carcinoma 
and adenocarcinoma cases by age was assumed to be as reported by the NHSCSP audit of 
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cervical cancers 15. Screen-detected cancers are defined as those that are diagnosed through 
colposcopy, where the referral to colposcopy was due to an abnormal cytology outcome. The 
number of cases detected by the screening programme was obtained using data from Health 
and Social Care Information Centre (HSCIC) and NHSCSP on cervical cancer outcomes at 
registered at laboratories, according to cytology referral, in 20127.  The distribution of cases 
among HPV types was estimated using the distribution of HPV types measured in residual 
tissue sections from routinely obtained diagnostic biopsies of cervical cancers archived in NHS 
pathology laboratories [n=555] by Howell-Jones and colleagues at PHE11.  
Co-infection of cancer–causing strains, as defined in our model, was observed in ~7.1%, and 
10%, of tissue samples taken from cervical cancers, and adenocarcinomas, respectively; ~3%, 
and 6%, of samples were positive for both hpv-16 and hpv-18 in cervical cancers, and 
adenocarcinomas, respectively. We generate cancer incidence for each model HPV-type alone 
plus co infection of hpv 16 and hpv 18 by scaling the incidence values with the observed 
distribution of types. There are not sufficient data to accurately project the co-infection with 
other strains; instead, we distribute the remaining joint infection cases according to the 
number of observed cancers associated with a single infection of each type involved.  
Parameterisation 
An MCMC simulation, using an adaptive Metropolis algorithm, was implemented using the 
FME package in R to simultaneously the parameters defining the natural progression of 
cytological abnormalities and incidence of cervical cancer for each HPV strain, in a population 
that is undergoing screening according to the current national algorithm. Each chain was run 
for a length of 20,000. Clearance and transmission parameters were sampled from the 
posterior distributions derived previously for each HPV type; 200 distinct combinations were 
used in total. 50 parallel chains were generated for each clearance-transmission parameter-
combination using randomly generated starting values.   
As before, a thinning interval of 50 was used to remove auto-correlation within each chain.  
Convergence was identified using the Geweke test statistic, a test of equality of the means of 
the first 10% and last 50% of the markov chain. A Gelman convergence diagnostic was then 
used to confirm convergence of the MCMC output in the parallel chains; a comparison of the 
empirical variance of each parameter within each chain should be comparable to the variance 
from all chains combined. The final parameter distributions reflect the joint distribution of the 
parallel chains generated using all 200 clearance parameter-combinations. Parameter values 
that best describe the observed cytological outcomes (Table A3) and observed squamous cell 
carcinoma and adeno carcinoma incidence (Table A4). Model predictions and observed 
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squamous cell cancer (Figure A4) and adenocarcinoma (Figure A5) incidence, according HPV 
type. 
A4 Parameterisation of Screening Attendance & Treatment 
Screening Algorithms 
Three alternative strategies are considered: (i) primary cytological screening with HPV  testing 
to determine further management of cytology abnormals (“primary cytology protocol”), which 
is current screening practices in England; (ii) primary HPV testing (“primary HPV protocol”), 
with cytology testing to determine further management of HR HPV positives; and (iii) primary 
HPV testing, as above, with an extended 5 year recall for all women (“5 year primary HPV 
protocol”). 
Under the primary cytology protocol, a negative test leads to recall in 3 years (or 5 years for 
women over 50 years old); a high grade cytological outcome leads directly to a colposcopy 
referral; and identification of a borderline or mild cytological abnormality is followed by HPV 
triage where a negative HPV outcome leads to a standard recall, while a positive result leads to 
an immediate colposcopy referral (Figure A6).  
Under the primary HPV protocol, a negative HR HPV test leads to recall to screening in 3 years 
(or 5 years for women over 50 years old), while a positive HR HPV test results lead to 
cytological assessment of the same sample; all non-negative cytological results (including 
borderline) are referred to colposcopy; a negative cytology leads to a 12-month follow up. In 
the follow up arm, 3 successive positive HR HPV results lead to referral for colposcopy (Figure 
A7).  
Under primary HPV 5 year protocol, a negative HR HPV test leads to recall to screening in 5 
years, for all women. A positive HR HPV test results lead to cytological assessment and follow 
up as defined for the primary HPV protocol.  
Age at First Screen 
A nelder-mead optimization was used to identify the distribution of age at first cervical 
screening that is best able to describe the observed fraction of women that have never 
attended screening with age [source: Cervical Screening Programme 2011-2012]. A 
lognormally distribution is used to characterise the age at which a women attends her first 
cervical screen (for age 24.5 years and above) (Figure A8(A)). Model predictions and data 
reported by the cervical screening programme in Figure A8(B). 
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Screening adherence 
We use the time between two successive screens to identify long-term behavioural screening 
pattern. The data is restricted to women on routine recall with no history of abnormalities. The 
interval between the last and penultimate screen is studied in women under 50 year with a 
prescribed interval of 3 years and data are stratified according to the previous inter-screening 
time (between screen (n-2) and (n-1)) – under 2.75, 2.75-3.5, 3.5-4.75, 4.75-5.5, 5.5-7.5, 7.5-
10, 10-15 and 15 plus years and never screened). The AIC, in addition to exploration of kurtosis 
and skew, revealed a log cauchy distribution best describes the observed data (Figure A8(C)); a 
non linear regression was used to identify best-fitting log-cauchy scale and location 
parameters as a function of previous inter-screen wait. We interpolate between the predicted 
mean and 90% interval to give a smooth distribution of inter-screening waiting that is then 
used to predict the time to next screen given an individual’s screening history (Figure A8(D)). 
Screening Outcomes 
The actions following colposcopy are the same in both protocols. A negative outcome at 
colposcopy is assumed to lead to discharge to standard recall; CIN1 is untreated but leads to a 
12 month follow up; while identification of precancerous lesions of grade CIN2 or worse leads 
to treatment followed by ‘Test of Cure’ triage at 6 months.  
The sensitivity of cytological testing is explicitly built into the model; cytology outcome is 
defined probabilistically and varies as a function of time since infection (described above). The 
sensitivity of the HPV test was assumed to lie between 90-95% for high risk HPV.   
Attendance and outcome at colposcopy under a primary cytology protocol are determined by 
cytology result at referral, as reported by the cervical screening programme 2012-2013 (Table 
A5). The probability of attending colposcopy, and the likely outcomes, are assumed to be 
identical for women referred following low-grade cytology followed by HPV positivity under a 
primary cytology protocol, as for women referred for a positive HPV test followed by low-
grade cytology result under a primary HPV protocol(Kelly et al., 2011). Colposcopy outcomes 
for women referred following a positive HPV test and high-grade cytology, under primary HPV 
protocol, are not significantly different from those reported following a high grade referral 
under the current primary cytology protocol. This has been evidenced in preliminary data from 
the pilot primary HPV programme. 
We assume that of all cases of CIN2 or worse that should all be recommended for treatment, 
83.1% return for treatment and 66.0% attend follow up appointments (source: cervical 
screening programme 2012-2013). The split between diagnostic biopsy and excision for those 
women that undergo treatment was assumed to be 63.2:2.6 in those originally referred due to 
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low grade abnormalities, and 37.6:49.1 in those attending colposcopy following a high grade 
referral (source: cervical screening programme 2012-2013). In the absence of recent data to 
inform this model parameter, the type of procedure recommended is assumed to be 
unchanged in the context of the HPV primary screening, however, this decision may be 
sensitive to knowledge that an individual is HR-HPV positive.  In accord with previous cost-
effectiveness studies of screening in England, the success rate of treatment is assumed to be 
95% for clearance of lesions, however, 16% of treated women are assumed to remain HPV 
positive(Legood et al., 2012). 
Age-dependent cancer survival rates 
The FIGO stage of cancer is taken to be as reported by the cervical cancer audit according to 
age at diagnosis (Table A6). Treatment following diagnosis of cervical cancer according to FIGO 
stage is determined by values reported by the Cervical Cancer Audit, 2010 (Table A7). 
Cancer mortality rates are calculated using 1 and 5 years survival rates published by ONS. We 
describe the survival using an exponential decay function following diagnosis of cancer and 
estimate an age-dependent mortality hazard. Rates are identified using a nelder-mead 
optimisation in R (Table A8). 
 
 
Figure A8. Model outline of HPV transmission and progression to cancer. The model 
simultaneously considers transmission of HPV-16, 18, 31, 33, 45, 51, 52 and 58 
 301 
 
  
 
 
 
Figure A2: Sexual behaviour parameters 
identified using data collected in natsal-3. (A) 
Cumulative probability of sexual debut as a 
function of age; age reported in NATSAL-3 
(points) and smooth monotone function that 
best describes the data (line). (B) Cumulative 
probability of relationship survival as a function 
of time since start of relatiosnhip; (C) age 
preference of male partners as a function of 
female age at start of relationship; mean (solid 
line); 75% interval (dark blue shaded region) 
and 95% interval (light blue shaded region). (D) 
Distribution of reported sex acts in a 4 week 
period for individuals in an active relationship. 
(E) Fraction of new partnerships that result in a 
single contact only.  
 
A B 
C D 
E 
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Figure A3: Observed type-specific HPV prevalence measured in residual samples from the 
NCSP (age 16-24 years – orange points) and NHSCSP (age 24-65 years – blue points) and best-
fitting model predictions – mean (solid black line), upper and lower 95% interval (grey shaded 
region). 
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Figure A4: Incidence of squamous cell carcinoma cases attributed to type-specific HPV 
infections; observed data based on incidence in England in 2012 and HPV-type prevalence 
detected in SCC tissue samples  (filled points) and best-fit model predictions (dashed lines 
shows median and shaded region represents 95% prediction interval). 
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Figure A5: Incidence of adenocarcinoma cases attributed to type-specific HPV infections; 
observed data based on incidence in England in 2012 and HPV-type prevalence detected in 
adenocarcinoma tissue samples (filled points) and best-fit model predictions (dashed lines 
shows median and shaded region represents 95% prediction interval). 
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Figure A6: Primary cytology protocol – current screening practise. 
 
 
Figure A7: Primary HPV protocol 
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Figure A8: Age at first cervical screen. (A)  
Best-fit probability density (likelihood) of 
first attending screening at given age. (B) 
Model predictions and observed values 
for percentage of women that have never 
attended for screening, as a function of 
age. 
Distribution of waiting time to next 
screen. (C): Observed and predicted 
distribution of ‘next’ inter-screen intervals 
when the previous interval was known to 
lie in the range 0-2.27, 2.75-3.5, 3.5-4.75, 
4.75-5.5, 5.5-7.5 or 7.5-10 years. (D) Best-
fitting waiting time percentiles (10th, 
25th, 50th, 75th, 90th) as a function of 
previous inter-screen interval. 
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Table A1. Rate of partner acquisition predicted for each behavioural category according to age  
Age range Partner 
acquisition 
rate (/year) 
Sexual Activity 
Group 
16-20 0.419 0 
16-20 0.769 1 
16-20 1.768 2 
16-20 3.872 3 
21-25 0.096 0 
21-25 0.339 1 
21-25 1.312 2 
21-25 3.649 3 
26-30 0.053 0 
26-30 0.103 1 
26-30 0.717 2 
26-30 2.649 3 
31-35 0.026 0 
31-35 0.037 1 
31-35 0.423 2 
31-35 2.519 3 
36-40 0.015 0 
36-40 0.016 1 
36-40 0.216 2 
36-40 1.297 3 
41-45 0.047 0 
41-45 0.039 1 
41-45 0.32 2 
41-45 1.29 3 
46-50 0.048 0 
46-50 0.02 1 
46-50 0.214 2 
46-50 0.968 3 
51-55 0.046 0 
51-55 0.027 1 
51-55 0.124 2 
51-55 1.276 3 
56-60 0 0 
56-60 0.045 1 
56-60 0.055 2 
56-60 0.161 3 
61-65 0 0 
61-65 0.027 1 
61-65 0.022 2 
61-65 0.636 3 
 
Table A2: Best fitting infection clearance and transmission parameters for HPV-16, 18, 31, 33, 
45, 51, 52, and 58 (best fitting values and 95% confidence interval.) 
Strain Weibull 
shape 
paramter 
Weibull 
scale 
paramter 
Cumulative 
probability 
of clearance 
at 24 
months in 
females 
Per-contact 
probability of 
transmission 
Male sero-
conversion 
(/year) 
Male rate of 
clearace 
(/year) 
 
HPV 16 0.833 20.8 0.679 0.536 0.042 51.001 
(0.711, 0.92) (12.7, 30.1) (0.561, 
0.793) 
(0.045, 0.98) (0.002, 0.09) (1.975, 
97.415) 
HPV 18 0.818 6.1 0.949 0.58 0.01 49.922 
(0.687, 
0.916) 
(2.8, 9.4) (0.93, 0.999) (0.051, 0.985) (0.003, 0.03) (2.61, 
96.616) 
HPV 31 0.755 18.2 0.713 0.452 0.035 50.609 
(0.618, 
0.867) 
(11.4, 24.3) (0.628, 
0.808) 
(0.023, 0.95) (0.014, 
0.049) 
(2.538, 
97.065) 
HPV 33 0.738 9.5 0.845 0.422 0.037 51.348 
(0.587, 
0.867) 
(5.3, 13.9) (0.782, 
0.913) 
(0.012,0.966) (0.014, 
0.0049) 
(2.776, 
96.175) 
HPV 45 0.748 13.7 0.774 0.418 0.036 49.239 
(0.598, 
0.867) 
(8.2, 19.5) (0.69, 0.861) (0.019, 0.974) (0.01, 0.05) (3.561, 
97.703) 
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HPV 51 0.813 5.7 0.907 0.518 0.012 50.723 
(0.686, 
0.908) 
(2.6, 10.4) (0.86, 0.993) (0.042, 0.975) (0.002, 
0.032) 
(2.848, 
98.391) 
HPV 52 0.786 17.9 0.721 0.454 0.037 48.677 
(0.658, 
0.892) 
(11.9, 23) (0.644, 
0.801) 
(0.024, 0.97) (0.016, 
0.049) 
(2.464, 
97.512) 
HPV 58 0.799 11.4 0.803 0.486 0.02 49.638 
(0.655, 
0.894) 
(5.8, 19.6) (0.695, 
0.925) 
(0.037, 0.965) (0.004, 
0.044) 
(3.281, 
96.428) 
 
Table A3. Model parameters that best describe the occurance of cytological abnormalities with 
time since infection. 
  pnorm1 pnorm2 pbord pmild pmod Expected wait 
to 
abnormality 
(years) 
HPV 16 0.334 0.001 0.723 0.658 0.737 3 
  (0.08, 1.574) (0, 0.004) (0.09,1.907) (0.046, 1.912) (0.048, 
1.906) 
  
HPV 18 1.381 0.005 1.098 0.848 0.954 0.7 
  (0.233, 1.982) (0, 0.038) (0.13, 1.944) (0.045, 1.939) (0.057, 
1.939) 
  
HPV 31 0.187 0 0.575 0.606 0.845 5.3 
  (0.018, 0.938) (0, 0.001) (0.03, 1.911) (0.023, 1.893) (0.037, 
1.948) 
  
HPV 33 0.421 0 0.451 0.123 0.838 2.4 
  (0.121, 1.671) (0, 0.003) (0.103, 1.685) (0.021, 0.491) (0.065, 
1.945) 
  
HPV 45 0.15 0.001 0.91 0.86 0.937 6.6 
  (0.006, 0.203) (0, 0.007) (0.039, 1.928) (0.031, 1.945) (0.047, 
1.939) 
  
HPV 51 0.998 0.004 0.827 0.723 0.933 1 
  (0.126, 1.965) (0, 0.039) (0.062, 1.87) (0.026, 1.887) (0.046, 
1.953) 
  
HPV 52 0.144 0.001 0.678 0.677 0.841 6.9 
  (0.028, 0.43) (0, 0.005) (0.039, 1.901) (0.021, 1.916) (0.036, 
1.942) 
  
 
Table A4. Squamous cell carcinoma and adenocarcinoma. Parameters that best fit the 
observed incidence data (man and 95%confidence interval).  
  Squamous cell carcinoma Adenocarcinoma Time delay (years) 
Strain Gamma Gamma 
rate 
parameter 
Rate of 
clinical 
diagnosis 
Gamma 
shape 
parameter 
Gamma 
rate 
parameter 
Infectio
n to 
detectin
g SCC  
Infection to 
detecting 
ADC shape 
parameter 
  Median (95% interval) 
HPV 
16 
5.643 0.024 0.01 4.995 0.01 15.3 2.083 
  (3.05, 8.175) (0.007, 
0.041) 
(0.008, 
0.015) 
(1.516, 
12.708) 
(0.004, 
0.022) 
(4.9, 
40.6) 
(0.083, 
11.833) 
HPV 
18 
15.006 0.121 0.013 37.931 0.129 10.1 1.667 
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  (2.419, 
71.206) 
(0.004, 
0.704) 
(0.009, 
0.23) 
(2.461, 
116.636) 
(0.01, 
1.154) 
(3.6, 
34.1) 
(0.5, 4.913) 
HPV 
31 
5.987 0.019 0.014 6.221 0.005 16.5 5.792 
  (2.87, 
39.785) 
(0.004, 
0.184) 
(0.01, 
0.035) 
(2.584, 
82.779) 
(0.003, 
0.016) 
(6.6, 
37.1) 
(1.167, 
17.944) 
HPV 
33 
5.529 0.017 0.011 6.212 0.01 15 2 
  (2.709, 
10.238) 
(0.004, 
0.044) 
(0.008, 
0.016) 
(1.174, 39.1) (0.004, 
0.125) 
(4.2, 
39.8) 
(0.167, 
8.492) 
HPV 
45 
3.823 0.005 0.02 7.096 0.004 24 21.333 
  (3.266, 
5.261) 
(0.003, 
0.009) 
(0.01, 
0.314) 
(2.998, 
33.578) 
(0.003, 
0.01) 
(5.9, 
69.3) 
(3.635, 
61.406) 
HPV 
51 
5.184 0.011 0.054 6.925 0.009 12.7 >100 
  (3.859, 
9.658) 
(0.005, 
0.036) 
(0.011, 
0.287) 
(2.269, 
118.528) 
(0.003, 
0.384) 
(5.5, 
25.5) 
>100 
HPV 
52 
5.922 0.019 0.011 5.572 0.011 16 3.417 
  (3.709, 
17.508) 
(0.006, 
0.076) 
(0.008, 
0.033) 
(1.395, 
44.809) 
(0.003, 
0.118) 
(6.8, 
41.8) 
(0.25, 
10.465) 
HPV 
58 
75.067 0.004 0.015 79.617 0.003 20.8 >100 
  (4.989, 
179.38) 
(0.003, 
0.025) 
(0.009, 
1.212) 
(7.121, 
187.572) 
(0.003, 
0.021) 
(18.6, 
23) 
>100 
 
Table A5: Colposcopy outcomes under primary cytology algorithm (annual screening report 
2012-2013), and preliminary outcomes form primary HPV pilot sites (October 2014). 
 
  
Percentage 
attendance 
Probability 
of normal 
outcome 
Probability 
CIN1 
detected 
Probability 
CIN2 or 
worse 
detected 
Current screening practise 
    
Borderline or Mild referral (n=21,977) 75.2% 55.4% 26.9% 17.7% 
Moderate or worse referral (n=38,570) 78.0% 7.4% 8.1% 84.5% 
Preliminary Primary HPV pilot outcomes 
    
Borderline or Mild referral (n=1473) 79.6% 66.1% 17.6% 16.4% 
Moderate or worse referral (n=853) 88.0% 10.9% 6.1% 83.0% 
 
Table A6: Observed state of cancer progression, according to age at diagnosis (source: Cervical 
Cancer Audit, 2010) 
Age at diagnosis (years) Cancer stage at diagnosis 
  1A 1B 1B+ 2 3 4 
25 47.8% 35.4% 5.3% 6.2% 1.8% 5.3% 
25 - 49 48.9% 35.7% 3.8% 7.7% 2.6% 3.0% 
50 - 64 21.3% 33.9% 8.3% 17.9% 11.3% 8.3% 
65 and over 6.6% 27.7% 8.4% 26.6% 17.9% 8.4% 
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Table A7: Treatment of cancers according to stage at diagnosis (source: Cervical Cancer Audit, 
2010) 
Treatment Cancer stage at diagnosis 
  1A 1B 1B+ 2 3 4 
None 4.6% 5.4% 19.8% 8.6% 12.3% 19.6% 
Cone 69.6% 18.1% 15.8% 0.7% 1.0% 15.8% 
Trachelectomy 1.0% 5.6% 1.0% 0.2% 0.0% 1.0% 
Hysterectomy only 20.4% 46.0% 19.8% 7.6% 1.5% 19.8% 
Radiotherapy (+/- hysterectomy) 1.5% 6.9% 8.9% 20.7% 24.1% 8.9% 
Chemotherapy (+/- hysterectomy) 40.0% 2.0% 4.0% 3.8% 6.9% 4.0% 
Chemo-radio therapy (+/- hysterectomy) 2.6% 16.1% 30.7% 58.4% 54.2% 30.7% 
 
Table A8: Age dependent mortality rate following diagnosis of cervical cancer 
Age at diagnosis (years) Rate of mortality 
15 - 39 0.03 
40 - 49 0.05 
50 - 59 0.10 
60 - 69 0.14 
70 - 79 0.28 
80 - 99 0.50 
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  Age 
 
  25 - 29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 All 
Number 
of 
cytology 
tests 
113,50
6 
78,541 56,889 48,383 42,112 27,393 17,042 11,200 1,362 396,427 
  (10538
9, 
11447
2) 
(74504
, 
78933) 
(53111
, 
55944) 
(46243
, 
48825) 
(39612
, 
42050) 
(25933
, 
27757) 
(16009
, 
17381) 
(9858, 
10867) 
(1148
, 
1330) 
(371807
, 
397559) 
Normal 
cytology 
73,074 50,432 36,920 31,457 28,136 18,188 11,007 7,096 836 257,145 
  (64168
, 
78791) 
(45013
, 
54626) 
(32069
, 
38938) 
(28284
, 
34286) 
(25077
, 
30190) 
(16254
, 
19760) 
(9638, 
12098) 
(5814, 
7359) 
(655, 
860) 
(226971
, 
276908) 
Borderlin
e changes 
30,994 21,683 15,517 13,164 10,922 7,214 4,671 3,159 401 107,725 
  (21793
, 
36741) 
(14651
, 
25864) 
(10289
, 
18471) 
(8886, 
15767) 
(7442, 
12888) 
(4945, 
8855) 
(3193, 
5661) 
(2090, 
3623) 
(253, 
460) 
(73542, 
128330) 
Mild 
dyskariosi
s 
7,257 4,969 3,497 2,972 2,440 1,602 1,073 731 94 24,634 
  (4723, 
9877) 
(3185, 
6839) 
(2255, 
4882) 
(1879, 
4219) 
(1519, 
3328) 
(976, 
2270) 
(697, 
1551) 
(414, 
982) 
(49, 
133) 
(15695, 
34081) 
Moderate 
dyskariosi
s 
1,845 1,194 776 640 499 319 238 172 25 5,707 
  (1083, 
2685) 
(707, 
1685) 
(438, 
1121) 
(356, 
939) 
(270, 
741) 
(166, 
496) 
(115, 
365) 
(75, 
254) 
(9, 
37) 
(3218, 
8324) 
Severe 
dyskariosi
s 
336 264 178 150 116 70 54 42 7 1,216 
  (180, 
617) 
(140, 
438) 
(86, 
298) 
(70, 
251) 
(45, 
193) 
(24, 
126) 
(14, 
101) 
(10, 
77) 
(0, 
15) 
(571, 
2117) 
Number 
of HPV 
tests 
534,95
8 
482,99
6 
467,56
1 
497,39
2 
498,22
2 
314,14
7 
251,36
1 
237,77
9 
31,49
7 
3,315,9
13 
  (51802
1, 
54678
9) 
(47473
2, 
48959
2) 
(46147
2, 
47172
6) 
(49157
0, 
50214
7) 
(49279
3, 
50314
5) 
(30944
0, 
31797
0) 
(24754
3, 
25496
2) 
(23361
9, 
24109
7) 
(3081
4, 
31922
) 
(326000
3, 
335935
1) 
HPV 
negative 
412,63
2 
391,94
2 
402,17
8 
441,72
5 
450,35
8 
282,19
4 
232,27
8 
225,19
0 
29,87
5 
2,868,3
72 
  (40138
6, 
42650
2) 
(38652
8, 
39938
1) 
(39918
9, 
40837
1) 
(43747
4, 
44695
9) 
(44663
2, 
45648
1) 
(27864
3, 
28611
8) 
(22899
7, 
23607
2) 
(22202
4, 
22918
4) 
(2934
3, 
30415
) 
(283021
8, 
291948
5) 
HPV 
positive 
122,32
6 
91,054 65,383 55,667 47,865 31,953 19,082 12,589 1,623 447,541 
  (11355
8, 
12335
9) 
(86234
, 
91814) 
(60973
, 
64874) 
(52903
, 
56426) 
(44998
, 
47996) 
(30054
, 
32422) 
(17890
, 
19516) 
(11037
, 
12250) 
(1370
, 
1588) 
(419017
, 
450246) 
Number 
of 
38,065 31,536 22,076 18,743 15,257 10,638 6,231 4,233 607 147,386 
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Table A9: Model-generated number and outcome of HPV, cytology and colposcopy tests, per 
annum, under a primary HPV protocol; mean (lower & upper bound). Resident female 
population size and age demographic as observed in England in 2013 (source: ONS). 
  
 
Table A10: Model-generated number and outcome of cytology and HPV tests, per annum, 
under a primary cytology protocol; mean (lower & upper bound). Resident female population 
size and age demographic as observed in England in 2013 (source: ONS). 
  Age 
 
  25 - 29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 All 
Number 
of 
cytology 
tests 
498,98
2 
443,94
1 
446,28
6 
474,10
1 
480,89
2 
297,60
5 
242,29
1 
231,93
2 
29,79
3 
3,145,8
25 
  (48387
8, 
51207
6) 
(43558
9, 
45184
1) 
(44052
1, 
45198
9) 
(46843
8, 
47948
5) 
(47512
5, 
48631
0) 
(29331
8, 
30202
0) 
(23857
6, 
24588
4) 
(22799
1, 
23577
9) 
(2912
7, 
30326
) 
(309256
4, 
319571
1) 
Normal 
cytology 
412,03
6 
399,52
3 
407,04
6 
436,01
1 
445,02
7 
282,33
3 
230,83
5 
222,19
9 
28,59
8 
2,863,6
09 
  (39817
9, 
42803
6) 
(39112
9, 
40968
0) 
(39996
3, 
41573
4) 
(42858
1, 
44473
9) 
(43757
5, 
45405
3) 
(27763
4, 
28742
9) 
(22688
7, 
23495
0) 
(21817
3, 
22670
4) 
(2796
6, 
29213
) 
(280608
7, 
293053
9) 
Borderlin
e changes 
50,691 30,266 26,259 25,065 23,365 11,157 8,290 6,968 852 182,912 
  (39466
, 
59278) 
(23093
, 
35795) 
(20093
, 
30876) 
(18903
, 
29785) 
(17509
, 
27851) 
(8105, 
14092) 
(5981, 
10573) 
(4851, 
8870) 
(566, 
1111) 
(138567
, 
218231) 
Mild 
dyskariosi
s 
25,302 10,390 9,543 9,565 9,193 3,157 2,409 2,092 258 71,910 
colposcop
ies 
  (32166
, 
40496) 
(27849
, 
32794) 
(19316
, 
22897) 
(16463
, 
19682) 
(13234
, 
15979) 
(9342, 
11255) 
(5438, 
6724) 
(3487, 
4337) 
(495, 
631) 
(127789
, 
154795) 
Normal 19,937 16,615 11,667 9,913 8,085 5,653 3,284 2,221 317 77,693 
  (16752
, 
21421) 
(14534
, 
17413) 
(10094
, 
12311) 
(8562, 
10581) 
(6890, 
8630) 
(4848, 
6068) 
(2798, 
3620) 
(1793, 
2346) 
(243, 
341) 
(66514, 
82732) 
CIN 1 9,755 8,123 5,701 4,845 3,950 2,763 1,606 1,087 155 37,985 
  (8203, 
10585) 
(7098, 
8627) 
(4844, 
6061) 
(4116, 
5193) 
(3314, 
4272) 
(2339, 
3029) 
(1340, 
1827) 
(836, 
1192) 
(116, 
170) 
(32204, 
40955) 
CIN 2 or 
worse 
8,373 6,798 4,709 3,985 3,221 2,221 1,341 925 135 31,708 
  (6910, 
9209) 
(5808, 
7293) 
(3987, 
5048) 
(3356, 
4343) 
(2672, 
3505) 
(1859, 
2461) 
(1099, 
1520) 
(696, 
1014) 
(95, 
150) 
(26483, 
34545) 
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  (19830
, 
31901) 
(6872, 
13693) 
(6072, 
13036) 
(5861, 
13303) 
(5424, 
12862) 
(1845, 
4708) 
(1337, 
3672) 
(1002, 
3218) 
(113, 
414) 
(48355, 
96806) 
Moderate 
dyskariosi
s 
6,462 2,423 2,122 2,076 1,948 609 476 409 50 16,576 
  (3383, 
9588) 
(990, 
3853) 
(710, 
3629) 
(568, 
3707) 
(447, 
3656) 
(177, 
1316) 
(127, 
1052) 
(89, 
1002) 
(9, 
127) 
(6500, 
27929) 
Severe 
dyskariosi
s 
4,490 1,339 1,317 1,384 1,359 349 281 264 34 10,819 
  (1726, 
6872) 
(226, 
2743) 
(162, 
2846) 
(125, 
3004) 
(102, 
3077) 
(35, 
1075) 
(24, 
912) 
(18, 
877) 
(1, 
109) 
(2418, 
21514) 
Number 
of HPV 
tests 
79,762 44,502 38,644 37,023 34,456 15,538 11,486 9,641 1,177 272,228 
  (69200
, 
89395) 
(36019
, 
50922) 
(30880
, 
44450) 
(29001
, 
43007) 
(26609
, 
40011) 
(12144
, 
18541) 
(8913, 
14207) 
(7156, 
11796) 
(852, 
1455) 
(220774
, 
313783) 
HPV 
negative 
47,335 21,399 21,356 22,679 22,642 8,369 6,735 6,404 820 157,739 
  (39064
, 
55019) 
(15231
, 
26365) 
(15017
, 
26678) 
(15726
, 
28588) 
(15640
, 
28593) 
(5710, 
11358) 
(4568, 
9517) 
(4223, 
8939) 
(534, 
1163) 
(115711
, 
196221) 
HPV 
positive 
32,427 23,103 17,288 14,344 11,814 7,169 4,750 3,237 357 114,489 
  (25567
, 
38220) 
(18142
, 
27066) 
(13498
, 
20284) 
(11314
, 
16924) 
(9158, 
13639) 
(5518, 
8728) 
(3736, 
5718) 
(2429, 
3694) 
(255, 
414) 
(89616, 
134687) 
Number 
of 
colposcop
ies 
32,687 20,252 15,622 13,419 11,395 6,125 4,151 2,948 333 106,931 
  (25702
, 
37379) 
(16269
, 
23738) 
(12428
, 
18423) 
(10517
, 
15983) 
(8738, 
13506) 
(4682, 
7340) 
(3159, 
5058) 
(2118, 
3480) 
(211, 
400) 
(83824, 
125307) 
Normal 20,405 11,423 9,054 7,978 6,943 3,438 2,349 1,705 195 63,490 
  (15428
, 
23532) 
(8924, 
13732) 
(6964, 
10953) 
(5874, 
9918) 
(4926, 
8739) 
(2470, 
4296) 
(1656, 
3058) 
(1098, 
2193) 
(117, 
260) 
(47456, 
76680) 
CIN 1 6,690 4,773 3,568 2,961 2,436 1,476 980 669 74 23,627 
  (5158, 
7987) 
(3715, 
5633) 
(2749, 
4201) 
(2239, 
3532) 
(1815, 
2858) 
(1087, 
1823) 
(713, 
1213) 
(469, 
797) 
(43, 
90) 
(17987, 
28133) 
CIN 2 or 
worse 
5,591 4,056 3,000 2,480 2,016 1,211 822 574 64 19,813 
  (4386, 
6599) 
(3213, 
4718) 
(2390, 
3478) 
(1941, 
2921) 
(1541, 
2347) 
(919, 
1467) 
(628, 
1017) 
(400, 
684) 
(40, 
78) 
(15456, 
23309) 
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